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Abstract
Activation of the hypothalamic-pituitary-adrenal (HPA) axis by stressors
results in the secretion of glucocorticoids, which contribute to the maintenance of
homeostasis and autoregulate the activity of the axis via negative feedback
mechanisms.
The aim of this PhD project was to examine whether HPA axis responses to
acute stress were different during pregnancy and to elucidate possible mechanisms
underlying these changes. We found that on day 21 of pregnancy the peak plasma
adrenocorticotrophic hormone (ACTH) and corticosterone secretory responses to 20
min of restraint stress were significantly reduced.
Using receptor autoradiography we found that between day 10 and day 21 of
pregnancy there was a progressive decrease in the binding of corticotropin-releasing
factor (CRF) to anterior pituitary sections. When we examined the responsiveness of
dispersed anterior pituitary cells to CRF and measuring the accumulation of cAMP,
we found that on day 21 of pregnancy the anterior pituitary was less responsive.
Using in situ hybridisation histochemistry to investigate the basal expression of CRF
and arginine vasopressin (AVP) genes in the parvocellular paraventricular nucleus
(PVN), we demonstrated that on day 21 of pregnancy there was a significant
reduction in CRF, but not AVP mRNA.
We examined whether there was an increase in the sensitivity of the HPA
axis to the glucocorticoid negative feedback signal. Using in situ hybridisation
histochemistry we measured the basal expression of the mRNAs for
mineralocorticoid (MR) and glucocorticoid (GR) receptors in the PVN and
hippocampus and found that neither mRNA was altered during pregnancy. We also
measured in vitro the bioactivity of the glucocorticoid-metabolising enzyme, 11 (3-
hydroxysteroid dehydrogenase type 1 (11 (3-HSD1) in PVN, anterior pituitary and
hippocampus and found that the enzyme activity increased almost 3-fold selectively
in the PVN on day 21 of pregnancy: lip-HSDl may act as a reductase, enhancing
feedback in vivo. We went on to examine the impact of inhibiting central 11 [3-HSD
on the response to forced swim (FS) stress. However, we found that central inhibition
this enzyme had no significant effect on the ACTH and corticosterone secretory
response. We pharmacologically adrenalectomized pregnant and virgin rats and
compared their ACTH response to exogenous corticosterone and found no difference
in the overall suppression of ACTH secretion, although on day 21 of pregnancy the
rats were less sensitive to the feedback signal within the first 30 min following the
corticosterone injection.
When we implanted intact virgin female rats with subcutaneous estrogen- and
progesterone-containing capsules, which elevated circulating estrogen and
progesterone levels to concentrations similar to those found in pregnancy, and then
exposed them to FS stress, we demonstrated that neither of these ovarian hormones
influenced the HPA axis responses to stress.
To examine whether central endogenous opioid peptides (EOP) influenced
the hypothalamic neuropeptide-containing neurones of the HPA axis, we
administered naloxone (nix) and then exposed the animals to FS stress. We
demonstrated that nix in virgin animals caused a significant suppression of the HPA
axis responses to FS stress while in day 21 pregnant rats it caused a small non¬
significant elevation. This result indicates that in virgin animals central EOP enhance
the HPA axis stress response and this enhancement is lost during pregnancy.
Thus there is a suppression of the responses of the HPA axis to acute stress in
late pregnancy. Adaptations at the anterior pituitary and central level of the axis that
may contribute to this attenuation include desensitization of corticotropes through
CRF receptor loss, and decreased production of CRF by PVN neurones.
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BNST bed nucleus stria terminalis
BSA bovine serum albumin
cAMP cyclic adenosine monophosphate
CBG corticosterone binding globulin
cDNA complimentary deoxyribonucleic acid
CRT corticotrophin-releasing hormone
cRNA complimentary ribonucleic acid
CTP cytosine triphosphate
Depc diethyl pyrocarbonate






HPB hypophysial portal blood
HPA Axis hypothalamic-pituitary adrenal axis








NAD nicotinamide adenine dinucleotide
NADP nicotinamide adenine dinucleotide phosphate
NADPH nicotinamide adenine dinucleotide phosphate (reduced form)
NTS nucleus of the solitary tract
PVN paraventricular nucleus
s.c. subcutaneous
TLC thin layer chromatography
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Chapter One
Introduction
1.1 The Stress Response
It is essential for life that the body maintains a constant internal environment or
homeostasis when challenged by either intrinsic and extrinsic forces, termed
stressors and this state of threatened homeostasis is often referred to as stress.
The body reacts to stress by the activation of a complex repertoire of responses
commonly known as the 'fight or flight' response, first described by Walter Cannon
back in the early 1900s. This adaptive mechanism involves a number of behavioural,
autonomic and neuroendocrine changes, which are coordinated by the CNS which
constantly receives information from brain centres, the periphery and the
environment. Thus, the stress response involves an extremely complex, but efficient
and flexible physiological network which coordinates the maintenance of
homeostasis.
1.2 Hypothalamic-pituitary-adrenal (HPA) axis
A well-characterised neuroendocrine change that occurs in response to stress is
the activation of the hypothalamic-pituitary-adrenal (HPA) axis (fig 1.1) which is a
centrally-driven system culminating in the secretion of glucocorticoids from the
cortex of the adrenal gland.
The hypothalamic paraventricular nucleus (PVN) is the central coordinator of
the HPA axis response to stress and receives information via stimulus-specific
pathways. The hypophysiotropic CRF-containing neurones located in the medial
paravocellular region of the PVN receive a rich afferent innervation (Sawchenko &
Swanson, 1985). Viscerosensory information from the oral, thoracic and abdominal
cavities is conveyed by ascending catecholaminergic pathways from the brainstem,
primarily from the nucleus of the solitary tract (NTS) and the adrenergic C2 cell
groups (Cunningham & Sawchenko, 1983). Several limbic structures, including the
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Fig 1.1 : Schematic diagram of the hypothalamic-pituitary-adrenal (HPA)
axis. NTS - nucleus of the solitary tract; GR - glucocorticoid receptor & MR -
mineralocorticoid receptor; 11P-HSD1 - 11 [Uhydroxysteroid dehydrogenase
type 1; PVN - paraventricular nucleus; CRH - corticotropin-releasing factor;
AVP - arginine vasopressin; ACTH - adrenocorticotropin hormone; CBG -
corticosterone binding globulin.
2
septum, amygdala and hippocampus are involved in conveying emotional stimuli
indirectly via the bed nucleus of the stria terminalis (BNST), the lateral and medial
septum, the fimbria and the preoptic area (Gray, 1991; Sawchenko & Swanson,
1983). Other stimuli, including humoral factors and availability of energy substrates
may act through a series of interconnected cell groups comprising the lamina
terminalis which lies partly outside the blood-brain barrier and is proposed to relay
information carried by macromolecules and ions in the bloodstream (Gross, 1987).
Axons from the parvocellular CRF neurones extend to the external layer of the
median eminence (ME) in the medial basal hypothalamus where they terminate on
capillaries of the hypophysial portal blood (HBP) system. Upon stimulation, CRP
and co-secretagogues, including arginine vasopressin (AVP), are released into the
hypophyseal portal blood system where they act in a synergistic manner to release
ACTH and other POMC-derived peptides from the anterior pituitary corticotrophs.
ACTH is the key regulator of glucocorticoid secretion by the adrenal cortex as it
increases the synthesis of glucocorticoids. Glucocorticoids are the final effectors of
activation of the HPA axis. They are involved in the control of whole body
homeostasis and the organism's response to stress. They play a key role in the
regulation of the basal activity of the HPA axis and on the termination of the stress
response by exerting negative feedback effects on the pituitary and specific brain
regions to inhibit the secretion of CRF and AVP from hypothalamic neurones and
ACTH from pituitary corticotrophs.
1.3 Paraventricular Nucleus
The paraventricular nucleus (PVN) comprises a group of cell bodies located in
the hypothalamus of the forebrain. It is a complex structure with distinct
magnocellular and parvocellular regions (Gurdjian, 1927). Retrograde neuronal
tracing techniques (Swanson & Kuypers, 1980) indicated that this nucleus consists of
at least eight distinct cell groups: three dense clusters of magnocellular neurones;
anterior, medial and posterior, each containing neurones that express AVP or
oxytocin: and an extensive parvocellular component that can be divided into five
separate regions; anterior, medial, dorsal, lateral and periventricular.
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Injection of two retrogradely transported fluorescent dyes, bisbenzimide-true
blue and Evans blue-granular blue, into the posterior pituitary labelled the majority
of cells in all three magnocellular subdivisions, with labelling of a few scattered cells
in the parvocellular subdivisions (Swanson & Kuypers, 1980). However, injection of
the dyes into the spinal cord or the dorsal vagal complex labels cells primarily in all
the parvocellular regions, particularly in the anterior, medial and lateral areas
(Swanson & Kuypers, 1980). These areas are rich in CRT-containing neurones
involved in the control of autonomic functioning. However, the most widely studied
population of PVN cell bodies are the CRF-containing neurones of the parvocellular
medial subdivisions. Their major projection is to the external zone of the ME and
they form the central effector of the HPA axis (Swanson & Kuypers, 1980).
1.3.1 Corticotropin-releasing factor (CRF)
In the late 1940s Harris (1948) proposed that the hypothalamus plays a key role
in the regulation of adrenocorticotrophic hormone (ACTH) secretion from the
anterior pituitary corticotroph cells. Then in 1955 Guillemin and Rosenburg and
Saffran and Schally independently demonstrated the presence of factors in the
hypothalamus that could increase the rate of ACTH secretion by the pituitary gland
incubated in vitro or maintained in organ culture. However, the isolation and
characterisation of the physiological corticotropin-releasing factor proved to be
problematic. Therefore the existence of this elusive hypothalamic factor was not
realised until the early 1980s when Wylie Vale and colleagues (Vale et al., 1981)
successfully isolated and characterised a 41 amino acid peptide from extracts of
ovine hypothalamus. The compound exhibited potent ACTH-releasing activity on
cultured anterior pituitary cells and was termed corticotropin-releasing factor (CRF).
Subsequently, the primary structure of CRF from rat (rCRF) (Rivier et al., 1983) was
determined and found to differ from ovine CRF (oCRF) by only seven residues. The
active portion of the molecule appears to reside in the carboxy-terminal (Aguilera et
al., 1983) since the absence of this portion prevents receptor binding. However, the
presence of the amino terminal residues is necessary for full function since the
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antagonist, a-helical CRF9 , which lacks the first eight amino acids, has a much
weaker affinity for the CRF receptor than the native molecule.
The complementary DNAs (cDNA) encoding the CRT precursor have also
been cloned (Furutani et al., 1983; Jingami et al., 1985b). This undergoes
posttranslational proteolytic cleavage and amidation to produce the active protein.
Analysis of the nucleotide sequence of the CRF gene demonstrated structural
similarities between the human and rat (Thompson et al., 1987): two exons separated
by an intron with the nucleotide sequence encoding the entire CRF precursor located
on the second exon.
1.3.2 Central distribution of CRF
The isolation of the CRF peptide and the subsequent cloning of the cDNA
allowed immunohistochemical and hybridisation histochemical methods to be
employed to study the distribution of the peptide and its mRNA.
Using polyclonal antibodies several investigators have found a widespread but
selective distribution within the CNS (Swanson et al., 1983; Merchenthaler, 1984).
The largest population of CRF-immunoreactive cell bodies has been located in the
dorsal aspect of the medial parvocellular region of the hypothalamic paraventricular
nucleus. Their major projection is to the external zone of the median eminence which
contains the primary capillary plexus of the hypothalamic-hypophysial portal blood
system. (Antoni et al., 1983; Liposits et al., 1983). Other hypothalamic nuclei such
as the supraoptic, suprachiasmatic, preoptic and arcuate nuclei (Daikoku et al., 1984)
also stain positively for CRF peptide.
A high density of CRF neurones is localised throughout the cortex; limbic
system: amygdala and bed nucleus of the stria terminalis (BNST); and brainstem
nuclei associated with autonomic functioning, locus coeruleus (LC) and parabrachial
nucleus.
Several ascending CRF pathways have been reported. Within the dorsal vagal
complex the nucleus of the solitary tract contains CRF cell bodies which project to
the parabrachial nucleus (Herbert & Saper. 1990) and is proposed to be the main
pathway for relaying somatosensory visceral information to the forebrain. The
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parabrachial nucleus also contains CRF perikarya, whose terminal axonal field lies in
the preoptic nucleus of the hypothalamus (Lind & Swanson, 1984). Following the
isolation and cloning of the CRF gene the localisation of central sites of CRF
synthesis were determined using both in situ hybridisation histochemistry and
Northern blot analysis and in general the locations of CRF mRNA expression
paralleled those of the immunohistochemical studies (Imaki et al., 1989; Thompson
et al., 1987).
1.3.3 Corticotropin-releasing factor receptor
Several detailed autoradiographic studies have described the distribution of the
CRF receptors in the pituitary and the CNS (De Souza et al., 1984; Wynn et al.,
1984).
Autoradiographs of rodent pituitary (Aguilera et al. 1987) show specific
binding sites for [125I]-oCRF in the anterior and intermediate lobes with no specific
binding evident in the posterior pituitary. Within the anterior pituitary the clustering
of the binding sites corresponds to the distribution of corticotrophs with a more
uniform distribution of binding occurring in the intermediate lobe of the pituitary,
characteristic of the homogenous population of POMC-derived peptide producing
cells in this lobe.
Receptor autoradiography in the brains of rodents and primates (De Souza et
al., 1985a; Millan et al., 1986a) demonstrated the highest concentration of CRF-
binding sites in brain regions involved in cognitive function, including the cerebral
cortex, limbic areas involved in emotion and stress responses, including the
amygdala, septum and hippocampus, and regions of the brainstem involved in the
regulation of autonomic function, including the LC and NTS. The cerebellum, spinal
cord and the olfactory bulb also displayed a high density of binding sites. The
densities and localisation of CRF-binding sites correspond well with the distribution
of CRF-immunoreactive fibres.
De Souza (1987) described in detail the binding characteristics of CRF to
membrane homogenates from rat anterior pituitary and brain regions. He
demonstrated that the binding was time-, temperature- and tissue concentration-
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dependent, saturable and reversible. Scatchard analysis revealed a high-affinity
binding (Kd = 0.2 nM) and a low affinity (Kd = 20 nM) form, thus fulfilling the
criteria of a bona fide receptor.
The CRF receptor is positively coupled to the adenylate cyclase second
messenger system via a guanine nucleotide-binding protein, resulting in an increase
in intracellular cAMP levels in rat anterior pituitary corticotrophs in vitro (Aguilera
et al., 1983). Further evidence that CRF receptors are linked to a guanine nucleotide-
binding protein was demonstrated by Grigoriadis & De Souza (1989) and Webster &
De Souza (1988) when they found that the specific binding of [125I]-CRF to rat
pituitary , brain and spleen homogenates was increased in the presence of divalent
ions such as Mg2+, whereas the addition of increasing concentrations of guanosine-5'
triphosphate (GTP) inhibited the binding. In vitro studies indicate that Mg2+ helps to
stabilise the high affinity form of the receptor-effector complex, while GTP promotes
the dissociation of the receptor protein from the guanine nucleotide-binding protein.
Initial studies into the biochemical characteristics of the CRF receptor revealed
that the molecular mass of the pituitary and the brain receptor differed in a number of
species i.e. rodents, pig and human, (Grigoriadis & De Souza, 1988). In the anterior
pituitary and intermediate lobe the apparent molecular mass was 75 kDa, while in the
rat brain the CRF-binding activity resided in a protein with an apparent molecular
mass of 58 kDa (Grigoriadis & De Souza, 1989). This receptor heterogeneity
between the brain and the anterior pituitary was subsequently discovered to be the
result of differential posttranslational glycosylation of the native protein, since
deglycosylation generates polypeptide with comparable molecular weights, 40 to 45
kDa.
Recently a cDNA encoding the pituitary CRF receptor was cloned from a
human Cushing's adenoma (Chen et al., 1993b), designated CRFR^- Subsequently, a











CNS - lateral septum,
ventromedial hypothalamic










» Urotensin > CRF41
Urocortin » Sauvagine
» Urotensin > CRF41
Table 1.1: The distribution and pharmacological profiles of the CRF receptor
subtypes: CRFRj; CRFR2a; and CRFR2p in the adult rat..
8
identity at the amino acid level. An in situ hybridisation study using a riboprobe
generated from the rat CRFR, cDNA demonstrated that CRF receptor mRNA
expression was present in several regions of the adult rat brain (Wong et al., 1994). It
is a member of a distinct family of seven transmembrane domain receptors (Chang et
al., 1993), which include calcitonin, vasoactive intestinal peptide and parathyroid
hormone receptors (Serve & Goldring, 1993).
De Souza and colleagues recently cloned and characterised a novel CRF
receptor, designated CRF-R2, from a rat hypothalamus cDNA library (Lovenberg et
al., 1995b). This receptor was demonstrated to exist as two splice variants, termed
CRF-R2a and CRF-R2p which differ in their amino-terminal sequence. Using RNase
protection assay and in situ hybridisation techniques the expression of the mRNA for
CRF-R2a was demonstrated to be almost exclusively in the brain, particularly in the
hypothalamus, lateral septum and olfactory bulb, whereas the mRNA for CRF-R2p
was present in both the brain, where it is thought to be associated with blood vessels,
and in peripheral tissues, such as the heart and skeletal muscle (Lovenberg et al.,
1995a). In the mouse only the homologue of CRF2p has been cloned and is expressed
almost exclusively in the heart and skeletal muscle (Kishimoto et al., 1995; Perrin et
al., 1995). The genomic structure and corresponding cDNA sequence of the human
CRF2a receptor were cloned and characterised (Liaw et al., 1996) from human
genomic cDNA libraries. Its pharmacological profile was comparable to that of the
rat CRF2a receptor. However, the genomic and cDNA sequences encoding a human
homologue of the rat CRF2p remain to be elucidated.
In addition to the CRF receptor subtypes differing in their anatomical
distribution, they also exhibit unique pharmacological profiles. CRF is more potent at
stimulating cAMP production in isolated anterior pituitary cells via CRFRj than
either sauvagine which was isolated from the skin of the South American frog
Phyllomedusa sauvagei (Montecucchi et al., 1980) and possesses more than 50%
homology with oCRF, or urotensin I, isolated from the urohypophysis of two species
of fish, Catostomus cyprimus and Catostomus catostomus. (Lederis et al., 1982).
However, both sauvagine and urotensin are more potent than CRF at CRFR2a and
CRFRzp. This led to the hypothesis that in mammals another CRF-like compound
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may be the natural ligand for these receptors. This was confirmed by the recent
isolation from the rat brain of a peptide called urocortin, which possesses homology
with sauvagine and urotensin and has a high affinity for both CRFR2a and CRFR2p
but not CRFR, (Vaughan et al., 1995). Recently the human urocortin has been cloned
and characterised (Donaldson et al., 1996).
1.3.4 Regulation of CRF receptors
The interaction between CRF and its specific receptor is a crucial event in the
activation of the HPA axis since it initiates the synthesis and release of ACTH and
other POMC gene products. Therefore, several in vivo and in vitro studies have
looked at the regulation of the pituitary CRF receptor, which has been identified by
in situ hybridisation studies to be the CRFR, subtype (Potter et al., 1994).
It is well known that chronic exposure of a tissue to the actions of its trophic
hormone can result in a reduced sensitivity of the organ to the same hormone. This
agonist-induced desensitisation has been demonstrated in several endocrine systems
and represents an adaptive response to prolonged hormone exposure (Catt et al;
1979).
Studies using radioreceptor binding techniques, functional assays and
hybridisation techniques have demonstrated that CRF possesses the ability to
regulate its own receptors in both the pituitary and brain. Pre-treatment of rat primary
anterior pituitary cell cultures with CRF (10"7 M) in vitro causes a rapid reduction in
its ability to subsequently stimulate cAMP synthesis and ACTH release (Reisine &
Hoffman, 1983). Another study found that there was a 36% decrease in CRF-binding
sites when dissociated fetal brain cell cultures were exposed to oCRF (10"6 M) for
three days. In vivo, high levels of CRF administered by the intracisternal (i.c) or
intracerebroventricular (i.c.v) route significantly reduced the number of CRF
receptors measured by a competitive binding assay. Using northern blot and RNase
protection analyses, CRF in vitro, dose- and time- dependently decreased CRFR,
mRNA levels in cultured rat anterior pituitary cells (Sakai et al., 1996; Pozzoli et al.,
1996). In the same study, the cells were treated with increasing doses of AVP. This
caused a similar reduction in CRF receptor expression although the decrease was
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longer lasting. Since CRF and AVP are coreleased into the hypophyseal portal blood
and the latter potentiates the ACTH-releasing activity of the former, some
investigators have looked at the effect of AVP on CRFR,. Aguilera's group
demonstrated in vivo that the loss of CRF pituitary receptors observed after
exogenous CRF administration was enhanced by a simultaneous infusion of AVP
(Tizabi & Aguilera, 1992), however only at doses that elevated plasma AVP to levels
in the range of those in the hypophysial portal circulation (Hauger & Aguilera, 1993).
The same group also demonstrated that the potentiated downregulation by AVP
occurred after repeated stress and not after 60 day water-restriction indicating that
chronic endogenous activation of the parvocellular but not the magnocellular
vasopressinergic system is responsible for this enhancement (Hauger & Aguilera,
1993).
Adrenalectomy (adx) caused a decrease in CRF! receptor binding (Wynn et al.,
1984; Hauger et al., 1987) and mRNA expression in the anterior pituitary (Sakai et
al., 1996; Makino et al., 1995a), presumably caused by the increased release of CRF
and AVP into the portal circulation following adx (Holmes et al., 1986b). The adx-
induced changes in CRF receptors can be completely reversed by glucocorticoid
replacement with dexamethasone (De Souza et al., 1985b). However, numerous
studies have investigated the effect of glucocorticoid treatment on CRF receptors
expression in intact animals and found an opposite effect to that in adrenalectomised
animals. Chronic administration of low doses of corticosterone (Hauger et al. 1987)
or high doses of the synthetic glucocorticoid, dexamethasone (Wynn et al., 1985) in
intact rats causes a dose-dependent decrease in the binding of [125I]oCRF to the
anterior pituitary. This led to the proposal that since low doses of naturally occurring
glucocorticoids downregulate anterior pituitary CRF receptors this may be of
physiological importance in the inhibitory action of glucocorticoids on ACTH release
and may reflect a general inhibitory effect of glucocorticoids on the corticotropin
Thus, as well as causing a rapid decrease in POMC gene transcription (Eberwine &
Roberts, 1984) glucocorticoids may also decrease the synthesis of intrinsic proteins
such as the CRF receptors. This was subsequently confirmed by Pozzoli et al (1996),
who demonstrated that treatment of cultured anterior pituitary cells with either
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dexamethasone or corticosterone time- and dose-dependently decreased receptor
mRNA expression. Similarly, in vivo Makino et al (1995a) found that following
chronic administration of corticosterone the CRHR, receptor mRNA expression was
reduced in the anterior pituitary. However, a receptor binding study by Hauger et al
(1987) found that although chronic corticosterone administration downregulated CRF
receptor binding in the anterior pituitary it did not affect receptor expression in brain
regions including, the cortex, amygdala and hippocampus. This result led to the
hypothesis that central CRF receptors are differentially regulated by corticosterone.
However, recently Makino et al (1995a) demonstrated that administration of
exogenous corticosterone via either daily injections or from slow-releasing sc pellets
resulted in a decrease in CRFR, mRNA in the PVN and lateral and basolateral
amygdaloid nuclei but not in the central nucleus of the amygdala or BNST. This
difference between studies may reflect the use of sensitive hybridisation techniques
in the latter study allowing the detection of small changes in mRNA levels which
may or may not be translated to the protein level.
Both acute and chronic stress cause a downregulation in CRF receptor mRNA
in the anterior pituitary (Luo et al., 1994) while upregulating receptor expression
exclusively in the PVN (Makino et al., 1995a). In addition, i.c.v infusion of CRF
results in an upregulation of CRFR, subtype specific to the PVN (Mansi et al., 1996),
providing evidence for a positive feedback effect of CRF on its own receptor in the
PVN (Silverman et al., 1989). However, other studies using whole hypothalamic
organ culture showed that activation of CRF receptors reduces the release of CRF
(Calogero et al., 1988). Therefore, the former observation may be due to CRF
diffusing away from the injection site and acting on other hypothalamic or
extrahypothalamic sites that send projections to the PVN.
Several mechanisms have been proposed for the CRF receptor'downregulation.
These include internalisation of the cell surface receptors (Catt et al., 1979). This is
supported by the observation that labelled CRF is internalised into corticotrophs
(Leroux & Pelletier, 1984). Interestingly, it has been hypothesised that the
potentiation of the CRF-induced downregulation by AVP may be mediated via
activation of the PKC pathway causing phosphorylation of the receptor and
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promoting internalisation (Holmes et al., 1987). Alternatively, diminished receptor
binding capacity due to uncoupling of the receptor from the adenylate cyclase has
also been postulated (Reisine & Hoffman, 1979). However, numerous studies
examining the modulation of CRF receptor gene expression by various agents
including CRF, AVP and glucocorticoids indicate that at least one of the important
mechanism of downregulation is reduced receptor mRNA expression (Makino et al.,
1995a; Pozzoli et al., 1996). Interestingly, a recent study demonstrated that the
cAMP and PKC pathways are involved in the modulation of the CRFR! mRNA
levels in the anterior pituitary possibly acting at both the transcriptional and
posttranscriptional level (Pozzoli et al., 1996).
1.3.5 Corticotropin-releasing hormone binding protein
The presence of a CRF binding protein (CRFBP) in the plasma of pregnant
women was confirmed by chromatographic studies by Linton et al (1988) where it
acts to bind plasma CRF, which circulates at high concentrations particularly during
the third trimester of pregnancy (Goland et al., 1986; Sasaki et al., 1984), and
reversibly neutralises its biological activity. It is a glycoprotein produced by the liver
(Suda et al., 1989a) and has a molecular mass of approximately 40 kDa (Linton et
al., 1988). Although it is also present, but at much lower levels, in the plasma of
nonpregnant females and males it appears to be absent from the plasma of rats and
sheep (Linton & Lowry, 1986; Linton et al., 1988). However, both rat and human
cDNAs encoding the CRFBP have been isolated (Potter et al., 1991). Potter et al
(1992) carried out an extensive immunohistochemical and hybridisation study
examining the central distribution of the CRFBP and found the highest expression
occurred in the cerebral cortex with lower levels in certain subcortical limbic
structures including, the amygdaloid complex and the BNST,' sensory relays
associated with the auditory, olfactory, vestibular and trigeminal systems and several
raphe nuclei in the brainstem. Dual immunostaining studies revealed limited
colocalisation of CRF and CRFBP. Interestingly, in several cell groups of the
forebrain CRFBP-immunoreactive terminal fields were in close association with
several CRF-immunoreactive cell bodies indicating that at select central loci CRFBP
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may be released from terminals to act to modify local synaptic, autocrine or paracrine
actions of CRF. However, in the PVN only a few scattered cells expressed CRFBP-
immunoreactivity or mRNA. This suggests that at the level of the PVN the CRFBP
does not influence the activity of CRT. In contrast, CRFBP is highly expressed in the
anterior pituitary corticotrophs, suggesting that at this site the binding protein, via an
undefined mechanism, may modulate the actions of CRF on ACTH release.
1.3.6 Arginine Vasopressin
Arginine vasopressin (AVP) is a nonapeptide hormone which was isolated and
characterised more than 40 years ago (Du Vigneaud et ah, 1953). Its classic role is in
fluid and electrolyte balance, therefore changes in plasma osmolality, blood pressure
or blood volume are the main stimuli for AVP secretion into the peripheral
circulation (for review see Robertson, 1992). It is synthesised as a larger prohormone
in magnocellular neurones in the posterior region of the PVN and in the supraoptic
nucleus (SON) of the hypothalamus (Brownstein et ah, 1980). It is carried by axonal
transport via the internal layer of the median eminence to nerve terminals in the
posterior pituitary, where it is stored for later release into the peripheral circulation.
The vasopressin gene is approximately 2kb in size and consists of three exons
and two introns, encoding a signal peptide, vasopressin, neurophysin II and a
carboxy-terminal glycopeptide (Schmale et ah, 1983). Following transcription,
splicing and translation the prehormone, preprovasopressin, is cleaved by signal
peptidases, making provasopressin, which contains vasopressin, neurophysin II and
the carboxy-terminal glycopeptide. The prohormone is processed into neurosecretory
granules through the Golgi apparatus, during which it undergoes postranslational
modifications such as processing, amidation and glycosylation to yield the mature
peptide secretory products (Richter, 1988).
In addition to its presence in magnocellular neurones, AVP is present in the
parvocellular neurones of the medial region of the PVN which project to the external
lamina of the median eminence (ME). At the ME AVP is stored and released into the
HPB system, where it regulates ACTH secretion from the anterior pituitary (for
review see Antoni, 1986). Many laboratories have reported that following adx in rats,
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between 70% and 90% of parvocellular CRF immunoreactive neurones exhibit
immunoreactivity for vasopressin (Kiss et al., 1984b; Sawchenko et al., 1984a) and
contain the mRNA for the vasopressin prohormone (Wolfson et al., 1985). At the
level of the median eminence 95% of CRF-containing axons and nerve terminals
contain AVP following adx (Whitnall et al., 1987b).
In intact rats, early studies indicated that AVP was expressed in less than 2% of
the parvocellular cell bodies in the PVN (Kiss et al., 1984b; Sawchenko et al.,
1984a). However, a more recent study using antibodies against AVP precursor-
derived peptides (pro-AVP peptides) demonstrated that more than half of the
parvocellular CRF-containing cell bodies stained positively for pro-AVP peptides. In
addition the AVP-containing and AVP-deficient CRF neurones were distributed
differently within the parvocellular PVN, with the former concentrated in the dorsal
medial region (Whitnall & Gainer, 1988). Previous studies by the same investigators
found a similar result in the ME where approximately half of the CRF-containing
parvocellular axons and nerve terminals of the median eminence contained AVP
precursor-derived peptides packaged in the same neurosecretory granule as CRF
(Whitnall et al., 1985). Therefore, the parvocellular CRF neurones can be divided
into two major subpopulations, based on the expression of pro-AVP peptides and a
differential distribution with the PVN.
Early work indicated that AVP and the yet undiscovered hypothalamic CRF
synergised to stimulate ACTH secretion from the anterior pituitary (Gillies & Lowry,
1979; Yates et al., 1971). Following the isolation of CRF several laboratories
confirmed the potentiating effect of AVP on CRF-induced ACTH release in vitro
(Beny & Baertschi, 1982; Gillies et al., 1982; Guguere & Labrie, 1982) and in vivo,
in rats pretreated with chlorpromazine, pentobarbital and morphine, which strongly
inhibits endogenous CRF secretion but preserves the anterior pituitary
responsiveness to exogenous substances (Arimura et al., 1967).
As in the case of other peptide hormones, AVP exerts its regulatory effects
through interactions with specific plasma membrane receptors of which there are two
main receptor types, V, (VR,) and V2 (VR2) (Jard et al., 1987). The VR2 are localised
on the renal tubular epithelial cells (Jard, 1988) where they mediate the antidiuretic
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effect and are coupled to adenylate cyclase. The VR, can be subdivided: VRla, the
classical pressor receptors are located on vascular smooth muscle cells and are
responsible for the vasopressor effects of AVP and on hepatocytes (Jard et al., 1987;
Michell et al., 1979). They mediate increases in the cytosolic Ca2+ concentrations via
activation of the phosphoinositide pathway (Jard, 1988). VRlb which are expressed
primarily on the anterior pituitary (Antoni, 1984; Baertschi & Friedli, 1985) can be
distinguished from the VRla subtype by different ligand specificities (Antoni, 1984;
Jard et al., 1986 ). The VRlb is coupled to the calcium-calmodulin-kinase C pathway
of signal transduction. This is supported by data showing that AVP enhances the
breakdown of inositol phosphates in primary pituitary cell cultures (Raymond et al.,
1985) and a study using individual cells reported increased cytosolic free calcium
and ACTH release following challenges with AVP (Leong, 1988).
One mechanism for the potentiation of the ACTH releasing actions of CRF by
AVP may involve enhancing CRF-induced cAMP formation (Guguere & Labrie,
1982) by possibly inhibiting cyclic nucleotide phosphodiesterases. AVP does not
appear to influence either the activation of adenylate cyclase by CRF (Gaillard et al.,
1984) or its binding to CRF receptors (Holmes et al., 1984).
The response of the parvocellular neurones expressing AVP mRNA to acute
stress appears to vary from no response or a small increase (Darlington et al., 1992;
Harbuz et al., 1994; Lightman & Young, 1988; Makino et al., 1995b) to a more
significant increase (Bartanusz et al., 1994; Herman, 1995), indicating that this may
reflect differences in the stress paradigm used. Other studies measuring changes in
AVP primary transcripts or heteronuclear RNA (hnRNA) in the parvocellular PVN in
response to stress consistently found an increase (Herman & Sherman, 1993; Ma et
al., 1997)
This stress-specificity is also seen in the release of AVP and CRF into the
hypophysial portal blood. Romero et al (1993) found that in colchicine-treated rats
insulin-induced hypoglycaemia but neither novelty nor restraint stress caused the
release of AVP into the hypophysial portal blood. These stress-specific results are
proposed to reflect the different populations of AVP-containing neurones in the
parvocellular PVN and the fact that they are likely to be regulated by different inputs.
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The role of AVP from magnocellular neurones in the regulation of ACTH
release is controversial. In a stress paradigm such as haemorrhage or water
deprivation, there are increased circulating AVP levels (Aguilera et al., 1993;
Robertson et al., 1992) which may gain access to VRlb on pituitary corticotrophs
(Donhanics et al. 1991). However, the majority of previous studies suggest that the
concentration of AVP in HPB is not altered following the removal of the posterior
pituitary (Gibbs, 1985; Horn et al., 1985). Hence, it was inferred that AVP released
by magnocellular neurones, which have axon terminals in the posterior pituitary,
does not reach the anterior pituitary in significant amounts. However, an in vitro
study (Holmes et al, 1986a) indicated that preterminal magnocellular axons in
passage through the ME may secrete AVP and in vivo PVN lesions did not
significantly decrease the amount of AVP released into the HPB (Antoni et al.,
1990). In addition, exocytosis of neurosecretory granules along vasopressinergic
axons in the internal lamina of the ME has been reported using the tannic acid
fixation method (Buma & Niewenhuys, 1988). Although the latter result may reflect
sprouting of SON axons within the ME.
AVP expression in the parvocellular PVN is negatively regulated by
glucocorticoids (Davis et al., 1986, Sawchenko, 1987a). A recent report using AVP
luciferase reporter gene constructs transfected into the human choriocarcinoma cell
line JEG-3 showed that dexamethasone suppressed gene activation but independently
of the putative glucocorticoid response element (GRE) on the AVP promoter region
(Iwasaki et al., 1997).
1.3.7 Oxytocin
Oxytocin (OT) is also a nonapeptide hormone differing from the primary
structure of AVP by two amino acid residues (a substitution of an isoleucine for a
phenylalanine and a leucine for an arginine). The elucidated nucleotide sequence of
the rat OT gene (Ivell & Richter, 1984) shows considerable homology both in
organisation and sequence with the AVP gene. Like AVP, OT is synthesised as an
inactive prohormone in the magnocellular neurones of the PVN, SON and
suprachiasmatic nucleus (SCN) of the hypothalamus, axonally transported via the
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internal lamina of the ME to the nerve terminals in the posterior pituitary where it is
released upon appropriate stimulation into the peripheral circulation.
Only one study demonstrated the presence of oxytocinergic nerve terminals in
the external lamina of the ME (Vandesande et al., 1977) using an affinity purified
antibody. They also reported that following lesioning of the PVN the OT-reactive
nerve terminals in the external lamina of the ME disappeared. The cell bodies giving
rise to these fibres could not be identified: magnocellular cell groups do not appear to
project to the external lamina of the ME, and the parvocellular oxytocin neurones in
the PVN appear to project to the spinal cord (Sawchenko & Swanson, 1985).
Therefore, the only well-defined oxytocinergic cell groups that send axons to the ME
are the magnocellular neurones of the PVN and SON.
In addition to its well-established role in parturition and lactation (Jenkins &
Nussey, 1991), OT appears be involved in the regulation of stress-induced ACTH
secretion from the anterior pituitary (Gibbs, 1986; Lang et al., 1983). In the rat, OT
can amplify the ACTH response to CRF, both in vitro (Antoni et al., 1983a; Gibbs et
al., 1984a) and in vivo (Rivier & Vale, 1985). High affinity receptors for OT, which
are clearly distinct from the VRlb, have been identified on rat anterior pituitary tissue
(Antoni, 1986b) and appear to be coupled to mechanisms increasing free cytosolic
Ca2+ concentrations by releasing it from intracellular stores which requires activation
of phospolipase C and production of inositol 1,4,5-triphosphate (Berridge & Irvine,
1989). Several studies have shown that OT is released from the ME into the portal
blood system (Antoni et al., 1990; Tannahill et al., 1991). In addition, the
concentration of OT in the HPB is significantly higher than in the periphery (Gibbs,
1984b) as is the case with both CRF (Gibbs & Vale, 1982) and AVP (Koeing et al.,
1986). In a study in PVN-lesioned rats the release of OT into the HPB was reduced
by 40% suggesting that a substantial amount of OT in the portal blood, as with AVP,
is likely to be derived from preterminal release from magnocellular neurones (Antoni
et al., 1990). All this evidence reinforces the notion that OT functions as a
hypophysiotropic hormone.
The release of OT from the posterior pituitary also appears to be an important
component of the stress response. Rats exposed to acute stresses, including
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immobilisation, ether, novel environmental, insulin-induced hypoglycaemia and
swim stress as well as osmotic stressors, including intraperitoneal injection (i.p) of
hypertonic saline all exhibit increased OT release into the circulation (Gibbs, 1984c;
Lang et al., 1983; Onaka & Yagi, 1993). A recent study examined the relative
importance of the SON and PVN for OT release during stress (Jezova et al., 1993).
The plasma OT concentrations in rats with either incomplete anterolateral cuts (ALC)
(leaving the fibres from the SON, but not the PVN, intact) or complete ALC cuts did
not increase following 30 min of immobilisation stress. This indicates that at least in
relation to immobilisation stress, the PVN is essential for stress-induced OT secretion
and without the PVN the SON cannot preserve OT secretion during stress.
Interestingly, CRF has been well documented as having a stimulatory action on OT
release (Bruhn et al., 1986) thus, during stress CRF may excite the OT-containing
cells. However a report by Higuchi et al (1990) found that following CRF
immunoneutralisation there was only a small reduction in OT release during
immobilisation at 60-120 min after the onset of the stress, while the initial high levels
of OT remained unchanged. This indicates that CRF may not have a prominent role
in the stimulation of OT from the posterior pituitary during stress.
1.4 Pituitary Gland
The pituitary gland is a compound endocrine gland located in a depression in
the floor of the cranial cavity and connected to the hypothalamus by a short stalk
called the infundibulum. It can be divided into a glandular portion, the
adenohypophysis, and a neural portion, the neurohypophysis. The adenohyphysis can
be further subdivided into a pars distalis, which comprises the bulk of the
adenohypophysis, a pars tuberalis and a pars intermedia. The neurohypophysis is
divided into a pars nervosa and the infundibulum. The pars distalis and pars tuberalis
are considered to form the anterior pituitary and the pars nervosa and pars intermedia
the posterior pituitary gland.
Its blood supply is derived from the internal carotid artery. The posterior gland
is supplied directly by branches of the two inferior hypophysial arteries. The
branches of the superior hypophysial arteries supply the hypothalamus and the
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infundibular stalk forming a capillaries plexus at this site. A system of veins arising
from this plexus delivers blood to the anterior pituitary and is termed the hypophysial
portal blood (HPB) system. It is via this HPB system that humoral substances, such
as CRF and AVP from the hypothalamus are delivered to the anterior pituitary.
1.4.1 Anterior pituitary
The anterior pituitary secretes several trophic hormones, including growth
hormone (GH), thyroid stimulating hormone (TSH), prolactin, follicle-stimulating
hormone (FSH), luteinising hormone (LH) and adrenocorticotrophin (ACTH). It is
composed of different cell types, reflecting the diversity of its functions. Prior to the
discovery of the influence of the hypothalamus the anterior pituitary was seen as the
'master gland' coordinating numerous bodily functions, including growth,
reproduction and metabolism. Corticotrophs are the cell type which secretes ACTH;
however, they only account for approximately 5% of the cell population (Morrill et
al., 1993). ACTH is a 39 amino acid peptide which stimulates the synthesis and
release of glucocorticoids from the adrenal cortex. It mediates it actions through G-
protein coupled receptors resulting in the accumulation of intracellular cAMP which
in turn increases the transcription of the P450 side-chain cleavage enzyme, the initial
and rate-limiting step of adrenal steroidogenesis (for review see Miller, 1988).
1.4.2 Posterior pituitary
The posterior pituitary is derived from neural cells in a region from which the
hypothalamus is also formed and consists of nerve fibres and terminals whose cell
bodies lie in the hypothalamus, particularly in the PVN and supraoptic nucleus
(SON) and modified astroglial cells, the pituicytes. Oxytocin (OT) and arginine
vasopressin (AVP) are the two hormones secreted by the posterior gland.
1.5 Proopiomelanocortin
Proopiomelanocortin (POMC) is the precursor for a variety of biologically
active neuroendocrine peptides. POMC mRNA is expressed in a variety of tissues,
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including the hypothalamus especially the arcuate nucleus, amygdala, cerebral cortex
(Civelli et al., 1982), adrenal medulla (Jingami et al., 1984), ovary and testes (Pinter
et al., 1984). However, its main site of expression is the pituitary gland in the
corticotrophs of the anterior pituitary and the melanotrophs of the intermediate lobe
(Civelli et al., 1982). The POMC molecule is posttranslationally processed to
different biologically active peptides in these two cells types: ACTH and P-
lipotropin, which is further processed to the opioid peptide P-endorphin (Lazarus et
al., 1976) being the major products of the corticotrophs; and a-melanocyte
stimulating hormone (a-MSH), corticotropin-like intermediate lobe peptide (CLIP)
and acetyl P-endorphin of the melanotrophs in rats (Eipper & Mains, 1980).
Genomic DNA fragments containing the POMC encoding sequences have been
isolated and sequenced from several mammalian species, including human
(Takahashi et al., 1983) and rat (Drouin et al., 1985). The POMC gene is composed
of three exons separated by two introns, with the third exon encoding all the
biologically active peptides.
The first in vivo studies used cell-free translation followed by
immunoprecipitation to indirectly quantify POMC mRNA levels in whole pituitaries.
Nakanishi et al (1977) were the first to show that adx, a procedure known to
stimulate ACTH release, caused a time-dependent increase in POMC levels which
could be reversed by glucocorticoid replacement. Subsequent studies using
hybridisation techniques demonstrated that the sensitivity of POMC mRNA levels to
glucocorticoids was displayed almost exclusively in the anterior pituitary (Birnberg
et al., 1983; Bruhn et al., 1984). Birnberg et al (1983) correlated the increase in
plasma ACTH with increases in anterior pituitary POMC mRNA in the several hours
to days following adx in the rat. They found that within eight hours of adx, plasma
ACTH levels had increased and then dropped as the ACTH content of the anterior
pituitary is depleted. This is followed by a gradual increase in the POMC mRNA
content of the anterior pituitary followed by an increase in the plasma ACTH,
reflecting the increase in synthesis and processing of the POMC peptides.
Administration of dexamethasone transiently increased the pituitary content of
POMC peptides most likely because it inhibits POMC peptide release, as seen in the
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fall in plasma ACTH levels, more rapidly than it inhibits POMC peptide synthesis.
Hence in this experiment, POMC mRNA correlated with secretion of POMC-derived
peptides in vivo.
In situ hybridisation studies have found similar observations of adx and
dexamethasone replacement on pituitary POMC mRNA expression. Fremeau et al
(1986) found that 14 days after adx the level of silver grains detected over the
corticotrophs was increased and that a short term dexamethasone treatment (100 mg,
i.p.) for 30 min to 120 min had no effect on reducing silver grain density over the
corticotrophs. Thus in agreement with the observation of Birnberg et al (1983)
glucocorticoids require several hours to elicit their inhibitory effect on POMC
mRNA levels.
Several in vivo studies have investigated the importance of the hypothalamic
PVN input in the regulation of POMC mRNA levels. Bruhn et al (1984) lesioned the
PVN, the major site of the CRF neurones projecting to the ME and showed a
decrease in the levels of POMC mRNA in the anterior pituitary. This indicates that
CRF and other hypothalamic factors may be responsible for the increase in POMC
mRNA expression following adx. A study by Dallman et al (1985) demonstrated that
in vivo the negative regulation of anterior pituitary POMC mRNA expression by
corticosterone occurs in a region at or above the level of the hypothalamus. They
found that following knife cuts that destroyed CRF and AVP input to the anterior
pituitary the POMC mRNA levels were decreased, but more importantly replacing
with increasing concentrations of corticosterone in these lesioned adx rats had no
significant effect on the level of anterior pituitary POMC mRNA.
Stress, a potent stimulator of the secretion of POMC-derived peptides in vivo,
has also been shown to stimulate POMC mRNA levels. Studies using either an
intermittent electrical footshock stress paradigm showed an approximate 2-fold
increase in POMC mRNA levels in the anterior pituitary after three days and this
remained elevated at seven days (Hollt et al., 1986), or three weeks of chronic
arthritis pain caused an 80% increase in anterior pituitary POMC mRNA levels
(Millan et al., 1986b).
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In general, studies into POMC gene expression using primary anterior pituitary
cell cultures or ATt20 cells (murine tumour cell line) have tried to identify the
mechanisms by which POMC gene expression is regulated at the cellular level.
The treatment of primary anterior pituitary cells or AtT20 cells with either
corticosterone or dexamethasone causes a decrease in the level of POMC mRNA.
Studies using AtT-20 cells found that dexamethasone was more potent than either
Cortisol or corticosterone in decreasing POMC expression and that its half-maximal
dosage was 3 nM (Roberts et al., 1979). Together these indicate that the
glucocorticoid effects are probably mediated through glucocorticoid receptors.
Similar effects were seen in primary cell cultures (Eberwine et al., 1987). Thus, it
appears that, at least in part, the effects of glucocorticoid treatment in vivo on anterior
pituitary POMC mRNA expression are mediated by direct effects on the
corticotropin However, the magnitude of the glucocorticoid effect in vitro is only half
that observed in vivo, suggesting that glucocorticoids are likely to be having effects
at other levels of the HPA axis, such as on hypothalamic CRF gene expression
(Jingami et al, 1985a).
CRF has been shown to have direct stimulatory effects on POMC gene
expression in both AtT-20 and anterior pituitary cells in dispersed cell culture. CRF
exposure for eight hours stimulated POMC mRNA levels approximately 3-fold in
AtT20 cells, an effect mimicked by the addition of 8-bromo-cAMP, a cAMP
analogue and phorbol esters, direct stimulators of protein kinase C (Affolter &
Reisine, 1985). The effect on POMC gene expression of CRF and other agents which
increase cAMP production, but not phorbol ester, could be blocked by fusion of
AtT20 cells with liposomes containing a cAMP-dependent protein kinase inhibitor
(Reisine et al., 1985). This, demonstrates that the increase in POMC mRNA by CRF
and cAMP analogues is due to activation of protein kinase A (cAMP-dependent
kinase). Studies in primary cultures show that both CRF and forskolin increase the
levels of POMC mRNA (Loeffler et al., 1985), again supporting a common role for
cAMP in regulating expression of the POMC gene. Meanwhile, activation of protein
kinase C is able to increase POMC mRNA independently of activation of protein
kinase A (Reisine et al., 1985).
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The release of POMC-derived peptides is calcium dependent so several groups
have explored the calcium dependence of factors which stimulate POMC gene
expression through cAMP-dependent processes. Loeffler et al (1986) found that
basal levels of POMC mRNA levels in primary cultures were inhibited by prolonged
incubation with the calcium channel antagonists D600, verapamil and nifedipine. In
addition, the latter partially blocked the stimulatory effect of forskolin. Dave et al
(1987) found that D600 did not effect basal POMC mRNA levels but significantly
attenuated the CRF-induced increase. However, the mechanism by which cAMP- and
Ca2+"dependent processes interact to increase POMC gene expression is not known.
Several studies have examined whether the changes in POMC mRNA levels
are due to increased mRNA synthesis i.e. increased rate of transcription or due to
decreased degradation of mRNA. An in situ hybridisation study using an intronic
POMC probe which allows the measurement of the nuclear primary transcript or
heteronuclear RNA (hnRNA), demonstrated that the adx-induced increase of POMC
mRNA levels in the anterior pituitary was the result of an increased transcription rate
in individual cells and in the number of cells detectably transcribing the POMC gene
(Fremeau et al., 1989). Several research groups have shown that glucocorticoids have
a rapid inhibitory effect upon anterior pituitary POMC gene transcription (Eberwine
& Roberts, 1984; Gagner & Drouin, 1985). The effects of dexamethasone are rapid,
with a significant decrease occuring within 15 min unlike its effects on mRNA levels
which require up to 48 h to maximally inhibit. However, corticosterone (500 pg i.p.)
took 45 min to 120 min to maximally inhibit transcription and did not produce as
large an inhibitory effect. The may reflect the presence of transcortin in the
corticotrophs which avidly binds corticosterone, preventing its actions, but does not
bind dexamethasone, thereby allowing the latter free access to GR while the in vivo
effects of corticosterone are likely to occur at the hypothalamus and therefore will
take longer to influence anterior pituitary POMC gene transcription. In addition,
dexamethasone has a 5-10 times higher affinity for GR than either Cortisol and
corticosterone.
A number of studies in primary anterior pituitary cell cultures have clearly
demonstrated that a physiological concentration of CRF rapidly stimulates POMC
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gene transcription at times well before the observed CRF-induced increase in POMC
mRNA levels (Gagner & Drouin, 1985; Eberwine et al., 1987).
While both glucocorticoids and CRF have direct effects on corticotrophs to
alter POMC gene transcription, the corticotroph in vivo is never exposed to only one
of these hormones, rather it is under the influence of a combination of both in the
intact animal. Gagner & Drouin (1985) measured POMC transcription in cultures
simultaneously exposed to both CRF and dexamethasone and found transcriptional
levels to be intermediate between control levels and those of CRF alone. Eberwine et
al (1987) went on to evaluate transcription of the POMC gene in primary cultures in
response to combinations of the two hormones under different orders of addition.
Dexamethasone pretreatment for varying periods of time inhibited subsequent CRF-
stimulated POMC gene transcription in a manner similar to the well established
inhibitory effects of glucocorticoids on subsequent CRF stimulation of POMC-
derived peptide release in vitro (Buckingham, 1979; Gillies & Lowry, 1978;
Widmaier & Dallman, 1984). Pretreatment of the cultures with dexamethasone for 10
min had little inhibitory effect on subsequent CRF-stimulated POMC gene
trancription, however, following 15 min of pretreatment the dexamethasone
inhibitory effect appeared. On the other hand, CRF pretreatment for 60 min
prevented the subsequent glucocorticoid inhibitory effect, while CRF pretreatment
for 10 min allowed dexamethasone to be fully inhibitory on POMC gene
transcription. Thus when POMC gene transcription is maximally activated,
glucocorticoids cannot inhibit transcription. The molecular mechanism underlying
this complex relationship is undefined; however, in vitro studies by Shipston &
Antoni (1992) demonstrated that CRF inhibited the synthesis of calmodulin, a
proposed effector of glucocorticoid feedback in AtT-20 cells, a murine corticotroph
tumour cell line.
The potentiation of CRF-induced ACTH secretion by AVP in vivo (Arimura et
al., 1967; Lui et al, 1983) and in vitro (Giguere & Labrie, 1982) is well established.
However, recent in vitro studies indicate that AVP does not potentiatate CRF-
induced accumulation of either cytoplasmic POMC mRNA (Suda et al., 1989b) or
hnRNA (Levin et al., 1989). More importantly, AVP by itself decreases POMC
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hnRNA levels in primary anterior pituitary cell cultures. Thus in vivo, this novel
inhibitory influence of AVP may allow a more refined regulation of POMC gene
expression than would be accomplished by CRF alone.
1.6 Adrenal gland
The adrenal gland is located on the superior pole of each kidney and is
composed of two distinct parts, a central medulla and an outer cortex which differ in
their origin, function and structure. Each gland is enclosed in a thick, connective
tissue capsule.
1.6.1 Adrenal cortex
The adrenal cortex is divided into three concentric layers: the zona
glomerulosa, a thin, outer layer adjacent to the capsule; the zona fasciculata, a thick,
middle layer; and the zona reticularis, a thin, inner layer adjacent to the medulla.
The parenchymal cells of the cortex secrete a variety of hormones collectively
referred to as corticosteroids. The cells of the zona glomerulosa secrete a class of
steroid hormones called mineralocorticoids. The most important one is aldosterone,
which functions in the maintenence of normal electrolyte balance. The cells of the
zona fasciculata, and to a lesser extent, those of the zona reticularis, secrete a class of
steroid hormones called glucocorticoids. Cortisol, in humans and non-human
primates, and corticosterone, in rats and mice, are the most important members of
this class and influence carbohydrate, fat and protein metabolism. Finally the cells of
the zona reticularis, and to a lesser extent those of the zona fasciculata, secrete small
amounts of sex steroids, primarily androgens. Quantitatively the most important
androgens secreted in humans are dehydroepiandrosterone sulphate,
dehydroepiandrosterone and androstenedione although in rats and mice thier
secretion is negligible.
1.6.2 Adrenal medulla
The chromaffin cells of the medulla secrete catecholamines, primarily
adrenaline (epinerphine) and smaller amounts of noradrenaline (norepinerphine).
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These substances produce effects similar to those induced by activation of the
sympathetic division of the autonomic nervous system, including increased heart
rate, respiration and blood pressure, reduced blood flow to viscera and skin,
stimulation of the conversion of glycogen to glucose and decreased digestion. Their
release into the peripheral blood circulation is initiated by preganglionic sympathetic
fibres innervating the chromaffin cells.
1.7 Glucocorticoids
The major glucocorticoid in man, non-human primates and sheep is Cortisol
and in rodents it is corticosterone. Studies with isolated, perfused adrenals
(Reichstein & Shoppee, 1943), analysis of urine from normal individuals (Conn et
al., 1951) or patients with Cushing's disease (Mason, 1950) and adrenal vein blood
(Nelson et al., 1951; Reich et al., 1950) demonstrated that Cortisol and corticosterone
were the primary secretory products of the adrenal cortex. They are 21-carbon
compounds synthesised from cholesterol and the hydroxy group at carbon-11 was
discovered to be required for therapeutic efficacy (Kendall, 1941; Olson et al., 1944).
Glucocorticoids are catabolic hormones which causes lipolysis, glycogenolysis
and protein catabolism, which directly and indirectly, via gluconeogenesis, increase
blood glucose levels (Munck, 1984). These actions assist the organism during stress
by, at least in part, increasing the availability of energy substrates at the expense of
existing energy stores and of anabolic processes. Glucocorticoids also suppress
immunological responses (Munck, 1984), decreasing inflammation when mobility
may be essential. However, prolonged exposue to elevated glucocorticoid levels can
present a serious risk, leading to a suppression of anabolic processes, muscle atrophy,
decreased sensitivity to insulin and a risk of steroid-induced diabetes, hypertension,
hyperlipidemia, hypercholesterolemia, arterial disease, amenorrhoea, infertility and
the impairment of growth and tissue repair as well as immunosuppression (Brindley
& Rolland, 1989; Munck, 1984). Thus, once the stress is terminated it is in the
organism's interest to 'turn-off the HPA axis stress response, thus the circulating
glucocorticoids feedback on the anterior pituitary and specific brain regions to inhibit
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the further release of CRF and ACTH as discussed above (Dallman et al., 1987;
Keller-Wood & Dallman., 1984; Plotsky et al., 1987b).
1.7.1 Corticosteroid Receptors
The majority of actions of glucocorticoids in the brain and periphery require
trancription and/or translation, and therefore can take from minutes to hours to
become manifest and are mediated by intracellular corticosteroid receptors. Two
types have been isolated, and cloned: the type I or mineralocorticoid (MR) receptor
(Arriza et al., 1987; Patel et al., 1990) and the type II or glucocorticoid (GR) receptor
(Hollenberg et al., 1985; Miesfeld et al., 1984). They are members of the
steroid/thyroid hormone receptor gene superfamily (Evans, 1988).
1.7.1.a Mode of action
In the absence of glucocorticoids, MR and GR are mainly cytoplasmic (Picard
et al., 1990; Robertson et al., 1993) and exist in a multimeric complex with a number
of accessory proteins (Hutchison et al., 1994) which are proposed to maintain the
receptors in a conformation that promotes ligand binding. Once steroid binding has
occurred, the 'activated' receptor dissociates from the accessory proteins and
migrates to the nucleus where it binds either as a homodimer (Glass, 1994) or as a
heterodimer (Trapp et al., 1994) to specific 'cis'-acting genomic DNA sequences, or
glucocorticoid response elements (GREs) to either induce or repress the rate of
transcription of target genes.
In the rat the DNA binding and ligand binding domains of both MR and GR
show more than 90% homology to the human receptors (Arriza et al., 1988; Miesfeld
et al., 1984; Patel et al., 1990). Thus, both MR and GR have been highly conserved
through evolution. Several studies have elucidated the primary structure of GR and
MR which are comprised of 777 and 984 amino acid residues, respectively (Evans,
1988). Detailed studies have examined the structure of the GR. The amino-terminal
or A/B domain is not conserved within the steroid/thyroid hormone receptor family
and is proposed to be involved in mediating transcriptional regulation of target genes
(Hollenberg et al., 1987). It also contains the recognition sites for antisera. The DNA
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binding or C domain, by contrast, is highly conserved (94% homology between GR
and MR). It posssesses two 'zinc finger' motifs, which attach to GREs (Glass, 1994;
Luisi et al., 1991). Other residues in this domain are involved in the transactivation
of target genes (Hollenberg et al., 1987). The conserved D domain comprises
approximately 42 residues and is proposed to be important for receptor translocation
to the nucleus. The E domain which represents the carboxy-terminal is involved in
binding the ligand. This region also binds accessory proteins, including HSP-90
(Chakraborti et al., 1991), is involved in dimerisation (Fawell et al., 1990) and has
transactivation and nuclear translocation activities (Godowski et al., 1988).
1.7.2 Corticosterone binding globulin (CBG)
Circulating CBG is present in most mammals, including man and the rat (Seal
& Doe., 1965) with the liver being the major site of synthesis in the adult (Hammond
et al., 1987; Smith & Hammond, 1989). Cloning and sequencing of the CBG cDNA
has revealed that it belongs to the serine protease inhibitor family (Hammond et al.,
1987). It is the major plasma protein binding corticosteroids and during the course of
the normal diurnal rhythm it has been estimated that approximately 90% of
corticosterone is bound to CBG in the circulation (Hammond, 1990; Siiteri et al.,
1982). Therefore, variations in plasma CBG levels will affect the free concentration
of glucocorticoids in the plasma and therefore influence the bioactive efficacy of the
glucocorticoid signal. In addition, anterior pituitary cells contain an intracellular
CBG, referred to as transcortin (de Kloet & McEwen, 1976; Koch et al., 1976) which
is proposed to be derived from plasma CBG. It exists in a membrane-bound form as
well as in the cytosol (Koch et al., 1978), where it functions much like plasma CBG
in that it sequesters free corticosterone and decreases binding to GR in the anterior
pituitary. Plasma levels of CBG are known to be influenced by several hormones,
including glucocorticoids, thyroxine and ovarian hormones (D'Agostino & Henning,
1982; Feldman et al., 1979). Adx increases while chronic corticosterone treatment
decreases plasma CBG levels (Feldman et al., 1979; Levin et al., 1987). More
recently it has been reported that acute stress can influences both plamsa and
intracellular levels causing a significant decrease 24 h after the end of the stress
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(Tannenbaum et al., 1997). Plasma CBG levels and hepatic mRNA levels in female
rats are higher than those found in male rats (Smith & Hammond, 1989) and estrogen
treatment enhances CBG levels in both man and the rat (Blomback et al., 1983; Gala
& Westphal, 1965). In support of a stimulatory influence of estrogen on CBG levels,
during pregnancy the levels increase (Seal & Doe, 1967). The influence of estrogen
is at least in part mediated via the sex-specific pattern of growth hormone secretion
(Jansson et al., 1989).
1.8 Feedback regulation of the HPA axis
Glucocorticoids, corticosterone in rodents and Cortisol in man, negatively
regulate both the basal and stress-induced activity of the HPA axis in a closed loop
manner. Under in vivo conditions at least three distinct time domains have been
identified in which glucocorticoids exert a negative feedback signal on stimulated
ACTH secretion: fast rate-sensitive; intermediate; and slow feedback (for review see
Keller-Wood & Dallman, 1984).
The existence of fast, rate sensitive feedback was first postulated by Dallman &
Yates (1969) and occurs within seconds to minutes of glucocorticoid exposure when
the plasma levels of the hormone are rising. However the effects only last as long as
the plasma levels are rising at a sufficient rate (Jones et al., 1972). Several in vitro
studies have demonstrated that glucocorticoids have rapid effects on both stimulated
CRF and ACTH secretion (Buckingham & Hodges, 1977; Vale & Rivier, 1977;
Vermes et al., 1977). While the early in vivo studies were based on administration of
exogenous glucocorticoid and measuring indirect indices of ACTH secretion
(Dallman & Yates, 1969; Kaneko & Hiroshige, 1978; Yates et al., 1972), a more
recent study demonstrated physiological evidence for the rate-sensitive fast feedback
inhibition of ACTH secretion (De Souza & Van Loon, 1989). They used a 2 min
restraint stress paradigm to elevate corticosterone levels and then applied a second
restraint during the period when the plasma corticosterone levels were significantly
rising. They found that although the maximum plasma ACTH concentrations were
not different, the rate of decline was significantly greater following the second
restraint. This can be interpreted as indicating that rate-sensitive feedback appears to
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act to terminate and limit the duration, but not the peak, of the ACTH response to
subsequent stress. Although the mechanism of inhibition is not known, the rapidity
of the effects indicate that protein synthesis is not involved. In support of this,
pretreatment of perifused pituitaries with cycloheximide, a protein synthesis
inhibitor, did not prevent rapid inhibition (Widmaier & Dallman, 1983). Thus, this
rapid steroid effect is not mediated by association with MR or GR, the classical
intracellular receptors. Accumulating evidence suggests that rapid corticosteroid
effects may be mediated through specific membrane receptors. Work by Orchinik
and colleagues using amphibian brain membrane preparations support the existence
of membrane receptors (Orchinik et al., 1991). They demonstrated using
radiolabelled ligand binding studies that [3H]corticosterone binding to neuronal
membranes was specific, saturable, reversible and of high affinity (0.14 nM). Further
support for the existence of a proteinaceous binding site was that specific binding
was eliminated by both heat denaturation and protease treatment. In addition it
displayed a distinct pharmacological profile differing from the intracellular corticoid
receptors. It was highly specific for corticosterone and Cortisol, but possessed a low
affinity for both dexamethasone and aldosterone. In vitro receptor autoradiographic
studies and subcellular fractionation studies indicated that the binding sites were
located in the region of the synaptic terminals and appear to be linked to a G protein
mediated second messenger system. The existence of corticosteroid membrane
receptors in the mammalian brain has been postulated. Chen et al. (1993a) and Towle
& Sze (1983) described low affinity corticosterone binding sites in the rat brain and
proposed that these membrane receptors may be involved in rapidly responding to
high levels of corticosterone that occur during stress. However, their existence still
remains controversial.
Dallman & Yates (1969) also hypothesised the existence of a delayed feedback
effect of corticosteroids on ACTH secretion which was dependent on the duration of
exposure to elevated levels of corticosteroids. One report found that in vitro
incubation of AtT-20 cells (a murine pituitary tumour cell line) with dexamethasone
for 5-25 h caused a significant decrease in ACTH release, however, following 2-3
days of dexamethasone exposure, both the amount of ACTH released and the ACTH
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cell content were significantly reduced (Watanabe et al., 1973). This led to the
hypothesis that the glucocorticoid delayed feedback exerts distinct effects over time.
Subsequently, delayed feedback was divided into intermediate and slow feedback
effects. Intermediate feedback requires corticosterone exposure for 2-10 h previously
and affects ACTH secretion but not synthesis. However, the mechanism of
intermediate feedback on ACTH secretion does require DNA-dependent RNA and
protein synthesis since the suppressive effects of the steroid are prevented in the
presence of either actinomycin D, a RNA polymerase inhibitor or cycloheximide
(Arimura et al., 1969; Philips & Tashjian, 1982). In addition, intermediate feedback
decreases CRF synthesis (Buckingham, 1979; Sato et al., 1975). Slow feedback by
corticosteroids results from constant corticosterone exposure for 12 h or longer and
inhibits both ACTH release and synthesis. In vivo, glucocorticoid injections reduces
the pituitary POMC mRNA levels in adx rats (Nakanishi et al.,\911) and in vitro,
dexamethasone, Cortisol and corticosterone specifically inhibit rnRNA coding for
POMC without altering the synthesis of other proteins (Roberts et al., 1979). See 1.5
Proopiomelanocortin.
Several experiments have studied the inhibition of basal ACTH release, and
suggest that this release is less sensitive to corticosteroid feedback; and that the
timecourse of steroid inhibition of basal secretion differs from the timecourse of
inhibition of stimulated secretion. Studies using incubated or perfused rat pituitaries
with concentrations of either dexamethasone or corticosterone which suppress the
ACTH response to exogenous CRF or hypothalamic-stalk median eminence extract
do not inhibit basal release (Buckingham & Hodges, 1977; Widmaier & Dallman,
1983). In studies designed to investigate the rapid inhibition of ACTH, no inhibition
was observed (Widmaier & Dallman, 1983). However, inhibition of basal ACTH
secretion does occur when monolayer cultures of pituitary cells are incubated with
corticosterone or dexamethasone for longer than four days (Fleischer & Rawls, 1970)
or with supraphysiological concentrations (Kraicer & Milligan, 1970). In vivo,
inhibition of basal ACTH secretion by glucocorticoids has also been demonstrated.
In normal human subjects Cortisol infusions inhibited basal ACTH secretion (Reader
et al., 1982). This difference between the in vitro and in vivo data suggests a
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difference in the mechanism of ACTH secretion. Basal ACTH secretion in vitro may
represent autonomous pituitary secretion while in vivo secretion may be being
stimulated by inputs from the brain.
Stress-induced ACTH release in vivo is inhibited by fast feedback within
seconds of the rise of plasma corticosteroids. It is then followed by a 'silent' period
during which no inhibition of adrenocortical responses to stress is observed, then 90
to 120 min after the rise in plasma corticosterone intermediate feedback is observed.
In rats, however, inhibition of basal pituitary-adrenal activity has been demonstrated
during the 'silent' period (Zimmerman & Critchlow, 1972). Inhibition of plasma
ACTH concentrations occurred 20 min after the onset of corticosteroid infusions and
continued over the next 90 min after the end of the 40 min infusion. In human
subjects plasma ACTH concentrations are reduced within 45 min after the onset of a
Cortisol infusion and the plasma ACTH concentrations remained suppressed as long
as the plasma Cortisol levels were high (Reader et al., 1982). Thus basal ACTH
secretion in normal animals is inhibited by corticosteroids but the temporal pattern of
inhibition is different from that of stimulus-induced secretion. The inhibition of basal
ACTH release in vivo is likely to represent of inhibition of the CRF neurone and/or
the afferent pathways mediating CRF stimulation under basal conditions.
1.9 Chronic Stress and Facilitation
The charateristics of the response of the HPA axis appears to depend on the
type of stress used. Several studies have demonstrated that exposure of rats to either
repeated (daily intermittent) or chronic (continuous) stress causes elevations in
plasma corticosterone levels, increased adrenal gland weight and changes in
peripheral corticosterone-sensitive tissues, such as decreased thymus gland weight
(Hauger & Aguilera, 1992; Hauger et al., 1988; Kiss & Aguilera, 1993). All these are
indicative of chronic activation of the HPA axis. However, regardless of this
chronically stressed animals appear to be fully responsive to new acutely applied
stress (Hauger & Aguilera, 1992; Hauger et al., 1988, 1990; Vernikos et al., 1982).
Studies into the sensitivity of the HPA axis to exogenous corticosterone have used
adx animals replaced with varying doses of corticosterone. It was found that chronic
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exposure to even the lowest dose of corticosterone decreased the amplitude of the
ACTH response to stress in the morning and prevented a response to a subsequent
stress (Akana et al., 1992). Similarly, to determine the role of CRF and vasopressin
in the enhanced pituitary responsiveness to a novel stress following chronic
activation of the HPA axis, Tziba & Aguilera (1992) gave CRF or CRF in
conjunction with AVP by subcutaneous infusion for 50 h, then exposed the rats to
acute ether or restraint stress. Unexpectedly, it was discovered that the animals
exposed to the chronic ACTH secretagogue treatment had a lower ACTH response
than control rats. Thus, it was hypothesised that chronic administration of exogenous
corticosterone or ACTH secretagogues inhibit further activity of the HPA axis but
endogenous secretion following stress does not, therefore stress itself must facilitate
subsequent responses of the system (Dallman, 1993).
Numerous studies have demonstrated that chronic stress increases (Kiss &
Aguilera, 1993; Makino et al., 1995b; Mamalaki et al., 1992) CRF mRNA
expression in the parvocellular PVN. However, other studies failed to find any
upregulation (Harbuz et al., 1992). This discrepancy between studies is likely to be a
consequence of using different stressors. Interestingly there is evidence suggesting
that during repeated or chronic stress there is a shift in the modulation of pituitary-
adrenal activity from CRF to AVP (Hashimoto et al., 1988; Scaccianoce et al.,
1991). Immunohistochemical studies have shown with chronic intermittent stress that
there is a progressive increase in the AVP content of nerve endings in the external
zone of the median eminence (De Goeij et al., 1991) and that the enhanced
immunoreactivity is due to an increase in the number of AVP-positive CRF nerve
terminals (Bartanuz et al., 1994, De Goeij et al., 1991; Whitnall, 1989). In a recent
study exposure to repeated immobilisation for 14 days resulted an increase in AVP
mRNA content greater than that seen for CRF mRNA (Makino et al., 1995b).
Several studies suggest that the release of CRF and AVP into the portal circulation
may be increased during chronic stress (Berkenbosch & Tilders, 1986; Whitnall,
1989). This is supported by the finding of Brown & Sawchenko (1997). It was shown
that CRF neurones displayed a sustained immediate early gene response to insulin-
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induced hypoglycaemia over 5 days of treatment, indicating chronic activation of
these specific neurones.
It has previously been shown that chronic immobilisation decreases the number
of CRFR, without affecting the Kd, in the anterior pituitary (Hauger et al., 1988,
1990), although not during exposure to cold stress (Hauger & Aguilera, 1992). This
may indicate enhanced release of CRF into portal blood or may represent an effect of
the higher circulating glucocorticoid levels seen in animals that are chronically
stressed. However, in vitro, anterior pituitaries have been shown to be more sensitive
to CRF from chronically stressed animals (Young & Akil, 1985). Thus there appears
to be a discrepancy between CRFR density and responsiveness of the pituitary
corticotrophs. This indicates that a post-receptor event may be responsible for the
change in pituitary responsiveness during chronic stress. A study to examine the
effect of chronic stress on components of the second messenger system linked to the
CRFR found that following 12 h of intermittent cold, swim stress the adenylate
cyclase (AC) activity and mRNA expression was significantly increased in the
chronically-stressed animals. This indicates that this enhanced AC activity may be
important in maintaining the responsiveness of the HPA axis during chronic stress
(Morrill et al., 1993).
The potentiating effects of AVP on CRF-stimulated ACTH release is well
known (Gillies & Lowry, 1979) and as mentioned above AVP expression appears to
increase substantially during a chronic stress paradigm (De Goeij et al., 1991). A
recent report examined the relationship between AVP receptor levels in the anterior
pituitary and AVP-stimulated ACTH release in vitro in rats subjected to chronic
stress paradigms. It was found that following 14 days of either repeated i.p.
hypertonic saline or immobilisation the binding of [3H]AVP to anterior pituitary
membrane-rich fractions was significantly increased and that AVP potentiated the
CRF-induced ACTH secretion more from acutely dispersed anterior pituitary cells
isolated from the chronically-stressed rats (Aguilera et al., 1994).
As previously mentioned the circulating levels of corticosterone are
substantially elevated in rats exposed to repeated or chronic stress. However, this
continuous elevation is not seen in basal ACTH levels. Kiss & Aguilera (1993) found
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that after 13 days of i.p. hypertonic saline injections, although the corticosterone
levels were high the plasma ACTH levels were not signifiantly elevated. Similarly,
Makino et al (1995b) found no elevation in ACTH following repeated
immobilisation stress. It was proposed that during repeated stress less ACTH is
required to transduce the centrally mediated call for glucocorticoid secretion from the
adrenals that have become hyperplastic and hyperresponsive to ACTH. This
phenomenon was demonstrated by Culman et al (1991) by giving systemic injections
of CRF to repeatedly stressed rats, and demonstrating that the corticosterone but not
the ACTH response was greater.
Alterations in glucocorticoid negative feedback have also been demonstrated to
occur during chronic stress and may account, at least in part, for the persistence of
the HPA axis resposiveness during chronic stress (Vernikos et al., 1982; Young et
al., 1990). A recent study reported a decrease in GR mRNA expression in both the
hippocampus and PVN in chronically stressed animals and proposed that this
reduction in GR mRNA levels possibly indicates a reduced negative feedback signal
and that this may be responsible for enhanced expression of AVP, since AVP mRNA
levels appear to be more sensitive to glucocorticoids than CRF mRNA, in chronically
stressed animals (Makino et al., 1995b). However, it was noted that this decrease in
GR mRNA levels may not necessarily reflect changes in receptor binding or function
since previous studies had shown dissociation between GR mRNA levels and
receptor binding (Bohn et al., 1994; Chao et al., 1989). Interestingly, previous
reports found no changes in hippocampal or PVN GR mRNA after seven days of
immobilisation stress (Mamakali et al., 1992) or a reduction in GR mRNA only in
CA1-2 or CA1 & CA3 in socially stressed rats (Chao et al., 1993). Again the
different duration or different type of stressor may account for these discrepancies.
Dallman and colleagues (Akana & Dallman, 1992) proposed that if stress
produces facilitation of subsequent stress-induced ACTH secretion that is normally
balanced by the corticosteroid signal secreted by the adrenals at the time of the initial
stress, then this would be revealed under conditions in which the adrenals cannot
secrete normal amounts of corticosterone. To obtain direct evidence that stress
facilitates subsequent stress responses they carried out a series of experiments using
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cyanoketone (CK), an inhibitor of 3f3-hydroxysteroid dehydrogenase . CK treatment
prevents the normal corticosterone response to an acute stress but maintains a
corticosterone circadian rhythm of normal amplitude. Basal and stress-induced
plasma ACTH and corticosterone were measured in rats stressed during the previous
12 h-period and in naive rats i.e not exposed to prior stress, at either the trough or
peak of the circadian rhythm. It was found that CK-treated rats previously stressed at
the peak of the circadian rhythm hypersecreted ACTH after a subsequent stress at the
trough and ones that had been previously stressed in the trough had elevated basal
peak ACTH levels, compared to either their naive controls or vehicle-treated rats.
These results provide direct evidence that prior stress induces facilitation of
subsequent activity in the HPA axis. They proposed that the site(s) of facilitation
occurs in parallel and with access to the CRF neurones because neither corticosterone
feedback nor facilitation induced by prior stress was observed on stress responses
provoked at the time of the peak basal, or on basal levels at the time of the trough.
One study indicating an influence of a neural input to the CRT neurones of the PVN
during chronic stress demonstrated that local administration of tetrodotoxin, which
blocks voltage-dependent Na2+ channels and thus nerve impulses, during chronic
footshock stress prevented the increase in CRF and AVP mRNA (Sawchenko et al.,
1993).
Catecholaminergic inputs to the PVN were initially proposed to be the site of
facilitation since during chronic stress the activity increased in several of the
catecholaminergic cells groups in the medulla and pons, including the NTS and LC
(Lachur et al., 1991) and using microdialysis noradrenaline activity in the PVN is
increased in repeatedly stressed rats (Pacak et al., 1992); chronic stress increases LC
tyrosine hydroxylase, the rate limiting enzyme which converts tyrosine to
dihydroxyphenylalanine, protein concentration and neuronal firing rate (Melia et al.,
1992). Interestingly, CRF fibres innervate the LC (Sawchenko 1987a) and during
chronic stress CRF content in the LC increases (Chappell et al., 1986). Repeated
infusions of CRF antagonist near the LC blocked the induction of TH induced by
repeated intermittent stress (Melia & Dunman, 1991). However, the LC only has a
moderate input to the CRF PVN neurones (Plotsky et al., 1989) and a study by
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Murakami et al (1997) using an inhibitor of dopaminep-hydroxylase, which prevents
the conversion of dopamine to noradrenaline, clearly demonstrated that
catecholamines did not play a major role in generating facilitation. Recently,
Bhatnagar et al (1995) measured fos mRNA expression in rats previously exposed to
chronic intermittent cold stress and found increased expression in several of the
subnuclei of the amygdaloid complex. Consistent with this observation is the
observation that CRF mRNA in the amygdala increases with increasing plasma
levels of corticosterone (Makino et al., 1994). Therefore, these results support the
notion that the amygdala complex may be a potential site for the phenomenon of
stress-induced facilitation.
1.10 The circadian rhythm of the HPA axis
Under normal conditions several mammals, including man and rodents, exhibit
a circadian or diumal rhythm in corticosterone, ACTH and CRF (Kwak et al., 1992).
The fluctuations in plasma glucocorticoids occur with the peak and nadir generally
coinciding with the initiation and the termination of the animal's active period,
respectively. Thus, in the rat, high levels of corticosterone are detected in the evening
as they awaken while the levels are at their lowest in the morning as they enter their
resting period.
Basal activity during the trough of the circadian rhythm is proposed to occur as
a result of constitutive secretory activity of the pituitary and adrenal gland without
hypothalamic input. On the other hand basal activity during the peak of the rhythm
requires input from the hypothalamus driven by the suprachiasmatic nucleus (SCN),
which appears to be the major pacemaker controlling the circadian HPA axis rhythm
(Szafarczyk et al., 1980). These propositions are supported by several findings.
Firstly, following lesions of the basal hypothalamus (Kaneko et al., 1980), the PVN
(Dallman et al., 1989b) or the SCN (Cascio et al., 1987), the morning ACTH levels
do not decrease, but the normal evening rise in ACTH and corticosterone is
prevented. Secondly, passive immunisation of rats with CRF antisera did not alter
trough ACTH and corticosterone levels but prevented the normal evening rise in both
(Bagdy et al., 1991). The circadian rhythm of ACTH and corticosterone follow each
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other closely. The circadian drive appears to become activated during the early
afternoon resulting in a rise in plasma ACTH which is closely followed by a
comparable rise in corticosterone. Peak ACTH levels are attained close to the start of
the active phase while corticosterone peaked about an hour or so into the dark phase
(Kwak et al., 1992). The SCN possesses both direct and indirect inputs to the PVN,
at least in part via vasopressinergic neurones (Watts et al., 1987) and bilateral lesions
of the SCN prevent the daily increasing phase of ACTH secretion (Szafarczyk et al.,
1979). In adddition, neuromorphological and pharmacological data indicate that
catecholaminergic projections from the brainstem appear to modulate the diurnal
HPA rhythm, possibly via the CRT neurones since lesions of the ventral
noradrenergic bundles prevent the normal daily rise in plasma ACTH levels
(Szafarczyk et al., 1985). Evidence also suggests that the mesencephalic
serotoninergic system innervating the SCN may have a stimulatory influence since
lesions prevented the normal ACTH rise (Szafarczyk et al., 1979) while GABAergic
interneurones may have an inhibitory influence on the circadian rhythm of the HPA
axis (Ixart et al., 1983).
A study by Kwak et al (1992) found that CRF mRNA expression in the PVN
exhibited a diumal rhythm. Increased CRF mRNA synthesis appears to occur in
advance of ACTH and corticosterone secretion and persisits despite the increase in
steroids in the afternoon. This increased trend in CRF mRNA during the light phase
is consistent with previous reports on bioactive CRF concentrations in the
hypothalamus and median eminence (Owens et al., 1990; Szafarczyk et al., 1980). In
addition, Hiroshige and Sakakura (1971) have found a close temporal relationship
between bioactive CRF activity in the median eminence and corticosterone in
plasma, with corticosterone immediately following changes in CRF concentrations.
Kwak et al (1992) also reported a sharp fall in CRF mRNA expression at the onset of
darkness, thus CRF expression was inversely related to plasma corticosterone at the
peak of the circadian rhythm. This may indicate that steroid inhibition decreases CRF
mRNA levels as the effects of steroid feedback overcome the circadian drive to the
CRF neurones. However, a subsequent study by Kwak et al (1993) found that adx
did not prevent the decrease in CRF mRNA, thus, indicating that this effect occurs
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via a steroid-independent mechanism. Work by Jacobson et al (1989) found that even
in the absence of steroids (in adx rats) the plasma ACTH levels still exhibited a
diurnal rhythm which reached a peak at 18.00 h and then declined thereafter,
suggesting that the diurnal drive weakens after the onset of the dark phase. Thus, the
diurnal oscillation of CRT mRNA levels may be regulated primarily by the presence
or absence of circadian drive rather than by corticosterone feedback. Although
resting concentrations of both ACTH and corticosterone exhibit a diurnal rhythm the
amplitudes of these oscillations are different, with corticosterone increasing several
fold greater than ACTH, resulting in a dissociation between plasma ACTH and
corticosterone in the evening (Kaneko et al., 1981). This observation led to the
hypothesis that the diurnal changes in corticosterone are due to diurnal changes in the
responsiveness of the adrenal to ACTH. It has subsequently been found that the
diurnal variation in adrenal responsiveness for ACTH per se is not responsible for the
diurnal variation in the plasma corticosterone levels. Rather, it appears that an
increased sympathetic drive via the splanchnic nerve contributes to the corticosterone
diurnal variation (Dijkstra et al., 1996). It was found that splanchnic nerve
transection significantly reduced resting evening corticosterone levels. This finding is
supported by earlier work in dogs and calves which revealed that stimulation of the
splanchnic nerve results in increased corticosterone output from the adrenal glands,
but only when physiological levels of ACTH were present in the circulation
(Edwards & Jones, 1987b; Engeland & Gann, 1989). Also transection of the
splanchnic nerves reduced adrenal sensitivity to both endogenous and exogenous
ACTH (Edwards & Jones, 1987a).
Studies in the rat have determined the mean daily basal plasma corticosterone
levels to be approximately 5 pg/dl (Akana et al., 1992) and it appears that the HPA
axis actively defends this concentration. A study by Akana et al (1992) using intact
rats implanted with pellets containing different concentrations of corticosterone (0%,
20%, 40% & 80% corticosterone) demonstrated that as the levels of corticosterone
were passively elevated the rise in the morning corticosterone levels were
counteracted by a decrease in the peak evening levels, thus allowing the maintenance
of the mean daily circulating levels. Studies on the adequate replacement of
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corticosterone in adx rats have revealed that morning basal ACTH levels are restored
to normal with circulating free corticosterone levels of approximately 2nM, and that
the IC50 for corticosterone on ACTH is 0.7 nM while during the evening peak, the
IC50 increases to 3.9 nM. Several laboratories have investigated the roles of the high
affinity MR (Kd = 0.5 nM) and the lower affinity GR (Kd = 2.5-5 nM) in the
regulation of the basal and stress-induced activity of the HPA axis (Bradbury et al.,
1991; Dallman et al., 1989a). Under basal morning conditions, it is proposed that
ACTH secretion is regulated via occupancy of MR (Akana et al., 1988). However,
both receptor types appear to be involved in the negative control of HPA axis
function at the evening peak and during stress (Bradbury et al., 1994; Ratka et al.,
1989).
Thus, the control of the circadian rhythm of the HPA axis and the maintenence
of a constant circulating mean daily level of corticosterone essential for normal
functioning of corticosterone involves complex interactions between stimulatory
drives and inhibitory feedbacks.
1.11 lip-Hydroxysteroid dehydrogenase
The enzyme 11 p-hydroxysteroid dehydrogenase (1 lp-HSD) plays an important
role in corticosteroid physiology by regulating the access of glucocorticoids to both
GR and MR (Table 1.1). To date two isoforms have been isolated and characterised:
11 P-hydroxysteroid dehydrogenase type 1 (lip-HSDl) and 11 P-hydroxysteroid
dehydrogenase type 2 (11P-HSD2).
llp-HSDl is a microsomal enzyme (Koerner, 1969) which catalyses the
interconversion of corticosterone to its inactive 11-keto metabolite, 11-
dehydrocorticosterone in rodents and Cortisol to cortisone in man. It utilises the
pyrridine nucleotide, NADP as a cofactor. Its Kd for corticosterone and Cortisol is in
the micromolar range (Lakshmi & Monder, 1988) and it has a ubiquitous
distribution.
More recently, a second isoform has been isolated, 11P-HSD2. It exclusively
catalyses the dehydrogenase reaction i.e inactivation of corticosterone and Cortisol.
Its activity is dependent on the presence of the pyrridine nucleotide, NAD . It possess
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11P-HSD1 11P-HSD2
Apparent mol. wt. 34 kda 40 kda
Tissue distribution Widespread part, liver & CNS Kidney, colon & placenta
Co-substrate NADP(H) NAD(H)
Reaction direction in:
- homogenates bidirectional dehydrogenase
- intact cells primarly reductase dehydrogenase
Km (nM):
- Cortisol 17000 50
- corticosterone 2000 10
- cortisone 200 »
- 11-dehydrocorticosterone 250 »
Table 1.2: Details of the two 11P-HSD isozymes: 11P-HSD1 & 11P-HSD2.
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a much higher affinity for both corticosterone and Cortisol, in the nanomolar range,
than the type 1 (Brown et al, 1993) and it has a much more selective distribution.
1.11.1 Ilf3-HSD1
In the 1950s sufficient quantanties of Cortisol became available to allow studies into
its metabolism. Burstein and colleagues (1953) found that oral administration of
Cortisol acetate to humans resulted in the secretion of 11-oxo C21 and CI9 steroids in
the urine and in the same year an enzyme responsible for catalysing the metabolism
of Cortisol to cortisone was discovered in rat liver (Amelung et al., 1953). It was later
termed "11 p-hydroxy dehydrogenase" (Hubener et al., 1956) but is now known as
11P-hydroxysteroid dehydrogenase (lip-HSD). In the early 1960s Osinski et al
(1960) reported that lip-HSD activity was dependent on the presence of the
pyrridine nucleotide cofactors: NADP for 11 (3-dehydrogenase activity and NADPH
for 11 (3-reductase activity. However, several studies clearly showed that the
oxidation and reduction of the Cu of glucocorticoids was not uniformly distributed
among tissues. Liver exhibited predominantly reductase activity while the
kidneyshows a high dehydrogenase activity (Burton & Turned, 1968). This led to the
conclusion that the differences in glucocorticoid metabolism in tissues was due to
either the presence of separate enzymes or tissue specific effects by a unique enzyme
(Bush & Mahesh, 1959). The physiological role of 11 (3-HSD activity is to act as a
crucial pre-receptor signalling pathway for corticosteroid receptors, maintaining in
vivo the specificity of the kidney and colonic MR for aldosterone (Edwards et al.,
1988; Funder et al., 1988) and regulating the access of corticosteroid to GR
(Whorwood et al., 1993).
It was originally proposed that 11 P-dehydrogenase and 11 P-reductase activities
existed as two separate enzymes in at least the fetal lung (Abramovitz et al., 1982)
and the liver (Lakshmi & Monder, 1985). In the late 1980s Lakshmi & Monder
(1988) successfully purified lip-HSD from rat liver microsomes, and showed that
the purified enzyme in vitro possessed exclusively 11 p-dehydrogenase activity,
thereby lending support to the 'two enzyme theory'. Subsequently, however,
Agarwal et al (1989) screened a rat liver cDNA library, using a rabbit anti-1 lp-HSD
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serum, and isolated a cDNA for 11J3-HSD. When the cDNA was transfected into the
Chinese hamster ovary cell line it exhibited equal 11 (3-dehydrogenase and 11(3-
reductase activity, thereby demonstrating that both activities were encoded by a
single protein. The 'liver-type' llp-HSD or 11(3-HSD1 is a 34 kD glycoprotein
(Lakshmi & Monder, 1988) and belongs to the short chain alcohol dehydrogenase
family (Krozowski, 1992). Numerous studies have shown that this enzyme has a
wide tissue distribution both centrally and peripherally. In vitro studies, measuring
predominantly dehydrogenase activity as it is known to be more stable then reductase
activity in vitro (Lakshmi & Monder, 1985), have found the enzyme activity in
peripheral tissues such as the liver, lung, kidney, ovaries and testis (Benediktsson et
al., 1992; Lakshmi & Monder, 1985; Nicholas & Lugg, 1982; Philips et al., 1989).
Immunohistochemical (Monder & Lakshmi, 1990) and in situ hybridisation studies
(Low et al., 1993; Tannin et al., 1991) confirmed the presence of the enzyme protein
in these tissues and as sites of enzyme synthesis, respectively, they were dependent
on the addition of exogenous NADP to the reaction. This is in agreement with the
finding that the brain maintains relatively low levels of pyrridine nucleotide cofactors
compared to other tissues and may account for a subsequent finding of no detectable
1 lp-HSD activity in whole hippocampal extract (Edwards et al., 1988; Funder et al.,
1988) since no exogenous NADP was used in the latter studies. More recent it has
been clearly demonstrated that 11P-HSD activity and mRNA is present in a number
of brain regions. Highest levels of activity and/or mRNA expression occurred in the
hippocampus, hypothalamus, cerebral cortex, cerebellum and the anterior pituitary
(Moisan et ah, 1990a, 1990b; Sakai et al., 1992).
To account for the bidirectionality of this enzyme in vitro investigators have
postulated that the direction of the enzyme in vivo may be controlled by the relative
proportions of the oxidised to reduced pyrridine nucleotide i.e. NADP:NADPH ratio
(Nicholas & Lugg, 1982; Torday et al., 1976) within specific cellular compartments.
Alternatively, local extremes in pH have also been postulated to influence the
direction of the enzyme (Deckx & DeMoor, 1966). However, having such
restrictions within the cell is rather an ineffective way to regulate the direction of one
enzyme since these perturbations are also likely to influence other important enzymes
44
in the local enviroment. Although in vitro the enzyme will interconvert
glucocorticoids, depending on which cofactor is present, there is mounting evidence
using clonal cell lines and primary cell culture that in vivo lip-HSD may act
predominantly as a reductase (Jamieson et al., 1995; Low et al., 1994a; Rajan et a!.,
1996). Thereby, enhancing rather than decreasing glucocorticoid access to GR.
1.11.2 11P-HSD2
The isolation and characterisation of the lip-HSDl enzyme was initially
thought to answer the paradox of why in vitro recombinant MR showed an equally
high affinity for both corticosterone, Cortisol and aldosterone yet in vivo MR in the
distal nephron selectively bound aldosterone despite a 1000-fold molar excess of
circulating glucocorticoids (Krozowski & Funder, 1983). However, it became
apparent that llp-HSDl was unlikely to be responsible for the aldosterone-
selectivity of the receptors due to its low affinity for corticosterone, its relatively
sparse expression in the kidney and its detection in the proximal tubules rather than
being colocalised with the MR in the distal tubules and collecting ducts of the kidney
(Rundle et al., 1989).
Recently, a high affinity NAD-dependent enzyme was partially purified from
human placenta (Brown et al. 1993) and cDNAs for this llp-HSD2 have been
cloned from human, sheep, rat & mouse (Albiston et al. 1994, Agarwal et al. 1994,
Zhou et al. 1995, Cole, 1995). It has low nanomolar affinities for glucocorticoids,
thus, making it more suitable for the physiological metabolism of corticosterone and
Cortisol. The purified protein has an apparent molecular weight of 40 kD. It is an
exclusive dehydrogenase i.e. inactivates glucocorticoids, and is therefore proposed to
be responsible for protecting the aldosterone-selective MR from occupation by
glucocorticoids in tissues such as the kidney. This proposal is further supported by
the finding of mutations and small deletions in the 11 (3-HSD2 gene in patients with
the syndrome of apparent mineralocorticoid excess (Mune et al., 1995; Wilson et al.,
1995) which results from illicit occupation of aldosterone-selective MR by Cortisol.
This reinforces the importance of the type 2 enzyme in protecting these receptors.
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1.12 Pregnancy
During pregnancy the mother undergoes numerous physiological adaptations in
order to support the developing fetus. Changes in water and electrolyte balance occur
resulting in increased total body water and haemodynamic changes also occur,
including increased cardiac output with the respiratory system also affected (Metcalfe
et al., 1988). In addition maternal metabolism is altered to provide the extra energy
required to support the developing fetus. Since glucocorticoids are involved in the
regulation of metabolism it is not too surprising to find that glucocorticoid regulation
is also affected by pregnancy.
Studies in man and other animals indicate that plasma glucocorticoid
concentrations progressively increase in pregnancy (Barlow et al., 1974; Carr et al.,
1981), consistent with their role as mobilisers of energy stores (Widmaier, 1992). As
far back as the mid-1960s, urine excretion of Cortisol was shown to be elevated in
pregnant women (Espiner, 1966) and later studies found a parallel increase in
maternal plasma (Nolten et al., 1980, Nolten & Rueckert, 1981). In the rat, Ogle &
Kitay (1977) reported a fall in corticosterone levels early in pregnancy followed by
an increase after midgestation to prepregnancy levels. A subsequent more detailed
study in the pregnant rat clearly demonstrated a fall in the daily mean levels of
corticosterone in early pregnancy which is followed by a progressive increase from
midpregnancy to term (Atkinson & Waddell, 1995). This elevated glucocorticoid
concentration in blood may simply reflect an increased secretion from the adrenal
cortex or a reduced metabolic clearance rate (MCR). The MCR of glucocorticoids
may decrease during pregnancy since the levels of CBG have been shown to rise
(Rosenthal et al., 1969). However, a recent a study by Waddell & Atkinson (1994)
clearly demonstrated that the MCR in the rat was maintained at pre-pregnancy levels
due to the additional transuterine extraction. In addition, the' level of free,
biologically-active Cortisol has been shown to progressively increase with pregnancy
(Demey-Ponsart et al., 1982; Nolten & Rueckert, 1981). However, despite these
elevated levels of Cortisol and corticosterone in the blood both pregnant women and
animals exhibit a normal circadian rhythm (Atkinson & Waddell, 1995; Nolten et al.,
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1980) and are responsive to physical stress, including surgical procedures (Namba et
al., 1980; Neumann etal., 1998).
To account for these elevated plasma glucocorticoid levels several workers
suggested that progesterone may play a role. It was proposed that the high circulating
levels of progesterone occurring during pregnancy might competively inhibit the
binding of Cortisol to GR, thereby preventing the feedback signal on ACTH release
(Rosenthal et al., 1969). However, work on hypophysectomised pregnant non-human
primates and rats found that both the adrenal weight and the plasma glucocorticoid
levels were partially maintained as long as a viable placenta was left in situ (Knobil
& Briggs, 1955, Hodgen et al., 1975). These results strongly indicate that the
placenta must release a substance possessing ACTH-like bioactivity.
Subsequently, the placenta has been found to synthesize a whole host of
hormones normally of hypothalamic or pituitary origin including CRF and POMC-
derived peptides such as ACTH and P-endorphin (Petraglia, 1991; Sirinathsinghji &
Heavens, 1989).
1.12.1 Placental CRF
Extracts of human placenta were first shown to contain immunoreactive and
bioactive CRF by Shibasaki et al. (1982). In humans, the placental concentration of
immunoreactive CRF increases from week ten of gestation. Immunocytochemical
studies have identified the site of CRF synthesis as the syncytiotrophoblast although
staining also occurred in the amnion, chorion and decidua (Riley et al., 1991). The
gene expressing preproCRF is present from week seven of gestation but remains low
until after midpregnancy and CRF mRNA is present with the transcript being of
similar size to its hypothalamic counterpart (Frim et al., 1988). Placental CRF
mRNA concentration increases over twenty-fold during the third' trimester which
parallels the increase in the concentrations of CRF in the maternal plasma.
The placental CRF secretion is influenced by several different factors. In
contrast to the effects of glucocorticoid on hypothalamic CRF synthesis and release
(Kovacs & Mezey, 1987), treating a mixed population of term placental cells with
dexamethasone or Cortisol enhances both preproCRF mRNA levels and the release of
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immunoreactive CRF (I-CRF) (Robinson et al., 1988). Prostaglandins (PGF2 and
PGE2) also stimulate CRF secretion from cultured, term placental cells (Petraglia et
al., 1987). Other substances, including noradrenaline, interleukin-ip, oxytocin and
AVP have all been shown to increase I-CRF release from cultured placental cells
(Petraglia et al., 1989), but whether these play important roles in vivo remains
unclear.
During human pregnancy the concentration of I-CRF in the peripheral blood
gradually increases from midpregnancy, progressing to a dramatic rise as term
approaches (Goland et al., 1986; Sasaki et al., 1987). In contrast, neither the rat nor
sheep exhibit high circulating levels during pregnancy and little evidence exists to
suggest that CRF is synthesised in the placenta of either of these species.
In humans the placenta also secretes CRF into the fetal compartment, although
at a slower rate than into the maternal compartment (Goland et al., 1986; Sasaki et
al., 1987). There is also a positive umbilical venous-arterial difference in I-CRF
concentrations at term (Goland et al., 1986; Sasaki et al., 1987), indicating placental
secretion of I-CRF into the fetus.
It is not known to what extent placental CRF modulates the secretion of ACTH
and other POMC-derived peptides from the maternal anterior pituitary. It has been
proposed to contribute to the elevated Cortisol plasma levels since a correlation
between urinary free Cortisol and maternal plasma CRF was observed during
pregnancy (Goland & Warren, 1989). However, although plasma ACTH levels
increase progressively with advancing pregnancy in humans (Carr et al., 1981) this
follows an initial fall so maximal levels during late pregnancy remain well within the
normal nonpregnant range, which is in marked contrast to the high levels of
circulating CRF found in late pregnancy. This has led several investigators to
postulate that in vivo there are constraints on the biological activity of circulating
CRF on the maternal anterior pituitary (for review see Thomson & Smith, 1989). It
may simply reflect the rising levels of glucocorticoids interfering with the
stimulatory effect of placental CRF on the anterior pituitary corticotrophs.
Alternatively, the kinetics of the CRF exposure may alter the sensitivity of the
corticotrophs. In vivo, the hypothalamus release CRF into the HPB system in a
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pulsitile manner (Ixart et al., 1987). In contrast, the anterior pituitary corticotrophs of
pregnant women are exposed to a sustained high concentration of CRF, and this may
serve to desensitize the anterior pituitary to CRF, via CRF receptor downregulation
(Reisine & Hoffman, 1983). This is supported in vivo by the demonstration that
pregnant women are insensitive to intravenous (i.v.) injections of CRF (Schulte et al.,
1988). Alternatively, the presence of the CRF binding protein (CRFBP) in human
plasma in greatly increased amounts in pregnancy, but not in rodents or sheep,
(Linton et al., 1988) has been proposed to hinder the bioactivity of placental CRF.
However, up to 38% of circulating CRF remains unbound and may thus affect
pituitary function (Saminen-Lappalainen & Laatikainen, 1990). In addition, Suda et
al (1988) found that the percentage of CRF bound CRF-BP decreases rapidly as term
approaches, and Linton et al (1993) have found that the plasma concentration of the
CRFBP declines in the last two weeks of pregnancy The placenta also secretes CRF
into the fetal compartment, the levels of which increase towards term (Goland et al.,
1986). In summary, concentrations of I-CRF drastically increase in both maternal and
fetal plasma during the third trimester of human pregnancy, paralleling increased
placental expression of preproCRF gene and the higher levels of I-CRF in placental
tissue. The rat does not produce placental CRF, so changes in the rat HPA axis in
pregnancy cannot be related to this extrahypothalamic source of CRF.
1.12.2 Proopiomelanocortin in the placenta
A placental source of ACTH in humans had been postulated for a long time
(Jailer & Knowlton, 1950). However, it was not until the mid-1970s that ACTH
immunoreactivity (I-ACTH) and bioactivity (B-ACTH) in the human placenta were
identified (Rees et al., 1975). Subsequently P-endorphin immunoreactivity was also
detected in placental extract (Nakai et al., 1978; Odagiri et al.,-1979), strongly
suggesting that POMC was synthesized in the placenta. This was confirmed by
Krieger and her associates using the 'pulse chase method', where they 'pulsed'
cultured trophoblastic cells with radiolabelled amino acids, then 'chased' the
incorporation of radioactivity into the newly synthesised ACTH and p-endorphin.
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Their results indicated that the placenta is not merely a storage site for POMC
peptides but actively synthesises them (for review see Kreiger, 1982).
Immunohistochemical studies have localised I-ACTH within the placenta to the
syncytiotrophoblast (A1 Timimi & Fox, 1986). Interestingly, it is expressed in the
same site as CRT, possibly indicating that paracrine interactions occur within the
placenta. In both human and rats placental POMC expression appears to be
constitutive as mRNA levels are maintained throughout pregnancy (Chen et al.,
1986); however, placental POMC mRNA is smaller than the pituitary POMC mRNA
by approximately 200 bases (Chen et al., 1986). This has led to the suggestion that
its translatable product(s) may not be secreted into the maternal circulation and that
POMC expression may be important to intracellular functioning rather than having a
classic endocrine function (Clark et al., 1990). In addition the post-translational
processing of the POMC molecule also differs between the placenta and the pituitary.
Size chromatography studies indicated that the ratio of a-MSH to ACTH was higher
in the placenta (Krieger, 1982). Consistent with ACTH not being released from the
placenta studies in humans have found that although plasma I-ACTH levels increase
slightly during pregnancy they remain within the normal range. In addition, in the rat
plasma ACTH levels are very low during pregnancy and no longer exhibit a diurnal
rhythm (Atkinson & Waddell, 1995).
However, in vitro human placental tissue has been shown to be capable of secreting
I-ACTH and treatment of cultured term placental cells or perifused term placental
fragments (Petraglia et al., 1987) with CRF stimulates the release of I-ACTH. It must
be kept in mind that I-ACTH measurements may not reflect true ACTH levels as
antibodies raised against ACTH can cross-react with other POMC-derived peptides,
including P-endorphin. However, a recent study found that B-ACTH is released from
placental tissue collected at both early and late gestation (Waddell & Burton, 1993).
Interestingly, in the case of the sheep, the placenta appears to be capable of secreting
POMC fragments into the maternal circulation in response to stress (Falconer et al.,
1988). Recent studies have shown that although the majority of B-ACTH released
from perifused placental fragments is attributable to I-ACTH, other placental
products also possess ACTH-like bioactivity (Waddell & Burton, 1993). In addition
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several placental products, including prolactin, growth hormone and a-MSH appear
to be able to stimulate the fetal adrenal cortex (Pepe & Albrecht, 1985; Rudman et
al., 1980). Thus, ACTH along with other POMC-derived peptides may in vivo be
released from the placenta during human pregnancy but it appear unlikely that ACTH
is released from the rat placenta. It may be the case that other POMC-derived
peptides such as [3-endorphin are more important during rat pregnancy.
1.13 Aims of the thesis
The first aim of this thesis was to determine whether during pregnancy the
neuroendocrine response of the HPA axis to an acute stress was attenuated. Previous
work had shown that the lactating rat was hyporesponsive to stress and that the CRF
gene expression in the PVN was significantly reduced on day 21 of pregnancy
compared to virgin rats. Taken together these indicate that the reproductive state may
influence the activity of the HPA axis.
The second aim of this thesis was to investigate possible mechanisms,
including decreased forward drive and enhanced sensitivity to glucocorticoid
negative feedback, which may underlie this attenuation.
We examined the gene expression of the two major ACTH secretagogues, CRF and
AVP, in the parvocellular neurones of the hypothalamic PVN under non-stress
conditions. Evidence suggests that the sensitivity of the anterior pituitary
corticotrophs to exogenous CRF is reduced during pregnancy, so we examined CRF
binding site density in the anterior pituitary. In order to see whether this is reflected
at the the second messenger level we measured the accumulation of cAMP following
exposure to CRF. See Chapter 4 for discussion of studies.
We carried out a number of studies to determine whether the HPA axis of the
pregnant rat was more sensitive to glucocorticoid negative feedback than the
nonpregnant rat. We examined the gene expression of the two intracellular
corticosteroid receptors, MR and GR, through which glucocorticoids mediate their
effects, in the PVN and hippocampus, two well characterised glucocorticoid feedback
sites.
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The microsomal enzyme lip-HSDl catalyses the interconversion of
glucocorticoids to their inactive keto-metabolites thereby regulating glucocorticoids
access to MR and GR. It has a wide central distribution and is expressed in several of
the classic glucocorticoid feedback sites including, the hippocampus, PVN and
anterior pituitary. We measured the in vitro enzyme activity in homogenates of these
tissues to see whether a change in enzyme activity occurred during pregnancy. Then,
in vivo we examined the impact on the HPA axis stress responsiveness of inhibiting
central 11P-HSD by the potent inhibitor, glycyrrhetinic acid.
Finally, in order to test the overall sensitivity of the HPA axis of the late pregnant rat
we pharmacologically adrenalectomised rats using metyrapone, 11 P-hydroxylase
inhibitor and aminoglutethimide, 20a-hydroxylase inhibitor and then administered
exogenous corticosterone and measured the fall in plasma ACTH concentrations. See
Chapter 5 for discussion of studies.
The central endogenous opioid peptide system is widspread and is known to
influence a variety of neuroendocrine neurones, including the hypothalamic
magnocellular oxytocin neurones during pregnancy. We examined whether a similar
enhanced opioid tone was occurring at the level of the hypophysiotropic neurones of
the PVN of the pregnant rat by administering the opioid antagonist naloxone and
measuring their stress response. See Chapter 6 for discussion of studies.
A close relationship exists between the HPA axis and the hypothalamic-
pituitary-ovarian axis with each known to be able to influence the other. In fact, it is
widely accepted that the ovarian steroids are responsible for the sexual dimorphism
of the activity of the HPA axis: higher activity in females. Since the attenuated stress
responsiveness occurs during pregnancy when the circulating levels of these steroids
are high it is quite conceivable that they may play a role. To determine this we
implanted virgin rats (ovaries intact) with s.c. estradiol and progesterone capsules
and measured their stress response. In addition, we examined whether the dramatic
fall in plasma progesterone levels in the last few days of pregnancy, due to
degeneration of the corpus luteum, influenced the HPA axis. This involved removing
the progesteone capsules two day prior to the stress experiment. See Chapter 7 for
discussion of studies.
52
There is evidence demonstrating that during pregnancy in both humans and
animals, such as the rat, the basal activity of the HPA axis is altered. It has
previously been shown in human pregnancy that following administration of
exogenous CRT less ACTH is secreted by the anterior pituitary and the axis appears
less sensitive to dexamethasone suppression (Owens et ai, 1987; Shulte et al, 1990).
Unlike the human the rat does not appear to have high circulating levels of CRF
during pregnancy. Thus, this lack of contaminating placental CRF has allowed us to
investigate changes which may be occurring centrally as well as at the anterior




2.1 In Vitro Assays
2.1.1 11(3-HSD 1 Enzyme Conversion Assays
2.1.1.a Tissue collection:
Virgin, day 16 and day 21 pregnant female Sprague Dawley rats were
decapitated and the brain and anterior pituitary rapidly removed. The cerebellum was
dissected and a small section of the outer cortex collected. The remaining brain was
mounted onto a vibroslice (Camden Instruments) and 400 jam coronal sections were
cut until an area containing the paraventricular nucleus (PVN) was reached (Fig 2.1).
Then a 600 jam section was taken and placed in a petri dish on ice and the PVN was
micropunched out of the section using a stainless steel needle with a flat tip (ID 1
mm). The remaining brain section was later stained histologically to verify the
location of the PVN. Finally, a 300 jam section containing the anterior hippocampus
was collected. All tissues were kept on ice until assayed.
2.1.1.b lip-dehydrogenase Activity
11 (3-dehydrogenase activity was measured by a method modified from Moisan
et al. (1990). Tissues were homogenised in a 1 ml homogeniser (BDH) in varying
volumes of ice-cold assay buffer C, pH 7.7 (300 mM NaCl, 1 mM EDTA, 20 mM
Tris-HCl, pH 7.5 (Sigma), 10% glycerol (BDH): 50 jal for PVN micropunches; 300
jal for anterior pituitary; 200 |al for hippocampus; and 500 jal for cerebellum. The
protein concentration of each sample was determined colorimetrically (Bio-Rad
protein assay kit), and then duplicate samples were incubated with 200 pM NADP
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Fig 2.1: A photograph of a representative brain slice showing the micropunched
PVN (A). The brain was cut using a vibroslice and an area around the PVN was
removed using a stainless steel needle (ID 1 mm). 3V - 3rd ventricle, OC - optic
chiasm & AH - anterior hippocampus.
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and 12 nM [1,2,6,7 3H]corticosterone (specific activity 81 Ci/mmol, Amersham
International) at 37 °C.
In preliminary studies the optimal assay conditions were established. These
were found to be a 60 min incubation with a protein concentration of 100 pg/ml for
cerebellum, 200 pg/ml for hippocampus, 500 pg/ml for anterior pituitary and a
concentration of 1000 pg/ml for the PVN micropunches (Figure 2.2). Each PVN
micropunch determination was made on tissue pooled from two animals. To assess
the backgound level of steroid conversion, blank samples (no protein) were run in
parallel with each assay.
At the end of the incubation 1 ml of ethyl acetate was added and the samples
centrifuged at 13,000 rpm for 5 min to extract the steroids. The upper aqueous layer
of the samples was transferred into fresh eppendorf tubes and dried at room
temperature in a fumehood overnight.
The steroids were then reconstituted in 100 pi of ethanol containing both
unlabelled corticosterone and 11-dehydrocorticosterone (2.5 mg/ml). A 10 pi aliquot
of each sample was pipetted onto a silica gel-coated aluminium thin layer
chromatography plate (TLC, Merck Ltd) until a total volume of 40 pi was applied.
Each TLC plate was divided into lanes allowing the loading of eight samples per
plate. The plates were then run in sealed tanks containing a mixture of
chloroform:95% ethanol (92:8) to separate corticosterone (Sigma) and 11-
dehydrocorticosterone (Sigma). The steroid bands were visualised under ultra-violet
light and scraped into eppendorf tubes containing 1 ml of Cocktail T scintillant
(Amersham International).
The radioactivity of each steroid fraction was quantified in a P-counter and the
data expressed as the percentage conversion of [3H]corticosterone to [3H] 11-
dehydrocorticosterone.
2.1.l.c lip-reductase Activity
11 P-reductase activity was determined by a method modified from Brown et al.
(1993). The anterior pituitary and hippocampus were homogenised in Buffer C, pH
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Fig 2.2: [Protein] vs. Incubation Time Curve. Increasing protein
concentrations of (O) cerebellum, (#) hippocampus, (□) anterior
pituitary & (■) hypothalamus homogenates were incubated with
[3H]corticosterone and 200 mM NADP for 60 min at 37 °C.
Data expressed as the % conversion of [3H]corticosterone (B)
to [3H]11-dehydrocorticosterone (A).
57
5-6 (300 mM NaCl, 1 mM EDTA 0.1 M potassium acetate, Sigma), and each
homogenate incubated in duplicate in the presence of 200 pM NADPH and [3H] 11 -
dehydrocorticosterone for 10 min at 37 °C.
[3H] 11-dehydrocorticosterone was prepared from [3H]corticosterone by a
variation of the method of Lakshmi and Monder (1988). Human placenta as a pure
source of 11 P-dehydrogenase activity (Brown et al. 1993) and therefore producing
the least contamination with corticosterone was used. Placental extract was incubated
with 1 mM NAD in buffer C (pH 7.7) containing 12 nM [1,2,6,7 3H]corticosterone
for a minimum of 2 h at 37 °C. The steroids were then extracted into an equal volume
of ethyl acetate, centrifuged and the upper layer dried down under air. The sample
was then resuspended in a volume of ethanol giving a specific activity equivalent to
that of the [3H]corticosterone used in the 11 P-dehydrogenase assays, and stored at -
20 °C until required. To check the purity of the [3H]11-dehydrocorticosterone, a
sample of the steroids was dried down and resuspended in 600 pi of 65:35
methanokHPLC H20 and run through a Waters HPLC system. Purity of the sample
was found to be greater than 98 %.
The steroids were extracted, separated and quantified by the same methods
employed for the measurements of 11 p-dehydrogenase activity. Data were expressed
as the % conversion of [3H]11-dehydrocorticosterone to [3H]corticosterone.
In order to be able to compare data between assays we included liver
microsomes, prepared by the method of Chirino et al. (1991), as internal standards in
both the dehydrogenase and reductase assays. The liver was removed from an adult
male Wistar rat and washed in ice-cold Buffer A, pH 7.4 (10 mM Tris, 1.5 mM
EDTA, 2 mM dithiothreitol, 100 mM sodium molybdate, 80% glycerol). It was then
cut into small pieces, weighed, transferred into a volume of fresh ice-cold Buffer A
(3 x w/v) and homogenised. The homogenate was then centrifuged at 20,000 g for 20
min to sediment the larger pieces of tissue and the resulting supernatant centrifuged
at 105,000 g for 60 min. The supernatant was discarded and the pellet resuspended in
Buffer A and recentrifuged at 105,000 g for another 60 min. Again the supernantant
was discarded and the pellet resuspended in a small volume of Buffer A. Protein
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concentration was determined colorimetrically and the microsomes diluted down
with Buffer A to give a protein concentration of 250 fig/ml, aliquoted and stored at -
80 °C until use.
The intra- and inter-assay coefficients of variation were 5% and 8 % and 9%
and 10% for the dehydrogenase and reductase activity assays, respectively.
2.1.2 ACTH Two-site Immunoradiometric Assay
The plasma ACTH concentrations were measured using a commercially
available kit (Euro-diagnostica B.V., The Netherlands), which employs two site-
directed polyclonal antibodies, developed by Hodgkingson et al. (1984). This
allowed the detection of the intact ACTH molecule without cross-reacting with
related fragments.
Unextracted plasma and reconstituted human ACTH standards in plasma (5-
1250 pg/ml) were incubated overnight at room temperature with a mix of [125I]sheep
anti-ACTH IgG and rabbit anti-ACTH IgG antibodies. The two antibodies reacted
non-competitively as the sheep IgG was directed against the amino terminal region of
the full-length human ACTH molecule while the rabbit IgG was specific to the
carboxy-terminal.
Separation of the bound from the free ACTH was achieved by the addition of a
precipitating reagent containing a sheep anti-rabbit IgG antibody followed by a short
30 min incubation at room temperature. This reagent caused the precipitation of the
1251 sheep antibody bound to the intact ACTH rabbit antibody complex. Finally, a
wash solution was added and the samples centrifuged at 2,000 rpm for 20 min at 4
°C. The resulting supernatant was aspirated to waste and the wash, centrifugation
and aspiration steps repeated. Standards and sample were quantified in a y-counter,
with the radioactivity in the precipitated bound fraction being directly proportional to
the concentration of ACTH in the sample. The data were calculated from the standard
curve (Figure 2.3) using the Microsoft MultiCalc programme and expressed in pg/ml.
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Figure 2.3: A representative ACTH standard curve from the Two-site
Immunoradiometric Assay.
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The sensitivity of the assay was 0.8 pg/ml and the intra- and inter-assay coefficients
of variation were 3% and 5%, respectively.
2.1.3 Corticosterone Radioimmunoassay
Total plasma corticosterone concentrations were measured with an in-house
radioimmunoassay. The plasma was diluted 10:1 with borate buffer (163 mM boric
acid, 81 mM sodium acetate, 0.5% BSA, pH 7.4) and heated at 75 °C for 30 min to
denature the protein in the samples. A 20 pi aliquot of each of the corticosterone
standards (0.625 - 320 mmol/1) or the diluted sample were incubated with a mix of
[1,2,6,7 JH]corticosterone (total counts, 11,000 cpm per tube) and rabbit anti-
corticosterone antibody (Dr C. Kenyon, HBP Unit, Glasgow) for 60 min at room
temperature. Afterwards, 50 pi anti-rabbit scintillation proximity assay (SPA)
reagent was added and the samples incubated overnight. This SPA reagent acts by
binding to the first antibody-corticosterone complex, bringing it in close contact with
the scintillant and allowing detection of the energy signal. In contrast, the
radioactivity of the unbound ligand goes undetected because it is not brought into
close enough contact with the scintillant. The samples were quantified in a (3-counter
and using the Microsoft MultiCalc programme, a standard curve (Figure 2.4) was
generated and the data expressed as ng/ml.
The sensitivity of the assay was 1.25 nmol/1 and the intra- and inter-assav
coefficients of variation were below 7% and 10%, respectively.
A preliminary study was carried out to confirm that our colony of female Sprague
Dawley rats possessed a normal corticosterone diurnal rhythm. All the rats exhibited
a robust circadian rhythm (Fig 2.4b) which was in agreement with the previously
reported range for female rats in the morning and the evening (Carey'et al, 1995;
Viau & Meaney, 1991). However, in subsequent studies we were unable to
consistently achieve these low morning levels. This may have occurred for a number
of reasons. Firstly, the levels may simply reflect a lasting effect of the anaesthetic for
jugular implantation since it has previously been shown that some anaesthetics
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Fig 2.4b: Corticosterone circadian rhythm in virgin female Sprague
Dawley rats (n = 6). Animals were fitted with right jugular vein cannula
and left to recover from the surgery for 4 days. On the morning of the
experiment a jugular venous sampling cannula was connected and the
animals left undisturbed for 90 min then a single blood sample (AM) was
collected. On the evening of the experiment again the sampling cannula
were connected 90 min prior to taking the blood sample (PM). Plasma was
assayed for corticosterone. Data expressed as ng/ml (mean ± S.E.M.)
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influence the secretion of ACTH secretagogues such as CRF (Sherwood & Fink,
1991) however, our basal ACTH levels fall within the normal range. Secondly, the
environment in which the animals were housed may preclude the measurement of
low basal corticosterone levels, although on the morning of the experiment the
animals were left undisturbed for a minimum of 90 min to allow the levels to return
to basal after the connection of the sampling cannulae. It should be noted that the
animals were housed singly for 10 days prior to experimentation and this may
account in part to the elevated basal values seen.
2.1.4 Corticosterone Binding Globulin Assay
Plasma samples obtained from basal blood collected via indwelling venous
cannulae were used to measure CBG levels by the method of Martin et al. (1977).
Endogenous steroids were removed by running 20 pi aliquots of plasma in
duplicate through Sephadex LH-20 columns and diluting them 50:1 with TEGMD
(30 mM Tris, I mM EDTA, 10% glycerol, 10 mM sodium molybdate, and 1 mM
dithiothreitol, pH 7.4). 150 pi of diluted plasma was then incubated for 24 h at 4 °C
with 200 nM [1,2,6,7 3H]corticosterone in the absence or presence of 0.1 mM
unlabelled corticosterone, representing total and non-specific binding, respectively.
Separation of the bound from the free corticosterone was achieved by passing
the samples through Sephadex LH-20 columns. The elutant was collected into
scintillation vials containing 3 ml of Picofluor scintillant and counted on a [3-counter.
The protein concentrations of the samples were measured colorimetrically (Bio-Rad
protein assay kit).
Plasma levels of CBG were expressed as pmol [3H]corticosterone bound/mg of
protein.
2.1.5 Enzyme Immunoassay (Magnetic Solid Phase) for 17(3-estradiol and
progesterone
To determine the plasma concentrations of 17p-estradiol (estradiol) and
progesterone achieved in animals s.c implanted with ovarian steroid capsules,
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commercially available enzyme immunoassay kits (Biodata Diagnostics, Italy) were
used. The estradiol and progesterone assays employ high affinity polyclonal and
monoclonal antibodies, respectively, and incorporate a magnetic solid phase
separation technique (Abraham, 1969) which eliminates the need for centrifugation.
These assays measured total circulating steroid concentrations as they contain a
specific agent which displaced the sex steroids from their respective binding proteins.
2.1.5.a Estradiol Asssay
Unextracted plasma, reconstituted estradiol (estra-1,3,5 (lO)-triene, 17p-diol)
standards (50 - 3000 pg/ml) and internal controls containing a known concentration
of estradiol were incubated with an anti-estradiol fluorescein-labelled rabbit
polyclonal antibody for 20 min at 37 °C. Afterwards a fixed amount of an estradiol-
derivative conjugated to the enzyme, bovine alkaline phosphatase was added and
incubated for a further 20 min. This competes for binding to the limited amount of
antibody.
The separation reagent containing sheep anti-fluorescein serum bound to
magnetic particles was added in excess and incubated for 5 min at 37 °C. Separation
of the bound from the free estradiol was achieved by placing the samples on a
magnetic rack for 2 min, this causes the magnetic particles to sediment in the tubes.
The supernatant was then decanted, a wash buffer added and the particles allowed to
resediment for a further 2 min. The decanting, washing and separation steps were
repeated. Afterwards the samples were incubated with the enzyme substrate,
phenolphthalein monophosphate (PMP) for 30 min at 37 °C. The bovine alkaline
phosphatase catalyses the hydrolytic removal of a phosphoryl group from PMP. The
enzyme reaction was terminated with the addition of a 'stop' solution, containing a
chelating agent, and a purple colour developed. The magnetic particles were then
allowed to sediment for a minimum of 10 min prior to the intensity of the colour
formed being measured photometrically (Serozyme I Photometer) at 550 nm. The
colour intensity was inversely proportional to the amount of estradiol in the sample.
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[Estradiol] (pg/ml)
Fig 2.5a: A representative Estradiol Standard Curve from the Enzyme
Immunoassay (Magnetic Solid Phase).
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The concentrations of estradiol in the plasma samples were determined directly from
the standard curve and expressed as pg/ml (Fig 2.5a). The sensitivity of the assay was
0.8 pg/ml and the intra- and inter-assay coefficients of variation were 6% and 7%,
respectively.
2.1.5.b Progesterone Assay
The plasma samples from animals treated with steroid-containing capsules
were diluted 1 in 5 prior to assay. In previous studies this dilution was found to bring
the progesterone concentration within the linear part of the assay standard curve.
Unextracted plasma, reconstituted progesterone standards (0.5 - 40 ng/ml) and
internal controls were incubated with fluorescein-labelled progesterone and an anti-
progesterone bovine alkaline phosphatase labelled mouse monoclonal antibody for
15 min at 37 °C. Bound progesterone was separated from the free by the same
method used in the estradiol assay. Briefly, following the addition of the sheep
antiserum to fluorescein bound to magnetic particles, the samples were incubated for
10 min at 37 °C and then placed on the magnetic rack for 2 min. The supernatant was
decanted, the remaining sediment washed and the magnetic particles resedimented
for a further 2 min and the resulting supernatant discarded. The enzyme substrate,
PMP was added and the samples incubated for 15 min at 37 °C. The reaction was
terminated by the addition of the 'stop' solution and the magnetic particles
sedimented for 10 min, prior to photometric quantification. As with the estradiol
assay, the concentration of endogenous progesterone was inversely proportional to
the colour intensity. From the standard curve the progesterone concentrations in the
plasma samples were determined and the data expressed as ng/ml (fig 2.5b).
The sensitivity of the assay was 0.48 ng/ml and the intra- and inter-assay
coefficients of variation were 4% and 8%, respectively.
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Fig 2.5b: A representative Progesterone Standard Curve from the
Enzyme Immunoassay (Magnetic Solid Phase).
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2.1.6 In Vitro Pituitary Segments
Day 10, 16 and 20 pregnant and female virgin rats were decapitated and the
pituitary removed and the neuro-intermediate lobe carefully dissected away. The
anterior pituitaries were then washed in Dulbecco's Modified Eagle's medium,
(Gibco-BRL), buffered with 25 mM (HEPES) to pH 7.4 containing 0.25% bovine
serum albumin (BSA) (Sigma, RIA grade V), and weighed. Using a dissecting
microscope and a straight-edged blade, the anterior pituitaries were cut into eight
equal sized segments and placed in 24-well cluster plates (Costar), one segment per
well, containing 1 ml of DMEM and incubated for 60 min at 37 °C. They were then
transferred to fresh cluster plates containing 250 pi per well of the phosphodiesterase
inhibitor, 3-isobutyl-l methylxanthine (IBMX) (0.5 mM) and incubated for a further
15 min at 37 °C. Thereafter, each segment was challenged with 250 pi of either
human CRH (hCRH) (final concentration 10 nM; Peninsula) or vehicle (DMEM) for
10 min at 37 °C, with the reaction terminated by the addition of 500 pi of ice-cold
0.2N HC1. The cluster plates were sealed with parafilm (BDH) and stored at -70 °C
until trituration and cAMP determination.
2.1.6.a Non-acetylated cAMP Radioimmunoassay
Following two rounds of freeze-thawing, pituitary segments were triturated
with gauge 26 needles, to break up the tissue, allowing the determination of total
cAMP levels (both intracellular and extracellular) by the method of Dafau et al.
(1973).
Following centrifugation at 2,500g for 10 min the resulting supernatant was
used in the assay. Duplicate 50 pi aliquots of cAMP standards (ranging from 12.5 -
3200 fmol/50 pi) and samples, along with 4 tubes each for total (1:1 mix of 0.2 N
HC1 and DMEM) and non-specific (1 mM cAMP) binding were incubated with 100
pi of specific rabbit anti-cAMP antibody (cAB4), 50 pi of [125I]cAMP (14 000
cpm/tube) and 10 pi of the second antibody mix (70% anti-rabbit IgG, 10.5% non
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immune rabbit (NRS) and 19.5% assay buffer (50 mM sodium acetate, pH 6.0 with
0.25% BSA), overnight at 4 °C.
The following morning 700 pi of ice-cold PEG-SERUM (20% polyethylene
glycol, 10% horse serum, 0.9% saline, and 50 mM Na acetate) was added and the
samples centrifuged at 2500g at 4 °C for 25 min. The supernatant was then decanted
and the pellet counted in a y-counter. The NSB was subtracted from the
standards/samples and from the standard curve the total cAMP accumulation in the
samples was determined and expressed as nmol/well.
2.1.7 Acutely Dispersed Anterior Pituitary Cells
Day 21 pregnant and virgin rats were quickly decapitated and the anterior
pituitaries removed and transferred into DMEM. After the removal of the neuro-
intermediate lobe, each pituitary was finely chopped with a straight-edged scapel
blade and then pooled together with other pituitaries within each group. The
pituitary pieces were then incubated with DMEM containing 0.25% trypsin (TRL),
10 mg/ml DNAse 1 (Sigma) and 0.25% BSA (MILES) for 20-30 min, to break up the
tissue, and every 5 min the pituitary pieces were gently dispersed with a 5 ml pipette,
then to inactivate the trypsin, DMEM containing 0.5 mg/ml lima bean trypsin
inhibitor (Sigma), 100 kallikrein units (KU) aprotinin (Sigma) and 0.25% BSA was
added. The remaining tissue fragments were then triturated by a 5 ml pipette tip fitted
with a cut-down 1 ml pipette tip for approx. 10 min. The resulting cell suspension
was filtered through a 100 pm nylon mesh and diluted with an equal volume of
DMEM containing 0.25% BSA, then centrifuged at approx. 600 g for 5-10 min to
pellet the cells. The supernatant was carefully removed and the cell pellet
resuspended in 1 ml of DMEM. This was then made up to 10 ml with DMEM
containing 100 KU aprotinin and the suspension gently rotated for 2 h to allow the
cells to equilibrate. Then the suspension was recentrifuged, the supernatant removed
and the pellet resuspended in 1 ml of DMEM containing 0.25% BSA. An aliquot of
the suspension was counted on a haemocytometer and the number of cells/ml
calculated. The suspension was then diluted down to give 2 x 105 cells/tube.
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These anterior pituitary cells were then exposed to either increasing
concentrations of hCRH: 0.1, 1 & 10 nM or vehicle (DMEM) for 10 min at 37 °C.
Each concentration was assayed in quadruplicate and the reaction was started with
the addition of the cells. To terminate the stimulation ice-cold 0.2 N HC1 was added.
The tubes were then sealed with parafilm and stored at -70 °C until assayed for
cAMP determination.
2.1.7.a Acetylated cAMP Radioimmunoassay
This assay is identical to the non-acetylated cAMP assay except for an
acetylation step. The acetylation of cAMP increases the sensitivity of the assay
approx. 100 fold. Therefore, it is possible to measure small changes in cAMP
production more accurately. We used this assay to measure the production of cAMP
in acutely dispersed anterior pituitary cells challenged with hCRH.
A mix of 1:2.5 (v/v) of fresh acetic anhydride:triethylammonium was prepared
at room temperature. While rapidly vortexing a 10 pi aliquot was added to tubes
containing 250 pi of either the cAMP standards (0.78-400 fmol/50 pi) or samples
which were then immediately placed on ice.
The assay then followed the same protocol as for the non-acetylated assay (see
above). Throughout the assay the tubes were kept on ice as acetylated cAMP is
highly unstable at room temperature.
The cAMP concentrations in the samples were quantified in a y-counter and
determined in the same way as for the total cAMP accumulation in pituitary
segments (see above), and then expressed as pmol/2 x 105 cells.
2.2 In Vivo Studies
2.2.1 Animal Maintenance
Female Sprague Dawley rats (230-250g) (Bantin and Kingman, UK) were
routinely used for in vivo studies. The animals were housed in groups of five per cage
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under standard laboratory conditions: controlled lighting (lights ondights off, 07
00:19 00 h), ambient temperature 22 °C with food and water ad libitum, on arrival at
the central animal facility, University of Edinburgh. They were then allowed a period
of at least two weeks to acclimatize to their new surroundings prior to
experimentation.
The animals were handled daily for a minimum of a week prior to an
experiment in order to reduce non-specific stress effects occurring during
experimentation.
2.2.2 Surgery
2.2.2.a Chronic jugular cannulation
Under halothane:nitrous oxide anaesthesia pregnant and virgin rats were
implanted with a jugular cannula for blood sampling. Using sterile procedures the
right jugular vein was carefully exposed and a silastic catheter (ID 0.5 mm; OD 1
mm), containing sterile heparinised saline (heparin 20U/ml 0.9% saline), was
inserted for a distance of 3 cm so that the tip lay within the right atrium of the heart.
To check that the cannula was in place a small volume of blood was drawn back
prior to the cannula being secured in place with suture thread. The cannula was then
exteriorised at the back of the neck, fixed in placed with a strip of tape which was
sutured to the skin and the cannula was sealed with a plug. The animals were then
allowed a minimum of three days to recover.
2.2.2.b Subcutaneous Silastic Capsule Implantation
Under halothane:nitrous oxide anaesthesia and using sterile procedures female
virgin rats were implanted subcutaneously with silastic capsules containing ovarian
steroids (modified from Bridges, 1984).
Silastic tubing (ID 0.2 cm; OD 0.3 cm) was cut to a length of either 1.5 cm or 3
cm for estradiol and progesterone capsules, respectively, and sealed at one end with
silicone sealant and autoclaved. Thereafter, sterile conditions were used.
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17(3-estradiol was dissolved in vehicle oil (89.7% arachis oil, 10% benzyl
alcohol, 0.3% cresol) to a concentration of 15 mg/ml and used to fill the estradiol
capsules, and crystalline progesterone was used to fill the progesterone capsules. All
capsules were then sealed, washed in absolute ethanol and incubated in phosphate-
buffered saline for a minimum of 24 h prior to implantation.
One 17p-estradiol or vehicle capsule was implanted on day one of surgery and
seven progesterone or empty capsules were implanted two days later. Then, after
approximately two weeks a jugular cannula was inserted to enable serial blood
sampling. As previously mentioned the animals were then allowed a minimum of
three days to recover prior to experimentation.
2.3 In Situ Hybridisation Histochemistry
In situ hybridisation histochemistry is a technique which allows the precise
localisation and identification of individual cells containing specific nucleic acid
sequences. It involves the hybridisation of single-stranded nucleic acid molecules
recognising one another and forming hydrogen bonds between complementary base
pairs. In the early studies in situ hybridisation was used primarily to detect DNA
targets and amplified ribosomal (r)RNA genes within cell nuclei (Gall & Pardue,
1969; John et al. 1969; Buongiorno-Nardelli & Armaldi, 1970). However, over time
the sensitivity of the technique has increased, thus allowing the detection of specific
messenger RNAs (mRNAs) expressed at very low levels in cells.
The stability of the hybrids formed, whether they are DNA-DNA, RNA-RNA
or DNA-RNA duplexes, is governed by several factors, such as temperature:
increasing temperature promotes dissociation of the duplexes; ionic strength: the
presence of salt acts in two ways to stabilise the nucleic acid duplexes. Firstly, by
neutralising the electrostatic repulsive forces between the negatively charged
phosphate groups on opposing strands and secondly by decreasing the solubility of
the bases and thus strengthening the hydrophobic interactions between them; % of
guanosine/cytosine (GC) base pairs: duplexes with high GC content are more stable
because of the increased number of hydrogen bonds they possess; and probe length:
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long complementary sequences, which contain more hydrogen bonds, allow the
orderly stacking of bases and thus result in less base pair mismatch occuring.
Choosing the correct probe for in situ hybridisation is a critical decision. There
are three main classes of probe 1) complementary DNA (cDNA) probes: cDNA
probes are double-stranded, relatively easy to label and use, have high specific
activity and thus give good amplification of the signal. However, the double strands
have to be denatured prior to application to the tissue sections and reannealing of the
strands has been shown to occur, thus significantly reducing the amount of probe
available for hybridisation (Cox et al., 1984); 2) oligonucleotide probes: these are
short (normally 15-50 base pairs long) single-stranded DNA oligonucleotides which
are quick and easy to produce. Their short probe length allows better penetration of
the tissue sections, however, it also means that less stringent hybridisation conditions
have to be employed leading to a loss of specificity; 3) RNA probes (riboprobes):
these are single-stranded RNA molecules produced from a cloned cDNA that is
introduced into a specifically designed plasmid transcription system.
We chose to use riboprobes for our in situ hybridisation studies because there is
no problem about reannealing since they are single-stranded, the transcription
reaction produces a labeled probe of a fixed length and high specific activity which
forms a highly stable hybrid. These probes have a tendency to hybridise to non¬
specific sites in the tissue sections, however, pre- and post-hybridisation techniques
are employed to reduce this.
To be able to determine the specificity of the hybridisation signal of the probe,
termed the antisense probe, a heterologous probe, termed the sense probe, which has
a similar length, GC content and specific activity as the antisense probe was included
in the in situ hybridisation studies. The lack of signal with the sense probe verifies
that probe binding is a result of its base sequence and not its physical properties.
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2.3.1 Plasmid Linearisation
2.3.l.a Rat Glucocorticoid receptor (rGR)
The pGEM4 plasmid containing a 674 base pair (bp) Pstl/EcoR fragment of
the rGR cDNA, corresponding to the steroid binding domain, (base pair 1734-2364)
was linearized by incubation with the restriction endonucleases, Ava 1 or EcoRl to
generate an antisense or sense DNA fragment, respectively, for 1-2 h at 37 °C (Seckl
et al., 1990). A kind gift from Dr Yau, Edinburgh.
2.3.l.b Rat Mineralocorticoid receptor (rMR)
The pGEM4 plasmid containing a 513 bp EcoRl fragment of the rMR cDNA,
corresponding to part of the steroid binding domain and 3' untranslated region, (base
pair 1692-2205) was linearized by incubation with either Hind III or EcoRl to
generate an antisense or sense DNA fragment, respectively, for 1-2 h at 37 °C (Seckl
et al., 1990). A kind gift from Dr Yau, Edinburgh.
2.3.l.c Rat Corticotropin-releasing factor
The Bluescript plasmid containing a 540 bp fragment of the rat corticotropin-
releasing factor (rCRF) cDNA (base pair 1525-2065) was linearized by incubation
with either Hind III or EcoRl to generate the antisense or sense DNA fragments,
respectively, for 1-2 h at 37 °C. A kind gift from Dr Diaz.
2.3.l.d Rat Arginine Vasopressin (rAVP)
The pGEM3 plasmid containing a 460 bp Hind III/EcoRl fragment of the rat
arginine vasopressin (rAVP) cDNA (base pair 7-467) was linearized with either
EcoRl or Hind III to generate the antisense or sense DNA fragment, respectively, for
1-2 h at 37 °C. A kind gift from Dr Sherman.
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To confirm that each plasmid had been cut correctly an aliquot of the reaction
mix in loading buffer (0.25% bromophenol blue, 0.25% xylene cyanol FF & 15%
ficoll 400) was run on a 1.5% agarose gel containing the alkylating agent ethidium
bromide at 10 mA and visualised under UV light.
2.3.2 Phenol/chloroform Extraction of the Plasmid
To clean the DNA fragments an equal volume of phenol/chloroform was
added, the mix vortexed then spun at 13 000 rpm for 2 min and the upper aqueous
layer, containing the DNA, collected into a fresh RNAse-free eppendorf. The
remaining lower organic layer was back-extracted i.e. 50 pi of (depc-H20) was added
and the vortexing and spin steps repeated. The resulting top layer was taken into the
fresh eppendorf and an equal volume of chloroform:isoamyl (24:1) was added. It was
then vortexed and centrifuged. The upper layer was taken into another fresh
eppendorf and the remaining organic layer back-extracted again. The DNA fragment
was ethanol-precipitated with 0.1 volumes of 3 M Na acetate and 2.5 volumes of
ethanol. The mix was vortexed, placed on dry ice for 10 min then centrifuged for 15
min and the supernatant removed. The resulting DNA pellet was carefully washed in
70% ethanol, vortexed and spun for 5 min. The supernatant was taken off and the
pellet dried in the Speedvac at a low speed for 15 sec. The DNA pellet was
resuspended in depc-H20 and to check that there was no contamination a 1 pi aliquot
was run on a 1.5% agarose gel. The remaining template was aliquoted into fresh
eppendorfs at a concentration of 1 mg/ml and stored at -20 °C.
2.3.3 35S-UTP-labelled cRNA Probes
All of the linearized cDNA fragments were incubated with excess cold
nucleotides (10 mM ATP, CTP & GTP), 200 mM DTT , a RNase inhibitor, 50 mM
35S-UTP (specific activity 40 mCi/ml) 1 pi of the specific RNA polymerases in the
presence of 5x transcription buffer to give a final volume of~ 10 pi.
76
2.3.3.a rGR cDNA
The rGR cDNA was incubated for 60 min with the RNA polymerases, T7 and
SP6 to produce antisense and sense transcripts, respectively. The incubation was
carried out at 37 °C for T7 and 40 °C for SP6 polymerases.
2.3.3.b rMR cDNA
The rMR cDNA was incubated with SP6 to generate the antisense and T7 to
transcribe the sense transcript. This is opposite to that for the rGR because the
polycloning site in the pGEM4 plasmid is in the opposite orientation to pGEM3.
2.3.3.c rCRH cDNA
To generate antisense and sense single-stranded RNA transcripts the rCRH
cDNA was incubated with T3 and T7 RNA polymerases, respectively, for 60 min at
37°C.
2.3.3.d rAVP cDNA
The antisense and sense transcripts were generated by incubating the rAVP cDNA
with SP6 and T7 RNA polymerases, respectively, for 60 min at 40 °C (SP6) and 37
°C for T7 reactions.
Following the above transcription incubations 2 pi of 5x transcription buffer, 1
pi of RNase-ffee DNase and 8 pi of depc-H20 were added to each transcription
reaction mix and incubated for 10 min at 37 °C. The reaction was stopped by placing
the tube on ice and the reaction volume was made up to 50 pi with depc-H20.
To purify the newly synthesised probe the mix was run through a 'Nick'
column (Pharmacia), prepared by loading 3 ml of Tris-EDTA (TE) buffer, pH 8.0 to
equilibrate the gel bed. The probe was applied to the top of the column followed by
400 pi of TE buffer. The elutant, which contained very little radioactivity as it
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contained predominantly free nucleotides, was discarded and a further 600 pi of TE
buffer applied to the column. This elutant was collected as it contained the labelled
cRNA probe.
To check the incorporation of the 35S-UTP a 1 pi aliquot of the probe was
counted in a (3-counter (2-5 xlO^ cpm) and to determine if degradation of the probe
had occurred 1 pi was run on a 6 M urea:5% polyacrylamide gel at 10 mA. Then, the
gel was placed against HyperP-max film, (Amersham International) overnight and
developed. The remaining probe was stored at -20 °C for a maximum of a week prior
to use for in situ hybridisation histochemistry.
2.3.4. Tissue Collection
Day 10, 16 and 21 pregnant and virgin Sprague Dawley rats were decapitated,
the brains rapidly removed, placed on tin foil on dry ice and covered with powdered
dry ice. Once completely frozen they were stored at -80 °C.
20 pm coronal brain sections containing either the PVN or the anterior
hippocampus were cut using a cryostat at -20 °C. The former area was identified by
staining every third section with pyronin Y (Sigma) and examining under a light
microscope. The sections were thaw-mounted onto gelatin and poly-L-lysine coated
slides and stored at -80 °C until used for specific in situ hybridisation analysis.
2.3.5 Tissue Fixation
Sections were fixed in 4% (w/v) paraformaldehyde/0.1 M Na phosphate buffer
(20 mM NaH2P04, 80 mM Na2HP04, pH 7.4) for 10 min at room temperature. This is
an alkylating agent which forms cross-links with nucleic acids and proteins thereby
maintaining tissue morphology and retaining target nucleic acids. The fixation step
was immediately followed by three washes in 2 x SSC (20 x SSC, Sigma) made up in
depc- H20 for 5 min each.
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2.3.6 Prehybridisation
To reduce background hybridisation of the probe all tissue sections were
treated with prehybridisation buffer (5M NaCl, 1 M Tris-HCl, pH 7.5, 50x
Denhardt's, 250 mM EDTA, 10 mg/ml salmon sperm DNA, 50 mg/ml yeast tRNA).
The components of this buffer decrease the non-specific binding to proteins,
polysaccharides and nucleic acids in the tissue sections. Sufficient prehybridisation
buffer diluted 1:1 with deionised formamide was made up to allow the application of
200 pi to each slide. The tissue sections were drained and dried around the edges
with lens tissue prior to the addition of the buffer and placed flat in the hybridisation
boxes on 3 MM Whatman paper soaked in box buffer (4 x SSC, 50% deionised
formamide in depc-H20) and incubated at 50 °C for 2 h.
2.3.7 Hybridisation
Similarly, sufficient hybridisation buffer was made up to apply 200 pi per
slide. The mix consisted of 50% deionised formamide, 10 x 106 counts/ml of
radioactive cRNA probe made up to the final volume with 2 x hybridisation buffer (5
M NaCl, 1 M Tris-HCl, pH 7.5, 50x Denhardt's, 250 mM EDTA, lOmg/ml salmon
sperm DNA, 2 g dextran sulphate & 50 mg/ml yeast tRNA). The mix was denatured
at 70 °C for 5 min, cooled on ice and 1 M DDT (10 pl/ml of probe) added.
The tissue sections were once again drained and dried around the edges prior to
the hybridisation mix being applied. The slides were then placed back in the
hybridisation boxes, sealed, and hybridised overnight at 50 °C.
The following day the slides were drained and washed three times in 2 x SSC
(NaCl, Na Citrate, Sigma) for 5 min each. They were then exposed to RNase
digestion. 200 pi of RNase buffer (5 M NaCl, 1 M Tris-HCl, pH 7.5, 250 mM
EDTA) containing 10 mg/ml RNase A (3 pl/ml of buffer), a nuclease which
specifically degrades single-stranded nucleic acids, was applied to each slide, which
were then incubated at 37 °C for 60 min.
Afterwards the slides were cycled through progressively more stringent
washes, beginning with a 30 min wash in 2 x SSC at room temp, followed by two
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washes in 0.1 x SSC at 60 °C for 60 min each. The sections were then dehydrated in
50%, 70%, and 90% ethanol in 0.3 M ammonium acetate for 2 min each. They were
then allowed to air-dry and placed against Hyperfilm(3-max (Amersham
International) for one week.
Following film development (D19, Kodak-Pathe, France) the slides were
dipped in autoradiographic emulsion (NTB2, Kodak, USA) and stored in lightproof
boxes at 4 °C for 21 days before being developed and counterstained with pyronin Y.
Silver grains were counted using a high-power (x40 objective) microscope linked to
a computer-based image analysis system (SeeScan). The number of silver grains per
neurone was counted. The data were expressed as the average no. of silver
grains/neurone in each brain region measured. Background was subtracted, which




Whole pituitaries from day 10, day 16 & day 21 pregnant or virgin Sprague
Dawley rats were collected following decapitation. Each pituitary was placed on
aluminum foil on dry ice and covered with powdered dry ice and then stored at -80
°C.
Each pituitary was sectioned horizontally at 20 pm in a cryostat at -20 °C and
mounted onto prechilled poly-L-lysine-coated slides and placed in cooled slide
boxes. Following cutting, the sections were desiccated: open slide boxes were placed
in a desiccator jar which had previously been cooled to 4 °C and contained silica
pellets (Sigma). The air was then evacuated from the jar using a vacuum pump and
the slides were allowed to desiccate overnight at 4 °C. The following morning the
slide boxes were quickly sealed with moisture-resistant adhesive tape and stored at -
20 °C until use.
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From each pituitary three slides were collected: two for total and one for non¬
specific binding. Each slide contained four pituitary sections.
2.4.2 CRF Receptor Autoradiography
Slides were preincubated for 20 min at room temperature in assay buffer (50
nM Tris/HCl , pH 7.4, 10 mM MgCl2, 2 mM EGTA, 0.1 mM bacitracin (Sigma,
Germany), aprotinin (100 KlU/ml, Trasylol, Bayer, Germany), and 0.1% BSA (RIA-
grade V, Sigma, Germany) and then carefully dried round the edges with tissues.
Subsequently, they were incubated in fresh buffer containing 0.2 nM I25I-ovine CRF
(specific activity 2200 Ci/mmol, Dupont, Germany) for 60 min at room temperature.
Non-specific binding was determined in the presence of 10"6 M unlabelled ovine CRF
(Sigma, Germany). The sections were then briefly rinsed and washed three times for
2 min in BSA-free ice-cold buffer,dipped in double-distilled H20 and dried in a
stream of cold air. The slides were then exposed to Agfascopic Video 5B film for 22
days at 4 °C.
Analysis and quantification of the autoradiographs were carried out microscopically
(objective xlO; additional magnification xl.6) using a computer-based image
analysis system (Joyce-Loebl MicroMagiscan).
The optical density was measured within a 100 pm^ frame over each section. Total
binding was measured over two different areas for the anterior pituitary and one area
each for the intermediate and the posterior pituitary gland. Non-specific binding was
measured over three different areas since the specific pituitary lobes were not
distinguishable. Background optical density was determined in two areas of the film
off the tissue for each slide and the mean subtracted from the tissue optical density.
The mean optical density was calculated for each rat pituitary lobe, the mean non¬
specific binding subtracted and the group mean calculated.
2.5 Statistical Analysis
Data from all in vitro assays and in situ hybridisation histochemistry studies
were analysed by Analysis of Variance followed by Newman-Keuls Student's test,
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except the cAMP accumulation data which was analysed by Student's t test and the
11P-HSD1 conversion assay which was analysed by Kruskal-Wallis followed by
Mann-Whitney U test..
All in vivo studies were analysed by Two way Analysis of Variance for
repeated measures followed by Newman-Keuls Student's test unless otherwise
stated. Significance was set at p < 0.05 and values were expressed as mean ± S.E.M.
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CHAPTER 3
An attenuated HPA axis stress response in pregnancy
3.1 Introduction
The activity of the HPA axis can be altered by several physiological and
pathophysiological conditions that challenge the internal homeostasis of the
organism. Aging (Hatzinger et al., 1996) and a number of psychiatric disorders,
including depression (Holsboer & Barden, 1996), anorexia nervosa (Gold et al.,
1986), panic anxiety (Gold et al., 1988b) and obsessive-compulsive disorder (Insel et
al., 1982) have been associated with chronic activation of the HPA axis as reflected
by enhanced CRF secretion and elevated basal plasma corticosterone concentrations.
Alternatively, conditions such as seasonal affective disorder or the postpartum period
have been associated with decreased CRF secretion and therefore a hypoactivity of
the HPA axis (Vanterpool et al., 1991; Chrousos & Gold, 1992).
The reproductive state of the organism also appears to have profound effects on
the responsiveness of the HPA axis. In lactation the basal circulating levels of both
ACTH and corticosterone have been shown to be increased (Yoogt et al., 1969). An
elevation of the morning corticosterone levels and a slight reduction in the peak
evening levels has been reported (Stem et al., 1973), resulting in a loss of the normal
corticosterone circadian rhythm. A recent detailed study by Atkinson & Waddell
(1995) confirmed the previous results. It was found that while corticosterone lost its
natural rhythm, due to a decrease in peak levels, ACTH maintained a normal rhythm
with elevation in both trough and peak levels. This dissociation between plasma
ACTH and corticosterone levels postpartum has been proposed to reflect changes in
the circulating ovarian steroid enviroment. During lactation the plasma levels of
estrogen are relatively low compared with those in pregnancy (Taya & Greenwald,
1982). Estrogen has been shown to increase adrenal responsiveness, although the
mechanism underlying this effect is unknown. Thus the fall in plasma estrogen
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concentrations postpartum may result in reduced adrenal sensitivity to ACTH (Kitay
et al., 1965) and the relative differences in circulating levels of ACTH and
corticosterone.
Furthermore, the classical stress response of the pituitary-adrenal axis appears
to be blunted in lactation (Stern et al., 1973). In response to a number of stressors
including physical (Altemus et al., 1995; Walker et al., 1995), noise stress (Windle et
al., 1997) and exposure to ether (Walker et al., 1992) the ACTH and consequently
the corticosterone responses in both humans and rodents are significantly reduced.
Several in situ hybridisation studies have revealed changes in gene expression
occurring in the hypothalamus of lactating rats exposed to an acute stress. In
response to an intraperitoneal (i.p.) injection of hypertonic saline (1.5 M) virgin
control animals showed a rapid induction in the expression of CRT and AVP
mRNA's in the parvocellular PVN. In contrast, the stimulation was completely
abolished during lactation (Lightman & Young III, 1989). However, removal of the
pups for a minimum of two days resulted in a return of the normal responsiveness of
the CRF mRNA to stress (Lightman & Young III, 1989; Stern & Levine, 1972).
Pregnancy may also be seen as a perturbation of the internal environment of the
mother; however until recently most of the reports were concerned with effects of
pregnancy on the basal activity of the HPA axis. In rats, increased corticosterone
levels and the maintenance of a diurnal rhythm have been reported (Dupouy et al.,
1975; Ogle & Kitay, 1977; Atkinson & Waddell, 1995). In addition, a concomitant
decrease in the plasma immunoreactive ACTH concentrations was found and a loss
of its circadian rhythm with progressing pregnancy. Again this dissociation between
plasma levels of these hormones may reflect the changes in the relative estrogen
plasma levels. During pregnancy the high estrogen levels (Shaikh, 1971) may
increase the sensitivity of the adrenal gland to ACTH (Kitay et al., 1965).
A recent collaboration between our group and R. Landgraf s group in Munich,
Germany was carried out to determine whether the hyporesponsiveness of the HPA
axis to an acute stress, seen in lactation, was established in pregnancy (Neumann et
al., 1998). Wistar rats at various stages of pregnancy, which had previously been
fitted with jugular cannulae, were exposed to a mild emotional stressor, the elevated
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plus-maze (EPM) (Liebsch et al., 1995) followed by a moderate physical/emotional
stressor, 90 sec of forced swimming (FS) (Abel, 1994) and their neuroendocrine
responses compared with virgin rats. It was found that from day 15 of pregnancy
there was a significant reduction (p < 0.01, two way ANOVA for repeated measures)
in the peak ACTH and corticosterone secretory responses compared to virgin and day
10 pregnant rats.
It is well documented that the responsiveness of the HPA axis varies between
rat strains. The Fischer (F344/N) rat strain shows an elevated HPA responsiveness to
stress, which is proposed to be mediated through impairment of the glucocorticoid
feedback signal. On the other hand the HPA axis of the Lewis rat strain is
hyporesponsive to acute stress, which was originally proposed to occur at the level of
the parvocellular CRF neurone itself (Sternberg et al, 1992), however, recently
Rivest & Rivier (1994) provided evidence that this hyporesponsiveness may reflect a
defect in the afferent signalling to these neurones.
It is also well known that stressors which may be physical or psychological
activate different afferent pathways to the PVN neurones. Thus unlike Hans Seyle's
(1936) concept of a 'general stress response' it is now accepted that there is stress-
specific activation of PVN neurones leading to the potential for differences in the
stress response to occur (Harbuz et al., 1994; Harbuz & Lightman, 1989).
Thus, we were interested in demonstrating that this phenomenon of an
attenuated HPA axis stress response occurred during pregnancy, as demonstrated by
Neumann et al. In this study we used Sprague Dawley rats and 20 min of restraint
stress, a primarily psychological stressor.
3.2 Material and Methods
Individually caged pregnant and virgin animals had a silastic jugular cannula
inserted by the method described in detail in Chapter 2. The experiment was carried
out three to four days following surgery to allow the animals to recover.
On the morning of the experiment, sampling cannulae attached to 1 ml
syringes filled with sterile heparinised saline (20 IU/ml 0.9% saline) were connected
between 07.00 and 08.00 h and the animals left undisturbed for 90 min. Following
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the collection of basal blood samples each animal was placed in a clear perspex
restraining tube (ID 5 cm, tube length 20 cm) for 20 min. Afterwards, they were
returned to their homecages and at 5, 15, 30 and 60 min post-stress blood samples
were collected. For each blood sample a volume of 0.3 ml (ACTH and corticosterone
measurements) was taken and immediately replaced with an equal volume of sterile
saline. All blood samples were collected into EDTA-coated tubes on ice and
centrifiiged at 3000 g for 5 min. The plasma was aliquoted (150 pi for ACTH and 50
pi for corticosterone) and stored at -70 °C until assayed by sensitive and selective
assays. For details see Chapter 2.
At the end of the experiment the animals were killed by an intravenous
overdose of anaesthetic (Sagatal) (600 pl/animal)and their pregnancy status checked.
3.3 Results
Two way ANOVA for repeated measures (RM) of the plasma ACTH and
corticosterone concentrations in both groups demonstrated a significant interaction
between time and group (p < 0.001); all other specific comparisons were derived
from Newman-Keuls t test (p < 0.05).
The basal concentrations of ACTH did not differ significantly between day 21
pregnant (n = 8) and virgin rats (n = 8), (12.9 ± 5.0 vs. 17.5 ± 4.2 pg/ml,
respectively). Following exposure to 20 min of restraint plasma ACTH levels
significantly increased in both groups (p < 0.05, 12- and 14-fold, pregnant and virgin,
respectively, at 5 min). However, the magnitude of the ACTH response to the
restraint stress was significantly less in the pregnant animals compared to virgin
controls at 5, 15 and 30 min post-stress (Fig 3.1a, p < 0 .05). At 60 min post-stress
the plasma ACTH levels had returned to basal concentrations.
Basal plasma corticosterone concentrations were not significantly different
between the day 21 pregnant and virgin groups (131.5 ± 15.1 vs. 111.8 ± 45.2 ng/ml,
respectively) and following the restraint stress corticosterone levels reached a
86
maximum 15 min post-stress (5- and 8-fold, p < 0.05, pregnant and virgin,
respectively) in both groups. As with ACTH, the magnitude of the corticosterone
response to the stress in the day 21 pregnant animals were significantly less at both 5
and 15 min post-stress (Fig 3.1b, p < 0.05). At 60 min post-stress the plasma
corticosterone levels had returned to baseline levels in both groups.
3.4 Discussion
The results from this study are in agreement with the observations of Neumann
et al (1998) that the hyporesponsiveness of the HPA axis to an acute stress is
established during pregnancy. In addition, our finding suggest that this phenomenon
is independent of the type of stress or the rat strain used.
In this study we were able to show a robust increase in plasma levels of ACTH
and corticosterone in response to 20 min of restraint in both pregnant and virgin rats.
This is in contrast to the finding in lactating rats where following hypertonic saline
i.p. there was no significant rise in the plasma corticosterone levels (Lightman &
Young III, 1989). However, in that study the basal corticosterone levels in lactating
rats were already higher than in the virgin controls, although not significantly so,
This fact may account for the absence of a response to the stress and in addition the
ACTH response was not measured. We found the peak plasma ACTH and
corticosterone responses were significantly reduced by 42% and 20%, respectively,
on day 21 of pregnancy which is comparable to the attenuations previously seen by
Neumann et al (1998) using physical/emotional stressors. These result could simply
reflect an enhanced metabolic clearance of ACTH and corticosterone during
pregnancy; however, a study by Waddell & Atkinson (1994) clearly demonstrated, at
least in the case of corticosterone, that the clearance rate did not differ between
pregnant and nonpregnant animals. The ACTH response to the restraint stress
exhibited a longer lasting suppression than the corticosterone response. This apparent
dissociation between the ACTH and corticosterone response may suggest that during
pregnancy the adrenal gland becomes highly sensitive to ACTH. Indeed, estrogen has
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Fig 3.1a: The effect of 20 min restraint stress on plasma ACTH levels in
pregnant and virgin rats. Basal blood samples (time 0) were collected
from day 21 pregnant (■, n = 8) and virgin (#, n =8) rats. Immediately
after, each animal was restrained for 20 min and blood samples collected
5, 15, 30 & 60 min after the end of the stress. Two way ANOVA for RM
followed by Newman-Keuls student's test: * p < 0.05 vs. virgin group at 5, 15
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Fig 3.1b: The effect of 20 min restraint stress on plasma corticosterone
levels in pregnant and virgin rats. Basal blood samples (time 0) were
collected from day 21 pregnant (■, n = 8) and virgin (#, n = 8) rats.
Immediately after, each animal was restrained for 20 min and blood
samples collected 5, 15, 30 & 60 min after the end of the stress. Two way
ANOVA for RM followed by Newman-Keuls student's test: * p < 0.05 vs.
virgin group at 5 & 15 min post-stress.
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The mechanism(s) underlying the suppression of the stress response in
pregnancy is/are not known. Several studies have examined the suppression of the
responsiveness of the HPA axis during lactation. Interestingly, removal of the pups
from the mother for a minimum of two days results in the return of the normal stress
responsiveness of the HPA axis (Lightman & Young III, 1989; Stern & Levine,
1972) leading to the suggestion that either suckling per se and/or an olfactory
stimulus from the pups may be responsible for this suppressed stress responsiveness.
However, it has subsequently been shown that suckling is a potent stimulator of the
HPA axis and probably accounts for the tonically elevated trough plasma ACTH and
corticosterone levels that occur during lactation (Walker et al., 1992). Circulating
levels of corticosterone are high in both late pregnancy and during lactation and may
be responsible for the dampened responsiveness of the HPA axis during stress. One
report suggested that the lactating rat was more sensitive to feedback (Schlein et al.,
1974), however, in this study dexamethasone was given and corticosterone, not
ACTH, was measured as the experimental end point. A more recent report by Walker
et al (1992) found no differences in the sensitivity to glucocorticoid feedback
between lactating and virgin rats. Studies looking at feedback sensitivity during
pregnancy have found either no difference or a decreased sensitivity (Keller-Wood,
1996; Owens et al., 1987; see Chapter 5).
A recent study by da Costa et al (1996) examined the expression of the
immediate early gene c-fos mRNA in specific brain areas of both late pregnant and
lactating rats following restraint stress. The mRNA expression of c-fos in the PVN,
the medial amygdala and the lateral septum, both of which possess connections with
the PVN (Sawchenko & Swanson, 1983) was significantly less in both late pregnant
and lactating rats following stress. Since c-fos mRNA expression is widely
recognised as a marker of neuronal activation (Sagar et al., 1988) these results
suggest that the modulation of afferent inputs to the PVN may be involved in
reducing the responsiveness of the HPA axis during both pregnancy and lactation.
However, as mentioned previously, quantitative differences appear to exist between
the stress responsiveness of the late pregnant and lactating rat. The latter has been
shown not to respond to a physical stress (Lightman & Young III, 1989), although
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others have shown a response to ether stress (Walker et al., 1992). Thus, other
mechanisms probably downstream from the afferent pathways may also have a role
in attenuating the stress response.
Therefore, we went on to investigate whether changes in the forward drive, or
in the negative glucocorticoid feedback signal on the HPA axis, or a combination of
both are responsible for this attenuation of the neuroendocrine stress responses in
pregnancy.
Why have an attenuated HPA axis response to acute stress during pregnancy?
Epidemiological studies in several different human populations have demonstrated
that indicators of an adverse intrauterine enviroment, including low birth weight are
associated with increased incidence of cardiovascular disease (Barker et al., 1993),
hypertension (Barker et al., 1990) and non-insulin-dependent diabetes mellitus
(Hales et al., 1991) in adulthhood, supporting the hypothesis that early life events
programme later blood pressure regulation and glucose homeostasis. Mechanisms
underlying prenatal programming are unclear, although maternal malnutrition has
been proposed to have a strong influence (Barker et al., 1993; Hales et al., 1991). An
alternative mechanism is exposure of the fetus to maternal glucocorticoids. Exposure
to excess glucocorticoids in utero results in retarded fetal growth (Reinisch et al.,
1978). More recently, it has been shown that adult offspring of pregnant rats treated
with a moderate dose of dexamethasone (100 pg/kg/day) have elevated systolic
blood pressures (Benediktsson et al., 1993). This supports the hypothesis that
prenatal exposure to glucocorticoids leads to the development of diseases, such as
hypertension, in adult life (Edwards et al., 1993). Under normal circumstances the
fetus is protected from high maternal levels of physiological glucocorticoids by
placental 11 (3-hydroxysteroid dehydrogenase type 2 (11[3-HSD2), which catalyses
the rapid conversion of active glucocorticoids (Cortisol in humans and corticosterone
in rodents) to inert 11-keto derivatives (cortisone and 11-dehydrocorticosterone,
respectively). It is highly expressed in the placenta, particularly in the
syncytiotrophoblast (Brown et al., 1996), and maintains the low fetal glucocorticoid
levels (Edwards et al., 1993). Several in vivo studies have shown the importance of
this enzyme in regulating the access of glucocorticoids to the fetus. When
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carbenoxolone, a potent inhibitor of 11 (3-HSD2, is administered to the mother the
adult offspring exhibit higher fasting plasma glucose levels (Lindsay et al., 1996a)
and elevated blood pressure (Lindsay et al., 1996b). A recent in situ hybridisation
study examined the expression of the 11 (3-HSD2 gene in the murine fetoplacental
unit and found that from embryonic day 16.5 its mRNA expression in the placenta
was switched off (Brown et al., 1996). This result suggests that near term the 11(3-
HSD2 barrier to glucocorticoids is removed. However, this finding does not correlate
with 11(3-HSD activity data, which is present in rodent term placenta (Brown et al.,
1993; Burton & Turnell, 1968) and thus possibily reflects persisting 11(3-HSD2
protein and/or the presence of the 11[3-HSD1 isoform or even an unique isoform.
Although the type 2 isoform is the predominant form in the placenta lip-HSDl
activity is also present. Burton & Waddell, (1994) measured the in vitro activity of
1 lp-HSDl in placental fragments isolated from day 16, day 19 and day 22 pregnant
rats. 11 P-reductase activity declined while 11 P-dehydrogenase activity increased
with advancing pregnancy, thus, there was a net increase in placental 11 P~
dehydrogenase activity towards term, consistent with a reduction in the transfer of
active glucocorticoids between mother and fetus. However, at midterm lip-HSD
enzyme activity in the human, baboon and rat placenta appear to be predominantly
reductive (Burton & Waddell, 1994). It is likely that the transfer of some maternal
glucocorticoids to the fetus is important during early development since in the
majority of species the fetus is incapable of synthesising its own glucocorticoids until
relatively late in pregancy (Dupont et al., 1991). In the rat, it has been reported that
the fetal adrenal cortex develops the capacity to synthesise corticosterone only after
day 17 of gestation (Milkovic et al., 1973); however, a more recent report indicated
that the fetus possessed this ability by day 14 of gestation (Cohen et al., 1990). Thus
placental lip-HSD activity appears to regulate rather than exclude maternal
glucocorticoids during fetal development.
The suppression of the HPA axis response to stress may be an additional
adaptive response by the mother to protect the fetus from exposure to excess
glucocorticoids. Free circulating levels, regardless of the higher CBG levels, have
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been shown to be elevated during pregnancy, especially toward term (Nolten &
Rueckert, 1981). In response to a stress the rise in plasma corticosterone levels will
be superimposed on an already high baseline. With progressing pregnancy these high
stress-induced levels may potentially swamp the protective llp-HSD placental
barrier and gain access to the fetal compartment at a time when excessive exposure
will be deleterious to the fetus. It is of interest that the suppression of the maternal
stress responsiveness by day 15 of pregnancy (Neumann et al., 1998) coincides with
the ability of the fetus to synthesise its own glucocorticoids (Cohen et al., 1990).
Alternatively, or in addition, the attenuated HPA axis responsiveness may be a
mechanism allowing the conservation of maternal energy stores which are required to
support the developing fetus, particularly in late pregnancy (Knopp et al., 1973;
Metcalfe et al., 1988), and during parturition. During stress the increased plasma
corticosterone levels mobilise energy stores to allow the organism to overcome the
stress. Thus, in the pregnant rat the lower stress-induced plasma corticosterone levels
will cause less energy mobilisation and the conservation of these stores.
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CHAPTER 4
Changes at the level of the PVN and in the responsiveness of the
anterior pituitary corticotrophs during pregnancy
4.1 Introduction
The observed attenuation of HPA axis responses to acute stress in pregnancy
(Neumann et al., 1998; see Chapter 3) may reflect adaptations occurring in the
central neural forward drive to the axis. The hypothalamic paraventricular nucleus
(PVN) is the central coordinator of the stress response as it receives extensive
afferent innervation from numerous brain regions (Cullinan et al., 1993; Cunningham
& Sawchenko, 1988; Gray et al., 1989; Sawchenko & Swanson, 1982, 1983; Weller
& Smith., 1982) through which inputs, both inhibitory and stimulatory, modulate the
activity of the axis. Major inputs arise from catecholaminergic cell groups in the
brainstem (Cunningham & Sawchenko, 1988; Sawchenko & Swanson, 1982) and
from the bed nucleus of the stria terminalis (BNST) which relays inputs from several
limbic structures including the hippocampus and amygdaloid complex (Cullinan et
al., 1993).
The parvocellular CRF neurones of the PVN provide the central neural drive to
the pituitary-adrenocortical axis during the diurnal peak and in response to stressful
stimuli (Akana & Dallman, 1992; Akana et al., 1992). These neurones receive
abundant innervation from both the noradrenergic A2 cell group (nucleus of the
solitary tract, NTS) and several of the adrenergic CI, C2 and C3 cell groups in the
brainstem (Cunningham et al., 1990) and at the ultrastructural level both
noradrenergic and adrenergic nerve terminals have been described on the dendrities
and cell bodies of the CRF-containing neurones (Liposits et al., 1986). Data from
animal and human studies indicate that the brainstem noradrenergic system is
activated alongside the HPA axis during stress (for review see Chrousos et al., 1988)
and catecholamines appear to stimulate the HPA axis through the release of CRF
(Plotsky et al., 1989).
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A number of studies have investigated the regulation of gene expression and
the release pattern into the HPB of several ACTH secretagogues including CRF.
Regulation appears to occur in a stress specific manner with physical and
psychological stressors exhibiting a different pattern of expression indicating that
different afferent pathways and neurotransmitters may be involved in these stresses
(Harbuz & Lightman, 1989). Following acute stresses such as restraint or swim stress
or i.p. hypertonic saline the levels of parvocellular CRF and AVP but not oxytocin
(OXT) mRNAs increased (Harbuz & Lightman, 1989; Herman & Sherman, 1993;
Kalin et al., 1994) and these changes are reflected in studies examining hypothalamic
content (Lightman & Young III, 1988; Moldow et al., 1987). Intracistemal injection
of colchicine disrupts fast axonal transport of secretatogues from the parvocellular
cell bodies in the PVN, thus creating an isolated pool of secretagogues in the median
eminence. Decreases in this pool following stimulation correlate with a release of
secretagogues into the HPB; it was found that exposure to a psychological stressor
decreased immunoreactive OXT (irOXT) but not the irCRF content of the median
eminence (Romero et al., 1993). This indicates that in addition to driving the ACTH
response during severe stress CRF functions in a permissive role in response to
milder stressors, by allowing weaker secretagogues such as AVP and OXT to exert
their effects (Plotsky et al., 1985a).
The removal of the glucocorticoid negative feedback signal by adrenalectomy
(adx) is a powerful stimulus to the HPA axis (Plotsky & Sawchenko, 1987). Several
hybridisation studies have investigated the effects on the expression of the CRF and
AVP genes. Pharmacological adx achieved with metyrapone, an 11 (3-hydroxylase
inhibitor, which prevents the conversion of 11-deoxycorticosterone to corticosterone,
caused increased immunohistochemical staining for CRF and AVP in the PVN,
median eminence CRF and AVP contents and concentrations in HPB by 72 h
(Plotsky & Sawchenko, 1987). With an intronic probe to the CRF gene it has been
demonstrated that within 30 min of metyrapone the CRF primary transcript levels are
increased (Herman et al., 1992). Other hybridisation studies following surgical adx
found an increase in CRF mRNA in the PVN ranging from 60% to 275% over
baseline levels (Beyer et al., 1988; Imaki et al., 1991; Young et al., 1986). However,
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other reports showed more modest increases in CRF mRNA levels (Albeck et al.,
1994; Swanson & Simmons, 1989). Quantitative differences between studies are
likely to reflect different methods of quantification. In contrast, AVP mRNA
expression and immunoreactivity in the parvocellular PVN consistently increase
following adx (Albeck et al., 1994; Davis et al., 1986; Sawchenko, 1987) and these
findings confirm in vitro data where the ratio of AVP:CRF released from the median
eminence increased from 2:1 to 9:1 following adx (Holmes et al., 1986).
A recent report using in situ hybridisation examined the basal expression of
CRF mRNA in the PVN during pregnancy and found that parvocellular CRF mRNA
expression on day 21 of pregnancy was significantly decreased (Douglas & Russell,
1994), indicating either an increased inhibitory influence consistent with an increased
negative feedback signal or decreased excitatory input at the level of the
parvocellular cell bodies. We sought to confirm this observation with a different
technique. We used a cRNA (riboprobe) rather than an oliogonucleotide probe
because riboprobes possess a higher specific activity therefore producing a stronger
signal upon hybridisation and making it more sensitive for measuring small changes
in mRNA expression (Tecott et al, 1987).
CRF exerts its physiological effects by binding to G-protein-linked membrane-
bound receptors (Chang et al., 1993) and in vitro, CRF increases intracellular cAMP
levels in cultured anterior pituitary cells (Aguilera et al., 1986). The CRF receptors
characterised so far are encoded by two separate genes and differ in their anatomical
distribution and pharmacological profiles. The CRFR,, which was the first to be
isolated, has a widespread central distribution (Wong et al., 1994) and is the
dominant form in the pituitary (Potter et al., 1994). CRF has a higher affinity for this
receptor subtype than either the related mammalian urocortin, amphibian sauvagine
or fish urotensin I. The CRFR2 exists as two splice variants, CRFR2ot and CRFR2P)
and these have distinct tissue distributions. CRFR2a is expressed in limited areas of
the brain, including the lateral septum and ventromedial hypothalamus, whereas
CRFR2(3 is found in peripheral tissues including the heart and skeletal muscle as well
as in the brain, where it is associated with blood vessels (Lovenberg et al., 1995a).
Urocortin, sauvagine and urotensin I are all more potent then CRF at increasing
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cAMP in cells transfected with either CRFR2 subtype (Kishimoto et al., 1995; Perrin
et al., 1995, Vaughan et al., 1995).
Regulation of pituitary CRFR binding has been readily demonstrated in rats
given exogenous CRF or glucocorticoid treatment and after exposure to stress or
following adx (Hauger & Aguilera, 1993; Hauger et al., 1987,1990; Wynn et al.,
1985). Later studies examining the regulation of the CRFRj gene found comparable
results. In cultured anterior pituitary cells CRF dose- and time-dependently decreased
CRF receptor mRNA expression (Pozzoli et al., 1996; Sakai et al., 1996) as did in
vitro and in vivo glucocorticoid treatment, exposure to either acute or chronic
immobilisation stress and adx (Makino et al., 1995; Sakai at al., 1996).
Neumann et al, (1998) reported that the ACTH response to exogenous CRF in
vivo was significantly attenuated from day 15 of pregnancy, indicating that an
adaptation may have occurred at the level of the anterior pituitary resulting in
decreased sensitivity to CRF.
We used receptor autoradiography to examine whether there was an alteration
in the density of CRF binding sites in the anterior pituitary during pregnancy. In
addition we examined the accumulation of cAMP in pituitary segments and acutely
dispersed anterior pituitary cells isolated from pregnant and virgin rats, in response to
exogenous CRF.
4.2 Material and Methods
4.2.1 CRF and AVP mRNA in situ hybridisation histochemistry
For details see Chapter 2. Briefly, individually housed day 10, 16 & 21
pregnant and virgin rats were tranferred separately to the experimental room where
they were decapitated between 09.30 h and 10.30 h to minimize the effects of stress.
The brains were rapidly removed and immediately frozen on dry ice. 20 pm cryostat-
cut coronal brain sections mounted onto gelatin and poly-L-lysine coated slides were
fixed in 4% paraformaldehyde, incubated with prehybridisation buffer for 2 h at 50
°C and then hybridised overnight at 50 °C with 35S-labelled antisense cRNA probes.
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T3 polymerase was used to transcribe the CRF riboprobe from a Xba I-
linearised pBluescript plasmid containing the rat CRF cDNA insert and SP6
polymerase was used to transcribe the AVP riboprobe from a ECoR I-linearised
pGEM3 plasmid containing the rat AVP cDNA insert.
The following morning the sections were washed in reducing salt concentration
to a maximum of 0.1 x SSC at 60 °C for 60 min. Then the sections were dehydrated
with increasing concentrations of ethanol in 0.3 M ammonium acetate and allowed to
air-dry. The sections were then placed against film for 7 days to check that the
hybridisation signal was specific. Afterwards they were dipped in photographic
emulsion and stored at 4 °C for 21 days before being developed and counterstained
with pyronin Y. The length of time that the sections were exposed against film and
after dipping in autoradiographic emulsion were based on previous trials in the
laboratory.
To determine the specificity of the hybridisation signal adjacent slides were
hybridised with 35S-labelled sense cRNA probes which were not complementary to
the CRF or AVP mRNAs. They were both transcribed using T7 polymerase. For
details see Chapter 2.
Analysis was carried out using a high power microscope (objective x40) linked
to a computer-based image analysis system (See scan). See Chapter 2. The number of
silver grains per neurone in the medial parvocellular PVN were determined; for each
animal, measurements were made on three sections. Background measurements were
made on adjacent areas of tissue and automatically subtracted from the PVN
measurements. The group means were then calculated and the data expressed as
percentages of virgin control.
4,2,2 [n5I]CRF binding in the pituitary
For details see Chapter 2. Briefly, day 10, 16 & 21 pregnant and virgin rats
were decapitated between 9.30 h and 10.30 h and the pituitary glands removed and
immediately frozen on dry ice. 20 pm cryostat-cut horizontal pituitary gland sections
were mounted onto gelatin and poly-L-lysine-coated slides and desiccated overnight
at 4 °C.
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For receptor autoradiography, sections were incubated with 0.2 nM
[l25I]ovineCRF (oCRF) (specific activity 2200 Ci/mmol) at room temperature for 60
min. Non-specific binding was determined in the presence of unlabelled oCRF (10-6
M). Sections were then washed three times in BSA-ffee Tris-HCl buffer at 4 °C for 2
min each, dried in a stream of cold air and exposed to film for 22 days.
Analysis of the autoradiographs was performed using a microscope (objective
xlO; additional magnification xl.6) linked to a computer-assisted image analysis
system (Joyce-Loebl Micromagiscan). Silver grain area per unit area (silver grain
density), was measured within a 100 pm2 frame over each section. Total binding was
measured over two different areas of the anterior pituitary, one area of the
intermediate lobe and one area of the posterior lobe per section; for each animal
measurements were made on three sections. Background measurements were made
on adjacent areas off the tissue for each pituitary and the background silver grain
density subtracted from the tissue grain density. For non-specific binding, three
measurements of pituitary grain density were made on sections incubated with excess
unlabelled oCRF; the pituitary lobes were not distinguished.
Mean silver grain density values were calculated for each rat per pituitary lobe
and the mean non-specific binding values subtracted from the total. Group means
were then calculated (Fig 4.3a).
4.2.3 In vitro CRF-induced anterior pituitary cAMP levels
4.2.3.1 Anterior pituitary segments
For details see Chapter 2. Briefly, day 10, 16 & 20 pregnant and virgin rats
were transferred singly to the experimental room between 9.30 h and 10.30 h where
they were decapitated and the anterior pituitaries rapidly removed. Each anterior
pituitary was cut into eight equally-sized segments under a dissecting microscope by
hand with a scapel blade. The segments were then incubated with DMEM and 0.5
mM IBMX, a phosphodiesterase inhibitor for 15 min at 37 °C in 24 well cluster
plates. The segments were then challenged with either 20 nM human CRF (hCRF)
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(final concentration 10 nM) or DMEM (vehicle) for 10 min and the reaction stopped
with the addition of ice-cold 0.2 N HC1.
Total cAMP levels were measured using a specific and sensitive
radioimmunoassay (Dufau et ah, 1973). See Chapter 2 for details.
4.2.3.2 Acutely dispersed anterior pituitary cells
For details see Chapter 2. Briefly, day 21 pregnant and virgin rats were
decapitated between 9.30 h and 10.30 h and the anterior pituitaries rapidly removed.
Each anterior pituitary was finely chopped by hand with a scalpel blade and pooled
into their respective groups; pregnant and virgin. The cells were dispersed with
trypsin at 37 °C and after approximately 25 min the trypsin was inactivated by the
addition of a trypsin inhibitor. The cells (2 x 10^ cells/tube) were then challenged
with hCRE; 0.1, 1 or 10 nM or DMEM for 10 min at 37 °C. The reaction was
initiated with the addition of the cells and terminated with the addition of ice-cold 0.2
NHC1.
Total cAMP levels were determined using a specific highly sensitive acetylated
cAMP radioimmunoassay. See Chapter 2 for details.
4.3 Results
4.3.1 CRF and AVP mRNAs: basal expression
In both in situ hybridisation studies the hybridisation signal was primarily
located in the cytoplasm of the cells and hybridisation with the sense probes in
adjacent sections did not produce a signal (Fig 4.1). The analysis of the in situ
hybridisation for AVP mRNA was carried out in the dorsomedial region of the PVN
since this area contains the highest density of AVP-positive CRF neurones (Whitnall
& Gainer, 1989). We also detected a few scattered magnocellular neurones within
this region which expressed extremely high levels of AVP mRNA within this region,
however, these were not included in the analysis.
The number of silver grains/neurone, corresponding to CRF mRNA expression,
in the medial parvocellular region of the PVN decreased during pregnancy (Fig
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4.1b). On days 10 and 16 of pregnancy, the CRF mRNA expression was slightly
decreased, although not significantly, compared to the virgin controls. On day 21 of
pregnancy, however, the number of silver grains/neurone was significantly decreased
(p < 0.05 vs. virgin) by approximately 30% compared to virgin controls.
The silver grain density over dorsomedial PVN neurones, representing AVP
mRNA expression, did not significantly differ between virgin and any of the days of
pregnancy examined (Fig 4.2).
4.3.2 [125I]oCRF autoradiography
This study was a collaboration with Prof. R Landgrafs group in the
Neuroendocrinology laboratories at the Max Planck Institute of Psychiatry, Munich,
Germany.
The silver grain density, representing specific [125I]oCRF binding site density,
was significantly reduced in the anterior pituitary on all days of pregnancy examined
(p < 0.01 vs. virgin) (Fig 4.3b). On day 10 and 16 of pregnancy the specific [125I]CRF
binding was decreased by approximately 50%. There was a further significant
decrease of 20% on day 21 of pregnancy (p < 0.05 vs. day 10 & 16 of pregnancy).
Specific [125I]CRF binding in the intermediate lobe was significantly reduced (p
< 0.05 vs. virgin) on day 21 of pregnancy only (Fig 4.3c).
The binding of [l25I]CRF in the posterior pituitary was undetectable above the
non-specific binding values.
4.3.3 In vitro CRF-induced anterior pituitary cAMP levels in virgin and
pregnant rats
4.3.3.1 Pituitary segments
In the presence of the phosphodiesterase inhibitor, IBMX, the basal and the
CRF-stimulated cAMP accumulation were significantly lower in pituitary segments
isolated from day 16 & 20 pregnant rats compared to the respective virgin controls (p
< 0.05 vs. virgin group, basal and CRF-stimulated cAMP values on day 16 of
pregnancy; basal values on day 20 of pregnancy; and p < 0.01 vs. virgin group, CRF-
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Fig 4.1a: Photographs of CRF mRNA hybridisation in the PVN of A virgin, B day 10
pregnant, C day 16 pregnant & D day 21 pregnant rats. E sense probe hybridisation.
Regions of the PVN: pm = posterior magnocellular ; mp = medial parvocellular, dp =
dorsal parvocellular ; & pv = periventricular. 3V = third ventricle.
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Fig 4.1b: CRF mRNA expression in the medial parvocellular region
of the PVN. Sections were analysed by a computer-based image
analysis system (SeeScan) as the mean number of silver
grains/neurone and data expressed as % of virgin control ± S.E.M.
ANOVA on raw data followed by Newman-Keuls student's test: * p <
0.05 vs. virgin group, n = 6/group.
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Fig 4.2 : AVP mRNA expression in the dorsal medial parvocellular
region of the PVN. Sections were analysed by a computer-based
image analysis system (SeeScan) as the mean number of silver
grains/neurone and data expressed as % of virgin control ± S. E.M..





Fig 4.3a: Representative photographs of the autoradiographs of [ I]CRF binding in
whole pituitary sections. A - virgin, B - day 10 of pregnancy, C - day 16 of
pregnancy, D - day 21 of pregnancy & E - non-specific binding. AP - anterior
pituitary, IL - intermediate lobe & PP - posterior pituitary.
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Fig 4.3b: Specific binding of [125I]oCRF in the anterior lobe from
pituitaries collected from day 10, 16 & 21 pregnant and virgin rats
( n = 6/group). Film was analysed by a computer-based image
analysis system (Joyce-Loebl Magiscan) and data expressed as mean
± S.E.M. silver grain density over a unit are. ANOVA followed by
Newman-Keuls student's test: * p < 0.05 vs. day 10 and 16 of
pregnancy and ** p < 0.01 vs. virgin group.
108
0.8 1
Virgin Day 10 Day 16 Day 21
Days of pregnancy
Fig 4.3c: Specific binding of [125I]oCRF in the intermediate lobe of
pituitaries collected from day 10, 16 & 21 pregnant and virgin rats
(n = 6/group). Film was analysed by a computer-based image
analysis system (Joyce-Loebl Magiscan) and data expressed as mean
± S.E.M. silver grain density over a unit area. ANOVA followed by






basal 10 nM CRF CRF - basal
Fig 4.4a: cAMP accumulation in anterior pituitary segments isolated
from (■) virgin and (□) day 10 pregnant rats, n = 4 and 6, respectively.
Anterior pituitary segments were incubated in vitro with 10 nM hCRF or
vehicle (DMEM) for 10 min and the reaction was stopped with the





basal io nM CRF CRF - basal
Fig 4.4b: cAMP accumulation in anterior pituitary segments isolated
from (■) virgin and (□) day 16 pregnant rats, n = 4 and 6, respectively.
Anterior pituitary segments were incubated in vitro with 10 nM hCRF or
vehicle (DMEM) for 10 min and the reaction was stopped with the
addition of ice-cold 0.2 N HC1. Data expressed as mean ± S.E.M. nmol





basal 10 nM CRE CRF - basal
Fig 4.4c: cAMP accumulation in anterior pituitary segments isolated
from (■) virgin and (□) day 20 pregnant rats, n = 8 in both groups.
Anterior pituitary segments were incubated in vitro with 10 nM hCRF
or vehicle (DMEM) for 10 min and the reaction was stopped with the
addition of ice-cold 0.2 N HC1. Data expressed as mean ± S.E.M.
nmol cAMP accumulation/well. Students t test: * p < 0.05, ** p < 0.01
vs. virgin group
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stimulated value on day 20 of pregnancy) (Figs 4.4b & 4.4c). No difference was
found in pituitary segments from day 10 of pregnancy compared to their virgin
controls (Fig 4.5a).
Importantly, the CRF-induced increment (CRF-stimulated minus basal) in
cAMP accumulation was significantly less on day 20 of pregnancy (p < 0.05 vs.
virgin group) compared to their virgin controls (Fig 4.4c).
Anterior pituitary weights did not differ between virgin (11.14 ± 0.20 mg, n =
16), day 10 (11.27 ± 0.14 mg, n = 6), day 16 (11.60 ± 0.31 mg, n = 6) and day 20
pregnant rats (12.10 ± 0.35 mg, n = 8)).
4.3.3 Acutely dispersed anterior pituitary cells
In the absence of the phosphodiesterase inhibitor, IBMX, the basal cAMP
accumulation was significantly greater in the cells from day 21 pregnant rats
compared to the virgin group (p < 0.05 vs. virgin controls) (Fig 4.5a). In both
pregnant and virgin groups the cAMP accumulation increased dose-dependently with
hCRF. At a concentration of 1 nM hCRF, the cAMP levels in the cells isolated from
day 21 pregnant rats were significantly lower compared to the virgin group (p < 0.01
vs. virgin controls). This effect was not seen at the higher dose of hCRF (10 nM).
The CRF-induced increments (CRF-stimulated minus basal) in cAMP levels in
response to all three doses of hCRF used were significantly reduced in the cells
isolated from the day 21 pregnant rats compared to the virgin group (p < 0.01 vs.
virgin controls, 0.1 and 1 nM hCRF; p < 0.05 vs. virgin controls, 10 nM hCRF) (Fig
4.5b).
4.4 Discussion
4.4.1 CRF and AVP mRNAs: basal expression
We confirmed the previous finding, using a cRNA probe rather than an
oliogonucleotide probe in the in situ hybridisation technique (Douglas & Russell,
1994) of a significant reduction in basal parvocellular CRF mRNA expression in the
PVN on day 21 of pregnancy, with a trend towards decreased expression on day 10
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Fig 4.5a: cAMP accumulation in acutely dispersed anterior, pituitary
cells isolated from (■) virgin and (□) day 21 pregnant rats, n = 4 cell
preparations/group from 2 virgin and pregnant rats in total. Cells were
incubated in vitro with 0 (basal), 0.1, 1.0 & 10 nM hCRF for 10 min
and the reaction was stopped with ice-cold 0.2 N HC1. Data expressed
as mean ± S.E.M. pmol cAMP accumulation/2 x 10 5 cells. Student's t




Fig 4.5b: cAMP accumulation in acutely dispersed anterior pituitary
cells isolated from (■) virgin and (□) day 21 pregnant rats, n = 4 cell
preparations/group from 2 virgin and pregnant rats in total. Cells were
incubated in vitro with 0 (basal), 0.1, 1.0 & 10 nM hCRF for 10 min
and the reaction was stopped with ice-cold 0.2 N HC1. Data expressed
as mean ± S.E.M. pmol cAMP accumulation/2 x 10 5 cells. Student's t
test * p < 0.05, ** p < 0.01 vs. virgin group.
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and 16 of pregnancy. In addition to measuring CRF mRNA expression we also
examined the basal mRNA expression of the other major ACTH secretagogue, AVP.
Measurements were made in the dorsomedial parvocellular region of the PVN as this
is the topographical location of the AVP-containing CRF neurones (Whitnall et al.,
1989). The levels of parvocellular AVP mRNA expression did not change
significantly with pregnancy although again there was a trend towards lower levels of
expression as pregnancy progressed. However, caution is appropriate in interpreting
this result as silver grains were localised only in a few scattered cells in the
dorsomedial parvocellular region. For the analysis we employed a thresholding
method where parvocellular neurones were detected as expressing AVP mRNA if the
number of silver grains in the neurone was five times greater than background. Other
studies have also employed a similar technique to analyse rapid changes in
parvocellular AVP mRNA levels and found inconsistent results (Harbuz &
Lightman, 1988; Ma et al., 1997) with no change in the earlier study, but an increase
in the later study in response to stress, indicating that the threshold method may not
be sensitive enough to detect a decrease from an already low level of mRNA
expression.
Parvocellular CRF neurones receive information from other brain regions and
from the periphery via the brainstem. Major inputs arise from ascending projections
from catecholaminergic cell groups in the brainstem. Several studies have shown that
under basal conditions following unilateral transection of these pathways, with the
specificity of the lesions confirmed histologically, there is a decrease in both the
irCRF content of the parvocellular PVN and median eminence and mRNA
expression in the paravocellular PVN. Thus, CRF expression appears to be under a
tonic stimulatory influence from these ascending pathways (Kiss et al., 1996;
Sawchenko, 1988). Both noradrenergic and adrenergic synapses have been identified
on the dendrites and cell bodies of CRF neurones (Liposits et al., 1985). Thus, the
reduced CRF mRNA expression on day 21 of pregnancy may be a consequence of
these pathways being inhibited. The inhibitory influence of endogenous opioid
peptides (EOPs) on the hypothalamic magnocellular oxytocin cell bodies during
pregnancy is well characterised (Hartman et al., 1986; Leng et al., 1988) and is
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proposed to be mediated by p-opioid receptors acting presynaptically on the
noradrenergic A2 (NTS) brainstem afferents (Onaka et al., 1995; Russell et al.,
1989). During pregnancy the hypothalamic content of p-endorphin has been shown
to increase (Wardlaw & Frantz, 1983) and using an immunofluorescence double-
labelling technique NTS afferents were found to innervate the parvocellular CRF
neurones (Cunnungham & Sawchenko, 1988). Thus in pregnancy there may be an
enhanced inhibitory P-endorphin tone on the nerve terminals of the NTS inputs to the
CRF neurones thereby inhibiting CRF gene expression. However, although CRF
mRNA after administration of naloxone was not examined, we have previously
found it does not increase basal ACTH secretion in pregnancy (see Chapter 6)
indirectly indicating that there is not an inhibitory opioid tone on the NTS afferents
to the CRF neurones.
Alternatively, the decreased parvocellular CRF mRNA levels may reflect the
high mean daily circulating levels of glucocorticoids which occur in late pregnancy
(Atkinson & Waddell, 1995). However, whether the free concentrations of
corticosterone also increase is not known since the levels of corticosterone binding
globulin has also been reported to increase with pregnancy (Seal & Doe, 1967). It is
well documented that glucocorticoids act at extrahypothalamic sites to regulate the
activity of the HPA axis. One of the best characterised is the hippocampus which
sends projections to the CRF-synthesising neurones of the PVN via the BNST
(Cullinan et al., 1993) and expresses high levels of GR immunoreactivity (Fuxe et
al., 1985). Studies have shown that damage to the hippocampal formation or
sectioning of the fimbria-fornix, another indirect pathway to the PVN, elicits
hypersecretion of CRF, AVP, ACTH and corticosterone and increased expression of
ACTH secretagogue mRNAs in the PVN, supporting the idea that the hippocampus
plays an inhibitory role in the regulation of the HPA axis (Herman et al., 1989, 1992;
Sapolsky et al., 1984,1989; Wilson et al., 1980). Another limbic structure which
sends projections to the parvocellular neurones via the BNST is the amygdaloid
complex (de Olmos et al., 1985; Sawchenko & Swanson, 1983) which also expresses
high levels of GR immunoreactivity (Fuxe et al., 1985). The amygdala has been
shown to be involved in the regulation of the HPA axis (Beaulieu et al., 1986;
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Feldman & Conforti, 1981; Carrillo, 1977; Dunn & Whitener, 1986; Matheson et al.,
1971; Redgate & Fahringer, 1973). However, it seems to possess both stimulatory
and facilitatory influences on ACTH and corticosterone secretion. Several lesion
studies have demonstrated an excitatory effect on stress-induced ACTH secretion
(Allan & Allan, 1974,1975; Beaulieu et al., 1986) while other studies found that
bilateral removal or electrolytic destruction of the amygdala results in enhanced
adrenocortical activity (Martin et al., 1958; Yamada & Greer, 1960) supporting an
inhibitory role for this limbic structure. The amygdaloid complex actually consists of
a number of subnuclei (for review see Price, 1981) and the stimulation of the separate
subnuclei appears to have differing effects on plasma corticosterone concentrations
(Dunn & Whitener, 1986). A recent report which examined the effect of lesions of
different regions of the BNST on unstimulated CRF mRNA expression indirectly
supports this finding. Lesions of the anterolateral BNST reduced basal CRF
expression while damage to the posterior intermediate and/or posterior medial BNST
increased CRF expression, thus reflecting the diverse limbic system inputs to the
BNST (Herman et al., 1994).
Numerous studies have demonstrated that corticosterone has direct effects on
CRF expression in the PVN and GR are localised on parvocellular CRF neurones
(Reul & de Kloet, 1985). Adx leads to an increase in CRF and AVP
immunoreactivity in the PVN (Kiss et al., 1984; Sawchenko et al., 1984) and this
enhancement can be prevented by corticosterone implants around the PVN (Kovacs
et al., 1986). CRF gene expression can be inhibited when capsules containing the GR
agonist, dexamethasone are implanted into the region of the PVN (Kovacs & Mezey,
1987). Glucocorticoid suppression of the CRF gene might be mediated through the
interaction of the activated GR with c-fos or c-jun and inhibition of the formation of
the AP-1 complex (Lee et al., 1991; Lucibello et al., 1990). Interestingly the human
CRF gene appears to possess a perfect half glucocorticoid-response element (GRE)
in its promoter region (Vamvakopoulos & Chrousos, 1993 ) and half-GREs have
been shown to confer delayed secondary glucocorticoid responses to another gene
product (Chan et al., 1991; Slater et al., 1993); however, in the promoter region of
the rat CRF gene no GREs have so far been identified (Seaholtz et al., 1988). If
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glucocorticoids were acting directly at the PVN to decrease CRF gene expression
during pregnancy we might also have expected to see a decrease in AVP mRNA
expression. Parvocellular AVP-containing neurones are sensitive to inhibition by
glucocorticoids. Removal of endogenous glucocorticoids by adx greatly increases the
expression and median eminence content of AVP whereas adx does not consistently
increase CRF mRNA (Albeck et al., 1994; Holmes et al., 1986) indicating that
glucocorticoid feedback is able to restrict parvocellular PVN AVP mRNA levels
more effectively than CRF mRNA expression. A recent report using reporter gene
constructs demonstrated that the AVP gene promoter region was negatively regulated
by glucocorticoids (Iwasaki et al., 1997). However, as mentioned previously our
finding of no significant change in AVP mRNA expression in the parvocellular PVN
during pregnancy indicates that the reduced CRF mRNA expression in the
parvocellular PVN during pregnancy is unlikely to be determined by glucocorticoids.
It is tempting to postulate that this decreased CRF mRNA expression in the
parvocellular cell bodies of the PVN would result in a decreased storage pool of CRF
in the median eminence and hence reduced release into the HPB upon stimulation
and contributing to the decreased secretion of ACTH, and subsequently of
corticosterone in response to an acute stress in late pregnancy (Neumann et al., 1998
see Chapter 3). Consistent with this hypothesis is the study of da Costa et al (1996)
which examined c-fos mRNA expression in response to an acute stress and found that
lower levels of c-fos expression occurred in the PVN of the late pregnant rat.
However, in order to determine conclusively that this decreased gene expression is
related to the releasable store of CRF further studies would have to be carried out.
One possibility is to use hypophysial blood sampling. Unfortunately, this procedure
involves major surgery and therefore has to be done under anaesthesia thereby
preventing the use of psychological stressors, such as restraint stress (Plotsky et al.,
1987). In addition, certain anaesthetics appear to affect the release pattern of ACTH
secretagogues into the HPB (Sherwood & Fink, 1991). Although mRNA analysis
studies provide a good indication of the influence of chronic physiological challenge
on gene transcription (Sherman et al., 1986; Znigg et al., 1986), the steady state level
of mRNA in a neurone does not necessarily reflect rapid changes in gene
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transcription and may not be the most sensitive way of detecting changes in stress
responsiveness in pregnancy. An alternative hybridisation method would be to use
probes directed towards intronic sequences of the gene thus allowing the detection of
primary transcripts or heteronuclear RNA (hnRNA), and several studies have
demonstrated that it provides an accurate temporal relationship between the acute
stimulus and gene transcription (Fremeau etal., 1986, 1989).
4.4.2 [125i] oCRF autoradiography and in vitro cAMP accumulation
The decreased ACTH and corticosterone response in vivo to exogenous CRF
(Neumann et el., 1998) may, in part, be explained by the significant decrease in
[125i]0crf binding on day 10 and 16 and a further decrease on day 21 of
pregnancy. However, in order to assess whether this decreased binding is due to a
reduced Kd or a decrease in the number of binding sites (Bmax), studies using
Scatchard analysis would have to be performed.
Several in vivo and in vitro studies have demonstrated that CRF possesses the
ability to downregulate its own receptors. It is a classical mechanism in several
endocrine systems which is considered to protect the target organ from over-exposure
to its trophic factor. It is not known whether CRF HPB levels are higher during
pregnancy. However, our CRF mRNA expression measurments do not support this
as expression is significantly reduced during pregnancy.
Circulating glucocorticoids may be responsible for the decrease in pituitary
CRF binding as they have been shown experimentally to decrease both the binding of
CRF to anterior pituitary membranes (Hauger et al., 1987,1990) and the levels of
CRFR, mRNA (Makino et al., 1995).
The cAMP data from the studies on both the pitutary segments and isolated
anterior pituitary cells indicate that the corticotrophs are less responsive to CRF
during late pregnancy which complements both the in vivo and the CRF receptor
autoradiography data. However, a discrepancy does exist between the cAMP
accumulation and the CRF binding data prior to day 21 of pregnancy. In the binding
data we found a 50% decrease in the CRF binding on day 10 and 16 of pregnancy
compared to virgins, however, exogenous CRF did not affect cAMP accumulation in
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pituitary segments until day 21 of pregnancy. This is likely to be a result of the large
CRF receptor capacity previously reported in corticotrophs (Antoni, 1986; King &
Baertschi, 1990), however, additional changes occurring at the level of the adenylate
cyclase complex cannot be ruled out. We demonstrated that this phenomenon of
reduced corticotroph sensitivity in late pregnancy also occurs in acutely dispersed
cells indicating that this reduced responsiveness was not a consequence of a cell to
cell contact. The difference in the basal cAMP values between pregnant and virgin
rats (significantly higher levels on day 21 of pregnancy) in the acutely dispersed cells
was unexpected and not easily explained. It may instead, reflect the absence of
IBMX in the cell preparation and indicate a difference in phosphodiesterase activity
in pregnancy; alternatively dispersing the cells may lead to a removal of an
autocrine/paracrine factor present in the anterior pituitary in pregnant animals which
suppressed the basal cAMP accumulation. Studies on ACTH secretion from
dispersed cells are needed.
In conclusion, parvocellular CRF mRNA expression, anterior pituitary CRF
binding site density and in vitro CRF-stimulated cAMP accumulation all decreased
in late pregnancy. These changes will affect the effectiveness of the forward drive,
both centrally and at the anterior pituitary level, to the F1PA axis and thus are likely




The glucocorticoid negative feedback signal during pregnancy
5.1 Introduction
Glucocorticoids, corticosterone in rodents and Cortisol in man, negatively
regulate both the basal and stress-induced activity of the HPA axis in a closed loop
manner. Under in vivo conditions at least three distinct time domains have been
identified in which glucocorticoids exert a negative feedback signal on stimulated
ACTH secretion: fast rate-sensitive; intermediate; and slow feedback (for review see
Keller-Wood & Dallman, 1984).
The existence of fast, rate sensitive feedback was first postulated by Dallman
& Yates (1969) and occurs within seconds to minutes of glucocorticoid exposure
when the plasma levels of the hormone are rising. However the effects only last as
long as the plasma levels are rising at a sufficient rate (Jones et al., 1972). Although
the mechanism of inhibition is not known the rapidity of the effects indicate that
protein synthesis is not involved and in support of this, pretreatment of perifused
pituitaries with cycloheximide, a protein synthesis inhibitor, does not prevent rapid
inhibition (Widmaier & Dallman, 1983). Several in vitro studies have demonstrated
that glucocorticoids have rapid effects on both stimulated CRF and ACTH secretion
(Buckingham & Hodges, 1977; Vale & Rivier, 1977; Vermes et al., 1977). While the
early in vivo studies were based on administration of exogenous glucocorticoid and
measurement of indirect indices of ACTH secretion (Dallman & Yates, 1969;
Kaneko & Hiroshige, 1978; Yates et al., 1972), a more recent study demonstrated
physiological evidence for the rate-sensitive fast feedback inhibition of ACTH
secretion (De Souza & Van Loon, 1989). They used a 2 min restraint stress paradigm
to elevate corticosterone levels and then applied a second restraint during the period
when the plasma corticosterone levels were significantly rising. They found that
although the maximum plasma ACTH concentrations were not different the rate of
decline was significantly greater following the second restraint. This indicates that
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rate-sensitive feedback acts to terminate and limit the duration, but not the peak, of
the ACTH response to subsequent stress.
Dallman & Yates (1969) also hypothesised the existence of a delayed feedback
effect of corticosteroids on ACTH secretion which was dependent on the duration of
exposure to elevated levels of corticosteroids. One report found that in vitro
incubation of ATt-20 cells (a murine pituitary tumour cell line) with dexamethasone
for 5-25 h caused a significant decrease in ACTH release, however, following 2-3
days of dexamethasone exposure, both the amount of ACTH released and the ACTH
cell content were significantly reduced (Watanabe et al., 1973). This led to the
hypothesis that the glucocorticoid delayed feedback exerts different effects over
time. Therefore, delayed feedback was divided into intermediate and slow feedback
effects.
Intermediate feedback requires corticosterone exposure for 2-10 h previously
and affects ACTH secretion but not synthesis. However, the mechanism of
intermediate feedback on ACTH secretion does require DNA-dependent RNA and
protein synthesis since the suppressive effects of the steroid are prevented in the
presence of either actinomycin D, a RNA polymerase inhibitor, or cycloheximide
(Arimura et al., 1969; Philips & Tashjian, 1982). Intermediate feedback has also
been shown to affect CRF synthesis and release (Buckingham, 1979; Sato., 1975).
Slow feedback by corticosteroids results from constant corticosterone exposure
for 12 h or longer and inhibits both ACTH release and synthesis. In vivo,
glucocorticoid injections reduce the pituitary POMC mRNA levels in adx rats
(Nakanishi et al., 1977) and in vitro, dexamethasone, Cortisol and corticosterone
specifically inhibit mRNA coding for POMC without altering the synthesis of other
proteins (Roberts et al., 1979).
Several studies have used in vitro pituitary model systems; primarily rat
corticotroph cells and AtT-20 cells, a murine pituitary tumour cell line which has
been demonstrated to be a good model for studying the influence of various factors
on the CRF second messenger pathway (Clark & Kemppainen, 1994). In contrast to
the in vivo situation, the characteristics of feedback in these cell systems are similar
regardless of whether glucocorticoids are applied for minutes to hours and therefore
is termed 'early' feedback. It has been proposed that early feedback may be mediated
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by inhibition of agonist-induced intracellular and/or extracellular Ca2+ transients
(Antoni et al., 1992; Link et al., 1993). In corticotroph cells this early inhibition of
ACTH release involves the induction of new mRNA and protein (Dayanithi &
Antoni, 1989) similar to in vivo intermediate feedback. Three mechanisms have been
proposed to account for the mechanism of action of proteins mediating early
glucocorticoid feedback. Firstly, lipocortin I, the inhibitor of phospholipase A2, may
mediate early glucocorticoid feedback (Flowers, 1988) since it is induced following
glucocorticoid treatment in the anterior pituitary. Secondly, it has been hypothesised
that glucocorticoids stabilise the actin cytoskeleton in the corticotrophs preventing
the fusion of the ACTH secretory granules with the cell membrane and thereby
9+ •
exocytosis (Castillino et al., 1992). Thirdly, calmodulin, the Ca receptor protein
2+
may play a role in mediating the early feedback by buffering the internal Ca
concentrations (Epstein et al., 1992). Consistent with this is the observation that
dexamethasone treatment increases calmodulin mRNA levels in AtT-20 cells
(Shipston & Antoni, 1992).
The influence of glucocorticoids on the activity of the HPA axis is
predominantly mediated via intracellular corticosteroid receptors which act as ligand-
bound transcription factors, binding to specific DNA sequences and acting to either
induce or repress the rate of transcription. The exception is the fast rate-sensitive
feedback which occurs too quickly to involve these intracellular receptors. However,
it has been shown that these rate-sensitive steroid feedback sites are saturable (Jones
et al., 1972) so it is hypothesised that glucocorticoids exert this effect via membrane-
bound receptors, although evidence for the existence of these steroid receptors is
limited (Chen et al., 1993; Towle & Sze, 1983).
Two intracellular receptor types have been identified, mineralocorticoid
receptors (MR) or type I and glucocorticoid receptors (GR) or type II (for review see
De Kloet, 1991) and these belong to the steroid/thyroid hormone receptor gene
superfamily (Evans, 1988). GR and MR differ in both their central distribution and
pharmacological profiles (Reul & de Kloet, 1985). GR is widely expressed
throughout the central nervous system (CNS) in both neurones and glia (Ahima &
Harlan, 1990; De Vellis et al., 1974). The highest densities of binding sites are found
in the hippocampus, cerebellum, amygdala, the hypothalamic paraventricular
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nucleus, the ascending monoaminergic neurones of the brainstem, including the
locus coeruleus and nucleus of the solitary tract (NTS), and in the anterior pituitary
(Bertini et al., 1989; Fuxe et al., 1985). Therefore, GR is highly expressed in several
of the postulated negative feedback sites for glucocortiocoids on the HPA axis. MR
has a more discrete central distribution with the highest density of binding sites
confined to several limbic system structures, including the hippocampus and septum
and in some brain stem nuclei (Reul & de Kloet, 1985). However, in situ
hybridisation studies have revealed a more uwidespread distribution, in particular
detectable but low levels of MR mRNA expression in the PVN (Seckl et al., 1993).
Studies using purified and recombinant receptors have demonstrated that GR
and MR differ in affinity for ligands (Arriza et al., 1987; Reul et al., 1987). In the
rodent, GR exhibits the highest affinity for synthetic glucocorticoids, such as
dexamethasone, and a lower affinity for physiological glucocorticoids, such as
corticosterone (Kd = 2.5-5.0 nM) and Cortisol. MR, on the other hand, shows the
highest affinity for corticosterone (Kd = 0.5 nM) and aldosterone, followed by
Cortisol. It also binds dexamethasone but with a much lower affinity (Luttge et al.,
1989).
Recent studies into the regulation of the HPA axis by physiological levels of
corticosteroids have demonstrated that replacing adx rats with a low constant signal
of corticosterone via s.c. implants prevented the elevation of morning plasma ACTH
levels but is insufficient to normalise stress-induced ACTH secretion (Akana et al.,
1988). Measurement of the free corticosterone found the levels were close to the Kd
of corticosterone for MR. In a subsequent study Dallman et al (1989a) showed that
low levels of corticosterone provided tonically to adx rats prevented basal morning
but not evening ACTH concentrations being higher than sham-adx rats. In addition,
similar levels of corticosterone have been found to be sufficient to prevent the adx-
induced increase in parvocellular CRF mRNA when examined in the nadir but not
the peak of the circadian rhythm (Kwak et al., 1993). The use of centrally
administered MR and GR antagonists initially suggested that MRs controlled basal
HPA activity, while GRs mediate the termination of the stress response (Ratka et al.,
1989). However, the requirement for more corticosterone to reduce HPA activity at
the circadian evening peak suggested that a shift in the control of basal HPA axis
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activity from MRs to GRs in the evening occurred (Dallman et al., 1989a). A recent
study by Bradbury et al (1994) further clarified the situation demonstrating that
dexamethasone is only capable of reducing evening plasma ACTH levels in adx rats
in the presence of low concentrations of corticosterone indicating that MR occupancy
is necessary for GR-mediated effects on diurnal peak ACTH levels. In addition MRs
appear to play a role in the termination of the stress response (Ratka et al., 1989)
since administration of a specific MR antagonist causes an elevated and prolonged
corticosterone response to stress in a similar manner to that observed following
administration of a GR antagonist. Therefore GR and MR appear to work
cooperatively in the control of the basal and stress-induced activation of the HPA
axis.
There is plenty of evidence to indicate that corticosteroids act at the anterior
pituitary, hypothalamus and extrahypothalamic sites to regulate the activity of the
HPA axis.The anterior pituitary as a locus for corticosteroid inhibition of the
pituitary-adrenal responses to stress is supported by both in vivo and in vitro studies
and by the fact that GR immunoreactivity occurs in POMC cells of the anterior
pituitary (Bertini et al., 1989). Systemic administration of dexamethasone has been
shown by some investigators to decrease pituitary sensitivity to CRF preparations in
animals with median eminence or hypothalamic lesions (Jones et al., 1977; De Weid,
1964). Dexamethasone has also been shown to suppress the plasma corticosterone
concentration in rats with forebrains, including the hypothalamus, median eminence
and pituitary stalk removed (Dunn & Critchlow, 1969). In vitro corticosteroids
inhibit stimulated ACTH release from incubated pituitaries (Buckingham, 1977),
monolayer cultures of pituitary cells (Fleischer & Rawls, 1970), isolated pituitary
cells (Portanova & Sayers, 1974 ), perfused pituitaries (Widmaier & Dallman, 1983)
and AtT-20 cells (Herbert et al., 1978). However, the relative importance of the
pituitary as a feedback site under physiological conditions is difficult to assess since
the majority of studies used the synthetic glucocorticoid, dexamethasone, which does
not bind to the intracellular corticosterone binding globulin, transcortin, which is
highly expressed in the anterior pituitary (De Kloet & McEwen. 1976; Koch et al.,
1976) where it is proposed to sequester corticosterone in the cell and prevent its
actions. Therefore, these studies may not necessarily reflect the relative importance
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of the anterior pituitary in vivo. Several studies have implicated the parvocellular
CRF neurones of the PVN as a site for glucocorticoid feedback. An
immunohistochemical study demonstrated that GR immunoreactivity was localised
in the PVN CRF neurones (Agnati et al., 1985). Local injections or implants of
corticosterone or dexamethasone effectively suppress pituitary-adrenal activity when
placed in the median eminence or anteromedial hypothalamus but not the pituitary
(Bohus & Strashmirov, 1970; Stark et al., 1968), indicating that the hypothalamus is
more sensitive to corticosterone. Interestingly, CBG protein is almost absent from the
adult rat brain (McEwen et al., 1986). Glucocorticoids have also been shown to
affect neural activity in the hypothalamus. Microionotophoresis of corticosterone
altered the firing rate of some hypothalamic neurones (Mandelbrod et al., 1974).
However, a recent in vitro experiment using explanted hypothalamic fragments from
monkeys showed that 6 h perfusion with 10"6 M dexamethasone did not alter either
the amplitude or the frequency of the pulsatile CRF secretion (Mershon et al., 1992).
This indicates that glucocorticoids may act at extrahypothalamic sites proximal to the
CRF neurones of the PVN. One of the best documented extrahypothalamic sites for
glucocorticoid feedback is the hippocampus, which has created much interest mainly
due to its high density of both GR and MR. A number of studies have indicated that
the hippocampus can influence both the circadian rhythm as well as the stress-
induced activation of the HPA axis. Lesions of the hippocampus or fornix, the major
efferent pathway of the hippocampal formation, reduces the diurnal variation in
plasma corticosterone by primarily raising the nadir level while the peak remains
unchanged (Fischette et al., 1980; Moberg et al., 1971). However, in these studies
the possibility of the lesion-induced rise in the morning corticosteroid levels
inhibiting the increase in the circadian peak could not be ruled out. Subsequently, a
study by Bradbury & Dallman (1989) demonstrated that hippocampal implants of the
GR antagonist RU 38486 in adx rats replaced with constant corticosterone levels
augment afternoon plasma ACTH levels. This indicates that the hippocampus
influences both circadian morning and evening ACTH secretion. Several lesion
studies corroborate an inhibitory influence of hippocampal inputs on the stress-
induced responses of the HPA axis. Dorsal or complete hippocampectomy increases
plasma corticosteroid responses to jugular vein cannulation under anaesthesia
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(Feldman & Conforti, 1980) while destruction of more than 50% of hippocampal
neurones with stereotaxic kainate infusion enhances the restraint stress-induced
increases in plasma corticosterone and prolongs the response (Sapolsky et al., 1984).
However, in a recent study it was found that lesions of the fimbria-fornix did not
enhance either the circadian rhythm or the stress-induced ACTH plasma levels
(Bradbury et al., 1993). The discrepancy between this and other studies may reflect
incomplete lesioning, but in the latter study the completeness of the lesion was
verified immunohistochemically. However, more recently a group identified an
indirect efferent inhibitory pathway from the hippocampus to the PVN via the BNST
(Cullinan et al., 1993), thus this additional pathway may maintain the influence of
the hippocampus after fornix transection. Other limbic brain areas which possess
high densities of MR and GR are the septum and the amygdaloid complex both of
which have been implicated in the control of ACTH release (Seggie, 1987; Yamada
& Greer, 1960). Both inhibitory and stimulatory effects on plasma corticosterone
have been demonstrated for the amygdala (Carrillo & Dunn, 1977; Yamada & Greer,
1960). The amygdaloid complex is composed of several individual nuclei which
project differentially to the hypothalamus (Krettek & Price, 1978) and in the
anaesthetised rat, Dunn & Whitner (1986) demonstrated that stimulation of the
different amygdaloid nuclei had different effects on plasma concentrations of
corticosterone.
The presence of both GR and MR in the brain encouraged investigators to
examine whether the enzyme, 11 (3-hydroxysteroid dehydrogenase (lip-HSD) was
expressed in areas of the brain where MR selectively binds aldosterone, such as in
the circumventricular areas (McEwen et al., 1986) and acts as a dehydrogenase as it
does in the kidney to prevent occupation of aldosterone-selective MR by
corticosterone (Edwards et al., 1988; Funder et al., 1988). However, it was found
that the majority of hippocampal MR bound corticosterone and aldosterone with
equal affinity in vivo and 11 p-dehydrogenase bioactivity was not detected in whole
hippocampal extracts in vitro (Edwards et al., 1988; Funder et al., 1988). This led to
the suggestion that this specificity-conferring mechanism was absent in the brain.
However, earlier studies had demonstrated that 11P-HSD bioactivity was present in
whole brain extract in the presence of NADP (Peterson et al., 1965). Subsequently,
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the presence of 11 p-HSD in the brain was determined immunohistochemically
(Sakai et al., 1992) and in situ hybridisation studies demonstrated that 11 P-HSD 1
possessed a widespread central distribution (Moisan et al., 1990b). Interestingly,
high enzyme activity and mRNA expression were detected in the hippocampus,
anterior pituitary and in a separate study using a non-radioactive probe in both
magnocellular and parvocellular neurones of the PVN (Seckl et al., 1993). This
suggested a role in the regulation of the glucocorticoid feedback signal. In vitro this
enzyme interconverts corticosterone to 11-dehydrocorticosterone in rodents and
Cortisol to cortisone in man, however, there is increasing evidence from using cell
lines (Agarwal et al., 1990; Duperrex et al., 1993; Low et al., 1994a) and primary
cultures of hepatocytes (Jamieson et al., 1995) and fetal hippocampal neurones
(Rajan et al., 1996) that suggests in vivo lip-HSDl acts almost exclusively as a
reductase, to reactivate, rather than to inactivate, glucocorticoids. The highest levels
of 11 P-HSD 1 mRNA expression and bioactivity occur in brain areas which express
high levels of GR, such as the cerebellum and hippocampus (Moisan et al., 1990a,
1990b) and it has been proposed that a major role of lip-HSDl is to modulate
corticosteroid access to GR rather than to MR (Moisan et al., 1990b; Monder &
Lakshmi., 1990; Teelucksingh et al., 1990; Whorwood et al., 1992).
11P-HSD1 is an inducible enzyme and several in vivo and in vitro studies have
demonstrated that it is regulated by a number of different hormones, including
glucocorticoids (Low et al., 1994b) , thyroid hormone, insulin (Whorwood et al.,
1993), estradiol and growth hormone (Low et al, 1993, 1994c).
In this study we investigated whether the attenuated neuroendocrine responses
of the HPA axis to acute stress were due to enhanced sensitivity of the HPA axis to
the glucocorticoid negative feedback signal. Firstly, we used in situ hybridisation
techniques to determine whether an upregulation in the expression of GR and MR
mRNA in the subfields of the hippocampus or in the parvocellular neurones of the
PVN occurred during pregnancy. Secondly, we measured in vitro lip-HSDl
bioactivity in the main glucocorticoid feedback sites; thirdly we examined the effect
of inhibiting central 11 p-HSD in vivo with the potent inhibitor, glycyrrhetinic acid
(GA) on the HPA axis responses to forced swim stress. GA is the active component
of liquorice and in vivo is a potent inhibitor of 11 P-HSD. Following administration it
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reveals both renal and colonic actions of Cortisol (Stewart et al., 1987) and produces
• 3 t t
a binding pattern of [ HJcorticosterone in the rat kidney which is indistinguishable
from [ HJaldosterone (Edwards et al., 1988). In vitro it has been shown to be a potent
inhibitor of central 11 [3-HSD activity (Moisan et al., 1990a) and lip-HSDl mRNA
levels in rat pituitary cells (Whorwood et al., 1993).
Finally, we tested the sensitivity of the whole axis in vivo by chemically
adrenalectomising pregnant and virgin rats with metyrapone, a 11 ^-hydroxylase
inhibitor which prevents the conversion of 11 -deoxycorticosterone to corticosterone
in the rat, and aminoglutethimide, the 20a-hydroxylase inhibitor which interrupts the
synthesis of all steroids as it prevents the conversion of cholesterol to pregnenolone
(Plotsky & Sawchenko, 1987).
5.2 Materials and Methods
5.2.1 GR and MR in situ hybridisation
For details see Chapter 2. Briefly, individually housed day 10, 16 & 21
pregnant and virgin rats were transferred separately to the experimental room where
they were decapitated between 09.30 h and 10.30 h. The brains were rapidly
removed and immediately frozen on dry ice. 20 pm cryostat-cut coronal brain
sections mounted onto gelatin and poly-L-lysine coated slides were fixed in 4%
paraformaldehyde, incubated with prehybridisation buffer for 2 h at 50 °C and then
hybridised overnight at 50 °C with 3:>S-labeled antisense cRNA probes.
T7 polymerase was used to transcribe the GR riboprobe from an Ava I-
linearised pGEM3 plasmid containing the rat GR cDNA insert, and SP6 polymerase
was used to transcribe the MR riboprobe from a Flind Ill-linearised pGEM4 plasmid
containing the rat MR cDNA insert.
The following morning the slides were washed in reducing salt concentration
to a maximum of 0.1 x SSC at 60 °C for 60 min. Then the sections were dehydrated
with increasing concentrations of ethanol in 0.3 M ammonium acetate, air-dried and
placed against film for 7 days. Afterwards they were dipped in photographic
emulsion and stored at 4 °C for 21 days before being developed and counterstained
with pyronin Y.
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To determine the specificity of the hybridisation signal adjacent slides were
hybridised with S-labelled sense cRNA probes which were not complementary to
the GR or MR mRNAs. The GR and MR sense probes were transcribed using SP6
and T7 polymerase, respectively.
Analysis was carried out using a high power microscope (objective x40) linked
to a computer-based image analysis system. Silver grains overlying cells indicated
the presence of mRNA. For the GR in situ hybridisation study the number of silver
grains per neurone was determined in the parvocellular PVN and the subfields of the
hippocampus (CA1, CA3, CA4 & dentate gyrus, DG) and for MR mRNA expression
the CA1, CA2, CA3, CA4 and DG hippocampal subfields were analysed; for each
animal measurements were made on three sections. Background measurements were
made on adjacent areas of tissue and automatically subtracted from the PVN or
hippocampal measurements. The group means were then calculated and the data
expressed as percentages of the virgin control.
5.2.2 lip-HSDl activity in vitro and in vivo
5.2.2.a In vitro llp-HSDl bioactivity in the anterior pituitary, PVN and
hippocampus.
See Chapter 2 for details. Briefly, on the day of the experiment separately
housed day 16 & 21 pregnant and virgin rats were decapitated between 9.00 h and
10.00 h for tissue harvest.
For the assay of 11 (3-dehydrogenase activity (conversion of corticosterone to
11-dehydrocorticosterone) anterior pituitary, micropunched PVN and hippocampus
from vibroslice brain sections, and part of the outer cortex of the cerebellum were
collected into tubes on ice and homogenised in ice-cold buffer C (pH 7.7). Following
colorimetric protein determination, PVN, anterior pituitary, hippocampus and
cerebellum homogenates were incubated at a protein concentration of 1000 pg/ml,
500 pg/ml, 200 pg/ml and 100 pg/ml, respectively with 12 nM [3H]corticosterone
and 200 mM NADP for 60 min at 37 °C. For each PVN measurement tissue was
pooled from two animals. For the assay of 11 P-reductase activity (conversion of 11-
dehydrocorticosterone to corticosterone) anterior pituitary and hippocampal
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homogenates at the same protein concentrations as above were incubated with
[3H]11-dehydrocorticosterone and 200 mM NADPH for 10 min at 37 °C.
The resulting steroids were then extracted into ethyl acetate, dried down and
reconstituted with ethanol containing cold corticosterone and 11-
dehydrocorticosterone, to allow the visualisation of the separate steroid bands, and
run on TLC plates. The bands were scraped into scintillant-containing vials and the
radioactivity measured in a P-counter. 11 P-dehydrogenase activity was expressed as
% conversion of [ Hjcorticosterone to [ H] 11-dehydrocorticosterone and 11P-
reductase activity was expressed vice versa.
5.2.2.b In vivo inhibition of llp-HSDl
This study was a collaboration with Prof. R Landgrafs group at the
Neuroendocrinology laboratories at the Max Planck Institute of Psychiatry, Munich,
Germany.
On the same day virgin day and pregnant Sprague Dawley rats underwent
surgery under halothane anaesthesia to implant chronic intracerebroventricular (i.c.v)
and jugular cannulae.
5.2.2.b.l Intracerebroventricular (ICV) cannulation surgery
Under halothane anaesthesia and using sterile procedures day 15 pregnant and
virgin rats were implanted with an ICV cannula for acute injections into the right
lateral cerebral ventricle.
The scalp was shaved and the animal placed into a stereotaxic frame. A midline
incision was made along the scalp and subcutaneous tissue gently scraped away from
the skull surface. The needle pointer in the holder of the stereotaxic frame was then
placed on bregma, the cruciform junction of bone plates in the the middle of the top
of the skull, and using the Vernier scale on the frame the needle point was moved 0.6
mm posterior and 1.6 mm lateral to bregma. A 2 burr (1 mm diameter) was used to
drill a hole in the skull at this site and the cannula fitted onto the end of the
stereotaxic needle and lowered into place. In addition two holes close to the cannula
hole were drilled using a 3 burr (1.5 mm diameter) and support screws inserted. The
ICV cannula was then fixed in place with dental acrylic and once this had hardened
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the scalp was sutured and a dummy cap placed on the cannula to seal it. The animals
were allowed three days to recover from the surgery before the first i.c.v injection.
5.2.2.b.2 Chronic jugular vein cannulation
See Chapter 2 for details. Briefly, under halothane anaesthesia and using sterile
procedures, day 15 pregnant and virgin rats were implanted with a chronic jugular
vein catheter six days prior to the stress experiment.
The right jugular vein was exposed and a 4 cm silicone tubing cannula (Dow
Corning, USA) connected to PE-50 polyethylene tubing containing sterile
heparinised saline (heparin 20 IU/ml 0.9% saline) was inserted approximately 3 cm
into the vessel until the tip reached the right atrium of the heart and exteriorised
dorsally in the cervical region. The cannula was then filled with 0.9% sterile saline
containing gentamycin (30000 IU/ml, Centravet, Germany) and flushed with the
same solution three days after surgery. The rats were then housed singly and handled
each day to familiarise them with the blood sampling procedure and to reduce non¬
specific stress responses during the experiments.
5.2.2.b.3 i.c.v. injection of 18P-glycyrrhetinic acid (GA), inhibitor of lip-HSD
Day 19 pregnant and virgin rats were infused i.c.v. over 2 min with either GA
(5 pg/5 pi) or vehicle (10% ethanol in sterile saline) at 07.00h and 18.00 h. The
following day the infusions were repeated. The dose of GA to give i.c.v. was derived
from a previous study where the drug had been administered s.c. (Seckl et al., 1993).
On the morning of day 21 of pregnancy the rats received their final infusion of
GA or vehicle at 07.00 h. At 08.30 h sampling cannulae were connected and the
animals left undisturbed for 90 min. At 10.00 h basal blood samples were collected
and then each animal was exposed to 90 s of forced swim (FS) stress (clear plastic
bucket, filled with tap water (19 °C) to a depth of approximately 40 cm). After the
swim the rats were gently dried with towels for 10 s and returned to their home
cages. Then 5, 15 and 50 min after the end of the stress blood samples were
collected. The volume of each sample was 0.3 ml and each was immediately replaced
by an equal volume of sterile 0.9% saline.
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At the end of the experiment to check that the tip of the i.e.v. cannula lay in the
cerebroventricular system 5 pi of coomassie blue dye was infused into the conscious
animal. It was then killed by halothane overdose and the brain removed and
sectioned by hand at the level of the implantation and the distribution of the dye
assessed. In addition the pregnancy status of each animal was determined.
All blood samples were collected on ice in EDTA-coated tubes containing 10
pi aprotinin (Dayer AG, Leverksem, Germany) and centrifuged at 4 °C at 5 000 rpm
for 5 min. Then plasma was divided into 80 pi aliquots for ACTH and 30 pi for
corticosterone measurements.
Plasma ACTH and corticosterone concentrations were determined by specific
and sensitive commercially available kits (ICN, USA) according to the respective
protocols (Neumann et al, 1998).
5.2.3 Pharmacological adrenalectomy (adx) with metyrapone
Individually caged day 16 pregnant and virgin control rats each had a silastic
cannula inserted into the right jugular vein by the method described in detail in
Chapter 2 and were allowed to recover for four days prior to experimentation.
At 07.00 h, day 20 pregnant and virgin rats had sampling cannulae connected
and were left undisturbed for 90 min then a basal blood sample (0.3 ml) was
collected to assess pre-drug ACTH and corticosterone levels. Pharmacological adx
was achieved by a modification of the method of Plotsky & Sawchenko (1987).
Metyrapone, an inhibitor of 11 p-hydroxylase, which prevents the conversion of 11-
deoxycorticosterone to corticosterone, (100 mg/kg) or saline (vehicle) was
administered s.c. three times over a 24 h period.
On the morning of the experiment sampling cannulae were connected at 07.00
h and a blood sample collected 60 min later. Immediately following the blood sample
the last metyrapone injection was given and 75 min later aminoglutethimide, an
inhibitor of 20a-hydroxylase which thus prevents the conversion of cholesterol to
pregnenolone, (200 mg/kg) was given s.c. and then at 10.00 h a third blood sample
was collected. Corticosterone (2 mg/kg) was administered s.c. then at 15, 30 and 60
min post-injection blood samples were taken. A blood volume of 0.3 ml was
collected at each time point and immediately substituted by an equal volume of
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sterile 0.9% saline. At the end of the experiment the pregnancy status of each animal
was checked.
All blood samples were collected into EDTA-containing tubes on ice and
centrifuged at 3000 g for 5 min. The plasma was divided into aliquots of 100 pi for
ACTH and 50 pi for corticosterone and stored at -80 °C and -20 °C, respectively.
Plasma concentration of ACTH was measured using a highly sensitive, specific
commercially available two-site radioimmunometric assay kit (Euro-diagnostics,
Netherlands) and corticosterone was measured by a specific scintillation proximity
assay. For details see Chapter 2.
5.3 Results
5.3.1 GR and MR basal mRNA expression
In all the in situ studies the hybridisation signal was primarily located in the
cytoplasm of the cells. We found the highest density of GR hybridisation occurred in
CA1 subfleld and the DG while the MR hybridisation was seen in the CA2 subfield.
Hybridisation with the sense probes in adjacent sections did not produce a signal.
5.3.1.a GR mRNA expression in the parvocellular PVN
Silver grain density in the parvocellular PVN did not differ significantly
between the virgin and pregnant rats or change across pregnancy (Fig 5.1a).
5.3.1.b GR mRNA expression in the hippocampal subfields
Silver grain density did not significantly differ in the CA1, CA3, CA4 or DG
hippocampal subfields between virgin and pregnant rats (Fig 5.1b). However, there
was a trend towards increased expression across pregnancy in the DG with a
significant increase occurring on day 21 of pregnancy (p < 0.05 vs. day 10 of
pregnancy).
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5.3.1.C MR mRNA expression in the hippocampal subfields
Silver grain density did not significantly differ in the CA1, CA2, CA3, CA4 or
DG hippocampal subfields between virgin and pregnant rats or across pregnancy (Fig
5.1c).
5.3.2 In vitro 11(3-HSD1 activity in the anterior pituitary, PVN and
hippocampus
5.3.2.a lip-dehydrogenase activity
We found the highest enzyme activity in the cerebellum followed by the
hippocampus and that this activity did not change during pregnancy (Fig 5.2a).
In contrast, activity in the homogenates from the anterior pituitary significantly
increased between day 16 and day 21 of pregnancy (p < 0.05, n = 10-12
determinations per group).
However, the greatest change occurred in the homogenates from the PVN
where activity approximately doubled between virgins and day 16 of pregnancy (p <
0.05, n = 4-5), with a further increase on day 21 of pregnancy (p < 0.05, n = 6).
5.3.2.b lip-reductase activity
The % conversion of [ H] 11 -dehydrocorticosterone to [ Hjcorticosterone in
hippocampal and anterior pituitary homogenates was low and did not significantly
differ between pregnant and virgin rats (Fig 5.2b).
5.3.3 The effect of GA on the HPA axis secretory response to FS stress
Two way ANOVA for RM of the plasma ACTH and corticosterone levels in
all groups demonstrated a significant interaction between time and group (p <
0.0001); all subsequent comparisons were derived from Newman-Keuls test (p <
0.05 indicates significance).
The basal plasma levels of ACTH fell below the detection limit of the assay (<
25 pg/ml) in all groups (Fig 5.3a). Five min after the end of the 90 s FS stress the
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Virgin Day 10 Day 16 Day 21
Fig 5.1a: GR mRNA expression in the parvocellular neurones
of the PVN in virgin, day 10, day 16 & day 21 of pregnancy.
20 |im coronal brain sections were hybridised with a 35S-labeled
GR cRNA probe over night. Sections were analysed by a computer-
based image analysis system and the data expressed as % of virgin
control ( n = 6/group, mean ± S.E.M.)
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Fig 5.1b: GR mRNA expression in the hippocampus of virgin (■),
day 10 (EH), day 16 (S) & day 21 (□) of pregnancy. 20 jim .
coronal brain sections were hybridised with a 35S-labeled GR
cRNA probe overnight. Sections were analysed by a computer-
based image analysis system and the data expressed as % of
virgin control (n = 6/group, mean ± S.E.M.). * p < 0.05 vs.
day 10 of pregnancy; ANOVA followed by Newman-Keuls
student's test on raw data.
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Fig 5.1c: MR mRNA expression in the hippocampus of virgin (■),
day 10 (H), day 16 (El) & day 21 (□) of pregnancy. 20 jam •
coronal brain sections were hybridised with a 35S-labeled MR
cRNA probe overnight. Sections were analysed by a computer-
based image analysis system and the data expressed as % of
virgin control (n = 6/group, mean ± S.E.M.).
139
30-,
PVN AP HP CB
Fig 5.2a: 11 (3-dehydrogenase activity in homogenates of PVN
micropunches (PVN), anterior pituitary (AP), hippocampus (HP) &
cerebellum (CB) from virgin (■), day 16 (E3) & day 21 (□) pregnant
rats. Brain tissue homogenates were incubated with [3H]corticosterone
and NADP at 37 °C for 60 min and steroids extracted into ethyl acetate
and separated by TLC. Data are expressed as % conversion of
[3H]corticosterone to [3H]ll-dehydrocorticosterone. * p < 0.05 vs.
virgin control, (n = 4-5 determinations for day 16 & n = 6
determinations for day 21 of pregnancy) & # p < 0.05 vs. day 16






Fig 5.2b: 1113-reductase activity in homogenates of anterior pituitary
(AP), hippocampus (HP) from virgin (■), day 16 (E3) & day 21 (□)
pregnant rats. Brain tissue homogenates were incubated with
[3H] 11 dehydrocorticosterone and NADPH at 37 °C for 10 min and
steroids extracted into ethyl acetate and separated by TLC. Data are
expressed as % conversion of [3H]11-dehydrocorticosterone to
[3H]corticosterone, n = 5-6 determinations .
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ACTH levels were significantly lower in the GA-treated pregnant group compared to
the GA-treated virgin group (p < 0.05) and in the vehicle-treated pregnant versus the
vehicle-treated virgin group (p < 0.05). The peak ACTH response occurred at 5 min
post-stress in all groups. At 15 min post stress the ACTH levels in both the GA-
treated and vehicle-treated pregnant rats were still significantly lower then in the
GA-treated and vehicle-treated virgin rats, respectively, (p < 0.05). Although the
plasma ACTH levels in the GA-treated rats were consistently lower than the levels in
the vehicle-treated pregnant rats at 5 & 15 min post-stress this was not statistically
significant. By 50 min post-stress the plasma ACTH levels had returned to basal and
were not significantly different between groups.
The basal corticosterone levels were not significantly different between groups
(Fig 5.3b). Exposure to 90 s of FS stress significantly increased the plasma
concentrations by 5 min in all groups (p < 0.05 vs. pre-stress level in respective
groups) and by 15 min post-stress the maximum corticosterone concentrations were
reached in all groups (p < 0.05). At 50 min post-stress the plasma corticosterone
levels in both pregnant groups remained elevated compared to their basal values (p <
0.05) while the levels had returned to baseline in both virgin groups. The plasma
corticosterone concentrations of the GA-treated and vehicle-treated pregnant groups
were also significantly elevated compared to the vehicle-treated virgin group at 50
min post-stress (p < 0.05).
5.3.4 Feedback sensitivity of the HPA axis in vivo
Two way ANOVA for RM of the plasma ACTH and corticosterone levels in
all groups demonstrated a significant interaction between group and time (p <
0.0001); all subsequent comparisons were derived from Newman-Keuls test (p <
0.05 indicates significance) unless otherwise stated.
The basal ACTH concentration prior to the metyrapone injections did not differ
between groups (Fig 5.4a). Following the metyrapone/aminoglutethimide
(met/amino) treatment the ACTH plasma levels were significantly increased. Twenty
four hours after the first injection of metyrapone the plasma ACTH levels had risen
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Fig 5.3a: The effect of glycyrrhetinic acid (GA) on the ACTH secretory
response to forced swim ( FS) stress. GA or vehicle (10% ethanol in
saline) was administered by intracerebroventricular infusion every 12 h
(07.00 & 19.00 h) for 48 h. Pregnant: GA (•, n = 7) & vehicle (O, n = 6)
and virgin: GA (■, n = 8) & vehicle (□, n = 8).
On the morning of the experiment the last i.c.v. infusion was given at 07.00 h
and 90 min later a basal blood sample was collected. Then the animals were
exposed to 90 s of FS stress and blood samples collected 5, 15 & 50 min after
the end of the stress.
GA-treated and vehicle-treated pregnant groups * p < 0.05 vs. GA-treated and
vehicle-treated virgin groups, respectively. Two way ANOVA for RM followed
by Newman-Keuls student's test.
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Fig 5.3b: The effect of glycyrrhetinic acid (GA) on the corticosterone secretory
response to forced swim ( FS) stress. GA or vehicle (10% ethanol in
saline) was administered by intracerebroventricular infusion every 12 h
(07.00 & 19.00 h) for 48 h. Pregnant: GA (•, n = 7) & vehicle (O, n = 6)
and virgin: GA (■, n = 8) & vehicle (□ , n = 8).
On the morning of the experiment the last i.c.v. infusion was given at 07.00 h
and 90 min later a basal blood sample was collected. Then the animals were
exposed to 90 s of FS stress and blood samples collected 5, 15 & 50 min after
the end of the stress.
*
p < 0.05 vs. all groups vs. their respective pre-stress levels & # p < 0.05 both
pregnant groups vs. vehicle-treated virgin group. Two way ANOVA for RM
followed by Newman-Keuls student's test.
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10- and 12-fold in the pregnant and virgin groups, respectively (p < 0.05 vs. pre-met
levels). There were no differences between the pregnant and virgin groups after
met/amino. Exogenous corticosterone time-dependently decreased plasma ACTH
levels. By 30 min post-injection the ACTH plasma concentration in the met-treated
virgin group was significantly lower than the pre-corticosterone levels (p < 0.05)
while in the met-treated pregnant group plasma ACTH was not significantly
decreased. However, by 60 min post-injection the ACTH levels of the pregnant
group was significantly lower than the pre-corticosterone level (p < 0.05). The
plasma ACTH levels did not significantly change in the vehicle-treated pregnant and
virgin groups throughout the experiment.
The pre-met corticosterone levels were not significantly different between
groups (Fig 5.4b). Following met/amino treatment the plasma corticosterone levels
decreased . Comparison of the change i.e decrement, between the pre-met and post-
amino levels demonstrated a significant decrease in the drug-treated groups
compared to the vehicle-treated groups (p < 0.05, Students t test). Following
exogenous corticosterone the plasma levels significantly increased (20-fold and 4-
fold in the drug-treated and vehicle-treated groups, respectively, p < 0.05). At 60 min
post-injection plasma levels of corticosterone remained elevated in all groups
compared to pre-drug levels (p < 0.05).
5.4 Discussion
5.4.1 GR and MR mRNA expression in the PVN and hippocampus
In some peripheral tissues the glucocorticoid/GR complex binds to the GR
gene and potently downregulates its transcription and translation (Burnstein et al.,
1991), however, at other peripheral sites glucocorticoids upregulate GR, including in
both T- and B-lymphocytes (Eisen et al., 1988). Therefore, glucocorticoid effects on
GR expression appear to be site-specific. Several studies have shown that central
GRs are downregulated by exposure to high levels of glucocorticoids (Reul et al.,
1987) and upregulated 1-3 days after adx in the hippocampus (Reul et al., 1989)
while MRs in the hippocampus are upregulated by adx (Reul et al., 1987).
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Fig 5.4a: The effect of exogenous corticosterone on the elevated plasma
ACTH levels following pharmacological adrenalectomy. A basal blood
sample was taken prior to the drug treatment, then the animals were given
a subcutaneous (s.c.) injection of either metyrapone (met, 100 mg/kg), the
11 (3-hydroxylase inhibitor or vehicle (0.9% saline) every 8 h over 24 h. On
the morning of the experiment another blood sample was collected followed
by the final met injection at 08.00 h. 75 min later a s.c. injection of either
aminoglutethimide (amino, 200 mg/kg), the 20a-hydroxylase inhibitor or
vehicle (DMSO) was given then after 45 min later a third basal sample
was collected. Immediately afterwards a s.c. injection of corticosterone
(2 mg/kg) was given and blood samples collected 15, 30 & 60 min
post-injection. Day 21 pregnant: met/amino (■, n = 5) & vehicle
(□, n = 3) and virgin: met/amino (#, n = 5) & vehicle (O, n = 5).
Statistical analysis: two way ANOVA for RM followed by


































Met (100 mg/kg) Amino
4 x 8 h (200 mg/kg)
Fig 5.4b: The effect of pharmacological adrenalectomy on the plasma corticosterone
levels. A basal blood sample was taken prior to the drug treatment, then the animals
were given a subcutaneous (s.c.) injection of either metyrapone (met, 100 mg/kg),
the 11 ^-hydroxylase inhibitor or vehicle (0.9% saline) every 8 h over 24 h. On the
morning of the experiment another blood sample was collected followed by the final
met injection at 08.00 h. 75 min later a s.c. injection of either aminoglutethimide
(amino, 200 mg/kg), the 20a-hydroxylase inhibitor or vehicle (DMSO) was given
then after 45 min later a third basal sample was collected. Immediately afterwards
a s.c. injection of corticosterone (2 mg/kg) was given and blood samples collected
15, 30 & 60 min post-injection. Day 21 pregnant: met/amino (■, n = 5) & vehicle
(□, n = 3) and virgin: met/amino (#, n = 5) & vehicle (O, n = 5).
Statistical analysis: delta values from pre-met minus + 26 h values analysed by
Student's t test, ** p < 0.01 vs. pregnant and virgin vehicle groups.
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dexamethasone 2-4 days after adx (Reul et al., 1989). This is proposed to be due to
enhanced MR mRNA translation and/or the stability of MR receptors by chronic
occupation of GR by dexamethasone. Stress also alters hippocampal GRs and MRs
with the effects being stress-specific (Holmes et al., 1995; Sapolsky et al., 1994).
However, this autoregulation of GR and MR is an acute phenomenon and the effects
are not sustained (Herman et al., 1989; Holmes et al., 1995).
In our in situ hybridisation studies we did not find a significant difference in
GR mRNA expression in either the PVN or the hippocampus and in MR mRNA
expression in the hippocampus between pregnant and virgin rats. MR mRNA
expression was not measured in the parvocellular PVN neurones primarily because
expression is extrememly low and several receptor binding studies have shown a
very low density of MR in the PVN (Ruel & de Kloet, 1985) suggesting that MR
may not play an important role in transducing the glucocorticoid feedback signal at
the level of the PVN.
However, we did find a small but significant increase in GR expression in the
dentate gyrus on day 21 of pregnancy compared to day 10 of pregnancy. Previous
studies have shown that the regulation of hippocampal GR mRNA is subregion
specific and appears to be confined to the dentate gyrus and CA1 subfield (Herman
et al., 1989; Holmes et al., 1995). This upregulation may reflect an enhanced
influence of central neurotransmitters, such as serotonin, which has been
demonstrated to exert potent long-term effects on hippocampal GR and MR
expression. Central serotonergic lesions in particular decrease hippocampal GR and
MR mRNA expression (Seckl et al., 1990; Yau et al., 1994).
The hippocampus is an extremely complex structure with connections existing
between separate cell fields (Amaral & Witter, 1989). This leads to the potential for
crosstalk to occur between different cell fields. One report using an anterograde
neuronal tracer identified a direct input from the ventral subiculum of the
hippocampus to the BNST. Subsequently, the axonal projections from the BNST to
the PVN were identified as GABAergic (Cullinan et al., 1993). Both in vivo and in
vitro studies indicate a centrally acting inhibitory role for GABA in the release of
CRF and the regulation of the HPA axis. In vivo, GABA administered i.c.v prevents
surgery-induced activation of the HPA axis (Makara & Stark, 1974) and the release
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of CRF into the HPB (Plotsky, 1987). Thus this increased GR mRNA expression in
the DG of the hippocampus may indirectly influence the activity of the HPA axis via
GABAergic interneurones during late pregnancy. However, the true physiological
impact of this small increase in GR mRNA expression in the dentate gyrus is
difficult to assess as far as conveying the glucocorticoid feedback signal on the HPA
axis is concerned since the hippocampus is not the sole negative feedback site in the
brain (for review see Jacobson & Sapolsky, 1991). In addition it should be noted that
changes in mRNA levels do not always correlate with changes in receptor binding or
function (Chao et al., 1989). Hippocampal MR expression did not significantly differ
in any of the subfields or the DG analysed.
We did not detect changes in corticosteroid receptor gene expression in the
hippocampus or the PVN during pregnancy, so the suppressed HPA axis
responsiveness to an acute stress in the pregnant rat seems unlikely to be due to
enhanced feedback sensitivity. Although we have hypothesised that the small
increase in GR expression in the dentate gyrus on day 21 of pregnancy may
indirectly influence PVN CRF expression via GABAergic interneurones. However, it
would be desirable to seek changes in MR and GR receptor binding.
5.4.2 Changes in 11(3-HSD1 activity in the PVN and anterior pituitary
In vitro, we found that the 11 P-dehydrogenase activity in the PVN doubled
between virgin controls and day 16, with an approximately tripling on day 21 of
pregnancy. Also the bioactivity in the anterior pituitary increased significantly
between day 16 and day 21 of pregnancy. The higher circulating levels of
corticosterone that occur during pregnancy (Atkinson & Waddell, 1995, Nolten &
Rueckert, 1981) may be responsible for this enhanced activity since the promoter
region of the 1 lp-HSDl gene possesses a putative glucocorticoid-responsive element
(Moisan et al., 1992) and several studies have shown that it is regulated by
glucocorticoids. Hippocampal and liver lip-HSDl activity and mRNA (Low et al.,
1994a; Moisan et al., 1990c) were significantly decreased 10 days after surgical adx,
and replacement with dexamethasone resulted in a significant increase (Low et al.,
1994a). Similarly animals exposed to chronic stress, in the form of adjuvant-induced
arthritis, displayed increased enzyme activity (Low et al., 1994b). Therefore, if this
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enhanced in vitro activity reflects enhanced dehydrogenase activity in vivo this
would indicate that during pregnancy in the PVN and to a lesser extent in the anterior
pituitary greater inactivation of corticosterone occurs leading to reduced levels of
glucocorticoids gaining access to GR and eliciting their feedback effects leading to a
reduced sensitivity to the negative feedback signal. However, this is inconsistent with
the hyporesponiveness of the HPA axis during stress.
Mounting evidence from primary cell cluture and clonal cell lines suggest that
in vivo this enzyme may preferentially act as a reductase: reactivating glucocorticoids
from their inactive metabolites. COS-7 cells (derived from monkey kidney)
transfected with lip-HSDl cDNA and primary cultures of rat hepatocytes and fetal
hippocampal neurones all exhibited predominantly 11 (3-reductase activity with little
11 P-dehydrogenase activity: converting glucocorticoids to their inactive metabolites
(Jamieson et al., 1995; Low et al., 1994a; Raj an et al., 1996). Therefore, we
hypothesised that this increased in vitro dehydrogenase activity in the PVN during
pregnancy may represent increased reductase activity in vivo, thus, resulting in an
enhanced local production of glucocorticoids in the PVN which may be responsible
for the previously demonstrated decrease in PVN CRF mRNA expression during
pregnancy (Douglas & Russell., 1994; see Chapter 4).
A previous report found that reductase activity measured in the brain in vitro
paralleled dehydrogenase activity (Lakshmi et al., 1991). So we examined in vitro
reductase activity in the anterior pituitary and hippocampus; however, we only
detected approximately half and a third, respectively, of the activity measured in the
dehydrogenase direction. Therefore, in our assay protocol in vitro reductase activity
appears to be more unstable than the dehydrogenase activity. This finding is in
agreement with other reports (Waddell & Burton, 1993), although one report found
that reductase activity measured from brain tissue was more stable than from liver
(Lakshmi et al., 1991). It has been proposed that the physicochemical environment of
the 1 lp-HSDl enzyme is important for reductase stability (Lakshmi & Monder,
1985). One study in the placenta suggested that homogenisation reduces reductase
activity by uncoupling the lip-HSDl enzyme from other intracellular system(s)
(Lopez-Bernal et al., 1982).
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5.4.3 The effect of centrally-administered GA on the stress responsiveness of the
HPA axis
In order to resolve the in vivo role of central 11 p-HSD in the modulation of the
glucocorticoid negative feedback on the HPA axis responses to stress we
administered GA, the active component of liquorice which potently inhibits central
11[3-HSD 1 (Moisan et al., 1990a), by intracerebroventricular infusion (i.c.v). A
previous report by our group demonstrated that following s.c. GA, the hypophysial
portal blood levels of CRF decreased at 45 min and 90 min post-injection suggesting
that central 11P-HSD may primarily act as a dehydrogenase and thereby regulate the
access of corticosterone to GRs expressed in feedback sites, including the PVN
(Seckl et al., 1993). However, systemic administration of GA will not necessarily
only cause direct inhibition of central 11 P-HSD.
In agreement with our own observation (see Chapter 3) and a previous study
(Neumann et al., 1998), the maximum plasma ACTH levels following the stress were
significantly decreased in the vehicle-treated pregnant group compared to the
vehicle-treated virgins. Similarly, the maximum plasma ACTH levels in the GA-
treated pregnant were significantly lower compared to the GA-treated virgin controls.
However, we demonstrated that central inhibition of 11 P-HSD does not have a
significant effect on the HPA axis responses to stress. Although at both 5 and 15 min
post-stress the plasma ACTH levels of the GA-treated pregnant rats were lower than
in the vehicle-treated pregnant group the difference between the two groups was not
statistically significant. If basal ACTH concentrations had been measurable we could
have calculated the increment between the pre-stress and 5 min post-stress ACTH
levels providing an more accurate measurement of the responsiveness of the HPA
axis following inhibition of 11 P-HSD. This lack of effect of GA on the HPA axis is
at odds with the previous report of Seckl et al (1993), who found decreased HPB
levels of CRF following s.c. administration of GA. This study strongly indicated that
GA, through the inhibition of 11 P-HSD, was enhancing corticosterone feedback at
the PVN and/or extrahypothalamic sites. Interestingly, they also reported an increase
in HPB levels of AVP and OXT. Since both of these are known ACTH
secretagogues (Antoni et al., 1983a; Giguere & Labrie, 1982) their increased release
may simply reflect a compensatory mechanism at the level of the PVN to maintain
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ACTH release in the presence of reduced CRF release. This inconsistency may
possibly reflect an incorrect GA concentration or an ineffective delivery of the drug.
It would be worthwhile to repeat this experiment but rather infuse the GA directly
into the PVN.
Interestingly, we found that at 50 min post-stress the plasma corticosterone
levels in both pregnant groups were significantly elevated compared to the vehicle-
treated virgin group. This is discussed in Chapter 6.
5.4 The sensitivity of the HPA axis to exogenous corticosterone in the pregnant
rat
Changes in glucocorticoid feedback during pregnancy appears to be a species
dependent phenomenon. Keller-Wood et al (1996) found that the sensitivity of
hypotension-induced ACTH secretion to inhibition by a Cortisol infusion was the
same in pregnant and nonpregnant ewes. Owen et al (1987) demonstrated that
pregnant women are insensitive to feedback inhibition by dexamethasone during
pregnancy which persists into the 2nd or 3rd postnatal week. To date no comparable
data exist in the rat. We chose pharmacological adx rather than surgical because a
previous report demonstrated that surgical adx on day 14 of pregnancy or later did
not eliminate the maternal levels of corticosterone and the plasma CBG levels
remained unchanged. The explanation is that during late pregnancy in response to
surgical adx fetal corticosterone can maintain maternal plasma corticosterone levels
and therefore the CBG levels (Cohen et al., 1990). We used a modified method of
Plotsky & Sawchenko (1987) with a reduced dose of metyrapone (100 mg/kg) since
a dose of 200 mg/kg had previously been reported to cause maternal weight loss and
fetal wasting or even death (Baram & Schultz, 1990). Following the
metyrapone/aminoglutethimide treatment the plasma corticosterone levels were
significantly reduced compared to the vehicle pregnant and virgin control groups (p
<0.01) with the levels achieved similar to those previously reported in pregnant rats
(Baram & Schultz, 1990). Confirmation of the suppression of the circulating levels
of corticosterone was provided by the fact that the plasma ACTH levels were
significantly elevated. The maximum concentration of plasma ACTH reached in the
virgin and day 21 pregnant animals were similar suggesting that the HPA axis of the
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pregnant rat was not under a stronger glucocorticoid influence and that ACTH
secretory capacity is similar in pregnant and virgin rats. Following the s.c.
administration of corticosterone plasma ACTH levels decreased over time. However,
comparison of pre-corticosterone levels with the levels 30 min post-injection
revealed that while the plasma ACTH levels in the virgin animals were significantly
lower at this time point in the pregnant groups ACTH levels were not significantly
reduced. This suggests that pregnant rats are as sensitive to delayed glucocorticoid
feedback (manifested between 45 to 60 min after exposure to the corticosteroid) as
virgin rats but are less sensitive to fast rate-sensitive feedback (manifested within
minutes of exposure to corticosteroid when the plasma levels of steroid are rising). A
similar finding was demonstrated in pregnant ewes where basal plasma ACTH levels
were less responsive to rapid inhibition by Cortisol (Keller-Wood et al., 1996).
In conclusion, we did not find that GR or MR mRNA expression in the PVN
and/or hippocampus was significantly increased between pregnant and virgin rats.
Although, we did detect a small but significant increase in GR expression in the
dentate gyrus across pregnancy, and this may lead to an enhanced inhibition of CRF
neurones in the PVN via GABAergic interneurones.
The enhanced lip-HSDl bioactivity in the PVN and to a lesser extent in the
anterior pituitary, measured in vitro, may in vivo reflect increased reductase activity
resulting in a greater local production of corticosterone; this may explain the
previously seen decrease in parvocellular CRF mRNA expression during pregnancy.
However, the effects of in vivo inhibition of central lip-HSD by GA tentatively
suggests that lip-HSD may act predominantly as a dehydrogenase, inactivating
glucocorticoids in brain regions associated with the regulation of the HPA axis,
including the PVN.
Finally, the HPA axis of the pregnant rat is as sensitive to delayed negative
feedback, or adx as in the virgin rat but is less responsive to rapid inhibition by
corticosterone which does not explain the reduced HPA axis responsiveness to
stressors in pregnancy. Thus the attenuated HPA axis response to acute stress in late
pregnancy is not due to an enhanced glucocorticoid feedback signal, rather to a
change in the forward drive to the HPA axis at the level of the PVN and anterior
pituitary (see Chapter 4).
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CHAPTER 6
The influence of central endogenous opioid systems on the HPA axis
during pregnancy
6.1 Introduction
Endogenous opioid peptides are widely distributed in the CNS and they are
derived from several large precursor molecules; proopiomelanocortin (POMC) gives
rise to several biologically active peptides, including ACTH, however; it also is the
precursor for P-endorphin; Proenkephalin A is the precursor for several opioid
peptides, including lue-enkephalin, met-enkephalin, met-enkephalin-arg-phe, met-
enkephalin-arg-gly-leu. Prodynorphin also contains several opiate active peptides,
including dynorphin A, dynorphin B (rimorphin) and a- and P-neoendorphin (for
review see Khachaturian et al., 1985).
The ability of endogenous opioid peptides (EOPs) and opiate drugs, such as
morphine, to influence the HPA axis has been known for more than half a century
(Selye, 1936). While studies performed in humans support a clear inhibitory role of
endogenous opioids (Grossman et al., 1986; Volavka et al, 1980), studies in rats have
demonstrated both inhibition (Slusher & Browning, 1961; Buckingham & Cooper,
1986) and a facilitation (De Souza & Van Loon, 1982; Buckingham & Cooper,
1986).
A number of in vivo and in vitro studies have tried to address the issues of
whether the influences of EOPs on the HPA axis are primarily inhibitory or
stimulatory; the location of their site(s) of action, such as on the corticotrophs in the
anterior pituitary or on the nerve terminals in the external zone of the median
eminence or on parvocellular CRF cell bodies in the PVN or on extrahypothalamic
nerve terminals in the PVN; and the specific opioid receptor subtypes involved.
Morphine, a naturally-occuring alkaloid from the poppy, Papaver somniferum
and etorphine, a synthetic p-opiates, in vivo cause a dose-dependent increase in
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plasma corticosterone (Iyengar et al., 1986) and in vitro FK33-824CH and Try-D-
Ala-Gly-MePhe-NH(CH2)20H, specific p-opioid receptor agonists, increase the
secretion of immunoreactive CRT (I-CRF) from isolated rat hypothalami
(Buckingham, 1982b; Buckingham & Cooper, 1986). Studies using the endogenous
opioid peptide, P-endorphin, derived from the POMC precursor, have shown mixed
effects. In vitro, P-endorphin treatment inhibits both spontaneous and stimulated
secretion of CRF from isolated hypothalami (Tsagarakis et al., 1990). In contrast,
Buckingham (1986) demonstrated that this effect was dose-dependent. Exposing
hypothalamic explants to P-endorphin over a concentration range of 10"^-10"^ M
inhibited bioactive CRT (B-CRF) release while exposure to much lower
concentrations (lO'^-lO-^ M) stimulated release. In vivo, however, P-endorphin
appears to have primarily an inhibitory effect on the HPA axis since i.c.v
administration decreases the spontaneous and nitroprusside hypotension-induced
release of I-CRF into the hypophysial portal system in anaesthetised rats (Plotsky,
1986) and the hypoglycaemia-induced elevations in hypothalamic CRF and anterior
pituitary POMC mRNA expression and plasma ACTH concentrations (Suda et al.,
1992). However, one report has shown that P-endorphin i.c.v. causes an elevation of
plasma corticosterone levels (Iyengar et u/,,1987). The consensus is that P-endorphin
fulfils a role as an endogenous ligand of the p-opioid receptor. However, in receptor
binding studies it has been shown to possess multiple opioid receptor affinities
(Wood et al., 1981). In animals made tolerant to morphine, U50 488H, a selective k-
opioid receptor agonist, or morphine and D-Ala^-D-Leu^-enkephalin (DADLE), a
specific 8-opioid receptor agonist, the effect of P-endorphin is only partially inhibited
(Iyengar et al., 1987) indicating that in vivo it posseses the ability to act at all the
opioid-receptor subtypes or might act at an additional receptor site. Some studies
suggest the existence of a unique P-endorphin or s-opioid receptor (Law et al., 1979;
Schulz et al., 1980), however, very little is known about this opioid receptor subtype.
One study investigating the influence of the a-opioid receptor on corticosterone
secretion in vivo reported that the potent a-opioid receptor agonists, D-cyclazocine
and D-ethylketocyclazocine, did not increase plasma corticosterone levels (Iyengar et
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al., 1986), therefore, indicating that the cr-opioid receptor subtype is not involved in
the regulation of the HPA axis.
The EOPs, met- and leu-enkephalins, derived from the proenkephalin A
precursor, have previously been shown to increase the CRF content in and secretion
from the hypothalamus when administered i.p. (Buckingham, 1982), however, a
subsequent study by the same group demonstrated that isolated rat hypothalami
incubated with D-Pen^-D-Pen^-enkephalin, a S-opioid receptor agonist, did not
respond, indicating that 5-opioid receptors are not involved in the initiation of the
secretion of the releasing hormone (Buckingham & Copper, 1986). Two subsequent
in vivo studies, however, clearly demonstrated that the 8-opiates potently and dose-
dependently increased plasma ACTH and corticosterone (Gonzalvez et al., 1991;
Iyengar et al., 1986) thus providing evidence of a 5-opioid input site into the HPA
axis.
An initial in vitro study found that the k-opioid receptor agonist, U50 488H,
was only weakly active at stimulating the release of CRF from isolated hypothalami
(Buckingham & Cooper, 1986) while other studies provided evidence that the k-
opioid receptor plays an inhibitory role on the function of the HPA axis (Plotsky,
1986; Tsagarakis et al., 1990). However, later in vivo studies clearly demonstrated
that k-opioid peptides and their receptors were involved in the regulation of the HPA
axis. Iyengar and colleagues (1986 & 1987) showed that synthetic opiates, U50
488H, MR2034 and trifluadom, and k-opioid peptides, dynorphin and met-
enkephalin-arg-phe, a C-terminally extended met-enkephalin which in vitro
possesses a high affinity for k-opioid receptors (Audigier et al., 1982), dose-
dependently and stereospecifically increased plasma corticosterone. Interestingly,
Iyenger et al (1986) found that the effects of trifluadom but not of U50 488H were
reversed by the opioid antagonist, WIN 44441-3 thus providing the first in vivo
evidence for multiple k-isoreceptors. Immunoneutralization of hypothalamic CRF by
a specific antiserum to rat CRF (CRF-AS) (Nikolarakis et al., 1987) resulted in a
complete abolition of the ACTH response to MR2034, indicating that k-opioid
receptor regulation of the HPA axis occurred at the hypothalamus or at
extrahypothalamic nerve terminals in the PVN.
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The role of the anterior pituitary gland in the opioid regulation of the HPA axis
was first investigated by Buckingham (1982) who found that neither morphine nor
met- and leu-enkephalin stimulated ACTH secretion from anterior pituitary quarters
and concluded that the anterior pituitary did not express either p.- and 5-opioid
receptors and therefore was not a regulation site for opioids. A subsequent study,
however, demonstrated that MR2034 stimulated the release of ACTH from primary
cultured anterior pituitary cells (Calogero et al., 1996) despite the paucity of K-opioid
receptors in this lobe (Boersma et al., 1994). This influence of k-opioid receptor
agonists at the level of the anterior pituitary helps to explain why the stimulating
effects of MR2034 on plasma ACTH and corticosterone were not completely
abolished in the presence of the CRT receptor antagonist, a-helical CRF9_4|.
However, stimulation at the level of the hypothalamus of other ACTH secretagogues
such as AVP and noradrenaline may occur. k-opioid peptides do not directly
influence the adrenal gland, since MR2034 had no effect on the release of
corticosterone from cultured adrenocortical cells or adrenal quarters in vitro
(Calogero et al., 1996).
Thus, p-, k-, 5- and possibly s-opioid receptors are involved in the regulation
of the HPA axis and EOPs appear to act at the level of the hypothalamus and
possibly on inputs from extrahypothalamic regions in male rats, and possibly on the
anterior pituitary.
An example of the influences of central EOPs on a neuroendocrine system
occurs in the hypothalamic-neurohypophyseal system (HNS) during pregnancy.
EOPs provide an inhibitory tone on both the magnocellular oxytocin neurones of the
SON and on the nerve terminals in the neurohypophysis (Leng et al., 1985) to
regulate the release of oxytocin. The oxytocin content of the posterior pituitary is
increased during pregnancy (Douglas et al., 1993; Schriefer, 1991) and this excess
store is secreted at parturition to stimulate uterine contractility and promote fetal
expulsion. Some studies have found no change in the expression of hypothalamic
oxytocin mRNA during pregnancy (Douglas & Russell, 1994) suggesting that this
accumulation, at least in part, may be due to a restraint on the secretion via EOPs.
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However, there have been other reports of enhanced expression, so this remains
controversial (Horwitz et al., 1994).
The endogenous opioid peptides exert their inhibitory tone by decreasing the
electrical activity of the oxytocin cell bodies in the magnocellular hypothalamus. The
EOP thought to be responsible is P-endorphin since the effect appears to be mediated
via p-opioid receptors located pre-synaptically on the noradrenergic nerve terminals
in the SON, arising from the A2 brainstem group, which is stimulated by uterine
cervical distension (Onaka et al., 1995). EOPs also act directly on the neurosecretory
terminals in the neurohypophysis to prevent the release of oxytocin. This effect is
proposed to be mediated possibly by dynorphin or more likely by C-terminally
extended enkephalin peptides acting via K-opioid receptors (Clarke et al., 1990),
since proenkephalin-derived peptides, and to a lesser extent dynorphin, have been
found to be colocalised with oxytocin in the posterior pituitary (Panula & Lindberg,
1987). Towards the end of pregnancy there is a downregulation of the K-opioid
receptors in the posterior pituitary (Sumner et al., 1992) which may reflect an excess
exposure to EOPs. However, the influence of the K-opioid peptides on the
neurosecretory nerve terminals in the posterior pituitary is proposed to be important
in initially building up the oxytocin stores. The physiological role of this increased
opioid inhibitory tone on oxytocin secretion during pregnancy is likely to be
important in controlling the speed of parturition.
In this study we were interested to see whether central endogenous opioid
systems were involved in the attenuation of the HPA axis during pregnancy since it is
well documented that the levels of the central EOPs change during pregnancy. For
example, the hypothalamic content of P-endorphin increases (Wardlaw & Frantz,
1983); dynorphin mRNA levels in the supraoptic nucleus and content in the
neurohypophysis are also enhanced; and although enkephalin expression in the
neurohypophysis increases (Schriefer, 1991), a recent study was unable to detect any
change in the expression of proenkephalin A mRNA in the PVN in late pregnancy
(Douglas & Russell, 1994).
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6.2 Materials and Methods
Virgin female Sprague Dawley rats were individually housed with sexually
experienced males and mated overnight. Pregnancy was determined by the presence
of a vaginal plug of semen and referred to as day 0 of pregnancy.
See Chapter 2 for details. Briefly, the individually caged pregnant and virgin
control animals each had a silastic cannula inserted in a jugular vein by the method
described in detail in and were allowed to recover for three to four days prior to
experimentation.
On the morning of the experiment, sampling cannulae attached to 1 ml syringes
filled with sterile heparinised saline (20 IU/ml 0.9% saline) were connected between
07.00 and 08.00 h and the animals left undisturbed for 90 min. Two basal blood
samples were taken at 09.30 and 10.00 h. A volume of 0.65 ml was taken at both
times and immediately substituted by sterile 0.9% saline. Then naloxone (5 mg/kg)
or vehicle (sterile 0.9% saline) was injected intravenously (i.v.) and blood samples
taken 5 and 15 min post-injection. The rats were then exposed to forced swim (FS)
stress (90 s): animals placed in a bucket filled with tap water (19 °C, depth of 40
cm). After the swim, they were gently towel dried for 10 s and returned to their home
cages where further blood samples were taken at 5, 15, 30 and 60 min post-stress. At
the end of the experiment the animals were killed by an i.v. overdose of anaesthetic
(Sagatal, ) and their pregnancy status checked.
All blood samples were collected into EDTA coated tubes supplemented with
aprotinin (0.039 TlU/tube, Sigma, UK), a protease inhibitor, on ice and centrifuged
for 5 min. The plasma was aliquoted (80 pi for ACTH, 50 pi for corticosterone and
30 ml for corticosterone binding globulin, CBG) and stored at -80 °C and -20 °C,
respectively, until assay. The plasma ACTH levels were determined by a
commercially available kit (ICN, USA) by Prof. R. Landgrafs group in Munich,
Germany. Plasma corticosterone and CBG levels were determined by specific and
sensitive assays. For details see Chapter 2.
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6.3 Results
6.3.1 The effect of naloxone (nix) on the HPA axis secretory responses to FS
stress
Two way ANOVA for repeated measures (RM) of the plasma ACTH and
corticosterone concentrations in both groups demonstrated a significant interaction
between time and group (p < 0.001); all other specific comparisons were derived
from Newman-Keuls t test (p < 0.05) unless otherwise stated.
There was no difference in the basal levels of ACTH between virgin and day
21 pregnant animals and nix did not significantly affect basal ACTH within 15 min
of administration in either the virgin or pregnant group (fig 6.1a). FS stress
significantly increased ACTH secretion in both vehicle- and nlx-treated virgin and
pregnant rats, compared to pre-swim levels (p < 0.05), reaching a maximum 5 min
post-stress. The ACTH secretory response to forced swim was significantly lower in
vehicle-treated pregnant rats compared to vehicle-treated virgin controls (p < 0.05).
Nix significantly attenuated the ACTH secretory response in virgins (p < 0.05) and
caused a small, but non significant increase in the secretory response in pregnant rats
which resulted in no difference between nlx-treated virgin and pregnant rats after
stress. Further analysis showed that the effect of nix on the ACTH secretory response
to stress was significantly different between the virgin and pregnant groups (t-test on
the differences between the plasma ACTH level after FS stress in nix- and vehicle-
treated groups and the calculated s.e.m. of the difference of the two independent
means, p < 0.05, virgin -103 ± 57 vs. pregnant +40 ± 29 pg/ml). At 15 min post-
stress there was no difference in plasma ACTH levels among groups. Plasma ACTH
levels in both virgin groups 60 min after the end of the stress Were significantly
lower than their respective maximum responses while the plasma level in the vehicle-
treated pregnant group was not significantly reduced; however, this is probably a















Fig 6.1a: Effect of naloxone (nix) on the ACTH secretory response to
forced swim (FS) stress in pregnancy. Groups are: virgin vehicle-treated
(O) & nlx-treated (#) and day 21 pregnant vehicle-treated (□ ) & nix-
treated (■). Two basal blood samples were collected. These were not
significantly different so were pooled together as a single basal-sample.
Nix (5 mg/kg) or vehicle (sterile 0.9% saline) were given i.v. 30 min
later and two samples collected 5 and 15 min post-injection. Immediately
afterwards, each rat was exposed to FS stress for 90 s and samples were
collected 5, 15 & 60 min post-stress. Data are expressed as group means
± S.E.M. Two way ANOVA for RM: p <0.0001 followed by Newmann
Keuls test; * p < 0.05 vs. pre-swim levels, # p < 0.05 vehicle-treated
virgin vs. all other groups at 5 min post-stress.
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Fig 6.1b: Effect of naloxone (nix) on the corticosterone secretory
response to forced swim (FS) stress in pregnancy. Virgin vehicle-treated
(O) & nlx-treated (#) and day 21 pregnant vehicle-treated (□) & nix-
treated (■). Two basal blood samples were collected; however, these
were not significantly different so were pooled together as a single basal
sample (time 0). Nix (5 mg/kg) or vehicle (sterile 0.9% saline) were
given i.v. 30 min later and two samples collected 5 and 15 min post-
injection. Immediately afterwards, each rat was exposed to FS stress for
90 s and samples were collected 5, 15 & 60 min post-stress. Data was
expressed as group means ± S.E.M. Two way ANOVA for RM
followed by Newmann Keuls test: * p < 0.05 vs. pre-swim levels
(timeO), # p < 0.05 vs. vehicle-treated virgin & % p < 0.05 pregnant vs.
virgin.
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addition, at this time point there was no difference in plasma levels among the
groups.
Similarly the basal corticosterone concentrations did not differ between virgin
and pregnant rats and nix did not affect plasma levels within 15 min of
administration in either the virgin or pregnant group (fig 6.1b). FS stress significantly
increased corticosterone secretion in all groups compared to pre-swim levels (p <
0.05) with the corticosterone secretory response at 5 min post-stress being
significantly less in vehicle-treated pregnant compared to vehicle-treated virgin
controls (p < 0.05). Nix did not affect the secretory response in virgin animals 5 min
after the end of the stress; however, it did significantly increase the response in the
pregnant rats (p < 0.05). Therefore, as with ACTH, the effect of nix on the stress
response was significantly different between virgin and pregnant rats (t-test on the
difference between the plasma corticosterone level after FS stress in nix- and vehicle-
treated groups and the calculated independent means, p < 0.05: virgin, - 60.3 ± 66.4
vs. pregnant +199.5 ± 62.3 ng/ml). The maximum corticosterone levels occurred 15
min post-stress with no difference among groups. Consistent with the plasma ACTH
levels, the plasma corticosterone concentrations 60 min after the end of the stress in
both pregnant groups remained elevated compared to virgin controls and were not
significantly reduced compared to their respective maximum responses.
6.3.2 Comparison of basal plasma CBG levels between pregnant and virgin rats
The basal levels of plasma CBG did not significantly differ between virgin and
pregnant rats (14.8 ± 3.6 vs. 16.2 ± 4.7 pmol [3H]corticosterone bound/mg of protein,
respectively (fig 6.2).
6.4 Discussion
In this study we revealed that central EOPs are involved in the stimulation of
ACTH secretory response during acute stress in female virgin rats and that during
pregnancy this endogenous opioid enhancing effect appears to be lost.
163
20 "1
Virgin Day 21 of pregnancy
Fig 6.2 : Plasma levels of corticosterone binding globulin (CBG) from
virgin (n = 5) and day 21 pregnant (n = 5) rats. Measurements were made
in basal blood samples collected prior to either naloxone/vehicle injection
or exposure to forced swim (FS) stress. Data are expressed as group means
± S.E.M. Student's t test: no significant difference.
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Nix did not affect the basal secretion of ACTH or corticosterone in either virgin or
pregnant groups. Thus, there appears to be no endogenous opioid tone on the basal
activity of the HPA axis. This finding is in agreement with one study which reported
that a single injection of 5 mg/kg naloxone did not affect plasma corticosterone
concentrations, although when two injections were given consecutively a significant
reduction was seen (Iyengar et al., 1986) and may therefore be a concentration-
dependent effect. However, several other studies have shown that administration of
either naloxone or naltrexone, another opiate antagonist, can stimulate both CRF and
ACTH secretion (Eisenberg, 1980; Nikolarakis et al., 1987; Plotsky, 1986). The
difference between those studies and ours may reflect the time period between
administration of nix and the blood sampling. However, electrophysiological studies
investigating the effects of nix on the electrical activity of oxytocin neurones have
shown that the maximum effect following systemic administration occurred 5 to 10
min post-injection (Bicknell et al., 1988). Therefore, in our study we would have
expected to see an effect of nix at the sampling times chosen. Alternatively, the
difference may reflect differences in routes of administration, in our study nix was
given i.v while in the other studies it was given either i.c.v (Plotsky et al., 1986) or
i.p. (Iyengar et al., 1986).
Virgin rats responded to FS stress with a robust increase in ACTH secretion in
both vehicle- and nlx-treated groups, however, the secretory response of the nlx-
treated animals was significantly reduced compared to its controls (p < 0.05). This
indicates that in vivo in response to an acute stress, such as FS stress, central EOPs
are involved in the stimulation of the HPA axis. This result is supported by several in
vivo studies (Buckingham, 1986; Iyengar et al., 1986, 1987; Gonzalvez et al., 1991;
Calogero et al., 1996). Our study does not, however, enable us to determine which
opioid receptor subtypes are involved since the dose of nix used was not only able to
antagonise the nlx-sensitive p-opioid receptor but was of a high enough
concentration to affect the more nlx-resistant §- and K-opioid receptors (Howlett &
Rees, 1986). Therefore, use of selective antagonists would be required to specifically
elucidate the receptors involved. A number of studies have reported that p-, §-, k-
opioid receptors at the level of the hypothalamus and possibly in the anterior
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pituitary are involved in the modulation of the HPA axis (Iyengar et al., 1987;
Calogero et al., 1996). Indeed, high concentrations of all opioids and their receptors
are present in the hypothalamus and median eminence: (3-endorphinergic neurones
originating in the arcuate nucleus have been identified as projecting to the median
eminence and neurones containing POMC-derived peptides appear to send fibres to
the PVN (Kiss et al., 1984a; Sawchenko et al., 1982); several hypothalamic nuclei
contain high concentrations of enkephalinergic neurones (Cuello, 1983) and although
it has previously been shown that the hypothalamus is almost devoid of 5-opioid
receptors proenkephalin mRNA has been colocalised to CRF neurones in the
parvocellular PVN and its expression appears to be responsive to acute stress
(Lightman & Young III, 1987); prodynorphin opioids are largely localised in the
magnocellular neurones of the SON and PVN which project to the posterior pituitary,
however, dynorphin has been colocalised with CRH and is believed to be co-secreted
into the hypophysial portal circulation (Roth et al., 1983). Therefore, the EOPs
present in the hypothalamus and pituitary may regulate the HPA axis via autocrine
and ultrashort positive feedback mechanisms in the virgin female rat.
The influence of nix on the corticosterone secretory response in virgin rats was
not as clear as with the ACTH response, so although the level at 5 min post-stress
was lower in the nlx-treated group it was not significantly different compared to
vehicle-treated controls. In addition, the peak corticosterone response occurred at 15
min post-stress, which agrees with previous reports (Neumann et al., 1998). This
may reflect the fact that peak corticosterone responses are at or near maximal levels
even at low stress intensities (Keller-Wood & Dallman, 1984) therefore plasma
ACTH measurements reflect more accurately what is occurring at the level of the
hypothalamus.
The ACTH secretory response to stress of the vehicle-treated pregnant rats was
significantly reduced compared to their virgin controls which is consistent with our
previous results (see Chapters 3 & 5) and Neumann et al (1998). Nlx-treatment
caused a small elevation in the ACTH secretory response, although it was not
significantly different; this results in there being no difference in the stress response
between virgin and pregnant nlx-treated rats, although this slight increase makes the
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effect of nix on the stress response significantly different between virgin (ACTH
decreased) and pregnant rats.
Therefore, during late pregnancy there is a loss of the stimulatory effect of
EOPs on the HPA axis during acute stress. This might be due to opioid receptor
downregulation or uncoupling of receptors from their second messenger system,
perhaps as a consequence of the increased hypothalamic EOP content during
pregnancy (Wardlaw & Frantz, 1983). Alternatively, it may reflect an inhibitory
opioid tone being substituted for a stimulatory one.
The pattern of the corticosterone secretory response in the vehicle-treated
pregnant group in general followed that of ACTH, with the secretion after stress
being significantly reduced compared to the vehicle-treated virgin controls
(Neumann et al., 1998).
The plasma level of corticosterone remained significantly elevated for longer in
nix- and vehicle-treated pregnant groups compared to their virgin controls. This
prolonged secretion, also seen in our other studies, may represent fetal contribution
of corticosterone (Cohen et al., 1990) since by day 21 of pregnancy the fetal HPA
axis is independently active (Dupont et al., 1991) and responsive to stress in the
mother (Robinson et al., 1988). Alternatively, the high circulating levels of estrogen
occuring during pregnancy may play a role by directly stimulating the adrenal gland
to secrete corticosterone (Holzbauer, 1957). In addition , the metabolic clearance rate
of corticosterone may be reduced during pregnancy due to increased circulating
levels of CBG (Seal & Doe, 1967). However, when we measured plasma CBG we
found the levels although slightly higher in the pregnant animals were not
significantly different compared to the virgin rats. This is in constrast to previous
studies where CBG levels have been shown to increase during pregnancy (Rosenthal
et al., 1969). The difference in findings may reflect techinical differences in the
binding assays used. However, a report by Waddell & Atkinson (1994), found that
the metabolic clearance rate of corticosterone was unaffected during pregnancy due
to the presence of the placenta and the extra transuterine extraction.
In conclusion, EOPs have a stimulatory effect on the HPA axis responses to
acute stress in virgin female rats while in late pregnant rats the HPA axis is no longer
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stimulated by opioid peptides and may possibly be under an inhibitory tone. This
may reflect an adaptation, through an as yet unknown mechanism, contributing to the
suppression of the HPA axis responses to acute stress in late pregnancy.
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Chapter 7
The influence of ovarian hormones on the HPA axis during
pregnancy
7.1 Introduction
A close association exists between the HPA axis and the hypothalamic-
pituitary-ovarian (HPO) axis. This interaction is clearly evident during aberrant
functioning of either axis, for example the absence of a normal adrenal diurnal
rhythm results in irregular ovarian cycles in rodents (Ramaley, 1975), while
abnormal ovarian steroidogenesis produces abnormal regulation in the HPA axis
(Biller et al., 1990).
In general, the HPA axis exerts inhibitory effects on the HPO axis, with CRF
and POMC-derived peptides, such as [3-endorphin, inhibiting hypothalamic
gonadotropin-releasing hormone secretion and glucocorticoids inhibiting pituitary
luteinizing hormone and ovarian estrogen and progesterone secretion and rendering
estrogen-target tissues resistant to the ovarian steroid. These effects are responsible
for the hypothalamic amenorrhoea of stress (Laatikainen, 1991) and the
hypogonadism that occurs in Cushing's syndrome.
In contrast, the majority of existing data support an activational role of ovarian
hormones, especially estradiol, in HPA axis regulation. As far back as the early
1960s it was demonstrated that the activity of the HPA axis exhibited a sexual
dimorphism. The pituitary ACTH content and plasma corticosterone concentrations
under basal conditions and the ACTH and corticosterone secretory responses to stress
are higher in females than in males (Critchlow et al., 1961; Kitay, 1963). Several
studies looking at whether basal plasma ACTH and corticosterone levels paralleled
the fluctuations in plasma ovarian hormone levels during the estrous cycle found that
both plasma ACTH and corticosterone concentrations were higher during late
proestrus, compared to all other days of the cycle (Butcher et al., 1974; Carey et al.,
1995). In addition, some studies have shown that stress-induced elevations in plasma
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ACTH and corticosterone levels are greater in animals in proestrus (Carey et al.,
1995; Viau & Meaney, 1991). Finally the hypothalamic PVN CRF mRNA content
and activity have been shown to increase on the afternoon of proestrus (Bohler et al.,
1990; Hiroshige & Wafa-Okada, 1973). All these effects coincide with the maximal
plasma levels of estradiol and progesterone. Thus, there is strong evidence in vivo
that the ovarian steroids have a regulatory influence on the HPA axis.
Direct evidence for a role of estradiol in the regulation of the HPA axis has
been provided by several studies. It has been demonstrated that administration of
exogenous estrogen increases the secretion of corticosterone from the adrenal gland
(Holzbauer, 1957) and that ovariectomy (OVX) causes the adrenal corticosterone
concentration to decrease. In addition estradiol has been shown to influence the HPA
axis at various levels. Exogenous estradiol, independently of ACTH, increases the
secretion of corticosterone from adrenal gland homogenates of ovariectomized rats
(Kitay et al., 1965) and also affects both the synthesis and release of ACTH from the
anterior pituitary (Kitay, 1963). However, a later report was unable to induce the
release of ACTH from the anterior pituitary by estradiol (Buckingham, 1982a). This
discrepancy may be due to differences in the length of time the tissues were exposed
to the steroid. Estradiol also stimulates the CRF gene directly via a specific estrogen-
response element located in the promoter region of the human gene (Vamvakopoulos
& Chrousos, 1993).
In vivo OVX decreases pituitary synthesis and release of ACTH and adrenal
synthesis of corticosterone (Coyne & Kitay, 1969; Kitay, 1963) which can be
reversed with estradiol treatment (Kitay, 1963). In OVX steroid replaced animals
basal and stress-induced plasma ACTH and corticosterone are enhanced in estradiol-
and estradiol plus progesterone-treated animals compared to OVX controls (Burgess
& Handa, 1992; Carey et al., 1995; Viau & Meaney, 1991).
In addition to estradiol stimulating the HPA axis via effects on CRF, ACTH
and corticosterone synthesis and release it may also influence the glucocorticoid
negative feedback mechanism mediated via GR and MR. Sex differences in MR and
GR binding parameters and levels of transcription have been reported. Chronic
estradiol treatment results in the loss of the ability of glucocorticoids to autoregulate
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GR and decreases GR binding and transcript levels in anterior pituitary,
hypothalamus and hippocampus (Burgess & Handa, 1992, 1993; Pfieffer & Barden,
1987). Effects of this steroid have also been described for MR. Carey et al, (1995)
found a decrease in both MR binding and transcript levels in the hippocampus
following estradiol-treatment in OVX rats which is in agreement with a report by
Burgess and Handa, (1993) who found that estradiol treatment induced a decrease in
MR mRNA expression in the hypothalamus and hippocampus. These changes
indicate a decrease in the potency of the glucocorticoid negative feedback signal,
thus resulting in a prolonged stress response (Burgess & Handa, 1992; Viau &
Meaney, 1991).
In contrast, there are reports of inhibitory effects of estradiol on the HPA axis.
Some studies have found following chronic administration of estradiol that the CRF
releasing activity of median eminence extract (Kitay, 1963) and hypothalamic CRF
content are decreased (Haas & George, 1989).
However, the mass of evidence points towards a stimulatory effect of estradiol
on the HPA axis.
The influence of progesterone on the HPA axis is less well-defined than that of
estradiol. Progesterone is known to bind to both GR and MR and in intact cells it acts
as an antiglucocorticoid by binding to GR and preventing its nuclear translocation
and thus activity (Kaiser et al., 1974; Rosseau et al., 1978). Infusion of low doses of
progesterone in nonpregnant ewes resulted in an antagonism of the cortisol-induced
inhibition of ACTH secretion (Keller-Wood et al., 1988). Although at higher
concentration it can exhibit partial agonistic activity. In vitro, progesterone has been
shown to decrease CRF-induced ACTH secretion from cultured pituitaries and to
inhibit hypothalamic CRF release (Buckingham, 1982a). In OVX rats, replaced with
estradiol plus progesterone, the ACTH and corticosterone responses during stress are
lower than those of the estradiol-treated animals suggesting that progesterone inhibits
the facilitatory effects of estradiol on the HPA axis (Viau & Meaney, 1991).
However, a subsequent study by Carey and colleagues (1995) did not support a
definite inhibitory role for progesterone since they found it did not affect either basal
or stimulated HPA axis activity although they did find that it attenuated the estradiol-
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induced decrease in MR binding capacity by reversing the estradiol -induced
decrease in MR mRNA expression in the hippocampus. This antagonism by
progesterone of estradiol-induced effects via its progesterone receptor is well
documented. However, in the same study cytosol binding analysis revealed that
progesterone in the presence or absence of estrogen priming decreased the apparent
binding affinity of MR. This may reflect occupation of MR by progesterone or one of
its metabolites, such as 11 (3-hydroxyprogesteone which is likely to be inhibitory
(Rupprecht et al., 1993). Interestingly, progesterone has previously been shown to
lower the affinity of the GR complex by increasing the rate of dissociation of
glucocorticoids from its receptor (Svec et al., 1980). Thus, the influence of
progesterone on the HPA axis appears quite complex and is likely to involve an
interaction with estradiol.
Thus, the ovarian steroids modulate the activity of the HPA axis. To date all
the reports examining the interaction between the HPA and HPO axes have
concentrated on the menstrual and estrous cycles or in OVX animals replaced with
ovarian steroids and not during pregnancy when plasma levels of estrogens and
progestogens are extremely high. Therefore in this study we wanted to see whether
these high circulating levels of ovarian steroids replicated in nonpregnant rats would
influence the response of the HPA axis to acute stress. In a separate study we
examined whether the dramatic fall in the plasma progesterone levels which occurs
during the last two days of pregnancy may be involved in the hyporesponsiveness of
the HPA axis to acute stress.
7.2 Materials and Methods
For details see Chapter 2. Briefly, in the first study intact female virgin Sprague
Dawley rats (230-250 g) were implanted with a s.c. estradiol- (15 mg/ml) or vehicle-
containing (89.7% arachis oil, 10% benzyl alcohol & 0.3% cresol) silastic capsule
followed two days later with seven progesterone-containing or vehicle (empty)
capsules. Two weeks later jugular cannulae were fitted under halothane: nitrous
oxide anaesthesia to allow for blood sampling. At the time of this surgery a blood
sample was collected for the measurement of plasma estradiol and progesterone
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concentrations. The animals were then allowed to recover for three days prior to
experimentation.
On the morning of the experiment between 07.00 and 08.00 h sampling
cannulae fitted with 1 ml plastic syringes, filled with heparinised sterile saline
(20IU/ml 0.9% sterile saline), were connected. Two basal blood samples were taken
at 9.30 and 10.00 h and then each animal was exposed to 90 sec of forced swim (FS)
stress. Following the stress the animals were gently towel-dried for 10 sec and then
returned to their home cages. Subsequent blood samples were collected 5, 15, 25 and
50 min after the end of the stress. A volume of 0.25 ml of blood was collected at each
time point and immediately replaced with an equal volume of 0.9% sterile saline.
At the end of the experiment a blood sample (0.8 ml) was collected for ovarian
steroid plasma determinations then the animals were killed by i.v. overdose of
anaesthetic (Sagatal, 600 pi/animal).
In a second experiment the same ovarian steroid s.c. implantation protocol as
above was used, except that during the jugular cannulation surgery the seven
progesterone capsules were removed from controls to simulate the fall in plasma
progesterone levels that occurs towards the end of pregnancy. The animals were then
left to recover for two days prior to experimentation.
On the morning of the experiment between 07.00 and 08.00 h sampling
cannulae fitted with 1 ml plastic syringes, filled with heparinised sterile saline
(20U/ml 0.9% sterile saline), were connected. Two basal blood samples were taken at
9.30 and 10.00 h and then each animal was exposed to 90 sec of forced swim (FS)
stress. Following the stress the animals were gently towel-dried for 10 sec and then
returned to their home cages. A final blood sample was collected 5 min after the end
of the swim. Following a blood sample an equal volume of 0.9% sterile saline was
infused back into the animal. At the end of the experiment the animals were killed by
i.v. overdose of anaesthetic (Sagatal, 600 pl/animal).
Plasma concentrations of ACTH, 17p-estradiol and progesterone were
measured using highly sensitive specific commercially available assay kits (Euro-
diagnostics, Netherlands and Serozyme, USA, respectively). Plasma corticosterone
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was measured by a specific scintillation proximity assay. In addition we measured
corticosterone binding globulin (CBG) concentrations, the plasma protein that binds
approximately 90% of corticosterone in the circulation, since a number of studies
have indicated that estrogen increases its level (Gala & Westphal, 1965; Seal & Doe,
1965). A binding assay was used to measure the CBG levels. For details see Chapter
2.
7.3 Results
7.3.1 Influence of estradiol and progesterone on the HPA axis secretory
response to FS stress.
The basal plasma ACTH concentrations did not differ between the ovarian
steroid- and the vehicle-treated groups (Fig. 7.1a). At 5 min after the FS stress the
plasma ACTH levels of both groups were significantly increased 4- and 5-fold,
steroid and vehicle-treated group, respectively, (p < 0.001). The maximum response
occurred at 5 min post-stress and was not significantly different between the two
groups, and at 60 min post-stress plasma ACTH levels had returned to basal.
The basal corticosterone concentrations did not differ between the steroid- and
vehicle-treated animals (Fig 7.1b). FS stress significantly increased the plasma levels
in both groups (p < 0.001). The maximum response occurred at 15 min post-stress in
the vehicle-treated group while in the steroid group the maximum corticosterone
levels were not reached until 30 min after the end of the FS stress, however, this was
not significantly different from the 5 or 15 min post-stress level. At 60 min post-
stress the plasma corticosterone concentration in both groups was still elevated,
however, they were not significantly different from basal values.
7.3.1.1 Influence of ovarian steroids on plasma CBG levels
The circulating CBG concentrations did not significantly differ between the
steroid and vehicle-treated groups (14.2 ± 1.3 and 13.6 ±1.8 pmol [3H]corticosterone
bound/mg of protein , respectively).
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Fig 7.1a: Effect of combined chronic estradiol and progesterone treatment with
silastic capsules implanted subcutaneously for 16 and 14 days, respectively, on the
ACTH secretory response to forced swim (FS) stress of ovary-intact female rats.
Vehicle- (O) & ovarian steroid-treated (#), n = 8 and 10, respectively. Two basal
samples were collected 30 min apart; however, these were not significantly
different so were pooled and expressed as a single basal sample (time 0). Then 30
min later each rat was exposed to FS stress for 90 s and blood samples were
collected 5, 15, 30 & 60 min post-stress. ANOVA followed by Newman-Keul
































Fig 7.1b: Effect of combined chronic estradiol and progesterone treatment with
silastic capsules implanted subcutaneously for 16 and 14 days, respectively, on the
corticosterone secretory response to forced swim (FS) stress of ovary-intact
female rats. Vehicle- (O) & ovarian steroid-treated (#), n = 8 and 10,
respectively. Two basal samples were collected 30 min apart, however, these were
not significantly different so were pooled and expressed as a single basal sample
(time 0). Then 30 min later each rat was exposed to FS stress for 90 s and blood
samples were collected 5, 15, 30 & 60 min post-stress. ANOVA followed by
Newman-Keul test: ** p < 0.001 vs. pre-swim levels (time 0) in both groups.
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7.3.1.2 Plasma estradiol and progesterone concentrations
The plasma estradiol concentrations approximately 16 days after the
implantation of the capsule and at the end of the experiment were 169.7 ± 25.6 and
132.0 ± 47.1 pg/ml, respectively (Fig 7.2a).
The plasma progesterone concentrations 14 days after the implantation of the
capsules and at the end of the experiment were 87.8 ± 15.6 and 60.0 ± 8.5 ng/ml,
respectively (Fig 7.2b).
The circulating levels of estradiol and progesterone in the vehicle-treated group
were 63.9 ± 7.1 pg/ml and 4.5 ± 1.2 ng/ml, respectively (pooled for 14/16 day and
final day of experiment; see fig 7.2a & 7.2b).
7.3.2 The influence of progesterone withdrawal on the HPA axis response to FS
stress.
The basal plasma ACTH concentrations did not differ among the ovarian
steroid-treated, progesterone-withdrawal and vehicle groups (Fig 7.3a). Following
exposure to FS stress the plasma ACTH concentration in all groups increased
significantly (p < 0.001: 8- and 7- and 10-fold for steroid-treated, progesterone-
withdrawal and vehicle group, respectively) at 5 min post-stress with the response
not being significantly different amongst the three groups.
The basal plasma corticosterone concentrations did not differ among the
steroid, progesterone-withdrawal and vehicle groups (215.4 ± 88.5, 196.7 ± 59.8 and
303.1 ± 100.1 ng/ml, respectively) (Fig 7.3b). The FS stress significantly increased
the plasma concentrations (p < 0.001: increased after 5 min) and the response were
not significantly different amongst the three groups.
7.4 Discussion
Although the sexual dimorphism in the activity of the HPA axis has been
known for a number of years and it is generally accepted that estrogens are important
in this phenomenon we did not find a significant difference in the basal plasma







Fig 7.2a: Plasma estradiol concentrations a) two weeks after s.c
implantation of estradiol-containing, progesterone-containing or
vehicle silastic capsules, b) at the end of the experiment (21 days
after capsule implantation). Students t test: ** p < 0.001 vs. vehicle




Fig 7.2b: Plasma progesterone concentrations a) two weeks after s.c
implantation of estradiol-containing, progesterone-containing or
vehicle silastic capsules, b) at the end of the experiment (21 days
after capsule implantation). Students t test: ** p < 0.001 vs. vehicle




Fig 7.3a: Effect of chronic estradiol and progesterone treatment with the removal
of the progesterone capsules two days prior to the experiment on the ACTH
secretory response to forced swim (FS) stress of ovary-intact female rats. Vehicle-
(■), ovarian steroid-treated ffl) & ovarian steroid treated with progesterone
withdrawal (□) n = 5, 6 & 7, respectively. Two basal samples were collected 30
min apart; however, these were not significantly different so were pooled and
expressed as a single basal sample (time 0). Then 30 min later each rat was
exposed to FS stress for 90 s and blood samples were collected 5 min post-stress.







Fig 7.3b: Effect of chronic estradiol and progesterone treatment with the removal
of the progesterone capsules two days prior to the experiment on the
corticosterone secretory response to forced swim (FS) stress of ovary-intact
female rats. Vehicle- (■), ovarian steroid-treated (g) & ovarian steroid treated
with progesterone withdrawal (□) n = 5, 6 & 7, respectively. Two basal samples
were collected 30 min apart; however, these were not significantly different so
were pooled and expressed as a single basal sample (time 0). Then 30 min later
each rat was exposed to FS stress for 90 s and blood samples were collected 5
min post-stress. ANOVA followed by Newman-Keul test: ** p < 0.001 vs. pre-
swim levels in all groups.
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groups. This is in agreement with the report of Viau & Meaney, (1991) who found
that in intact female rats neither basal ACTH or corticosterone concentrations varied
across the estrous cycle. However, other studies have found that although the
morning ACTH and corticosterone levels did not differ, in samples taken in the late
afternoon or early evening of proestrus there were elevated levels of both (Carey et
al., 1995). This was confirmed by measurements of the free plasma corticosterone
fraction (Carey et al., 1995). Thus the reason why we did not see an elevation in our
basal ACTH and corticosterone measurements may partly be due to the fact that all
our basal samples were collected in the morning.
In response to 90 sec of FS stress the plasma levels of both ACTH and
corticosterone increased significantly in all groups. The maximum ACTH response
occurred 5 min post-stress and the magnitude was similar in both groups. The
maximum plasma corticosterone concentrations in the vehicle-treated group were
achieved 15 min post-stress, which is consistently seen in all our stress paradigm
studies, while the steroid-treated group's corticosterone levels did not reach a
maximum until 30 min post-stress. It may be postulated that this difference may
reflect a reduction in the central forward drive to the axis since a previous report
found that chronic estrogen treatment decreased hypothalamic CRF content (Haas &
George, 1989). Alternatively, it may reflect a prolonged response due to an
attenuation of the delayed negative feedback. It has previously been demonstrated
that in estradiol-replaced OVX rats there is a decrease in GR binding and
transcription (Burgess & Handa, 1992; Pfieffer & Barden, 1987) and that both
estradiol and progesterone treatment in OVX rats have effects on MR (Burgess &
Handa, 1993; Carey et al., 1995). In general, MR with its high affinity for
corticosterone is proposed to be solely responsible for regulating morning ACTH
levels (Dallman et al, 1989a) while GR is important in controlling the peak basal and
stress ACTH levels (Bradbury et al., 1991),. however, evidence exists which suggests
that occupancy of MR is necessary in the regulation of both peak basal and stress
levels of ACTH (Bradbury et al., 1994; Ratka et al., 1989). If either of these were the
cause a delay would be expected for plasma ACTH levels to reach a maximum, but
this was not found. More importantly, however; is that plasma corticosterone
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concentrations at both the 15 min and 30 min time points were not significantly
different from the 5 min post-stress value.
By 60 min the plasma ACTH levels had returned to basal values, while the
corticosterone levels in both groups remained elevated. Similarly, a previous report
found that the clearance rates of ACTH and corticosterone were not different in OVX
steroid-replaced rats (Viau & Meaney, 1991). In support of this we found no
difference in the circulating levels of CBG between groups. Again our data is in
disagreement with previous studies. Several groups have reported that estrogen
treatment in both humans and rats increase plasma levels of CBG (Blomback et al.,
1983; Gala & Westphal, 1965)
The lack of influence of the ovarian steroids on both the basal activity and
stress activation of the HPA axis question whether the circulating levels of estradiol
and progesterone in the virgin animals with implants were comparable to those found
in pregnancy. However, we can discount this as initial observations during jugular
cannulation surgery strongly indicated that the plasma levels of estradiol and
progesterone were elevated since mammary tissue development was marked and,
measurement of plasma ovarian hormone concentrations showed that circulating
levels were similar to those previously reported during pregnancy (Shiakh, 1971;
Wiest, 1970).
During the last few days of pregnancy the circulating levels of progesterone
dramatically fall while estradiol levels remain consistently high until parturition. This
fall in plasma progesterone is due to the degeneration of the corpus luteum, the major
source of progesterone during pregnancy in rodents (Taya & Greenwald, 1981). A
recent report by Windle et al, (1997a) suggested that the hyporesponsiveness of the
HPA axis to stress of lactating rats may be due to this fall in plasma progesterone. In
our study, we did not detect a difference in the maximum secretory responses to
acute stress in the progesterone withdrawal animals. However, the measurements
were not extended beyond the 5 min post-stress. However, we have found that
reduced HPA axis responses to a stressor are evident from day 16 of pregnancy,
some 5 days before collaspe of the corpus lutea (Neumann et al, 1998). It is
important to note that the majority of chronic ovarian steroid studies used OVX rats
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replaced with estradiol and/or progesterone and OVX rats as controls. In our study
ovary-intact rats were used to enable comparison with the studies on pregnant rats in
which intact virgins were used as controls. Thus, interpretation of previous studies on
OVX rats is difficult in the context of changes in pregnancy.
In conclusion, from our study it seems that estradiol and/or progesterone, at
plasma concentrations equivalent to those found in pregnancy, are not mediators of
the hyporesponsiveness of the HPA axis seen during late pregnancy.
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GENERAL DISCUSSION
My PhD project examined the responsiveness of the HPA axis in late
pregnancy and investigated possible mechanisms which may underlie the
demonstrated hyporesponsivess of the HPA axis to acute stress in the late pregnant
rat.
8.1 Attenuated HPA axis stress response during pregnancy
In this study we demonstrated that in late pregnancy the HPA axis of the rat is
less responsive to acute stress (Fig 3.1a & Fig 3.1b) which is in agreement with the
observation of Neumann et al (1998). In addition, we propose that this phenomenon
is not dependent on either the stress paradigm or the rat strain used indicating that
this may be an important physiological adaptation in pregnancy. This attenuated
HPA axis stress responsiveness is similar to the suppression previously seen in
lactating rats (Stern et al., 1973; Walker et al., 1992; Windle et al., 1997). A recent
report examining the central mRNA expression of the immediate early gene, c-fos in
response to acute stress (da Costa et al., 1996) found that in both late pregnant and
lactating rats the expression was significantly lower, not only in the parvocellular
PVN, but also in the medial amygdala, a subnucleus of the amygdaloid complex, and
the lateral septum following stress. Interestingly, both these structures possess
indirect connections to the PVN (Sawchenko & Swanson, 1983) and are known to
influence the activity of the HPA axis (Dunn & Whitener, 1986). Since the
expression of c-fos mRNA is considered a marker of neuronal activation this result
suggests a common mechanism of reduced activation of specific afferent pathways to
the PVN may be involved in producing the hyporesponsiveness of the HPA axis in
both the pregnnant and lactating rat. However, the HPA axis is a multilevel system
and is regulated at these various levels by numerous factors, therefore other
regulatory mechanisms downstream from the afferent pathways cannot be ruled out
in contributing to the suppressed stress-induced HPA axis activity during pregnancy.
The reduced responsiveness of the HPA axis to stress might possibly be an
additional adaptive mechanism to protect the fetus from excess exposure to
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glucocorticoids. In addition it may be involved in maintaining maternal energy stores
required for the support of the developing fetus and in preparation for parturition.
Thus the late pregnant rat like the lactating rat has an attenuated HPA axis
response to acute stress which involves modulation of afferent pathways to the
parvocellular neurones of the PVN; however, additional modulation may occur at the
hypothalamic and anterior pituitary level.
8.2 Changes at the level of the PVN and in the responsiveness of the anterior
pituitary corticotroph during pregnancy
We confirmed the finding of Douglas & Russell (1994) that on day 21 of
pregnancy basal CRF mRNA expression in the parvocellular neurones of the PVN
was significantly reduced; although not earlier in pregnancy (Fig 4.2). This is
interesting since the suppressed stress response is seen from day 15 of pregnancy
(Neumann et al., 1998), suggesting that this reduced CRF mRNA expression is not
the major contributor to this attenuation. We also examined the expression of
parvocellular AVP mRNA since under certain circumstances, such as following adx,
AVP becomes the predominant ACTH secretagogue (Albeck et al., 1994; Holmes et
al., 1986) indicating that not only does CRF drive ACTH release from the anterior
pituitary but has a permissive action on AVP (Plotsky et al., 1985). However, we did
not find a significant change in AVP mRNA levels although it tended to decrease
(Fig 4.2). Thus, in late pregnancy there appears to be either an increased inhibitory or
decreased excitatory influence on the parvocellular neurones of the PVN which may
be mediated directly or indirectly.
The high levels of circulating glucocorticoids that occur during pregnancy
(Atkinson & Waddell, 1995; Nolten & Kueckert, 1981) may be responsible for an
increased inhibitory influence on the PVN. Glucocorticoids are well known to inhibit
the parvocellular CRF neurones directly (Kovacs & Makara, 1988; Kovacs & Mezey,
1987; Kovacs et al., 1986). However, our AVP mRNA data do not support a direct
effect of corticosterone at the level of the PVN. Parvocellular AVP-containing
neurones are highly sensitive to feedback by glucocorticoids and removal of
endogenous corticosterone causes a greater upregulation in AVP expression
compared to CRF (Albeck et al., 1994). Thus, if the high levels of corticosterone
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were directly inhibiting gene expression at the level of the PVN we would have
expected to observe a comparable decrease in both CRF and AVP mRNA
expression. Glucocorticoids also inhibit parvocellular CRF neurones indirectly via
actions at extrahypothalamic sites. The best characterised being the hippocampus
(Herman et al., 1989, 1992b; Salpolsky et al, 1984, 1989).The hippocampus has been
shown to modulate basal HPA axis activity as well as the stress response (Bradbury
& Dallman, 1989). Thus, corticosterone may be influencing parvocellular gene
expression by acting indirectly via extrahypothalamic sites such as the hippocampus.
Alternatively, a decreased excitatory input from the catecholaminergic cell
bodies in the brainstem to the parvocellular PVN (Cunningham & Sawchenko, 1988)
may account for the decreased CRF expression. These cell groups appear to have a
tonic stimulatory input to the PVN CRF neurones since transection of this afferent
pathway results in a decrease in parvocellular CRF mRNA levels (Kiss et al., 1996).
Interestingly, these catecholaminergic cell groups, including the NTS which has a
major projection to the parvocellular CRF neurones, all express GR (Fuxe et al.,
1985; Reul & de Kloet, 1986). Thus, glucocorticoids may modulate PVN CRF gene
expression indirectly at the level of the brainstem by influencing the activity of these
catecholaminergic cell groups.
In both human and rat pregnancy the sensitivity of the anterior pituitary in vivo
to exogenous CRF is diminished (Goland et al., 1990; Neumann et al., 1998). This
insensitivity may be partly explained by our observation of reduced density of CRF
binding sites in the anterior pituitary with progressing pregnancy (Fig 4.5a).
However, in order to ascertain whether this decreased binding reflects a decrease in
receptor affinity (kd) or a decrease in receptor number (Bmax) subsequent receptor
binding studies using Scatchard analysis will have to be carried out. CRF has been
shown to possess the ability to downregulate its own receptors (Reisine & Hoffman,
1983), however, increased release of CRF into the HPB is not supported by our
parvocellular PVN CRF in situ hybridisation data. Alternatively, glucocorticoids
have been shown in vitro to decrease CRF binding to anterior pituitary membranes
(Hauger et al., 1987) and in vivo to reduce the mRNA expression of CRFRi (Makino
et al., 1995a). Although the precise mechanism of this reduction is unknown it is
proposed to be an additional inhibitory mechanism through which glucocorticoids
187
regulate the release of ACTH (Hauger et al., 1987). An interesting finding was the
decrease in CRF binding in the intermediate lobe of the pituitary gland on day 21 of
pregnancy although the relevance of this reduction on the responsiveness of the
anterior pituitary is unknown. It had previously been shown that these CRF receptors
are not affected by either the removal of endogenous glucocorticoids or by
replacement with dexamethasone (De Souza et al., 1985b). However, the existence
of an independent source of CRF in the intermediate lobe has been proposed
(Saavedra et al., 1984) which is proposed to regulate peptide secretion from the
intermediate lobe. Therefore increases in this CRF pool may result in receptor
downregulation; however, it is not known whether this pool increases during
pregnancy.
The in vitro cAMP accumulation data showing a reduced cAMP response to
exogenous CRF during late pregnancy (Fig 4.4c & Fig 4.5a) complements the CRF
binding data (Fig 4.3b). The discrepancy between the levels of cAMP accumulated
and the density of CRF binding in the anterior pituitary prior to day 20 of pregnancy:
a 50% decrease in CRF binding, without producing a concomitant decrease in cAMP
accumulation, probably reflects the large CRFR pool which exists in the anterior
pituitary (King & Baertschi, 1990). The demonstration of a reduced cAMP
accumulation in acutely dispersed anterior pituitary cells clearly demonstrated that
the decreased responsiveness of the anterior pituitary corticotroph to CRF does not
require cell to cell contact. One possible mechanism, may involve lipocortin I, the
Ca2+ and phospholipid binding protein, which is expressed in the anterior pituitary
and is induced by steroid-treatment (Smith et al., 1990a). It has been proposed to
mediate some of the inhibitory effects of corticosteroids (Flower, 1988).
Thus, decreased CRF mRNA expression in the PVN and in the density of
CRFR binding sites in the anterior pituitary leading to decreased cAMP
accumulation are likely to contribute to the stress hyporesponsiveness of the HPA
axis during pregnancy.
Future experiments
As mentioned in Chapter 4 it would be useful to know whether CRF and/or
AVP gene expression in response to an acute stress is reduced in the late pregnant
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animals. The best way to determine this would be to carry out an in situ hybridisation
study using an intronic probe, which allows detection of the primary transcripts and
would provides a direct measurement of transcription.
As cAMP is an ubiquitous second messenger it is inappropriate to directly
extrapolate it to the amount of ACTH being produced by these cells. Therefore, to
support and strength the in vitro cAMP data it is important to measure the amount of
ACTH being secreted by the anterior pituitary corticotrophs following exposure to
exogenous CRF.
8.3 The glucocorticoid negative feedback signal during pregnancy
The sensitivity of the HPA axis to the glucocorticoid feedback signal during
pregnancy is species-dependent. Owens et al (1987) reported a reduced feedback
sensitivity in humans that extends up to three weeks postpartum while Keller-Wood
(1996) found it unchanged in the sheep, but no such data exist in the rat. Thus, the
attenuated stress response may potentially reflect an enhanced glucocorticoid
feedback signal on the HPA axis of the pregnant rat. However, neither MR or GR
mRNA levels varied in the hippocampus or in the parvocellular PVN, respectively,
during pregnancy compared to virgin rats (Fig 5.1a, 5.1b & 5.1c). Although a small
increase in GR expression was detected in the dentate gyrus of the hippocampus
which may indirectly influence the PVN via a GABAergic input (Cullinan et al.,
1993) the physiological impact of this is unknown. Interestingly other studies
examining GR expression have found that changes in mRNA levels do not
necessarily reflect changes in receptor binding or function (Bohn et al., 1994; Chao
et al., 1989). Therefore it would be pertinent to undertake further studies using either
immunohistochemical or receptor binding techniques to clarify the situation.
The enzyme 11 (3-HSD1 regulates the access of glucocorticoids to GR in
numerous tissues (Moisan et al., 1990b; Whorwood et al., 1992) and is located in
several tissues involved in the regulation of the HPA axis including the anterior
pituitary, PVN and hippocampus (Moisan et al., 1990a; Seckl et al., 1993) and thus
may be involved in regulation of the glucocorticoid feedback signal (Seckl et al.,
1993). In the rat , in vitro enzyme activity increased during pregnancy in the PVN
and to a lesser extent in the anterior pituitary (Fig 5.2a). Accumulating evidence
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using clonal cell lines and primary cell culture indicate that this isoform acts
predominantly as a reductase in vivo. Thus, we postulated that the enhanced
dehydrogenase activity in vitro may in vivo act as a reductase resulting in an
increased local production of corticosterone, particularly in the PVN which may be
responsible for the decreased parvocellular CRF mRNA expression. To test the
potential physiological influence of central 11P-HSD on the stress reactivity of the
HPA axis we inhibited the enzyme by giving an i.c.v. infusion of glycyrrhetinic acid
(GA), the active component of liquorice which is a potent inhibitor of the enzyme
(Stewart et al., 1987; Edwards el al., 1988). We were unable to demonstrate a
significant effect fof GA on the ACTH secretory response to acute stress (Fig 5.3a).
To test the full responsiveness of the HPA axis to glucocorticoid feedback we
pharmacologically adrenalectomised with metyrapone and aminoglutethimide and
examined the sensitivity of the mechanisms regulating ACTH secretion to exogenous
corticosterone (Fig 5.4a). The HPA axis of the pregnant rat responded in a similar
manner to removal of endogenous glucocorticoids as the virgin rat. Thus indicating
that the HPA axis of the pregnant rat is not under a greater inhibitory influence of
glucocorticoids. Interestingly, for 30 min after administration of exogenous
corticosterone the plasma ACTH levels in the pregnant rats, unlike in the virgin
controls, actually showed reduced feedback sensitivity. This result indicates that
pregnant rats may be more resistant to the fast feedback effects of glucocorticoids
which occur as the plasma level of the steroid is rising. Similarly, a recent report in
pregnant sheep found that basal plasma ACTH levels were less sensitive to inhibition
by exogenous corticosterone at 20 min after administration (Keller-Wood, 1996).
The physiological relevance of this reduced sensitivity is unclear since fast feedback
has been shown to increase the rate of decline of plasma ACTH levels following
stress rather than decrease the peak levels achieved (De Souza & Van Loon, 1989).
However, it is clear that enhanced negative feedback is not involved in the
suppression of the acute stress response in pregnancy and that pregnant rats appear to
have an unchanged sensitivity to intermediate glucocorticoid feedback.
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Future experiments
Although the in situ hybridisation studies for MR and GR did not show a
difference in gene expression between pregnant and virgin animals in the
hippocampus it has previously demonstrated that mRNA levels do not always reflect
what occurs at the protein level. Therefore, to conclusively show that there is no
difference it might be desirable to use receptor binding assays.
In order to directly show that inhibition of central llp-HSD infuences the
activity of the HPA axis duringa stress administration of GA directly into the PVN
may provide a clear-cut answer.
8.4 The influence of central endogenous opioid systems on the HPA axis during
pregnancy
Endogenous opioid peptides (EOPs) such as p-endorphin, met- and leu-
enkephalin and dynorphin have a wide central distribution (for review see
Khachaturian et al., 1985). Since during pregnancy the levels of central EOPs
change, including an increase in the hypothalamic content of p-endorphin (Wardlaw
& Frantz, 1983) and in late pregnancy EOPs restrain stimulation of oxytocin
neuronal activity and secretion by brainstem inputs (Douglas et al., 1995) there may
be a common, central opioid mechanism inhibiting neuroendocrine responses in
pregnancy. Similarly central opioid peptides may have a role in causing the
suppression of the HPA axis stress response in pregnancy. In our study
administration of the opioid antagonist naloxone (nix) did not influence the basal
plasma levels of ACTH or corticosterone in either day 21 pregnant or virgin rats (Fig
6.1a,b). This indicates there is no endogenous opioid tone on the basal activity of the
HPA axis. In contrast, several other studies have shown that nix stimulates CRF and
ACTH secretion in vivo (Eisenberg, 1980; Jezova et al., 1982; Nikolarakis et al.,
1987; Plotsky, 1986). This discrepancy may reflect differences in the route of
administration of nix (Iyengar et al., 1986; Plotsky et al., 1986) or differences in
sampling times. It is worth noting that the other studies used male animals. Although
no data exists to suggest a sexual dimorphism in the influence of EOP it has been
previously reported that a sexual dimorphism exists in the sensitivity to endogenous
opioids of oxytocin secretion in response to a stress (Carter et al., 1986; Carter &
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Lightman, 1987). Thus, a similar phenomenon may occur with regard to basal HPA
axis activity. In virgin rats EOPs are involved in the stimulation of the HPA axis
following an acute stress since nix treatment significantly decreased the plasma
ACTH response to forced swimming (Fig 6.1a). The site(s) of action are unknown
although it is more likely to be a central mechanism since the expression of opioid
peptide receptors is absent or extremely low in the anterior pituitary (Boersma et al.,
1994; Calogero et al., 1996). Thus, central EOPs may enhance stress-induced ACTH
secretion by acting at the level of the parvocellular CRF neurones and/or at
extrahypothalamic sites, including the catecholaminergic brainstem cell groups since
they have a large central distribution. In contrast, during late pregnancy this
stimulatory effect of EOP on the stress response is lost and this may reflect a
desensitisation of the system possibly at the level of the hypothalamus since their
levels rise with the progress of pregnancy (Wardlaw & Frantz, 1983). Alternatively,
the small increase in the maximum ACTH response to stress in the pregnant animals
following nix treatment may actually suggest that during pregnancy there may be a
switch from a stimulatory opioid to an inhibitory influence on the stress
responsiveness of the HPA axis. Thus, central EOPs may be involved in the
suppression of the HPA axis to acute stress in pregnancy.
Future experiments
In the above study at the dosage used nix acted as a non-specific opioid
antagonist so we were unable to determine the opioid peptide(s) involved, possible.
In vivo studies using specific opioid antagonists would allow the determination of the
opioid peptide(s) involved in influencing the HPA axis, particularly in the virgin rats.
8.5 The influence of ovarian hormones on the HPA axis during pregnancy
A close relationship exists between the HPA axis and the hypothalamic-
pituitary-ovarian (HPO) axis. In contrast to the primarily inhibitory influence of the
HPA axis on reproductive function, the vast majority of studies have demonstrated
that estradiol treatment in ovariectomised rats has a stimulatory role in HPA axis
regulation (Buckingham et al., 1978; Carey et al., 1995; Raps et al., 1971; Viau &
Meaney, 1991). Ovarian hormones, and estradiol in particular, are thought to be
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responsible for the sexual dimorphism of the activity of the HPA axis, with females
exhibiting a higher activity under basal conditions and in response to stress
(Critchlow et al., 1963; Kitay, 1961). However, some studies suggest that chronic
treatment with estradiol may cause an inhibitory influence by decreasing the ACTH
releasing activity of median eminence extract and hypothalamic CRF content (Haas
& George, 1989; Kitay, 1963). The influence of progesterone is not so well-defined;
at low concentrations it acts as an antiglucocorticoid while at higher concentrations it
has partial agonistic activities (Keller-Wood et al., 1988). The circulating estradiol
and progesterone in the treated animals reached levels comparable to those
previously reported in pregnancy (Shiakh, 1971; Weist, 1970). There was no
difference in the basal plasma levels of either ACTH and corticosterone between the
groups (Fig 7.1a & Fig 7.1b). This was not unexpected as our blood sampling was
carried out in the morning and previous reports suggest that the enhancing effects of
ovarian steroids are seen only on the elevated levels in the late afternoon or early
evening (Buckingham et al., 1978; Carey et al., 1995). The responses of the ovarian
hormone- and the vehicle-treated animals to the forced swimming stress paralleled
each other, reaching similar maximum plasma levels of ACTH and corticosterone.
Several of our observations have occurred on day 21 of pregnancy, the day
prior to parturition, including the decreased CRF mRNA expression in the PVN and
the decreased CRF receptor density in the anterior pituitary. At this time the plasma
levels of progesterone have dramatically fallen due to the degeneration of the corpora
luta, the major source of progesterone in rat pregnancy. When we looked at the effect
of withdrawal of progesterone on the responsiveness of the HPA axis to stress we
found no difference. Thus, ovarian hormones do not appear to be involved in
inducing this decreased HPA axis responsiveness in pregnancy.
Biological implications for the mother of abnormal functioning of the HPA axis
Both physiological conditions such as aging (Hatzinger et al., 1996) and
pathophysiological conditions such as depression (Holsboer & Barden, 1996) involve
perturbations of the HPA axis. Similarly, human pregnancy is associated with an
increased incidence of mental illness and mood disturbance in both the immediate
antenatal and postnatal periods. The changes in circulating levels of many hormones
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during pregnancy and their dramatic fall at parturition has led investigators to
examine their relationship with mood disturbance. Much interest has focussed on the
potential changes in the HPA axis during pregnancy and the development of
postnatal depression. Similar disturbances of HPA axis activity to those seen in
endogenous depression appear to occur in pregnancy. In both situations basal
concentrations of corticosteroids are elevated, while a diurnal rhythm is maintained
(Atkinson & Waddell, 1995; 1988; Nolten et al., 1980); in humans, the suppression
of plasma Cortisol by dexamethasone is blunted; and the responsiveness of the
anterior pituitary to injected CRF is depressed in both humans and rats (Gold et al.,
1988; Neumann et al., 1998). However, whether the mechanism(s) of these changes
is/are identical is not clear. Gold et al (1988) postulated that the endocrinological
abnormalties observed in endogenous depression were due to hypersecretion of CRF
from the hypothalamus. This notion is supported by the finding that normal subjects
given a continuous infusion of CRF exhibit a similar pattern and magnitude of
hypercortisolaemia to that seen in major depression (Schulte et al., 1985). However,
our findings of decreased CRF gene expression in the PVN during pregnancy in the
rat suggests that enhanced hypothalamic CRF secretion does not occur during
pregnancy. In humans, secretion of CRF from the placenta into the circulation has
been postulated to influence the maternal HPA axis (Waddell, 1993) however,
measurements of the plasma levels of CRF during pregnancy do not correlate with
the development of mood disorders (Smith et al., 1990b). It is interesting to note that
the abnormalities in HPA axis activity continue for several week after delivery when
the plasma levels of CRF have returned to prepregnancy levels (Owens et al., 1987)
and altered HPA axis activity occurs in pregnancy in species such as rodents and
sheep which do not possess elevated levels of plasma CRF during pregnancy (Linton
et al., 1986).
Several studies have examined the relationship between the disturbances in the
HPA axis in pregnancy and the development of postnatal mood disturbances. The
development of postnatal 'blues' was found to be significantly related to plasma
Cortisol levels measured at 38 weeks of pregnancy (Handley et al., 1980). Another
study looked at the relationship of abnormalities in the dexamethasone test
preformed postnatally and the development of mood disorder; however, no
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significant correlation was found (Smith et al., 1990b). Newham et al (1984)
examined the relationship between P-endorphin and postnatal mood and
demonstrated a relationship between plasma levels of this opioid peptide at 38 weeks
with the occurance of postnatal blues. Also Smith et al (1990b) found a significant
correlation between between the fall in P-endorphin levels from 38 weeks to day 2
postpartum and the degree of mood disturbance in the first week. It should be noted
that all these studies focussed on peripheral levels of Cortisol and P-endorphin which
may not represent the concentrations to which the neurones of the limbic system
involved in regulating mood changes are exposed to.
The neuroendocrine response of the HPA axis is required for the survival of the
organism during times of stress, therefore possessing a reduced stress response
would be expected to be detrimental to the mother. However, we found that the
pregnant rats survived acute experimental stress well and do not appear to be more
anxious than nonpregnant rats in the elevated plus maze (Neumann et al., 1998). One
explanation would be that their high circulating levels of glucocorticoids are
sufficient to maintain an adequate bodily response to stress. It would be of interest to
examine how well pregnant rats cope with chronic stress.
I hope my work has contributed to the understanding of the mechanisms underlying
the HPA axis stress hyporesponsiveness of the HPA axis to acute stress during late
pregnancy.
However, my main wish is that I have generated as many questions as I have
answered, thus providing the building blocks for further work in this area.
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Attenuated neuroendocrine responses to emotional and
physical stressors in pregnant rats involve adenohypophysial
changes
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1. The responsiveness of the rat hypothalamo—pituitary—adrenal (HPA) axis and
hypothalamo-neurohypophysial system (HNS) to emotional (elevated plus-maze) and
physical (forced swimming) stressors and to administration of synthetic corticotrophin-
releasing hormone (CRH) was investigated during pregnancy and lactation. In addition to
pregnancy-related adaptations at the adenohypophysial level, behavioural responses
accompanying the neuroendocrine changes were studied.
2. Whereas basal (a.m.) plasma corticosterone, but not corticotrophin (adrenocorticotrophic
hormone; ACTH), levels were increased on the last day (i.e. on day 22) of pregnancy, the
stress-induced rise in both plasma hormone concentrations was increasingly attenuated with
the progression of pregnancy beginning on day 15 and reaching a minimum on day 21
compared with virgin control rats. A similar attenuation of responses to both emotional and
physical stressors was found in lactating rats.
3. Although the basal plasma oxytocin concentration was elevated in late pregnancy, the stress-
induced rise in oxytocin secretion was slightly lower in day 21 pregnant rats. In contrast to
vasopressin, oxytocin secretion was increased by forced swimming in virgin and early
pregnant rats indicating a differential stress response of these neurohypophysial hormones.
4. The blunted HPA response to stressful stimuli is partly due to alterations at the level of
corticotrophs in the adenohypophysis, as ACTH secretion in response to CRH in vivo
(40 ng kg-1, i.v.) was reduced with the progression of pregnancy and during lactation.
In vitro measurement of cAMP levels in pituitary segments demonstrated reduced basal
levels of cAMP and a lower increase after CRH stimulation (10 nM, 10 min) in day 21
pregnant compared with virgin rats, further indicating reduced corticotroph responsiveness
to CRH in pregnancy.
5. The reduced pituitary response to CRH in late pregnancy is likely to be a consequence of a
reduction in CRH receptor binding as revealed by receptor autoradiography. [i25I]CRH
binding in the anterior pituitary was significantly reduced in day 11, 17 and 22 pregnant
rats compared with virgin controls.
6. Anxiety-related behaviour of the animals as revealed by the time on and entries into the
open arms of the elevated plus-maze was different between virgin and pregnant rats with
decreased number of entries indicating increased anxiety with the progression of pregnancy
(except on pregnancy day 18). The emotional behaviour, however, was not correlated with
the neuroendocrine responses.
7. The results indicate that the reduced response of the HPA axis to stressors described
previously during lactation is already manifested around day 15 of pregnancy in the rat and
involves physiological adaptations at the adenohypophysial level. However, alterations in
stressor perception at higher brain levels with the progression of pregnancy may also be
involved.
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In addition to its normal circadian variation, the
hypothalamo—pituitary-adrenal (HPA) axis activity is
altered by physiological or pathophysiological states that
challenge the internal homeostasis of the organism. In
addition to chronic stress (Fuchs & Fliigge, 1994),
psychiatric diseases (Holsboer & Burden, 1996) or ageing
(Hatzinger, Reul, Landgraf, Holshoer & Neumann, 1996),
pregnancy and lactation might represent a similar challenge
due to the profound physiological adaptations occurring in
the mother. Thus, in pregnancy there is increased
sensitivity of the adrenal gland to cortieotrophin (ACTH)
and increased glucocorticoid secretion in several species
(Dupouy, Coffigny & Magre, 1975; Carr, Parker, Madden,
MacDonald & Porter, 1981; Waddell & Atkinson, 1994;
Keller-Wood, 1996). However, there are no detailed studies
regarding the responsiveness to stressors of the HPA axis
reflected primarily by plasma ACTH and corticosterone
concentrations, or of underlying mechanisms of possible
pregnancy-related changes in HPA axis activity, or of
associated behavioural alterations. The responsiveness of the
HPA axis is reduced during lactation (see below), and we
have now studied whether such altered responsiveness is
established in pregnancy. Reduced reactivity of the
maternal HPA axis may protect both the pregnant rat and
her offspring from harmful excessive levels of glucocorticoids
(for review, see Weinstock, 1997).
During lactation, the activity and regulation of the HPA
axis are altered in ways that are dependent on the presence or
suckling of the young (Walker, Lightman, Steele & Dallman,
1992; Windle et al. 1997). Thus, an increase in glucocorticoid
secretion and a flattening of the diurnal rhythm in
glucocorticoid secretion have been described (Stern, Goldman
& Levine, 1973; Walker et al. 1992; Fischer, Patchev,
Hellbach, Hassan & Almeida, 1995). In addition, secretion of
ACTH from the anterior pituitary and, consequently, of
Cortisol (humans) and corticosterone (rats) from the adrenal
glands is reduced during physical (Altemus, Deuster,
Galliven, Carter & Gold, 1995; Walker, Trottier, Rochford &
Lavallee, 1995), ether (Lightman & Young, 1989; Walker et
al. 1992) and noise stress (Windle et al. 1997), and in response
to cardiovascular stimuli (Keller-Wood, 1996). Furthermore,
there are indications of altered emotional behaviour in
lactating rats (Hard & Hansen, 1984; Walker et al. 1995).
Besides the well-described stress responses of the HPA axis
:here is also activation of the hypothalamo-neuro-
lypophysial system (HNS), releasing either oxytocin or
vasopressin or both from the neurohypophysis into blood, in
■esponse to various stressors (Lang, Heil, Ganten,
Hermann, Unger & Rascher, 1983; Kasting, 1988; Wotjak,
vubota, Ganster, Liebseh, Neumann & Landgraf, 1996).
During lactation, the stimulated oxytocin secretion is
•educed in response to physical stress (Carter & Lightman,
987; Lightman, 1992; Neumann, Pittman & Landgraf,
9956; Walker et al. 1995) and hyperosmotic or pharmaco-
ogical stimulation (Patel, Chowdrey & Lightman, 1991;
voehler, McLemore, Tang & Sum my-Long, 1993; Neumann,
Landgraf, Bauce & Pittman, 1995a). However, the reactivity
of the oxytocinergic system during pregnancy has not been
studied.
The present study was designed to test the secretory
responses of the HPA axis and the HNS to the emotional
and physical stressors of exposure to the elevated plus-maze
and forced swimming, respectively, during pregnancy. We
then studied the responsiveness to exogenous corticotropin n-
releasing hormone (CRH) in the pregnant and virgin rats to
seek changes at the level of the adenohypophysis in
mechanisms regulating ACTH secretion from corticotrophs.
We further sought modifications in CRH receptors or their
coupling in corticotrophs by measuring cAMP production by
anterior pituitaries from pregnant and virgin rats in vitro in
response to CRH, since cAMP is a second messenger that is
positively coupled to the CRH receptor in the pituitary
(Antoni, 1986; King & Baertschi, 1990); we measured
[125I] CRH binding-site density in the pituitary to examine
the possibility of CRH receptor downregulation. Finally, to
see if there is an alteration in emotionality accompanying
the attenuated HPA axis and HNS responses to stressors,
the anxiety-related behaviour of pregnant and virgin rats
on the elevated plus-maze (Pellow, Chopin, File & Briley,
1985) was monitored.
Preliminary results have been presented (Neumann,
Johnstone, Landgraf, Russell & Douglas, 1996; Douglas,
Johnstone, Hatzinger, Neumann, Landgraf & Russell, 1996).
METHODS
Animals
In experiment 1, virgin female Wistar rats (260-290 g) were mated
overnight with sexually experienced males, and pregnancy was
confirmed by the presence of a vaginal plug of semen in the mating
cages the following morning (day 1 of pregnancy). Rats were
housed in groups of four to six under standard laboratory
conditions at the Max Planck Institute of Psychiatry (12:12 h
light—dark cycle, lights on at 07.00 h, 22 °C, 60% humidity, food
and water ad libitum) for at least 5 days before surgery and after
delivery from the supplier (Charles River, Sulzfeld, Germany).
Another group of virgin Wistar rats was mated overnight and
housed singly 3 days prior to parturition; surgery was performed
on day 4 to 6 of lactation. Lactating rats were kept with their
litters until just before the experiments.
For experiments 2 and 3, virgin and pregnant Sprague-Dawley
rats (Bantin and Kingman, UK), mated as above, were housed
singly (12: 12 h light—dark cycle, lights on at 07.00 h, 21 °C, food
and water ad libitum) at the University of Edinburgh for at least
5 days prior to the experiment.
Experiment 1: ACTH, corticosterone, oxytocin and
vasopressin secretory responses to emotional and
physical stressors and to CRH in virgin, pregnant
and lactating rats
Surgery for blood sampling
Under halothane (2-3%) anaesthesia and using sterile procedures,
rats were implanted with chronic jugular vein catheters 6 days
before the start of the experiments. The jugular vein was exposed
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and a silicone tubing catheter (4 em; Dow Corning) connected to a
PE-50 polyethylene tubing was inserted approximately 3 cm into
the vessel until the tip reached the right atrium; the catheter was
exteriorized dorsally in the cervical region. The catheter was tilled
with sterile saline (0-9%) containing gentamioin (30000 i.u. ml" ;
Centravet, Germany) and was flushed with the same solution after
3 days. Following surgery, rats were housed singly and handled
carefully each day to familiarize them with the blood sampling
procedure and to reduce non-specific stress responses during the
experiments.
Behavioural testing and stress procedures
Elevated plus-maze. The elevated plus-maze has been validated
for the detection of emotional responses to anxiogenic and
anxiolytic substances (Pellow et at. 1985) and to stressful external
stimuli (Heinrichs, Pich, Miczek, Britton & Koob, 1992; Liebsch el
al. 1995). The plus-maze was used to assess the emotional state and
as a mild emotional stressor (novel environment) in our experiment.
The test is based on creating a conflict between the exploratory
drive of the rat and its innate fear of open and exposed areas. Thus,
increased open-arm exploration indicates reduced anxiety-related
behaviour. As described in detail by Liebsch el al. (1995), the
apparatus consists of a plus-shaped platform elevated 70 cm from
the floor. Two of the opposing arms (50 cm x 10 cm) are closed by
40 cm-high side and end walls (closed arms), whereas the other two
arms have no walls (open arms). At the beginning of the test, the
rat was placed onto the central area (10 cm x 10 cm) of the maze.
The following parameters were recorded by means of a video
camera-computer set-up during the 5 min exposure: (1) entries
into open arms (ratio of open-arm entries to total number of entries
into all arms), (2) time spent on the open arms (ratio of time spent
on open arms to total time spent on all arms), and (3) overall
activity (total number of entries into closed arms).
Forced swimming. Forced swimming represents an ethologically
relevant complex physical and emotional stressor for rats (Abel,
1994). With the extension tubing of the venous catheter still
attached, rats were forced to swim for 90 s in a black plastic
cylinder (40 cm in diameter and 50 cm in height) filled with tap
water (19°C) to a depth of ca 40 cm. After the swim, the rats
were gently dried using towels for 10 s and returned to their home
cages.
Experimental protocols
Stressors in virgin, pregnant and lactating rats (day 1). Five
days after surgery, the responses of the HPA axis and the HXS to
emotional and physical stressors were tested in virgin rats (289 +
4-20 g; mean + s.e.m.; n — 19), in rats on day 10 (327 + 4-40 g;
n = 6), day 15 (355 + 7-30 g; n = 7), day 18 (374 + 10-5 g; n — 1)
and day 21 (430 + 4'30 g; n = 7) of pregnancy and, in a separate
experiment, in lactating rats (days 9-12 of lactation, 345 + 5-80 g;
n = 7) and their virgin controls (295 + 5-90 g; n - 5).
At 08.00 h the catheters were attached to an extension tubing
connected to a 1 ml plastic syringe filled with sterile heparinized
saline (30 i.u. ml"), and the rats were left undisturbed for 90 min.
Either 0-2 ml (for detection of AtJTH and eortieosterone) or 0-6 ml
(for AGTH, eorticosterone, oxytocin and vasopressin, and lactate
as an indicator of muscle activity) blood samples, replaced
immediately by sterile 0-9% saline, were taken under basal
conditions at 09.30 and 10.00 h and after the respective stress
exposure. For transfer to the elevated plus-maze, the catheter was
disconnected and closed. Rats were then placed on the elevated
plus-maze for 5 min, returned to their home cage and the catheter
was reattached to the syringe. Ten minutes later, a blood sample
was taken and immediately afterwards rats were exposed to the
forced swim stress (90s). Further blood samples were taken 5. 15
and 25 min after forced swimming.
At the end of the experiment, catheters were gently flushed with
0-3 ml gentamicin solution and closed.
Stimulation with i.v. CRH in virgin, pregnant and lactating
rats (day 2). On the following day at 08.00 h, the rats were
weighed, then the catheter was reconnected to a syringe tilled with
heparinized saline as described above, and at 09.30 and 10.00 h
basal blood samples (0-2 ml for ACTH and corticosterone) were
taken. Further blood samples replaced by sterile saline were
collected 10, 30 and 50 min after i.v. bolus injection of human
G'RH (40 ng kg-1, 80 rig ml-1; Bissendorf Peptide, Wedemark,
Germany).
At the end of the experiment, the rats were killed by an overdose of
halothane and pregnancy state was carefully checked in all rats
post mortem.
Treatment of blood samples
All blood samples were collected on ice in EDTA-eoated tubes
containing 10 p\ aprotinin (Trasylol; Bayer AG) and centrifuged at
4°C (5000 r.p.m., 5 min). Plasma samples were stored at —20 °C
(80 p\ for ACTH, 200 /d for oxytocin and vasopressin. 50 p\ for
lactate) or —80 °C (30 ju\ for corticosterone) until assay.
Radioimmunoassays (RIAs) for ACTH, corticosterone,
oxytocin, vasopressin and plasma lactate measurement
Plasma ACTH and corticosterone concentrations were measured
using commercially available kits (ICN) according to the respective
protocols. The intra- and inter-assay coefficients of variation were
below 7 and 10%, respectively. Plasma ACTH and corticosterone
concentrations from virgin and pregnant, and virgin and lactating
rats, respectively, were estimated in different assays.
Oxytocin and vasopressin concentrations were estimated in
extracted plasma samples by highly sensitive and selective RIAs
(detection limit, 0-1 pg sample-1; cross-reactivity of the antisera
with other related peptides, including vasopressin and oxytocin,
was < 0*7 %) (for a detailed description see Landgraf, 1981).
Plasma lactate concentrations were measured enzymatically (MPR1
Lactat; Boehringer Mannheim).
Experiment 2: in vitro basal and CRH-stimulated
cAMP levels in pituitary segments from virgin and
pregnant rats
Conscious virgin (n = 10) and day 11 (« = 6), day 17 (n = 6) and
day 21 (n = 8) pregnant Spiugue-Dawley rats caged separately
were transferred individually to the experimental room immediately
before decapitation between 09.00 and 11.00 h to minimize stress.
Pituitaries were rapidly removed and washed in 0*5 ml Dulbecco's
modified Eagle's medium (Gibco BRL), buffered with 25 dim Hepes
to pH 7'4 and containing 0'25% bovine serum albumin (BSA;
Sigma, R1A grade V) (thereafter solution referred to as DMEM).
The posterior lobe was removed, anterior pituitaries weighed, and
cut free-hand under microscopic control into eight similar segments.
Pituitary segments were incubated for at least 1 It at 37 °C in 1 ml
of DMEM in 24-well cluster plates (Costar). Subsequently, each
segment was transferred into fresh DMEM (250 /d) containing
0'5 inM of the phosphodiesterase inhibitor 3-isobutyl-l -rnethyl-
xanthine (IBMX). After incubation for 15 min at 37 °C, segments
were challenged for a further 10 min with either 250 fA of 20 dm
CRH (final concentration IOiim; Peninsula, St Helens, L'K) or
vehicle (DlMEM). The reaction was terminated by the addition of
0'5 ml ice-cold 0-2 N HCI, and culture plates were sealed with
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>arafilm and stored at —70°C until trituration and cAMP
letermination.
Determination of cAMP
Ifter two rounds of freeze-thawing (—70 to 0 °0), pituitary
egments were homogenized by trituration through a gauge 26
'.eedle. cAMP accumulation in duplicate samples of the acidic
xtract (pituitary tissue + extracellular medium) was determined
sing a specific double-antibody precipitation RIA as previously
escribed (Woods, Shipston, Mullens & Antoni, 1992). Intra- and
iter-assay variability was less than 5 and 10%, respectively.
Experiment 3: measurement of [l2SI]CRH binding-
ite density in the pituitary gland
brgin rats and rats on pregnancy day 11,17 and 22 (n = 6 in each
roup) were housed singly for at least 1 week prior to tissue
ollection. Between 10.00 and 11.00 h the rats were decapitated and
he whole pituitary carefully removed. Each pituitary was placed
n a piece of aluminium foil on dry ice, covered in powdered dry
:e and stored at —70 °C.
lorizontal pituitary cryostat sections (20 /im) were thaw-mounted
nto poly-L-lysine-coated slides, desiccated overnight at 4°C and
tored at —20 °C in sealed boxes until use.
'or receptor autoradiography, sections were preincubated for
0 min at 21 °C in 50 mil Tris-HCl (pH 7-4) containing 10 mM
lgCl2, 2 mM EGTA, 0-1% BSA (RIA grade V), 100 KIU ml"1
protinin (Trasylol), and 0-1 mm bacitracin (Sigma). Incubation was
irried out subsequently in fresh buffer for 60 min with 0-2 n.M
2oI]CRH (ovine; specific activity, 2200 C'i mrnof1; DuPont). Non-
Decific binding was determined in the presence of 1CT6 m
nlabelled ovine CRH (Sigma). The sections were washed three
mes in BSA-free Tris-HCl buffer at 4°C for 2 min, dipped in
istilled water and rapidly dried in a stream of cold air. Dried
sctions were exposed to Agfascopix Video 5B films for 22 days.
.uantification of autoradiographs was performed microscopically
: 10 objective lens; x 1-6 additional magnification) with a computer-
isisted image-analysis system (Joyce-Loebl MicroMagiscan; Vickers,
ateshead, UK). Silver grain area per unit area (silver grain
snsity) was measured within a 100 /im x 100 /im frame over each
:ction. Total binding (silver grain density) was measured over two
ifferent areas per anterior pituitary section, one area for pars
itermedia and one area for the posterior pituitary gland; for each
limal such measurements were made on three pituitary sections,
imilar measurements were made on two adjacent background
•eas off the tissue for each pituitary. Background silver grain
msitv was subtracted from tissue grain density. For tissue
icubated with excess cold CRH, three measurements per section of
ituitary grain density were similarly made (pituitary lobes could
)t be distinguished). Mean density values were calculated for each
it per pituitary lobe, and the mean non-specific binding value
ibtracted from the total. Group means were then calculated.
■tatisticai analysis
ata are presented as group means + s.e.m. To estimate total
nount of hormone release in response to a given stimulus, the
•ea under the curve corrected for baseline (AUG) was calculated
;ing trapezoidal integration (Forsythe, Keenan, Organick &
enberg, 1969). In addition, increments (S) were calculated as the
aximal poststimulation increase minus baseline values.
atistical analysis w;is performed by means of statistical software
B-Stat V5.4, Dynamic Microsystems, USA, and SigmaStat,
ridel Scientific). The tests used were two-way (factors: pregnancy
state x time) and one-way (factor: time) analyses of variance
(ANOVA) for repeated measures followed bv Newman—Iveuls test
(ACTH, corticosterone, oxytocin, vasopressin, lactate), or
completely randomized one-way ANOVA (AUC, ratio, S, plus-
maze parameters during various pregnancy states, cAMP levels,
CRH receptor autoradiography data) followed by Newman-Keuls
test. I' < 0-05 was considered statistically significant.
RESULTS
Experiment 1: neuroendocrine responses to
emotional and physical stressors and to CRH in
virgin, pregnant and lactating rats
Emotional and physical stressors (day 1)
ACTH and corticosterone. Basal plasma levels of ACTH
and corticosterone at 09.30 or 10.00 h did not differ
significantly between virgin rats and rats on day 10, 15, 18
or 21 of pregnancy (P — 0*77), although basal corticosterone
levels in day 21 pregnant rats tended to be higher compared
with all other groups (Fig. 1).
Mild emotional stress (5 min exposure to the elevated plus-
maze) followed by a complex physical-emotional stressor
(90 s forced swimming) significantly increased the secretion
of ACTH and, consequently, of corticosterone in all groups
(P < 0-0001; Fig. 1). The maximum rise in circulating
hormone levels was reached 5 min (ACTH) and 15 min
(corticosterone) after forced swimming. There was an
inverse relationship between the stage of pregnancy and the
magnitude of ACTH secretion in response to the elevated
plus-maze with a ca 6'0- and 7*2-fold increase in virgin and
day 10 pregnant rats, and a 3T- and 1-9-fold increase in
day 18 and day 21 pregnant rats, respectively. Similarly,
subsequent forced swimming caused a 15- and 16-fold
increase in plasma ACTH concentration in virgin and day
10 and only a 9-5- and 8-3-fold increase in day 18 and day
21 pregnant rats, respectively, compared with basal values
[P < 0-0001; Fig. 1). Secretion of corticosterone in response
to both the elevated plus-maze and forced swimming was
also found to be significantly lower at the end of pregnancy
(P < 0-005) with significant differences between virgin and
day 10 pregnant rats, and day 18 and day 21 pregnant rats
(P < 0"01; Fig. 1). The increasingly blunted neuroendocrine
response to the emotional and physical stressors with the
progression of pregnancy was also reflected by significantly
reduced AUC values for ACTH (virgin, 17T + 1-08 arbitrary
units (a.u.); day 10, 18*8 + 1-14 a.u.; day 15, 9-90 +
1-45 a.u.; day 18, 9-50 + 1-48 a.u.; day 21, 8-20 + 3-90 a.u.;
P< 0-01 days 15, 18 and 21 vs. day 10 and virgin);
corresponding AUC values for corticosterone were not
different between groups.
When the responses to exposure to emotional and physical
stressors, respectively, throughout pregnancy were compared,
as reflected by respective ACTH increments, the pregnancy-
related difference in responsiveness was more pronounced
during exposure to the elevated plus-maze, as there was a
6-2-fold difference in the increments between virgins and
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Figure 1
ACTH (A) and corresponding corticostorone (/?)
concentrations in plasma collected from the jugular
vein of conscious virgin and day 10, 15, 18 and 21
pregnant rats on experimental day 1 under basal
conditions (at 09.30 and 10.00 h) and 10 min after
exposure to the elevated plus-maze (EPM; 5 min),
as well as 5, 15 and 25 min after forced swimming
(FS; 90 s, 19 °C). Five days before the experiment,
rats were fitted with a jugular vein catheter under
halothane anaesthesia and caged singly afterwards.
Data are presented as means + s.e.m.; numbers in
parentheses indicate group size. Two-way ANOVA
for repeated measures for ACTH (corticosterone);
factor: time x group, P < 0-0001 (P < 0-0083).
* P < 0-01, virgin and day 10 vs. day 18 and 21;
t P < 0-01, day 15 vs. day 21; I P < 0-01, day 10 vs.
day 18 and 21.
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day 21 pregnant rats compared with a 1-7-fold difference
after the forced swimming between these two groups
(P < 0-05). In a further series of experiments on Sprague—
Dawley rats in Edinburgh, similar attenuation of ACTH and
corticosterone secretion in response to swim stress alone was
found in late pregnant rats (A. J. Douglas, H. Johnstone, A.
Wigger, R. Landgraf, J. A. Russell & I. D. Neumann,
unpublished data).
In lactating rats, the ACTH and corticosterone responses to
both exposure to the elevated plus-maze and forced
swimming were significantly less than those in virgin rats
[P < 0-0001; Fig. 2). Basal ACTH and corticosterone
concentrations, respectively, were similar in both groups.
Oxytocin and vasopressin. Basal plasma levels of
oxytocin differed significantly among virgin and pregnant
rats (one-way ANOVA, P< 0-006; Fig. 3), with increased
basal oxytocin levels on days 18 and 21 compared with
virgin and day 10 pregnant rats (P < 0-01). The blood
sample taken 15 min after forced swimming was used for
the oxytocin and vasopressin assay. However, including pre-
and poststimulation values of all groups, two-way ANOVA
for repeated measurements did not reveal statistical
differences among groups (factor: time x group; P — 0-532).
When pre- and poststimulation values were compared
(factor: time; P< 0-0001), forced swimming significantly
increased the oxytocin concentration in the plasma only in
virgin and day 10 and day 15 pregnant rats (P < 0-05), but
Figure 2
Plasma ACTH (A) and corticosterone (B)
concentrations in virgin rats and between days 9
and 12 of lactation under basal conditions and in
response to exposure to the elevated plus-maze
(EPM) followed by forced swimming (FS) according
to the protocol described in the legend to Fig. 1.
Data are means + s.e.m.; numbers in parentheses
indicate group size. Two-way ANOVA for repeated
measures for ACTH and corticosterone; factor: time
x group, P < 0-0001; * P < 0-01, vs. lactating rats.
Except for the ACTH level 10 min after EPM in
lactating rats, ACTH and cortieosterone
concentrations were significantly increased at each
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Basal FS + 15 min Oxytocin Vasopressin
Figure 3
Plasma oxytocin concentration in conscious virgin and pregnant rats under basal conditions and 15 min
after exposure to forced swimming (FS + 15 min) (A) as described in the legend to Fig. 1 and the
calculated ratio between stimulated and basal neuropeptide concentrations for both oxytocin and vaso¬
pressin (B). Data are means ± s.e.m.; numbers in parentheses indicate group size. Two-way ANOVA for
repeated measures; factor: time, P < 0-0001; factor: group, P< 0-503, factor: time x group, P < 0-7134.
*P<0-05, vs. corresponding basal values; fP< 0-045, vs. virgin, day 10 (Kruskal-Wallis test,
P< 0-0027).
not in day IS and 21 pregnant rats (Fig. 3). The reduced
response to this kind of a combined emotional and physical
stressor in late pregnancy is also reflected in a significantly
lower ratio between poststimulation and prestimulation
levels on day 21 compared with day 10 pregnant rats
(P < 0-05; Fig. 3).
In contrast to oxytocin, forced swim stress did not provoke
an increase in vasopressin release into the blood, in either
virgin or in pregnant rats (factor: time; P= 0-203) as
reflected by the respective ratio values (Fig. 3).
In lactating rats between days 9 and 12 of lactation, basal
oxytocin and vasopressin levels did not differ in comparison
with virgin rats (oxytocin: 7-30 + 0-50 vs. 8-05 + 0-90 pg
ml-1, P= 0*45; vasopressin: 11T + 2-85 vs. 12-0 + 4-15 pg
ml-1). The stress-induced increase in oxytocin secretion was
significantly reduced (lactating: 1-3-fold, virgin: 2-7-fold
increase; P< 0-0002) and did not reach statistical
significance in the lactating group at any time point, i.e. 5,
15 or 50 min after the swim stress.
Again, plasma vasopressin levels remained unchanged in
response to forced swimming in both virgin and lactating
rats.
Lactate. In a separate follow-up study, when plasma lactate
levels in day 21 pregnant and virgin rats both under basal
conditions and in response to forced swimming were
compared, plasma concentrations after stress were found to
be significantly higher in late pregnant rats (from 8-13 +
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Figure 4
Anxiety-related behaviour of virgin and day 10, 15, 18 and 21 pregnant rats on the elevated plus-maze on
day 1 of the experiment as indicated bv the percentage of time spent on the open arms (D) and by the
percentage of entries into the open arms (I). For details see legend to Fig. I. One-way ANOVA;
percentage time: /'< 0-021; f/'cO-Ol, vs. day 15 and 21. One-way ANOVA; percentage entries:
/'< 0-027; I /'< 0*05, vs. dav 10. * P < 0-01, vs. virgin, day Hlandday 18. Data are means +s.k.m.
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Table i. Total cyclic AMP content in segments of the adenohypophysis of day 11, day 17 and
day 21 pregnant rats and their respective virgin controls incubated either in vehicle (Basal) or CRH




Dav 11 (6) 7-06 + 0'76 13-4 + 1-28 6-92 ±1-15
Virgin (4) 6-90 ± 1-60 14-3 ± 3-48 7-72 ± 2-04
Dav 17(6) 6-10 + 0-78* 15-3 + 0-83* 9-22 ± 0'68
Virgin (4) 10-4 ± 1-31 18-8 ± 1-81 8-38 ± 1-42
Dav 21 (8) 5-20 + 0-27* 11-5 + 0-70* 6-30 ± 0-68**
Virgin (8) 7-06 ± 0-89 16-3 + 1 "38 9-26 ± 0-86
Data are means + s.e.m.; numbers in parentheses indicate group size. ** P < 0*01, * P < 0'05, vs.
respective virgin group.
14- / + 2-29 mmol 1 n = l each; P<0-01) with no
significant differences in basal levels.
Anxiety-related behaviour on the elevated plus-maze.
With respect to their anxiety-related behaviour, virgin rats
and rats at different stages of pregnancy differed
significantly (P < 0*021; Fig. 4). In general, pregnant rats
evidently became more anxious with the progression of
pregnancy, i.e. on days 15 and 21, compared with virgin
and day 10 pregnant animals, as indicated by a reduced
percentage of entries into the open arms (P < 0-05; Fig. 4)
as well as the tendency for a reduced percentage of time
spent on the open arms during the 5 min exposure on the
plus-maze. On day 18 only, pregnant rats spent significantly
more time on the open arms and thus seemed, by this
measure, to be less anxious compared with day 15 and dav
21 pregnant animals (PcOCll; Fig. 4). The locomotor
activity, reflected by the total number of entries into the
closed arms, did not differ among groups (P = 0-57).
Lactating and virgin rats did not differ in their anxiety-
related behaviour (16*3 + 3T7 vs. 13'8 + 2'29% of total
time spent in open arms, respectively).
Intravenous administration of CRH (day 2)
ACTH and corticosterone. On day 2 of the experiment,
basal levels of circulating corticosterone, but not ACTH,
between 09.00 and 10.00 h differed significanth' among
groups (P < 0'0001), with elevated corticosterone levels on
day 22 of pregnancy compared with virgins and rats on
days 11, 16 and 19 of pregnancy (P < 0-01; Fig. 5).
Intravenous administration of CRH (40 ng kg-1) increased
ACTH and, consequently, corticosterone secretion in all
groups studied (factor: time; P< 0-0001 for both). Maximum
Virgin (19) Day 11 (6) Day 16 (7) Day 19 (7) Day 22 (7)
Figure 5
ACTH (4) and corresponding corticosterone (B)
concentrations in plasma collected from the
jugular vein of conscious virgin and day 11, 16,
19 and 22 pregnant rats on experimental day 2 in
response to i.v.CRH (40 ng kg-', arrow). For
details see legend to Fig. 1. Insets show the area
under the curve corrected for baseline (AUG; in
arbitrary units (a.u.)). Data are means + s.e.m.;
numbers in parentheses indicate group size.
* P < 0-01, virgin and pregnancy day 1 I vs. days
19 and 22; f P < 0'05, pregnancy day 11 as. days
16 and 19; t /'< 0*01, pregnancy day 22 as.all
other groups; § P < 0*01, ** P < (H)5, vs. virgin
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hormone levels were reached 10 min (ACTH) and 30 min
(corticosterone) after administration of CRH. CRH was less
effective with the progression of pregnancy (factor: time x
group; P<0'05 for both) with significant differences in
ACTH secretion at 10 min among virgin (4-4-fold increase),
day 11 (4-0-fold) and day 16 (2-6-fold), day 19 (1-6-folcl) and
day 22 (1-5-fold) pregnant rats. This was also reflected by
reduced AUC values for both ACTH and corticosterone on
days 16, 19 and 22 of pregnancy (Fig. 5).
In lactating rats, basal ACTH levels tended to be higher
compared with virgin rats (18-2 + 3-71 vs. 8-76 ± 1-78 pg
ml-1, n.s.). There was a significant difference between
actating and virgin rats in their response to i.v. CRH
[P < 0-001) with no significant response in lactating rats
ind a 2-4-fold increase (P < 0-01) in virgin rats at 10 min.
Experiment 2: in vitro basal and CRH-
stimulated cAMP levels in pituitary segments
from virgin and pregnant rats
In the presence of the phosphodiesterase inhibitor IBMX,
basal as well as CRH-stimulated cAMP accumulation was
significantly lower in pituitary segments isolated from day
17 and day 21 pregnant rats compared with the respective
virgin groups (Table 1), whereas no such difference was
found in pituitary segments from day 11 pregnant rats
;ompared with their virgin controls. Importantly, the CRH-
nduced increment (CRH-stimulated minus basal) in cAMP
iccumulation was significantly attenuated in late pregnant
rats on day 21 of pregnancy {P <0-05; Table 1) indicating a
"educed efficacy of CRH-stimulated accumulation compared
vith virgin controls.
There was no difference (ANOVA, P < 0-066) in anterior
pituitary weights between virgin (11-1 + 0-2 mg), day 11
(11-1 + 0-14 mg), day 17 (11-6 + 0-37 mg) and day 21
'12-1 + 0-35 mg) pregnant rats.
Experiment 3: measurement of [125I]CRH
unding-site density in the pituitary gland
125I]CRH binding-site density as reflected by silver grain
tensities was estimated in the anterior, posterior and
ntermediate pituitary lobes of virgin and day 11, 17 and
12 pregnant rats. Compared with virgin rats, there was a
significantly reduced [125I]CRH binding in the anterior
pituitary of all pregnancy groups studied (P < 0-01 vs.
virgin; Fig. 6) and a further reduction in specific [l25I]CRH
binding on day 22 compared with days 11 and 17 of
pregnancy (P < 0-05; Fig. 6). [I25I]CRH binding in the
intermediate lobe of the pituitary was detectable and was
found to be reduced in day 22 pregnant rats (P < 0-05 vs.
virgin). In the posterior pituitary, virtually no specific
[I2SI]CRH binding was detectable.
DISCUSSION
The present results demonstrate that, in rats, the
attenuated HPA axis responsiveness to stressors observed
during lactation is already manifested in mid-gestation.
Specifically, we showed a significant hyporesponsiveness to
both emotional (elevated plus-maze) and physical (forced
swimming) stressors from day 15 until day 21 of pregnancy
as well as during lactation, reflected in a reduced stress-
induced secretion of ACTH from the adenohypophysis and
reduced corticosterone secretion from the adrenal gland.
Similarly, the oxytocin secretory response to forced
swimming tended to be reduced on the last days of
pregnancy. The attenuated response of the HPA axis is
likely to be at least partly due to a reduced reactivity of
corticotrophs to CRH as demonstrated in vivo by reduced
CRH-stimulated ACTH secretion from the adenohypophysis
into blood and in vitro by lower stimulation by CRH of
cAMP production in corticotrophs of the adenohypophysis.
Moreover, receptor autoradiography revealed a significant
reduction in [125I]CRH binding-site density in the anterior
pituitary of pregnant (days 11, 17 and 22) compared with
virgin rats. Independent of the reproductive state, the
neuroendocrine responses to the emotional stressor did not
correlate with the anxiety-related behaviour of the animals
on the elevated plus-maze.
Basal and stress-induced activity of the HPA
axis and HNS during pregnancy
In our study, basal (a.m.) levels of ACTH remained stable
throughout pregnancy, including on day 22; these findings
are comparable with the trough ACTH values in pregnant
rats described by Atkinson & Waddell (1995). In human and
ovine pregnancy, increased basal ACTH concentrations may




El Day 22 Figure 6
Specific [' 51]CRH binding in the anterior and intermediate lobe of
pituitaries collected from virgin, day 11, day 17 and day 22 pregnant
rats (». = 6 each). The fihn was <|uantitied by image analysis to measure
silver grain density (arbitrary units; a.u.). Data are means + s.e.m.
* P < 0-05 and ** P < 0-01, vs. virgin; f P < 0-05, vs. day I 1 and day 17
poignant groups.
Anterior pituitary Intermediate iobe
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1994). In the rat, the placenta may be a source of circulating
ACTH (Chen, Chang, Krieger & Bardin, 1986), although
this is uncertain (VVaddell, 1993), but this is not released in
response to maternal stress (Ohkavva, Takeshita, Murase,
Kambegawa, Okinaga & Arai, 1991). Similarly, basal
cortieosterone concentrations did not differ between virgin
and pregnant rats, except for an increase on day 22 of
pregnancy, the first expected day of parturition. Previously,
decreased plasma corticosterone concentration has been
found early in pregnancy (Ogle & Kitay, 1977; Atkinson &
Waddell, 1995) followed by a return to prepregnancy levels
and a further increase on the last day(s) of pregnancy as we
found. This late increase in plasma corticosterone
concentration may reflect increased sensitivity of the
adrenal glands to ACTH, reduced metabolic clearance rate
(Waddell & Atkinson, 1994), stimulation by increased
ovarian oestrogen secretion or a contribution by the fetal
adrenal glands (Dupont, Rheaume, Simard, Luu-The,
Labrie & Pelletier, 1991).
Our novel finding is that the response of the HPA axis to
both emotional and physical stressors is significantly
blunted in the pregnant rat, beginning around day 15.
These adaptations of the HPA axis manifest in mid-
gestation seem to persist throughout lactation thus
confirming and extending recent results (Altemus et al.
1995; Walker et al. 1995; Neumann et al. 19956; da Costa,
Wood, Ingram & Lightman, 1996; Windle et al. 1997).
However, the mechanisms of adaptation may not be the
same in pregnancy and lactation. Diminished ACTH
secretion in response to stimuli including CRH in
pregnancy has been described also in sheep (Keller-Wood,
1994), baboons (Goland, Wardlaw, MacCarter, Warren &
Stark, 1991) and humans (Magiakou, Mastorakos, Rabin,
Dubbert, Gold & Chroussos, 1996).
The pregnancy-related adaptations of the stress response
include the HNS with oxytocin being released in response
to a variety of stressors in the rat (Lang et al. 1983;
Kasting, 1988; Wotjak et al. 1996). There are increased
stores of oxytocin in the neural lobe (Douglas, Dye, Leng,
Russell & Bieknell, 1993) and basal oxytocin secretion
increases toward the end of pregnancy as confirmed in the
present study (Fig. 3). However, the stress-induced rise in
oxytocin release in late pregnancy was slightly attenuated
and did not reach statistical significance in day 18 and 21
pregnant rats; restraint by endogenous opioid peptides may
be important (Douglas et al. 1995). Similarly there is an
increased basal and attenuated stress-induced local release
of oxytocin within the hypothalamic paraventricular
nucleus (PVN) at the end of pregnancy (Neumann et al.
1997). The altered oxytocin responses in pregnant rats
differ from the pattern of attenuated responses of the HPA
axis, which were markedly reduced from day 15 of
pregnancy onward, through lactation (Figs 1 and 2). [n
lactation, the oxytocin response was essentially abolished,
consistent with previous reports of reduced responses to
non-suckling-related stimuli (Garter & Lightman, 1987;
Lightman & Young, 1989; Patel et al. 1991; Koehler et al.
1993; Neumann et al. 1995a,6).
Mechanisms of the attenuated HPA axis activity
during pregnancy
The physiological adaptations of the HPA axis during
gestation occur at several levels including limbic feedback
systems (Johnstone, Douglas, Seckl & Russell, 1997), CRH/
vasopressin neurons within the hypothalamus (Douglas &
Russell, 1994), cortieotrophs of the adenohypophysis as
shown in the present study, and cortical cells of the adrenal
gland (Carr et al. 1981; Waddell & Atkinson, 1994). An
enhanced glucocorticoid feedback especially at hippoeampal,
but also hypothalamic, brain areas would negatively control
CRH/vasopressin neurons and, thus, attenuate ACTH
secretion. With respect to glucocorticoid feedback control
during pregnancy, various species-dependent results have
been published with unchanged (Keller-Wood, 1996) or
reduced feedback sensitivity (Owens et al. 1987). Changes in
glucocorticoid receptor binding capacity within the hippo¬
campus as observed in lactation (Meanev, Viau, Aitken &
Bhatnagar, 1989) are being studied in our laboratories also
during pregnancy (Johnstone et al. 1997). However, the
stress response is also reduced in adrenalectomized lactating
rats (Walker et al. 1992), so altered feedforward control
mechanisms of the HPA axis could be involved. The
pregnancy-related alterations in plasma levels of the sex
steroids, oestrogens and progesterone, could alter hippo-
campal mineralo- (Carey, Deterd, de Koning, Helmerhorst
& de Kloet, 1995) and glucocorticoid (Burgess & Handa,
1992) receptor binding, hypothalamic CRH expression
(Douglas & Russell, 1994; Grino, Hery, Paulmyer-Lacroix
& Anglade, 1995) and ACTH and corticosterone secretion
(Viau & Meaney, 1991; Burgess & Handa, 1992). However,
it is uncertain whether the secretion of hypothalamic
corticotrophin-releasing factors is reduced during pregnancy
(Plotsky, 1986).
In the present study several lines of evidence indicate
pregnancy-related alterations at corticotrophs of the
pituitary synthesizing and releasing ACTH. In rats between
days 16 and 22 of pregnancy, these cells showed a reduced
response to CRH in vivo as reflected in a reduced ACTH
secretion (Fig. 5). Although receptor autoradiography
revealed a reduction in CRH receptor density in pregnant
rats beginning on day 11 no significant reduction of CRH-
stimulated cAMP accumulation was observed until day 17
of pregnancy. The normal CRH response, in terms of cAMP
accumulation in vitro, observed between days 10 and 16 in
the face of a marked reduction in CRH receptor density is
most probably a result of the large CRH receptor capacity
reported in corticotrophs (Antoni, 1986; King & Baertschi,
1990). This suggests that the reduced CRH-stimulated
ACTH response observed in vivo at days 11 — 17 of
pregnancy is not a consequence of alterations in CRH
receptor coupling to the cAMP pathway but results from
alterations either downstream of cAMP accumulation in
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corticotrophs or as a result of pregnancy-induced changes at
higher levels of the HPA axis. The reduced CRH-stimulated
cAMP accumulation at day 21 of pregnancy, perhaps
resulting from a further- decrease in CRH receptor density,
may underly the mechanisms of attenuated ACTH
responses in vivo at this time. However, it should he noted
that, in the rat, the placenta does not synthesize CRH as
found in several other mammalian species (Jones, Gu &
Parer, 1989; Robinson, Arbiser, Emanuel & Majzoub, 1989;
Goland et at. 1991); thus, the downregulation of pituitary
receptors is not likely to be due to an increased level of
circulating CRH of peripheral origin.
We can exclude the possibility that reduced locomotor
activity during exposure to the elevated plus-maze or forced
swimming led to reduced HPA axis responses in pregnant
rats, since (i) the total number of entries into the closed
arms of the plus-maze, and (ii) the amount of time that
animals spent struggling, swimming or floating during
forced swimming were similar among groups. The increase
in plasma lactate concentration, indicative of muscle
activity during the swim stress (Abel, 1994), was even
higher in late pregnant rats. Alternatively, reduced stressor
perception, resulting from lowered stimulatory inputs from
suprahypothalamic, e.g. limbic and cortical, brain areas and
the brainstem to the hypothalamic PYN containing CRH/
vasopressin neurons could be postulated; consistent with
this is reduced stress-induced c-fos mRNA expression
within the parvocellular part of the PVN in late pregnant
and lactating rats (da Costa et al. 1996). Although our
experimental design did not allow a clear distinction
between emotional and physical components, our
observations suggest that the pregnancy-related reduction
in ACTH secretion is at least as pronounced in response to a
mild emotional as it is to a predominantly physical stressor
(Fig. 1), thus supporting the notion of reduced stress
perception.
Significance of reduced HPA axis and HNS
responsiveness during pregnancy
Negative effects of exogenous ACTH on implantation and
the progress of gestation were described and interpreted as
an excessive stimulation of secretion of steroids other than
corticosteroids from the adrenal gland (Chatterjee & Harper,
1970). Daily treatment with ACTH during the last third of
gestation causes abnormal development of the young,
prolonged pregnancy and impairs the onset of maternal
behaviour (Fameli, Kitraki & Stylianopoulou, 1993).
kSimilarly, increased HPA axis activity during pregnancy
triggered by excessive stress adversely affects the
behavioural (Fameli, Kitraki & Stylianopoulou, 1994) and
endocrine development of the offspring (for review see
Weinstock, 1997). Comparable findings were observed in the
offspring of aged pregnant females with impaired
glucocorticoid feedback and thus elevated corticosteroid
levels during pregnancy (Erisman, Carnes, Takaluishi &
Lent, 1990). Thus, the dampened stress response of the
maternal HPA axis during normal pregnancy described in
the present study may provide a protective mechanism
against excessive levels of circulating ACTH/corticosteroids
during the sensitive period of fetal HPA axis development
and maturation.
In contrast, the attenuated stress-induced release of
oxytocin at the last day(s) of pregnancy may serve the
purpose of storing neurohypophysial oxytocin prior to
delivery when demands for neurohypophysial oxytocin are
high.
Dissociation between neuroendocrine and
behavioural responses throughout pregnancy
The neuroendocrine responses to the emotional stressor were
not correlated with the anxiety-related behaviour of virgin,
pregnant or lactating rats. Thus, despite a continuous
reduction in the HPA axis responsiveness with the
progression of pregnancy, pregnant rats (except on day 18
of pregnancy) were evidently more anxious on the elevated
plus-maze compared with virgin controls. Interestingly, in
contrast to pregnant animals, lactating rats tended to be
less anxious on the elevated plus-maze. A reduced anxiety
in lactating rats has been shown by studying the duration of
freezing in response to an auditory stimulus (Hard &
Hansen, 1984). These behavioural alterations, however,
might be related to the complex patterns of maternal
behaviour which include an increased aggressive behaviour
towards conspecifics (Erskine, Barlield & Goldman, 1978).
Generally, in both pregnant and lactating rats, the results
indicate an independent regulation of HPA axis activity and
anxiety-related behaviour thus confirming recent results
(Pich, Heinrichs, Rivier, Miczek, Fisher & Koob, 1993;
Walker et al. 1995).
In conclusion, we have demonstrated reduced responsiveness
of the HPA axis to various stressors in pregnancy. This
involves reduced corticotroph responsiveness to CRH with
reduced CRH receptor density at the adenohypophysis.
This adaptation may protect the fetuses from lifelong
adverse effects of exposure to excessive glucocorticoids.
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Abstract
Endogenous opioid regulation of neurohypophysial and
hypothalamo—pituitary—adrenal (HPA) axis hormone
secretion in response to forced swimming (90 s in deep
water at 19 °C) was investigated in virgin and 21-day-
pregnant rats. There was no difference in basal plasma
oxytocin concentrations between pregnant and virgin rats,
but the opioid antagonist, naloxone, increased basal oxy¬
tocin secretion in the pregnant rats. Forced swimming
increased oxytocin secretion similarly in pregnant and
virgin rats, and this response was enhanced by naloxone. In
pregnant rats naloxone had a greater effect (by 3T-fold)
than in virgins, showing stronger endogenous opioid
restraint of an enhanced oxytocin secretory response to
stress in pregnancy. Vasopressin secretion was not in¬
creased with forced swimming in virgin or pregnant rats,
and naloxone had no effect. ACTH and corticosterone
secretion in response to forced swimming was attenuated
in pregnant rats compared to virgin rats, measured at
5 min. Naloxone had no effect on basal plasma ACTH or
corticosterone concentration, but it reduced ACTH secre¬
tion in virgin rats 5 min after forced swimming; in
pregnant rats naloxone had no such effect. Naloxone
removed the pregnancy-related attenuation in corticoster¬
one secretion measured at 5 min after forced swimming.
Fifteen minutes after forced swimming, plasma cortico¬
sterone concentrations were not different between groups.
In the late-pregnant rats, the increases in plasma ACTH
and corticosterone induced by forced swimming were
significantly prolonged compared to virgins. The results
show that endogenous opioid inhibition emerges in preg¬
nancy to restrict the responses of oxytocin neurones to a
stressor. In contrast, the endogenous opioid enhancement
of mechanisms regulating HPA axis secretory responses in
virgin rats is not evident during pregnancy.
Journal of Endocrinology (1998) 158, 285-293
Introduction
In addition to the well-known stimulation of
hypothalamo—pituitary—adrenal (HPA) axis hormone
secretion by a wide variety of stressors, there are robust
neurohypophysial secretory responses to stressors; for
example, forced swimming, immobilisation, social defeat
and intrapentoneal hypertonic saline induce increased re¬
lease of oxytocin into the blood (Lang ct al. 1983, Gibbs
1986, Wotjak et al. 1996), whereas ether, haemorrhage,
hypoxia and noxious stimuli increase the release of vaso¬
pressin (Gibbs 1986, Yagi 1992). Oxytocin secretion in
response to a stressor is restrained by endogenous opioids in
female, but not in male, rats (Carter et al. 1986, Carter &
Lightman 1987a), and opioids also influence HPA axis
activity (Buckingham & Cooper 1984, Plotsky 1986, Suda
et al. 1992, Calogero 1996). Both oxytocin and HPA
axis stress responses are reduced in lactation (Carter Ik
Lightman 1987b, Higuchi et al. 1988, Walker et al. 1995,
Windle et al. 1997). We have recently shown that the HPA
axis response to stress is attenuated in pregnancy from day
15 onward (Neumann et al. 1998) as well as in lactation
(e.g. Walker et al. 1995, Windle et al. 1997). Although
pituitary mechanisms account for part of these inhibited
secretory responses (Johnstone et al. 1997, Neumann et al.
1998), central, hypothalamic mechanisms are also likely to
play a part, as parvocellular paraventricular nucleus (PVN)
neurone expression ofFos in response to stress is attenuated
in pregnancy (da Costa ct al. 1996). Because stimulation of
oxytocin neurone activity and secretion by the brainstem
input are restrained by endogenous opioids in late preg¬
nancy (Douglas et al. 1995), and secretion of another stress
hormone, prolactin, is also inhibited by opioids in preg¬
nancy (Soaje tk Deis 1994), we hypothesised that there
may be a common, central opioid mechanism inhibiting
neuroendocrine stress responses in pregnancy.
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We have now investigated whether endogenous opioids
modify oxytocin secretion in response to a stressor in
pregnancy. We have also compared the secretion of"
oxytocin with vasopressin secretion. In addition, we have
sought a role for endogenous opioids in restraining the
HPA axis secretory responses in pregnancy.
Material and Methods
Animals
Virgin female Sprague—Dawley rats (260—290 g body
weight) were mated overnight with sexually expenenced
males and pregnancy was confirmed by finding a vaginal
plug of semen (day 1- of pregnancy). Rats were housed
singly under standard laboratory conditions (12 h
light : 12 h darkness cycle, lights on at 0700 h, 22 °C, 60%
humidity, food and water available ad libitum) for at least
7 days before surgery.
Surgery Under halothane anaesthesia and with sterile
procedures, rats were implanted with a chronic jugular
vein catheter (silastic tubing inside diameter 0-5 mm,
outside diameter 0-75 mm, Altec, Alton, UK) 3-4 days
before the experiment. The catheter was filled with
heparinised (20IU/ml, Multipann, CP Pharmaceuticals
Ltd, Wrexham, UK) sterile isotonic (0-9% w/v) saline.
After surgery, the rats were housed singly and familiarised
to daily handling.
Effect of naloxone on secretory responses to forced swimming in
pregnant rats
Three to four days after surgery, the effect of naloxone (a
general opioid antagonist) on neurohypophysial and HPA
axis hormone secretory responses to forced swimming was
tested. Blood samples were taken before and after treat¬
ment with naloxone or vehicle in virgin («=7, body
weight 282 ± 6 g; n=8, body weight 286 ± 9 g respect¬
ively) and 21-day-pregnant rats (n=7, 364 ± 9 g; n—8,
362 ± 9 g respectively), and subsequently after a period of
forced swimming.
At 0800 h, the catheter was attached to an extension
tubing (polythene, outside diameter TO mm) connected to
a syringe tilled with sterile heparinised saline (20 IU/ml),
and the rats were left undisturbed for 90 min. Blood
samples (0-65 ml), substituted immediately by sterile 0-9%
saline, were taken under basal conditions at 0930 h and
1000 h. Then naloxone (5 mg/kg, 50 pl/100 g body
weight) or vehicle was injected i.v. and a further sample
taken 15 min later. After an interval of 20-30 min, rats
were exposed to forced swimming, a combined physical
and emotional stressor (Abel 1994). With the extension
tubing of the venous catheter still attached, rats were
forced to swim for 90 s in a bucket filled with tap water
(19 °C) to a depth of about 40 cm. After the swim, the rats
were gently dried, using towels, for 10 s and returned to
their home cages. Further blood samples were taken 5, 15
and 60 min after forced swimming. All blood samples were
collected on ice in tubes containing EDTA (5% solution,
15 pl/100 pi blood) supplemented with aprotinin (0-039
trypsin inhibitor units/tube; Sigma, Poole, Dorset. UK)
and centrifuged. Plasma samples (200 pi for oxytocin and
vasopressin, 80 pi for ACTH and 50 pi for corticosterone)
were stored at — 20 °C until required for assay.
Hormone assays
Oxytocin and vasopressin concentrations were measured
in extracted plasma samples by highly sensitive and selec¬
tive radioimmunoassays (limit of detection 0-1 pg/sample;
cross-reactivity of the antisera with other related peptides,
including oxytocin or vasopressin,<0-7%; for a detailed
description see Landgraf 1981).
Plasma ACTH was measured by radioimmunoassay
using a commercially available kit (ICN, Costa Mesa, CA,
USA). The intra- and interassay coefficients of variation
were less than 7 and 10% respectively. Total plasma
corticosterone was measured by radioimmunoassay using a
scintillation proximity method. Briefly, plasma samples
were denatured by incubation in borate buffer (133 mM
boric acid, 68 mM NaOH; pH 7-4, 1 : 9 v/v) containing
bovine serum albumin (0-5%) in a 96 well microtitre plate
(Falcon) at 80 °C for 30 min. Then the samples and a
range of standards were incubated with ^H-corticosterone
(Amersham Life Sciences, Little Chalfont, Bucks, UK;
11 000 c.p.m. per well) and anti-corticosterone antibody
(1 : 10 000 dilution, rabbit anti-rat, a gift from the High
Blood Pressure Unit, Western General Hospital, Glasgow,
UK) in a total volume of 70 pi for 1 h at room tempera¬
ture. Scintillation proximity assay reagent (anti-rabbit,
Amersham Life Sciences, 50 pi. which holds antibody-
bound radioactivity in close proximity to scintillant) was
mixed in and incubated for a further 24 h at room
temperature before counting in a P-scintillation counter.
The intra-assay coefficient of variation was 6%.
Statistical analysis
Statistical analysis was performed by means of statistical
software (Sigmastat, Jandel Scientific, Erkrath, Germany).
Data are presented as group means ± s.e.m. Because the
data were from four groups, representing two reproductive
states, and each set contained repeated measurements from
the same animal, two-way analysis of variance (ANOVA,
reproductive state x time) for repeated measures fol¬
lowed by Newman-Keuls post hoc test was used to
compare the interactions between all data. One-way
ANOVA was also utilized to compare basal values and
calculated increments in secretory responses. To analyse
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Figure 1 Effect of naloxone on neurohypophysial hormone secretory responses to forced
swimming in pregnancy. Plasma oxytocin (a) and vasopressin (b) concentrations in virgin,
vehicle-treated (VEH, O, n=7) and naloxone-treated (NLX, ©, n=8) rats, and in 21-day-
pregnant vehicle-treated (□, n=7) and naloxone-treated (■, n=8) rats. Newman-Keuls post
hoc tests, *P<0-05 compared with before swim in all groups; fP<0-05 compared with all
other groups at same time point. +P<0-05 pregnant naloxone-treated group compared with
pregnant vehicle-treated group and compared with before injection (P<0-01 one-way
ANOVA for repeated measures). #P<0-01, t-test, increment in plasma oxytocin above basal
in virgin naloxone-treated group compared with virgin vehicle-treated group.
specifically the different responses to stress after naloxone
compared with those after vehicle in the pregnant and
virgin rats, the standard error of the difference between the
means (vehicle- and naloxone-treated) 5 min after forced
swimming was used (t-test, Swinscow 1983). P<0-05 was
considered statistically significant.
Results
Effect of naloxone on neurohypophysial hormone secretory
responses to forced swimming in pregnancy
Two-way ANOVA for repeated measures of the plasma
oxytocin concentrations in all groups showed a significant
difference between groups (P<0-()()1) and across time
(P<0-001); all other specific comparisons were derived
from post hoc tests (P<0-05), unless stated otherwise. Basal
plasma oxytocin concentration was not significantly differ¬
ent between virgin and pregnant rats, and after forced
swimming, plasma oxytocin concentration increased sig¬
nificantly in all groups within 5 min after the swim
compared with values before the swim (Fig. la); there was
no significant difference in the response between the
vehicle-treated virgin and pregnant rats. Within 15 min
after the forced swimming, the plasma oxytocin concen¬
tration had returned to pre-stress values in the virgin and
vehicle-treated pregnant rats. Naloxone increased basal
plasma oxytocin significantly only in pregnant rats (one¬
way ANOVA for repeated measures, P<0-()5, Fig. la).
Naloxone also significantly enhanced the oxytocin
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secretory response to forced swimming in both virgin
(5- 1-fold greater than basal concentration, compared with
2-6-fold greater in vehicle-treated virgin rats; P<0-01,
r-test, Fig. la) and pregnant rats (15-9-fold greater than
basal concentration, compared with 1-9-fold greater than
basal in vehicle-treated pregnant rats; P<00001, f-test,
Fig. la); the effect of naloxone in pregnancy was 3-1-fold
greater than in virgins. Plasma oxytocin concentration
remained increased in the naloxone-treated pregnant rats
15 min after the swim, but returned to the concentration
recorded before the swim in the naloxone-treated virgin
rats.
Basal plasma vasopressin concentration was not signifi¬
cantly different between pregnant and virgin groups, and
did not alter after naloxone or with forced swimming in
any group (Fig. lb).
Effect of naloxone on HPA axis secretory responses to forced
swimming in pregnant rats
ACTH Two-way ANOVA for repeated measures of the
plasma ACTH concentrations in all groups showed a
significant interaction between time and group (P<0-001);
all other specific comparisons were derived from post hoc
tests (P<0-05), unless stated otherwise. Basal plasma con¬
centrations of ACTH did not differ significantly between
virgin and day 21 pregnant rats; forced swimming signifi¬
cantly increased ACTH secretion in both groups com¬
pared with values before the swim and basal values,
reaching a maximum at 5 min after the swim (Fig. 2a).
The ACTH response to forced swimming was signifi¬
cantly lower in pregnant rats compared with that in virgin
controls (Fig. 2a), and in the virgin rats the plasma ACTH
concentration was significantly less 60 min after the forced
swimming than at the peak response, whereas there was
no significant decrease in the pregnant—vehicle group
(Fig. 2a). Naloxone alone had no significant effect on
ACTH concentrations within 15 min after administration
in either virgin or pregnant rats (Fig. 2a). However,
naloxone significantly attenuated the secretory response to
swimming in virgins and there was a significant difference
between the virgin vehicle-treated group and all other
groups at 5 min after the stress stimulus; the plasma ACTH
concentration in naloxone-treated pregnant rats did not
differ from that in vehicle-treated pregnant rats (Fig. 2a).
The increase in plasma ACTH 5 min after forced swim¬
ming, calculated as the difference from the mean basal
concentration, was 245 ± 46 pg/ml in virgin rats and the
increases in vehicle-treated pregnant (118 ± 20 pg/ml)
and naloxone-treated virgin and pregnant rats
(154 ± 30 pg/ml, 151 ± 16 pg/ml respectively) were sig¬
nificantly less (one-way ANOVA. P<0-05). Naloxone did
not significantly affect the plasma concentration of ACTH
at 60 min after the swim. Further analysis showed that the
effect of naloxone on the stress response was significantly
different (P<0-05) between virgin and pregnant rats (f-test
on the difference between the plasma ACTH concen¬
tration in the naloxone- and vehicle-treated groups after
forced swimming and the calculated s.e.m. of the differ¬
ence between the two independent means: virgins
— 103 ± 58 pg/ml; pregnant +40 ± 29 pg/ml).
Corticosterone Two-way ANOVA for repeated
measures of the plasma corticosterone concentrations in all
groups showed a significant interaction between time and
group (P<0-0001); all other specific comparisons were
derived from post hoc tests (P<0-05), unless stated other¬
wise. Basal plasma concentrations of corticosterone did not
differ between virgin and day 21 pregnant rats, and forced
swimming significantly increased corticosterone secretion
compared with values before the swim and basal values in
all groups (Fig. 2b); the corticosterone secretory response
to forced swimming in pregnant rats was significantly
less than that in virgin rats (at 5 min after the swim only;
Fig. 2b). There were no differences among the groups at
15 min after the swim, although concentrations remained
similar to those at 5 min within groups. Sixty minutes after
the forced swimming, in the pregnant rats the plasma
corticosterone concentration had not decreased from the
high concentrations at either 5 or 15 min, but that in the
virgin rats had returned to basal values (Fig. 2b). Naloxone
had no significant effect on basal corticosterone concen¬
tration compared with vehicle within 15 man after admin¬
istration and did not significantly affect the secretory-
response to stress in virgins (Fig. 2b); however, the
corticosterone concentration 5 min after swimming in
pregnant rats treated with naloxone was significantly
greater than that in the vehicle-treated pregnant rats
(Fig. 2b). The increments in plasma corticosterone 5 and
15 min after forced swimming, compared with the mean
basal concentration, did not show any significant differ¬
ences (one-way ANOVA, P= 0-38, P=0-94 respectively,
data not shown). Naloxone did not significantly affect
the plasma corticosterone concentrations at 60 min after
the swim. Further statistical analysis (f-test on the differ¬
ence between the plasma corticosterone concentration
in naloxone- and vehicle-treated groups after forced
swimming and the calculated s.e.m. of the difference
between the two independent means) showed that the
effect of naloxone on the stress response was significantly
different (P<0-05) between virgin and pregnant rats
5 min after stress (virgins — 60±66ng/ml; pregnant
+200 ± 62 ng/ml).
Discussion
We have shown that the oxytocin secretory response to
forced swimming (a combined physical and emotional
stressor, Abel 1994) persists into late pregnancy, with no
differences in plasma concentrations between pregnant
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Figure 2 Effect of naloxone on HPA axis secretory responses to forced swimming in
pregnancy in the same groups of rats as in Fig. 1. Data are mean ± s.e.m. plasma ACTH (a)
or corticosterone (b) concentration in vehicle-treated virgin rats (□) and 21-day-pregnant
rats (cross-hatched columns), and naloxone-treated virgin rats (stippled columns) and
21-day-pregnant rats (stippled, cross-hatched columns). Two blood samples were taken
before vehicle or naloxone treatment (Basal is the mean of these), further blood samples
were taken 5 and 15 min after treatment (post NLX/VEH is the mean of these) and 5, 15
and 60 min after forced swimming (Post SWIM), (a) Newman-Keuls post hoc tests,
*P<0-05 compared with before swim; tP<0-05 compared with virgin vehicle-treated group
at same time point; +P<0-05 compared with peak secretion at 5 min after swim in same
animals, (b) Newman-Keuls post hoc tests, *P<0-05 compared with before swim; tP<0-05
compared with virgin vehicle-treated group at same time point; +P<0-05 compared with
same groups at 5 and 15 min.
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and virgin rats (see also Neumann ct al. 1988); this
contrasts with lactation, when the oxytocin secretory
response to a stressor is greatly reduced (Carter &
Lightman 1987/), Higuchi et al. 1991, Neumann et al.
1995). Oxytocin secretion in response to forced swimming
in pregnancy was strongly enhanced by naloxone, which
thus indicates that endogenous opioids actually mask an
exaggerated response after exposure to this stressor. The
lack of a vasopressin response to the forced swim stress
used in our studies is consistent with previous reports of
findings in male and female rats (Lang et al. 1983, Kasting
1988, Wotjak et al. 1996), and shows a highly selective
activation of the neurohypophysial oxytocin system by the
swim stressor. Oxytocin secretory responses to stress,
therefore, are restrained by endogenous opioids during
pregnancy. Endogenous opioids have previously been
demonstrated to inhibit oxytocin, but not vasopressin,
secretory responses to immobilisation stress in male
(Samson et al. 1985) and female virgin rats (Carter et al.
1986), and we now show similar endogenous opioid
inhibition ot oxytocin responses to forced swimming in
female rats. Both p.- and K-opioid systems may be respon¬
sible (Carter & Lightman 1987a). Endogenous opioids are
co-localised and co-secreted with oxytocin and vasopressin
(Watson et al. 1982, Meister et al. 1990) and there is
substantial evidence that endogenous K-opioids restrain
stimulated oxytocin secretion at the level of the neurose¬
cretory terminals in the neurohypophysis (Bicknell & Leng
1982). However, previous studies have indicated that, at
the level of the neurohypophysis, endogenous K-opioid
inhibitory mechanisms are down-regulated at the end of
pregnancy (Sumner et al. 1992, Douglas et al. 1993),
suggesting a greater role for p-opioids, which act centrally
and not at the neurohypophysis (Russell et al. 1993).
It is clear that endogenous p-opioids strongly inhibit
oxytocin neurone activity and secretion in late pregnancy
(Douglas et al. 1995), and that this is manifest mainly on
oxytocin neurone cell bodies and their inputs, rather than
on the nerve terminals in the neurohypophysis (Douglas
et al. 1993). The present study has demonstrated that an
endogenous opioid mechanism not only restrains oxytocin
secretion from an expanded neurohypophysis store in
pregnancy (Douglas et al. 1993), but also strongly restricts
the oxytocin neurone response to forced swimming in
pregnancy, as with responses to other stimuli, such as
peripheral administration of cholecystokinin during gesta¬
tion (Douglas et al. 1995), and to birth (Hartman et al.
1986, Leng et al. 1987, 1988, Lawrence et al. 1992). This
action could be on oxytocin cell bodies themselves, as they
have opioid receptors (Inenaga et al. 1994, Sumner et al.
1992), or on the input pathways to these neurones
mediating the stress stimulus, perhaps from the brainstem
(Onaka et al. 1995). However, endogenous opioids are not
responsible for the reduced responsiveness of oxytocin
neurones to osmotic stimulation in pregnancy (Bull &
Russell 1992), or to electrical stimulation of lamina
terminalis (Bull et al. 1994) and thus there is likely to be a
selective action of opioids on inputs to oxytocin neurones.
No consistent changes have been described in magno-
cellular or parvocellular neurone prodynorphin or
proenkephalin A mRNA expression, which are indicators
of opioid synthesis, in pregnancy (Schrieter 1991, Douglas
& Russell 1994, Douglas et al. 1993). However, an
increased hypothalamic content of p-endorphin (Wardlaw
& Frantz 1983, Dondi et al. 1991, Broad et al. 1993) and
pro-opiomelanocortin mRNA in the arcuate nucleus
(Redmond et al. 1996) have been described before par¬
turition, which may account for the central endogenous
opioid influence on oxytocin neurones in pregnancy.
In parturition, the increased secretion ot oxytocin is
reduced by the stress of environmental disturbance and the
intervals between pup births increase (Leng et al. 1987,
1988). The evident dichotomy between these reports and
the stimulation of oxytocin secretion by stressors in virgin
female and male rats in other previous studies (Lang et al.
1983, Gibbs 1986, Carter & Lightman 1987b, Wotjak
et al. 1996) and in the present study on pregnant rats, may
be apparent rather than real. Thus the effects of a stressor
on oxytocin secretion in parturition could be secondary to
the slowing of parturition through another mechanism,
with consequent reduced positive feedback stimulation of
oxytocin secretion. The effect of naloxone to increase
oxytocin secretion in these environmentally disturbed rats
(Leng et al. 1987) may simply reveal the underlying
stimulatory effect of environmental stress on oxytocin
secretion as in pregnancy.
This study confirms that secretion of ACTH and
corticosterone in response to a stressor are reduced during
late pregnancy (Neumann et al. 1998) and this is compar¬
able to the reduced HPA axis response to stressors pre¬
viously repotted in lactation (e.g. Walker et al. 1995).
Naloxone attenuated the increase in ACTH concentration
in virgins in response to forced swimming, revealing that
endogenous opioids enhance ACTH secretory responses.
Naloxone did not attenuate ACTH secretion in response
to forced swimming in pregnant rats, indicating loss ot
the endogenous opioid-enhancmg effects on the ACTH
secretory response seen in virgin rats. Corticosterone
responses showed a trend similar to those of the ACTH
responses: there was a pregnancy-related attenuation in
corticosterone concentration 5 min after forced swimming
and naloxone reversed this; also, high ACTH and cortico¬
sterone concentrations after the swim were prolonged in
pregnant rats compared with those in virgin rats. How¬
ever, naloxone did not cause a decrease in the corticoster¬
one response to forced swimming in virgin or pregnant rats
at either 5 or 15 min after the swim, although the cortico¬
sterone response in virgin rats was not significantly greater
than that in virgin or pregnant rats given naloxone. This is
in contrast with the response of ACTH, perhaps because
the maximal response of the adrenal cortex to ACTH is
limiting (Keller-Wood et al. 1984). In addition, adrenal
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sensitivity to ACTH is increased in pregnancy (Carr et al.
1981, Dupouy et al. 1975, Waddell & Atkinson 1994), and
therefore changes in corticosterone concentration will not
necessarily parallel those of ACTH.
We have previously shown that, in pregnancy, down-
regulated anterior pituitary mechanisms contribute to the
attenuated HPA axis responses, as there is a reduced
pituitary ACTH secretory response to exogenous
corticotrophin-releasing hormone (CRH) in vivo
(Neumann et al. 1998), attenuated cAMP production in
response to CRH in vitro and decreased CRH receptor
binding (Johnstone et al. 1997). We have now shown that,
in pregnancy, the enhancing action of endogenous opioid
on ACTH release in response to forced swimming, which
is normally seen in virgins, is removed. The reduction in
ACTH secretion in response to the stressor after naloxone
in virgins is consistent with the findings ofprevious studies
showing that opioid antagonists reduce ACTH and corti¬
costerone secretion in response to a stressor in male rats
(degli Uberti et al. 1995). Naloxone is likely to be exerting
its effects on the HPA axis via the hypothalamus (Wang
et al. 1996), and thus may affect hypothalamic—pituitary
mechanisms through CRH release. p-Opioids appear to
mediate the naloxone-induced reduction in stress re¬
sponses (Cover & Buckingham 1989), whereas K- and
5-opioids may modulate HPA axis hormone secretion
under basal conditions (Iyengar et al. 1986, Plotsky 1986).
The k-opioid effects probably occur within both the
hypothalamus (Nikolarakis et al. 1987) and the anterior
pituitary (Calogero 1996). We are not aware of any direct
action of naloxone on the adrenal cortex.
The removal of endogenous opioid enhancement on
central mechanisms regulating HPA axis responses to
stressors in pregnancy may partly underlie the reduced
activation of parvocellular PVN neurones by immobilis¬
ation (da Costa et al. 1996) and decreased CRH mRNA
expression in the PVN (Douglas &c Russell 1994).
Together, these changes constitute evidence for reduced
feed-forward activity in the hypothalamo—pituitary com¬
ponent of the HPA axis in pregnancy. The prolonged
increase in ACTH and corticosteroid secretion after stress
in the pregnant rats is evidently not consistent with
enhanced fast negative feedback in pregnancy, but is
consistent with either a prolonged adrenocortical secretory
response or reduced metabolic clearance, perhaps as a
result of increased circulating corticosteroid binding
globulin in pregnancy (Seal & Doe 1967). Maternal plasma
corticosterone concentrations may be additionally contrib¬
uted to by the fetus (Dupouy et al. 1975). In addition,
increased oxytocin secretion after the swimming stress may
enhance the secretion of ACTH or corticosterone, or both,
by actions on the corticotrophs or adrenal cortex (Samson
& Schell 1995, Stachowiak et al. 1995, Link et al. 1993).
The placenta limits the exposure of the fetus to high
concentrations of maternal HPA axis hormones, as ACTH
does not cross from the maternal to the fetal circulation
(Dupouy et al. 1980) and the transfer of glucocorticoid is
regulated by several placental enzymes, of which 1 1 (3
hydroxysteroid dehydrogenase Type II (Seckl et al. 1995)
predominates in the last few days of pregnancy, inactivat¬
ing corticosterone (Burton & Waddell 1994). Thus the
reduced immediate peak ACTH secretory response to the
stressor in pregnancy may act in concert with placental
mechanisms to protect the fetus from excessive concen¬
trations of corticosteroid toward the end of pregnancy
which could have potentially lifelong deleterious effects
(Weinstock 1997). Possible changes in feedback mech¬
anisms in pregnancy are currently under further
investigation.
In conclusion, oxytocin neurone secretory responses to
exposure to forced swimming are not reduced, but are
instead strongly restrained from responding in an exagger¬
ated fashion, by endogenous opioids in late pregnancy.
This opioid restraint will contribute to conservation of the
neurohypophysial store of oxytocin for primary use in
promoting utenne contractions in parturition, when about
a third of the oxytocin content is depleted within about 2 h
(Fuchs & Saito 1971). HPA axis secretion in pregnancy in
response to forced swimming is no longer stimulated by
endogenous opioids, which may contribute to protecting
the fetus from exposure to excessive concentrations of
corticosteroid in the mother during initial responses to
stress.
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490.7
EXPRESSION OF GLUCOCORTICOID (GR) AND MINERALOCORTICOID
(MR) RECEPTORS IN THE DEVELOPING RAT BRAIN. C. R. Ncal. Jr.V D. M,
V3y.uucy. and S. J. Watson. Jr. Menial Health Research Insmutc. University of
Michigan Malical Sch<x>l. Ann Arbor. Michigan 48109-0720.
In addition to the stress of severe illness, premature human neonates may he
exposal to glucocorticoid treatment in utcro and as neonates. Little is known about
the inlluencc of exogenous steroids and stress on normal development of the LHPA
axis. In order to better study such elTccts, this study was undertaken to describe the
normal expression of GR and MR in the rat brain at various developmental stages.
Pregnant rats and postnatal pups were perfused with Zambom's fixative. Embryos
(El 1-E14). fetal brains (E16-E22) and postnatal brains (PI-P21) were post-fixed for
5 days, then soaked in 10% sucrose, frozen at -4()°C and cut into I5qm sections. A
347bp fragment of the 3'UT common coding region of MR. a I05bp fragment of the
yMR exon and a 5(X)bp fragment of the aGR exon were used for in situ
hybridization. GR mRNA was detected caudal in mesencephalic epithelium at EI4,
in hippocampal ncuroepithelium at El7. in hypothalamus and cortical plate by El8.
and cortex and amygdala by E22. Signal increased in hippocampus and PVN to P14
before approaching adult patterns. MR was first detected in mesencephalic
epithelium at E14, cortical ncuroepithehum at E18. and hippocampus and amygdala
at E22. Signal was low in PVN up to P3. then decreased to adult. Cortical signal
was stronger in rostral regions. yMR mRNA signal mirrored that of MR
anatomically, but with decreased signal intensity in most regions except cortex and
hippocampus where it was similar. These findings demonstrate an increase in GR
and MR mRNA expression in the CNS from E14 to P14, which is greater than that
seen in the adult. '/MR appears to account for a majority of MR expression during
development. Immunocytochcmical studies of ihe MR and GR receptors will be
performed to correlate these findings. These findings suggest that early steroid
treatment may effect brain development. Sun*mc4 by ni.mii Gram ZT32.villl5794.i7.
490.3
PRENATAL PROGRAMMING OF HIPPOCAMPAL MR AND GR GENE
EXPRESSION BY INHIBITION OF IIB-HYDROXYSTEROID
DEHYDROGENASE (11 p-HSD)
I..A.M. Wt'lhery NIC. Holmes and JR. Seckl*. Molecular Endocrinology
Laboratory. Molecular Medicine Centre. University of Edinburgh. Western
General Hospital. Edinburgh EH4 2XU
Prenatal exposure to corticosteroids has been postulated permanently to program
hypothalamic-pituitary-adrenal activity. Normally the fetus is protected from
maternal glucocorticoids by feio-piacental 11 P-HSD (type 2). which converts
comcosterone into inactive I l-dehydrocorticostcrone. This study investigated the
effect of inhibition of feto-placental 11 p-HSD using carbenoxolone (CBX) on
subsequent liippocampai MR and GR gene expression. Female Wistar rats were
injected subcutaneously with CBX (12.5 ing/day) or vehicle throughout pregnancy,
or were left undisturbed. The CBX injections reduced offspring birthweight by
13%. whereas littersize was not affected. At 12 weeks of age, offspring of CBX-
treated rats showed reduced GR gene expression in CA2 (14%) and CA4 (19%)
compared to vehicle-treated offspring as measured by in situ hybridisation. MR
mRNA expression was reduced in dentate gyrus (13%). CAI (14%) and CA2
(11%). These results were similar to the effects of prenatal dcxamcthasone
treatment'. The onset of reduced hippocampal MR and GR gene expression was
not immediate and in fact at postnatal day 7 MR mRNA expression was higher in
CBX-otfspring, specifically in dentate gyrus. Inhibition of 11 P-HSD prcnatally
programmes reduced hippocampal MR and GR gene expression, probably by
allowing increased access of glucocorticoids to the fetal circulation.
LAMW is sponsored by a Wellcome Prize Studentship.
'Levut NS. Lindsay RS. Holmes MC. Seckl JR (19%) Neurocndocrinology 64(6):412-418
490.9
CHANGES IN 11 p-HYDROXYSTEROID DEHYDROGENASE TYPE I (110-
HSD I) ACTIVITY AND GLUCOCORTICOID RECEPTOR mRNA IN THE
PREGNANT RAT HIPPOCAMPUS AND PARAVENTRICULAR NUCLEUS
^Dept. of Physiology, & "Molecular Endocrinology Laboratory. MRC 3rain
Metabolism Unit. University of Edinburgh. Edinburgh. U.K.
The neuroendocrine stress response of the hypothalamic-pituitary-adrenai (HPA)
axis and PVN CRH mRNA expression are decreased on day 2! of pregnancy
(Neumann et ai. 1996: Dougias Russell. 1994). To seek evidence for increased
glucocorticoid negative feedback on the HPA axis we measured activity of (lie
glucocorticoid-metabolising enzyme 11 P-HSD 1 in specific brain regions in pregnant
and virgin rats. We also used quantitative in situ hybridisation to measure mRNAs
for glucocorticoid (GR) and mineraiocorticoid (MR) receotors in the hippocampus
and the PVN. II P-HSD I activity in the hippocampus did not change during
pregnancy, but in the PVN the activity increased by 54% between virgin and day 16
of pregnancy (p < 0.05, n - 4-5) and further increased by 29% on day 21 (p < 0.05. n
■ 6). GR mRNA expression in the dentate gyrus increased from day 10 to 21 of
pregnancy (p < 0.01, n * 5-6), but did not change in CAI, CA3 & CA4. GR mRNA
expression in the PVN did not change significantly but tended to increase in late
pregnancy. MR mRNA expression was not altered with pregnancy. Increased 110-
HSD reductase activity in the PVN is expected to increase local glucocorticoid
production. Together with increased GR mRNA expression in the dentate gyms,
which has an indirect input to the PVN, this may enhance negative feedback on the
HPA axis resulting in suppressed forward drive to the axis.
H.AJ is a BBSRC researcn student
I. Neumann I.. Johnstone H., Landgrat R., Russeil J.A. & Douglas A.J. (1996). J.
Endocrinol. 148, suppl. P131.
2. Douglas A.J. & Russeil J.A. (1994). Gene Therapy I, S85.
490.10
ACUTE BLOCKADE OF CORTICOSTEROID (CORT) RECEPTORS
DURING RESTRAINT STRESS IMPAIRS THE EXPRESSION OF
HABITUATION TO THE STRESSOR WHEN MEASURING PLASMA
CORT. BUT NOT WHEN MEASURING PVN C-FOS INDUCTION IN
RATS M.A. Cole* MS Chi, B.A. Kalman. P.J Kim. R.L. Spencer. Dept. of
Psychology. Univ. Colorado. Boulder. CO 80309.
We investigated the interaction of CORT negative feedback with the
expression of habituation of the HPA axis response to repealed stress. Male.
Sprague-Dawiey rats were restrained 1 hr a day in Plexigias tubes for 6
consecutive days. On day 6. I hr prior to restraint stress, rats were injected s c.
with a combination of the selective Type I (RU28318. 50mg/kgj and Type II
(RU40555, 30 mg/kg) CORT receptor antagonists or vehicle. In 3 prior
studies using this same procedure, the expression of habituation, which was
marked by a significant decrease in plasma CORT. was significantly reversed
by the day 6 antagonist treatment. The present study examined the concurrent
effect of this CORT receptor antagonism on c-Fos protein induction in the
PVN of the hypothalamus. Six groups (n=6) were tested: 1) Vehicle + No
Restraint, 2) Antagonist + No Restraint. 3) Vehicle + Restraint. 4)
Antagonist + Restraint. 5) Vehicle + Restraint (with 5 prior restraint
sessions). 6) Antagonist + Restraint (with 5 prior restraint sessions). C-Fos
immunoreactivity was visualized on brain sections using
immunohistochemistry (primary Ab: rabbit anu C-Fos. Santa Cruz-052). Cell
counts indicate that the habituation of PVN c-Fos induction to repealed
restraint stress is not reversed by the acute antagonists. This result suggests
that the habituation expression reversal for CORT secretion by the antagonists
is a consequence of mechanisms that do not involve PVN c-Fos induction.
Possible mechanisms include 1) decreased inhibitory or increased excitatory
inputs to the PVN not involving PVN c-Fos induction or 2) CORT dependent
mechanisms within the PVN not involving c-Fos induction (supported by
DK49143; RU28318 and RU40555 were kindly provided by Roussel Uclaf.
Romainville, France).
490.11
CHARACTERIZATION OF IN VIVO BRAIN MINERALO¬
CORTICOID RECEPTOR (MR) REGULATION USING WHOLE-
CELL WESTERN BLOT. B.A. Kaiman*. P.J. Kim. M.A. Cole. J.P.
Herman. R.L. Spencer. Behavioral Neuroscience Div., Dept. of
Psychology, University of Colorado, Boulder, CO 80309 Sc. Dept. of
Anatomy, University of Kentucky, Lexington, KY 40536.
We have used an anii-MR antibody (MR 214; a polyclonal antibody
directed against an MR fusion protein pGEX) in the western blot
procedure to characterize the regulation of MR in whole-cell
hippocampal homogenates. This procedure has an advantage over
binding studies in that circulating steroids need not be removed before
sacrifice, thus avoiding potential re-regulation of receptors. In a study
where male Spraguc-Dawley rats were killed 24 hr following sham
surgery or adrenalectomy (ADX) or 5 days following ADX. a
difference in the time-course of regulation was observed between MR
and glucocorticoid receptors (GR). While the majority of up-
regulauon of GR occurred between I and 5 days following ADX. the
majority of MR upregulation occurred within 24 hr of ADX. This
difference does not appear to be due to a difference in cellular
compartmentaiization of receptors based on comparisons of whole-
cell v. cytosolic homogenates. Consistent with binding data, we also
found that 5-day treatment with corticostcrone (200 mg pellet) but not
the GR-specific agonist RU-28362 (10 (ig/hr) was able to block the
ADX-induced upregulation of MR. These findings suggest that
hippocampal MR is regulated by corticosterone and upregulates more
rapidly than GR. We wish to thank Dr. Stanley J. Watson for his kind
gift of MR 214 antibody (supported by grants. DK49143 Sc
AG 12962).
490.12
VALIDATION OF THE IN VIVO USE OF RU28318 AND RU40555
FOR ANTAGONISM OF MINERALOCORTICOID RECEPTORS
(MR) AND GLUCOCORTICOID RECEPTORS (GR),
RESPECTIVELY. P.J. Kim*. B.A. Kalman. M.A. Cole. R.L.
Spencer. Dept. of Psvchology, Univ. of Colorado, Boulder. CO
80309.
This study examined the suitability of using RU28318 (putative MR
antagonist) and RU40555 (putative GR antagonist) to selccuvely block
in vivo corticosteroid actions mediated by MR and GR. In vivo
occupancy of MR and GR by antagonists was inferred from studies
examining the dose/time response effects of antagonist treatment of
adrenalectomized rats on available cytosolic MR and GR binding in the
hippocampus. In addition, studies were conducted to test the ability of
the antagonists to block an effect of a MR or GR agonist. We found
that RU28318 ( 50mg/kg, sc) selectively occupied MR in the
hippocampus. Further. RU28318 treatment showed no significant
agonist effects, however RU28318 was able to block the suppressive
effects of aldosterone (I20j<g/kg, sc) on saline intake in
adrcnalcctomized rats. RU40555 (30mg/kg, sc) selectively occupied
GR in the hippocampus. Further, RU40555 showed no significant
agonist properties, however RU40555 was able to block the
suppressive effects of dexameihasonc (50jig/kg, sc) on stress-induced
corticosterone secretion. Thus, RU28318 appears to be an elfcctive
MR antagonist and RU40555 appears to be an effective GR antagonist
in vivo. [Supported by UROP program at the Univ. of CO, and
USPHS grants DK49143 and MH54742. RU28318 and RU40555
were kindly provided by Rousscl Uclaf, Romainville, Franccj
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P1 91 '"I-oCRH BINDING .AND CRH STIMULATION OF cAMP PRODUCTION 3Y THE RAT ANTERIOR
PITUITARY IN VITRO ARE REDUCED IN LATE PREGNANCY
HA Johnstone,1'2 I Neumann/ G Liebsch." M Shipston/ JR Seckl' and JA Russell." Department of Molecular
Endocrinology Laboratory, Molecular Medicine Centre. Edinburgh EH4 2XU. : Department of Physiology,
University Medical School. Edinburgh EH8 9 AG. ' Max Planck Institute of Psychiatry. Munich. Germany.
The hypothalamic-pituitarv-adrenal axis response to stressors is attenuated in late pregnancy, and CRH is less
effective in stimulating ACTH secretion in vivo (Neumann et al. 1996). So we have now measured basal and
CRH-stimulated levels of cAMP. the second messenger for the pituitary CRF-1 receptor (CRHR,), in anterior
pituitaries from day 20 pregnant and virgin rats, and receptor binding using i:5I-oCRH on fresh frozen pituitary
sections. Animals were decapitated and the anterior pituitaries cut into eight segments and incubated in the
presence or absence of lOnM CRH for 10 mins. The tissues were then triturated in ice-cold 0.2N HC1 for
analysis by cAMP RIA. For CRHR, autoradiography, 20um sections were incubated with l25I-oCRH in the
absence (total binding) or presence (non-specific binding) of excess cold oCRH. Film was exposed for 3 weeks
and the silver grain density measured with an image analyser. CRH increased cAMP content less in pituitaries
from day 20 pregnant rats than in virgins (315 ±34 vs. 463 ± 43 pmol/50pl ± sem. p < 0.01., n = 8). CRHR,
autoradiography showed less binding in the anterior pituitary from day 21 pregnant vs. virgin rats (0.21 ± 0.04
vs.0.52 ± 0.04 grain density, p < 0.01). Grain density was also reduced in the intermediate lobe in pregnancy.
The results indicate reduced density of CRHR, in the anterior pituitary in late pregnant rats, leading to a
reduced cAMP response to CRH, and thus to a reduced ACTH response to stressors in vivo at the end of
pregnancy.
References: Neumann I., Johnstone H., Landgraf R., Russell JA. & Douglas AJ. (1996). J. Endocrinol. 148,
suppl. P131. (HAJ is a BBSRC research student. Supported by a British Council/DAAD ARC grant).
P1 92 DOES THE EXCESS CANCER INCIDENCE AND MORTALITY IN ACROMEGALY HAVE A GENETIC
BASIS?
S M Orme, J Crockford*, D T Bishop* and P E Belchetz ; Department of Endocrinology, The General Infirmary
at Leeds and *ImperiaI Cancer Research Fund Epidemiology Centre, Leeds LSI 3EX.
We have previously reported an excess overall cancer mortality in acromegaly (O/E ratio 1.33 p=0.001), with an
excess colon cancer incidence (O/E 1.98 p=0.022) and mortality (O/E 2.8 p=0.001). This study suggested a
relationship between cancer mortality and post treatment growth hormone (GH) levels in acromegaly.
However, if there is a genetic predisposition (such as the loss of a tumour suppressor gene) to develop cancer in
certain acromegalics, which may not be related to the degree of GH hypersecretion, then this cancer excess may
also be reflected in an increased cancer incidence and mortality in the relatives of acromegalics.
We therefore investigated the first degree relatives of 30 acromegalics (257 subjects; 32 acromegalics, 60 parents,
93 siblings and 72 children). We compared cancer rates between the families studied and data from the Yorkshire
Cancer Registry, by life table analysis.
There was no increase in all cause cancer rate or colon cancer rate (O/E 1.047 p=0.476) in the first degree relatives
of these acromegalics.
In conclusion these data do not support the hypothesis that cancer excess and particularly colon cancer excess in
acromegaly has a genetic basis.
Orme SM. McNally R. Staines A, Cartwright RA & Belchetz PE. Mortality in Acromegaly; Relationship with
Duration of Disease and Growth Hormone Level. 4th International Pituitary Congress.San Diego 1996.
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period using an unpaired t test. Electrophysiological
recordings were obtained from thirty arcuate neurones
(mean tiring rate: 074 + 014 spikes s_1, mean + s.e.m.)
that projected to the median eminence. The activity of
eighteen of these cells was unaffected by injection of
MK-0677 (0-76 ± 0-10 to 0-72 ± 0-10 spikes s"1, n = 8) or
GHRP-6 (0-43 + 0-10 to 048 + 0-11 spikes s-1, n=10).
However, the activity of five arcuate neurones was
significantly increased following injection of GHRP-6
(0-80 + 0-16 to 1-85 + 02 spikes s_1, P<0-01) and a
further seven cells were excited by injection of MK-0677
(0*95 + 0*12 to 1 -63 + 0'16 spikes s-1, P<0-01). Both
drugs significantly elevated the mean firing rate at 10 min
after injection and the firing rates remained elevated for the
subsequent 30 min. Cells excited by either GHRP-6 or
MK-0677 could not be subsequently activated by a second
injection (at least 40 min after the initial injection) of the
same secretagogue, negating the possibility of examining the
actions of both secretagogues on the activity of single
neurones. These results suggest that the, orally active GH
secretagogue, MK-0677, activates a subpopulation of
neuroendocrine arcuate neurones in a similar manner to
GHRP-6 and may therefore prove a useful tool in
investigating the central control of GH release.
This work was supported by Merck Research Laboratories.
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Changes in ll/?-hydroxysteroid dehydrogenase
type 1 (ll/?-HSD 1) activity in the rat hypothalamic
paraventricular nucleus (PVN) and anterior
pituitary during pregnancy
Heather A. Johnstone, J.R. Seckl* and J.A. Russell
Department of Physiology, University Medical School,
Edinburgh EH8 9AG and *Molecular Medicine Centre,
University of Edinburgh, Edinburgh EH4 2XU
At the end of pregnancy (day 21) corticotropin-releasing
hormone (CRH) mRNA expression is significantly decreased
in the PVN (Douglas & Russell, 1994), consistent with
attenuation of the neuroendocrine stress response in late
pregnancy (Neumann et al. 1996). This may reflect an
increased glucocorticoid negative feedback on the
hypothalamic-pituitary-adrenal (HPA) axis at the level of
the PVN. 11/J-HSDl is a NADPH-dependent enzyme
which, in vitro, reversibly metabolizes glucocorticoids to
their inactive metabolites (Moisan et al. 1990), thus
regulating their access to both mineralocorticoid (MR) and
glucocorticoid (GR) receptors, but in vivo it can also activate
glucocorticoids (Rajan et al. 1996). Altered activity of
11/THSDl in the hypothalamus could thus regulate
feedback onto CRH neurones.
We have measured 11/f-HSD 1 activity in the brain in
day 16 and day 21 pregnant rats and in virgin controls,
which were decapitated for tissue harvest. Micropunched
PVN from vibroslice brain sections, dissected hippocampus
and cerebellum and the anterior pituitary were
homogenized, then incubated at a protein concentration of
either 200 or 500 /tg ml-1 with 200 mm NADP+ and 12 mi
[1,2,6,7 3H]corticosterone (specific activity 82 Ci mmof') for
60 min at 37 °C. Each PVN determination was made on
micropunches from two rats. The steroids were then
extracted into ethyl acetate, dried down, reconstituted and
run on TLC plates. ll/?-HSD activity was expressed as
percentage conversion of [3H] corticosterone to
[3H] 11-dehydrocorticosterone.
We found that 11/J-HSD activity in the hippocampus
(26-17 ± 1-77, 23-63 ±2-40 and 26-52 + 1-74%,
means + s.e.m., virgins, day 16 and day 21, respectively),
and the cerebellum (21-15 + 3-27, 21-33 + 1-19 and
23-51 + 1-97%) did not change during pregnancy. In
contrast, activity in the anterior pituitary significantly
increased between day 16 and day 21 (16-81 + 1-89 to
22-7 + 0-97%, P < 0-05, Mann-Whitney test, n = 10-12
determinations). However, the greatest change occurred in
the PVN where activity approximately doubled between
virgin controls and day 16 (4-10 + 0*53 to 8-83 + 1-17%,
P< 0-05, n = 4-5), with a further increase at day 21
(12-50 ± 3-80%, P< 0-05, n — 6).
The PVN is central to the activation of the HPA axis in
response to stress. It receives inputs from the periphery as
well as from other brain areas, and is an important site for
the synthesis of several ACTH secretagogues, including
CRH. Thus increased ll/?-HSD 1 reductase activity in
pregnancy may contribute to an enhanced negative feedback
by generating glucocorticoids within the PVN and the
anterior pituitary.
H.A.J, is supported by a BBSRC Research Studentship.
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